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  Foreword 
 
 
 In the past, issues of international drug control have often been summarized in 
a model that incorporates a simplistic relationship between the supply of drugs and 
demand for them. Over the years, however, it has become apparent that problems of 
international drug control are among the most complex problems facing the world 
and that they cannot be solved by superficial measures.  
 As the International Narcotics Control Board demonstrated in its annual report 
for 2004, the fundamental interaction between the supply of and demand for drugs is 
anything but straightforward. The same applies to alternative development, which 
the Board has chosen to examine in the first chapter of its report for this year. 
 Alternative development started 30 years ago as “crop substitution”. It was 
based on the premise that illegal drug crops, in particular opium poppy and coca 
leaf, could be substituted by legal cash crops that would provide the crop growers 
with similar or even higher incomes. According to that simple model, the cultivation 
of illegal drug crops would then become undesirable, which would reduce the 
supply of raw materials and ultimately reduce drug abuse.  
 Unfortunately, experience has shown that this somewhat narrow and 
mechanical approach has not been very effective, although there have been isolated 
examples of successful alternative development. In practice, attempts at crop 
substitution have demonstrated that stopping the illicit cultivation of crops from 
which drugs are extracted and encouraging the cultivation of other crops are much 
more complex tasks than initially anticipated. It is now known that such 
programmes can only be successful if the people who grow the crops have an 
economically viable alternative to illicit cultivation and that the programmes must 
be combined with law enforcement and drug prevention activities. Furthermore, 
such measures will only be viable if they are conceived and implemented as long-
term processes. They can never be a “quick fix”.  
 Today, alternative development is viewed as a continuing process in which the 
involvement of the target communities, the growers of illicit crops, is the key to 
success. The objective of preventing and, eventually, eliminating the illicit 
cultivation of plants from which drugs are extracted can only be achieved in the 
context of sustainable development efforts and within the framework of a 
comprehensive and permanent solution to the problem of illicit drugs. Alternative 
development is thus about providing holistic, legitimate alternatives for people 
whose only livelihood so far has come from the drug business. It is worth noting 
that, until now, alternative development has focused mostly on the growers of opium 
poppy and coca leaf, neglecting the fact that many cannabis plant growers 
throughout the world are in similar situations. Like opioid and cocaine abuse, the 
increasing abuse of cannabis cannot be resolved without also addressing the supply 
side of the equation and that too will require sustained alternative development 
programmes.  
 However, the concept of alternative development needs to be expanded even 
further, beyond the rural communities that cultivate illicit crops. Indeed, it seems 
likely that it is only possible to have a significant effect on the world drug problem 
if alternative development becomes much more inclusive, addressing the needs of 
the many other groups involved in drug abuse. For example, there are many 
communities, in particular in the larger cities of the world, that are so mired in the 
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drug problem that they deserve immediate attention and action. Although those 
communities are not in remote, mountainous areas, they are nonetheless isolated and 
sometimes even more marginalized than the communities where illicit crops are 
grown.  
 The links between drug abuse, deprivation, unemployment and certain types of 
criminal behaviour are well known. None of them, individually or collectively, 
cause drug abuse any more than drug abuse is the sole cause of crime, poverty and 
unemployment. However, the adverse conditions and behaviours often coexist and 
reinforce each other. In such an environment, with a readily available supply of 
drugs, the criminal lifestyle that accompanies drug abuse may be much easier and 
more attractive than legitimate activities. It is proposed therefore that the principles 
of alternative development, in its broadest sense, should be applied in socially 
marginalized urban environments, as well as in the remote rural areas where earlier 
efforts were focused. That will require sustained and comprehensive efforts to tackle 
social deprivation and to develop legitimate alternative occupations and lifestyles. 
 A much broader application of alternative development in both rural and urban 
societies will reap greater dividends than if it is practised in either of those societies 
alone because of the symbiotic nature of the relationship between supply and 
demand. Both rural farmers and socially marginalized city dwellers need and are 
entitled to a legitimate livelihood; renewed efforts should be made to reach both, 
striving to create environments less conducive to the production and abuse of drugs. 
These are not simple solutions; however, the truth is that there are no simple 
solutions in international drug control. 
 
 
 
   Hamid Ghodse 
    President of the International Narcotics Control Board 
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 I. Alternative development and legitimate livelihoods 
 
 
1. Alternative development1 is a drug control 
strategy to reduce or eliminate the illicit supply of 
drugs derived from illicitly cultivated plants. It is a 
concept related to integrated development that has been 
applied in rural areas of developing countries where 
such plants, mainly opium poppy (Papaver 
somniferum) and coca bush (Erythroxylum coca), are 
grown. The decision to cultivate illicit drug crops is the 
product of many complex interacting factors at various 
levels, ranging from the household level to the 
international level, and encompassing both the supply 
of and demand for illicit drugs worldwide. The most 
successful approach to getting growers of illicit drug 
crops to discontinue that activity involves a 
combination of disincentives and incentives. Thus, law 
enforcement and the threat of penalties and/or forced 
eradication, combined with the prospect of legitimate 
alternative livelihood and broad sustainable economic 
assistance, including in the areas of education, health 
care and the development of infrastructure, may be the 
solution. 
2. The international drug control treaties have 
provisions relating to the eradication of illicitly 
cultivated drug crops. Article 14 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 19882 states that parties to 
the Convention may cooperate to increase the 
effectiveness of eradication efforts and that such 
cooperation may include support, when appropriate, 
for integrated rural development leading to 
economically viable alternatives to illicit cultivation. 
Those alternatives will be bolstered if the authorities 
make clear that illicit drug crop cultivation will not be 
tolerated. 
3. In the Political Declaration adopted by the 
General Assembly at its twentieth special session 
(Assembly resolution S-20/2, annex), the Assembly 
reaffirmed the need for a comprehensive approach to 
the elimination of narcotic drugs in line with the 
Action Plan on International Cooperation on the 
Eradication of Illicit Drug Crops and on Alternative 
Development (Assembly resolution S-20/4 E) and 
stressed the special importance of cooperation in 
alternative development. 
4. Since the adoption of the Political Declaration 
and the Action Plan in 1998, the importance of 
alternative development has been emphasized in 
numerous resolutions adopted by the General 
Assembly (resolutions 53/115, 54/132, 55/65, 56/124, 
57/174 and 58/141) and the Commission on Narcotic 
Drugs (resolutions 43/6, 45/14 and 48/9). In its 
resolution 45/14, for example, the Commission called 
on Member States to exploit more fully the potential of 
alternative development as an appropriate means of 
drug control. More recently, in its resolution 48/9, the 
Commission considered that alternative development 
should be regarded by the international community not 
only as a means of reducing illicit drug supply, but also 
as a means of consolidating sustainable development in 
those communities and territories affected by illicit 
crops and as a part of the strategy against poverty 
undertaken by States to fulfil the commitments of the 
United Nations Millennium Declaration (Assembly 
resolution 55/2). Alternative development programmes 
are implemented by Governments of affected countries, 
sometimes with funding and technical support from the 
United Nations Office on Drugs and Crime (UNODC) 
and other members of the international community. 
The goal of those programmes is to reduce and 
eventually eliminate the cultivation of illicit drug 
crops. 
5. The present chapter contains a review of 
experiences in implementing alternative development 
programmes and highlights best practices, models for 
increasing the effectiveness of such programmes. At 
the same time, it takes into account challenges and 
concerns. The chapter also presents an examination of 
whether the concept of alternative development 
requires rethinking and repositioning in order to 
maintain or enhance its relevance as an international 
drug control strategy, in rural as well as urban areas. 
 
 
 A. Background 
 
 
6. Alternative development plays an important part 
in efforts to achieve the global objective of reducing 
and eliminating the availability of narcotic drugs and 
psychotropic substances for illicit, non-medical 
purposes. In part, alternative development is based on a 
simple model of supply and demand in which reducing 
the cultivation of plants such as opium poppy and coca 
bush, which are used to produce narcotic drugs, should 
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lead to a reduction in the availability and subsequent 
abuse of those illicit drugs. However, the existence of 
such a simple interaction between the supply of and 
demand for illicit drugs is increasingly being 
questioned, including by the International Narcotics 
Control Board, most recently in its report for 2004.3 
7. Alternative development has been implemented 
for over 30 years in countries in Asia, in particular in 
Thailand, since 1969, in Turkey since the early 1970s 
and in the Andean countries, in particular Peru, since 
1981. The earliest alternative development efforts were 
initially conceived as crop substitution projects for 
areas where opium poppy was cultivated. In the late 
1980s, the substitution approach to controlling illicit 
crop cultivation became broader, promoting rural 
development in general and providing sustainable 
legitimate livelihoods for those who had been growing 
illicit drug crops. The fulfilment of defined drug 
control objectives remains a priority objective, and 
alternative development has generally been considered 
in conjunction with different law enforcement 
measures, including eradication of illicit drug crops.  
8. The main premise of crop substitution was that 
illicit drug crops could be substituted by legal cash 
crops, which would provide the crop growers with a 
similar or even higher income. It was only in 1994 that 
projects with a less narrow focus began to be planned 
and implemented in coca bush cultivation areas, as 
well as, to a very limited extent, in the cannabis plant 
cultivation areas of the Bekaa valley in Lebanon, 
where eradication efforts had previously taken place. 
Over the years, the previous narrow and mechanical 
approach proved to be less effective than expected. 
9. A truly comprehensive concept of alternative 
development would include not only the cultivation of 
alternative crops, but also the development of 
infrastructure, the provision of a viable means of 
transporting legal products to markets and the 
provision of assistance in the areas of education and 
health care. In addition, alternative development 
programmes are only possible where adequate security 
and stability can be ensured. Unless Governments are 
able to establish their authority and provide a safe 
environment, alternative development has no chance of 
being effective. The international community should 
provide assistance to Governments in their efforts to 
maintain security in areas where alternative 
development is to be introduced.  
10. Alternative development has been implemented 
in countries with very different characteristics, both in 
Asia (for example, in Afghanistan, the Lao People’s 
Democratic Republic, Myanmar, Pakistan, Thailand 
and Viet Nam) and in Latin America (in Bolivia, 
Colombia and Peru). Most of those countries have 
experienced declines in illicit drug crop cultivation.4 
Those declines may be attributed partly to alternative 
development efforts and partly to other factors. In 
several of the countries (Bolivia, the Lao People’s 
Democratic Republic, Pakistan, Peru and Thailand, as 
well as, to a lesser extent, Colombia), growers of illicit 
crops have improved livelihoods with less or no illicit 
crop production. In 2004, the total area under opium 
poppy cultivation in all countries except Afghanistan 
amounted to only 32 per cent of the total in 1994; and 
only 43 per cent of the total area under coca bush 
cultivation in 1995 remained under such cultivation in 
2003.5 
11. Alternative development has generally been 
implemented in areas affected by the cultivation of 
opium poppy and coca bush rather than in areas 
affected by the cultivation of the cannabis plant:6 only 
two donor-supported alternative development projects 
have been implemented in areas affected by cannabis 
plant cultivation—one in the Rif valley in Morocco 
and the other in the Bekaa valley in Lebanon (where 
opium poppy was also being cultivated). Thus, there is 
limited experience with donor-supported alternative 
development programmes in cannabis plant cultivation 
areas.7 There is also limited experience with preventive 
alternative development. 
12. Countries in which opium poppy and coca bush 
are illicitly cultivated have taken action with respect to 
alternative development using their own limited 
resources. For example, they have incorporated 
alternative development in national drug control master 
plans and tried to create a better investment climate in 
areas where drug crops are cultivated. Some countries 
have made significant investments in infrastructure to 
reduce the isolation of illicit drug crop cultivation 
areas from the mainstream of national socio-economic 
development. Some countries, such as Colombia, are 
working to create favourable market conditions for 
products and produce from alternative development 
areas. Overall, however, countries affected by illicit 
drug cultivation on a larger scale must consolidate 
general policy and structural changes in order to reduce 
the size and impact of the illicit drug economy. They 
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cannot do that without the active support of the 
international community. The strategy for alternative 
development in the Andean subregion may constitute a 
framework for ensuring such international support. 
 
 
 B. The difficult context of alternative 
development 
 
 
13. Although occasionally there is “impatience” 
within the international community regarding the 
length of time required to achieve results through 
alternative development programmes, it must be 
stressed that such programmes are implemented under 
the most difficult conditions. A longer time frame is 
required to achieve both drug control and sustainable 
development objectives.8 Difficult conditions are 
present in all of the above-mentioned countries that are 
conducting alternative development programmes. 
Indeed, some of them are post-conflict societies or 
societies that continue to be marred by conflict. The 
conditions or factors that hinder the implementation of 
alternative development are discussed below, together 
with the issue of why a longer time frame is needed for 
alternative development to achieve both sustainable 
development and drug control goals. 
 
  Socio-economic conditions 
 
14. The income derived from illicit drug crop 
cultivation is not always secure. In addition, narcotic 
crop growers are frequently marginalized in terms of 
their relationship to government structures, and women 
and children in particular are often in a vulnerable 
position. Some crop growers do not own the land they 
farm, nor do they have effective civil society 
organizations through which they can negotiate with 
organizations and institutions in the private or public 
sector. They have a low level of empowerment, and 
traditional community-based institutions may be weak; 
thus, the crop growers are more likely to fall under the 
influence of criminal networks. The fact that women in 
that segment of society are often socioculturally and 
economically disadvantaged makes it more difficult to 
mobilize them for alternative development. In South-
East Asia, for example, it is mostly ethnic minority 
groups in the highland areas that have been involved in 
illicit drug crop cultivation. Often, the lack of socio-
economic investment in these communities exacerbates 
their isolation from the mainstream.  
  Geographical and ecological factors 
 
15. In countries in South-East Asia, many of the 
illicit opium poppy cultivation areas are found in 
remote mountainous border areas. That is partly true 
for Afghanistan as well. In Pakistan, areas used for 
opium poppy cultivation are also largely situated in 
remote border areas. Some of the coca bush cultivation 
areas in Latin America are also scattered in remote 
areas and lack adequate infrastructure. 
16. Because of the remoteness of many opium poppy 
and coca bush cultivation areas in hilly or mountainous 
terrain, improvements in infrastructure are expensive 
and private investors are reluctant to make any 
investments in such areas. Moreover, such cultivation 
often takes place in the most ecologically fragile 
forested areas of the countries concerned and/or have 
major importance as watersheds. A considerable 
proportion of them are located in and around national 
parks. That is also true of areas used for the illicit 
cultivation of cannabis plants. Surveys conducted by 
UNODC show that the fragile ecosystem of the Rif 
valley area in Morocco, an important centre for 
cannabis production, is threatened by deforestation and 
soil erosion, caused by continued illicit cultivation of 
cannabis plants. 
17. In the absence of secure land use rights, patterns 
of sustainable land use are unable to develop, thus 
further endangering the tropical and semi-tropical 
ecosystems. The severely degraded soil and the 
ecological fragility of those areas limit the agro-
economic options available to growers of illicit crops. 
 
  Investment and marketing 
 
18. It is difficult to secure investment and to market 
produce in geographical areas that are remote and 
difficult to access; in such areas, farmers are unable to 
sell their products easily, including products intended 
to be “substitutes” for illicit drug crops, such as coffee, 
cacao, rubber, vegetables, fruit, wood, flowers and 
handicrafts. The terms of trade may be unfavourable to 
them, as market prices are determined far from the 
alternative development areas. Market price instability 
(for example, the world prices for coffee and cocoa) 
causes uncertainty among farmers, as it means that 
their livelihood will continue to be vulnerable. At the 
same time, farmers may perceive that marketing 
conditions are better for illicit crops. In many countries 
where illicit crop cultivation takes place, the illicit 
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drug crop markets are better developed and more 
firmly entrenched than the licit crop markets. That 
leaves crop growers even more vulnerable to becoming 
economically dependent on drug traffickers. 
 
  Lack of services 
 
19. There is often an absence of government services, 
especially health, education and agricultural extension 
services, in areas where illicit drug crop cultivation 
flourishes, in particular when those areas are located in 
remote, border and/or conflict-ridden areas of the 
country. Other necessary services, such as banking, 
communication or transport facilities, may also be 
absent. 
 
  Law and order 
 
20. Some illicit crop cultivation areas are 
characterized by various types of conflict and/or lack 
of law and order. In the main coca bush cultivation 
areas in Colombia, for example, despite its many 
efforts, the Government has been unable to maintain a 
level of peace and security that allows people to pursue 
their livelihood without fear. In Africa, Asia and Latin 
America, money obtained from the sale of illicit drugs 
has been used to purchase weapons and to support war 
and rebellion. People living in such areas may have 
little direct experience with the State except for the 
military or law enforcement authorities. That may 
result in a lack of trust between the people and the 
local government, making it even more difficult to 
develop the necessary partnerships between civil 
society organizations and government and to provide 
services and/or encourage investment in such areas. 
21. As a result of the above-mentioned factors, 
growers of illicit crops may fall under the influence of 
armed groups who use the proceeds of drug trafficking 
to support their activities against the State. Illicit crop 
growers may also have closer ties to armed groups, 
drug traffickers and other criminal organizations than 
to government organizations and may even perceive 
those ties as being beneficial. Moreover, many 
developing, transitional and post-conflict societies lack 
a well-functioning legal system, which is fundamental 
to drug control efforts.9 
 
 
 C. Principles of alternative development 
 
 
22. Best practices in socio-economic development 
normally refer to practices followed in the course of a 
project or programme that have led to a successful 
outcome, to solutions to certain problems and to a 
positive impact that is sustainable. Best practices in 
alternative development are closely related to sound 
principles of development. They explicitly include 
gender and poverty considerations.10 However, the 
conditions required for best practices to develop and 
flourish are often not available in alternative 
development projects, particularly if the projects are 
being implemented under the difficult conditions 
outlined above. If sustainable drug control is to be 
successful at the community or farm level, it will need 
the proper conditions, including political stability, 
security and good governance. 
23. The principles described below relate to 
alternative development in the context of households 
that would be included as target groups under national 
poverty reduction strategies; the proceeds from 
cultivation of illicit drug crops account for a significant 
part of the income of such households. The principles 
do not refer to smaller groups of “opportunistic” 
growers of illicit drug crops, who have not previously 
been dependent on such crops for their livelihood, or to 
“plantation” growers. Given the specificities of each 
area, there is no manual or definitive guidelines for 
alternative development. However, concrete measures 
for building capacity and awareness on the part of 
government and civil society institutions (including 
non-governmental organizations) are urgently required 
to implement the principles. The principles are as 
follows: 
 (a) Political will, funding and long-term 
commitment are required of all stakeholders, including 
national and local governments, the local population 
and the international community; 
 (b) Alternative development should be 
consistent with sustainable development policies, 
strategies and practice in the affected communities; 
 (c) The design of alternative development 
programmes must take into account both the 
complexity of livelihoods based on the cultivation of 
opium poppy, coca bush and cannabis plant and the 
role that those crops play in growers’ lives. Thus, the 
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issues of governance, the environment, human and 
social capital and sustainable development must be 
used as the basis for a comprehensive, sustainable 
approach to alternative development; 
 (d) The full participation of the crop growers, 
their families and the community is necessary in 
designing, implementing, monitoring and evaluating 
alternative development strategies. That participatory 
approach must be complemented by collective and 
collaborative initiatives, allowing large-scale projects 
to be implemented; 
 (e) Law enforcement must accompany 
alternative development programmes. Law 
enforcement efforts should be sensitive to the crop 
growers’ living conditions and should involve a variety 
of measures, including measures that create 
disincentives to discourage growers from cultivating 
illicit crops. Trust in law enforcement must be 
increased, including through vigorous efforts to fight 
corruption;11 
 (f) Law enforcement measures in illicit crop 
cultivation areas should focus on the drug trafficking 
and criminal organizations and their armed networks, 
which are often the impetus behind growers’ decisions 
to cultivate illicit crops. Disrupting the operations of 
drug trafficking organizations cuts the supply chain 
and excludes the buyers of the illicit crops; as a result, 
illicit drug crops cease to be a source of income for 
growers and, consequently, eradication can be more 
easily implemented; 
 (g) Measures for drug abuse prevention, 
education and treatment should be integrated into 
alternative development programmes, as the higher 
exposure of families to drugs in illicit crop cultivation 
areas, combined with other factors such as 
vulnerability, hopelessness and disempowerment, may 
put them at higher risk of drug abuse and addiction; 
 (h) Alternative development must be integrated 
into all general development and investment efforts at 
the local, national and international levels to optimize 
efforts to diminish the illicit drug economy and thus 
becomes a cross-cutting issue.12 
24. When implementing alternative development 
projects and programmes, both Governments and 
international donors are understandably eager to 
achieve the maximum possible reduction in the area 
under illicit drug crop cultivation within the shortest 
possible time frame. Too little recognition, however, 
has been given to the conditions supporting alternative 
development, which are required for best practices to 
lead to “best results”. If those conditions, which arise 
from the policy and funding, the marketing or the law 
and order/security contexts, are absent, alternative 
development programmes are bound to have limited 
results. When the expectations of Governments and 
donors are unrealistic, it can be counterproductive and 
lead to unintended results, such as a sudden lack of 
alternative sources of income for the people concerned. 
Parallel efforts, involving law enforcement and 
eradication on the one hand and the provision of 
legitimate alternative livelihood on the other, are 
necessary. 
 
 
 D. The alternative development balance 
sheet 
 
 
  Achievements  
 
25. Alternative development has contributed to a 
reduction in areas cultivated with illicit drug crops. A 
development-oriented approach has improved the 
livelihood of crop growers while leading, in some 
cases, to sustained reductions in illicit drug crop 
cultivation. A consistent development-oriented 
approach, such as that which has been practised in 
Thailand, can achieve good results in terms of 
significant illicit drug crop reductions. In Thailand, the 
total area under opium poppy cultivation amounted to 
17,900 hectares in the crop year 1965/66, whereas in 
2000 it had been reduced to only 330 hectares—a 
reduction of 98 per cent.13 There is also evidence in 
other countries that a consistent development-oriented 
approach can have good results. In the Lao People’s 
Democratic Republic, for example, the total area under 
opium poppy cultivation dropped by 75 per cent, from 
about 26,000 hectares in 1998 to only 6,600 hectares in 
2004.14 In Colombia, the total area under illicit coca 
bush cultivation decreased by one half, from 
163,000 hectares in 2000 to 80,000 in 2004; and in 
Peru, the total area under such cultivation declined 
from about 115,000 hectares in 1995 to 44,200 in 
2003—a reduction of 62 per cent.15 While not all of 
the above-mentioned declines may be attributed to 
alternative development, it has made a significant 
contribution.  
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26. Experiences with alternative development also 
indicate that long-term commitments are required and 
that the conditions supporting socio-economic 
development must be firmly in place. 
 
  Challenges and concerns 
 
27. Although alternative development programmes 
provide initial assistance to crop growers, the problem 
of long-term sustainability of secure livelihoods may 
remain. The licit crops that growers may choose to 
cultivate for the market (for example, coffee) are 
subject to the price fluctuations or other market 
uncertainties associated with many agricultural 
products. Alternative development programmes have 
also been faulted for promoting products that had no 
viable markets to begin with. Owing to changes in the 
structure of international tariffs and trade, markets for 
products from alternative development areas may not 
remain open or may become subject to insurmountable 
competition. Despite repeated calls by the international 
community, including by the General Assembly, for 
improved market access for the products of alternative 
development programmes, difficulties in strengthening 
the licit economy via legitimate marketing channels 
remain.16 
28. One issue often overlooked is the need for 
providing adequate facilities for providing credit—
perhaps microcredit as part of alternative development 
programmes—for illicit crop growers. Currently, 
legitimate credit facilities are often not available to 
illicit crop growers. As a result, growers who have 
given up cultivating illicit crops but whose livelihood 
is not secure are more likely to return to cultivating 
such crops. 
29. One related issue is that of creating a balance 
between development efforts and law enforcement 
measures in illicit crop cultivation areas. How should 
that balance be achieved so that a majority of crop 
growers do not end up being worse off, as that would 
increase the possibility of them being lured back to 
cultivating illicit crops? Through what mechanisms 
can, for example, development and law enforcement 
officials cooperate with crop growers’ representatives 
in peace and security? Law enforcement officers in 
alternative development areas require special training 
to ensure that they are involved with the communities 
in a positive manner, so that they are not seen as acting 
against the well being of the people in those 
communities. 
30. To date, alternative development has been 
implemented largely in the context of individual rural 
development projects and/or programmes in isolated 
areas. This predominance of project-by-project 
implementation does not provide adequate 
opportunities for alternative development to have an 
impact on drug control on a larger scale or on 
conditions related to drug control. The vast majority of 
illicit crop growers, particularly the large number of 
cannabis plant growers in developing countries, have 
unfortunately never received direct alternative 
development assistance.17 It is also unrealistic to 
believe that this majority could ever be reached 
through individual projects. The “project-by-project” 
approach has made it more difficult to bring alternative 
development into the mainstream of general 
development policies and programmes because the 
attention of both governments and donors has been 
focused on individual or pilot projects rather than on 
the need for change in overall policies and 
programmes. Moreover, such geographically limited 
projects rarely provide adequate scope for the 
integration of development and law enforcement 
measures. 
31. Although the Commission on Narcotic Drugs has 
made numerous calls for preventive alternative 
development, no country has yet implemented such 
programmes, despite the fact that, in areas where there 
is a high level of poverty, there is often a high risk of 
illicit crop cultivation. Preventive alternative 
development will provide valuable lessons in 
understanding the mechanisms and dynamics involved 
in preventing an illicit drug economy from being 
established. 
32. Another concern, one that has become virtually 
inseparable from illicit crop cultivation, is the 
environment, which is an especially serious problem in 
coca producing areas. It is estimated that more than 
88,000 hectares of coca bush were cultivated in the 
Amazon in 2004, affecting important rainforest and 
natural ecosystems and having serious implications for 
the global environment. In addition, the initial 
processes for cocaine manufacture may also be taking 
place close to where the coca itself is harvested, 
resulting in dangerous chemical waste. It has been 
estimated that hundreds of thousands of tons of 
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chemicals are used annually for cocaine manufacture in 
the Andean subregion.18 Chemical residues tend to be 
dumped into the rivers and streams of already fragile 
ecosystems. 
33. Regrettably, there are virtually no alternative 
development projects or programmes in Africa, despite 
the large amount of cannabis produced in that region. 
Likewise, cannabis production and drug abuse do not 
receive sufficient attention in poverty reduction 
strategies prepared by African countries. While most 
countries in Africa produce cannabis, there are some 
17 countries that produce it in significant quantities. In 
its report for 2003, the Board noted that food shortages 
in sub-Saharan Africa were being exacerbated by the 
increasing cultivation of cannabis plant.19 In some 
member States of the Southern African Development 
Community (SADC), for example, maize cultivation 
has been given up in favour of cannabis plant 
cultivation. African women are particularly 
disadvantaged in that, while they are primarily 
responsible for food grain production, it is their fields 
that are being taken over by men for the cultivation of 
illicit crops as cash crops. 
34. The gender issue must be given higher 
prominence in alternative development programmes—
and in drug control in general—than it has been given 
to date. In more traditional agricultural communities 
throughout the world, women are responsible for many 
farming operations. In other words, without women’s 
active involvement in different parts of the farming 
process, illicit crop cultivation in some areas might not 
be possible. Though women may also be against illicit 
crop cultivation because it increases the risk of their 
own family members becoming drug abusers or 
addicts, women are often not in a position to influence 
decisions concerning their families.  
 
 
 E. Complex and changing drug scenarios: 
the need to reduce illicit drug demand 
 
 
35. The structure of drug problems has changed 
markedly over the centuries; in the past 50 years, there 
have been significant changes in terms of the drugs 
abused, the methods of abuse, the age of drug abusers, 
the location of the drug abuse, the size and 
sophistication of drug trafficking networks etc. 
Distinctions that were once made between developed 
consumer countries and developing producer countries 
are no longer relevant. In addition, at the microlevel, 
there is a certain inelasticity of demand among 
established addicts, which means that the view that 
“reduced illicit drug production equals higher drug 
prices, which equal lower drug demand” may not hold 
true. Although addicts may be more likely to seek 
treatment when drug prices rise, appropriate treatment 
facilities may be lacking, particularly in developing 
countries. Therefore, pursuing alternative development 
to reduce illicit drug supply without introducing 
prevention and treatment programmes for drug abusers 
is counterproductive. As the Board pointed out in its 
report for 2004,20 there must be a thorough integration 
of supply and demand strategies, analyses and 
programmes. 
36. Drug demand and supply change all the time. 
Those changes include the pricing and marketing of 
plant-derived drugs such as heroin and cocaine, 
synthetic opioids, and synthetic drugs, including 
various amphetamine-type stimulants. Some of those 
drugs have legitimate uses as pharmaceuticals, creating 
complex interactions between the licit and illicit drug 
markets. There are many factors that interact to result 
in different drug abuse scenarios with different 
outcomes. For example, reductions in illicit drug 
supply have at times resulted in increases in street-
level prices and the desired reduction in illicit drug 
demand. At other times, however, drug traffickers have 
been able to adjust the purity of drugs at the street 
level to keep prices constant and retain their “market 
share”. In both cases, the outcomes may not last long, 
which further indicates the necessity of making a long-
term commitment to the provision of legitimate 
alternative livelihoods. 
37. Although reduced drug crop production assists in 
weakening illicit drug availability in certain areas, the 
overall demand for illicit drugs remains.21 This 
demand may be met from the illicit supply of synthetic 
drugs. In Thailand, which has successfully reduced 
opium production, there has been an upsurge of 
amphetamine-type stimulants: people who had 
previously been involved in opium trafficking 
networks are now trafficking in amphetamine-type 
stimulants. More preventive alternative development 
efforts, in both urban and rural areas, would have made 
a difference. 
38. The case of Thailand shows clearly that society 
should not reduce its commitment to drug abuse 
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prevention, education or treatment programmes merely 
because there have been reductions in the supply of 
certain drugs such as opium and heroin. Throughout 
East and South-East Asia, with the changing illicit drug 
market patterns, many drug abusers have switched 
from smoking opium to injecting heroin, thereby 
significantly increasing the risk of blood-borne 
infection. While reduction of the supply of any illicit 
drug is a highly desirable goal, adequate prevention, 
education and treatment programmes are also 
necessary to ensure an overall and long-lasting 
reduction of drug abuse. 
39. The necessity of ensuring that alternative 
development programmes—and programmes aimed at 
sustainable development in general—take adequate 
account of HIV/AIDS issues is often overlooked. That 
is partially because drug abuse, which has, in some 
cases, contributed to the spread of HIV/AIDS, is often 
perceived only as an urban phenomenon. However, 
given the fact that there is usually an increase in drug 
abuse along major drug trafficking routes and near 
major drug-producing areas, drug demand reduction 
and HIV/AIDS prevention programmes should be 
integrated into alternative development programmes 
whenever possible.  
 
 
 F. Future direction of alternative 
development 
 
 
40. Given the complexities of the global drug 
situation, the time has come to ask whether the current 
perception of alternative development is adequate to 
meet new challenges. Perhaps the first issue that needs 
to be addressed is the lines of distinction that continue 
to be drawn between drug supply and demand. In its 
report for 2004, the Board examined the relationship 
and interaction between the supply of and demand for 
illicit drugs and the synergistic impact of 
complementary efforts; it also emphasized the need to 
utilize balanced, combined and integrated approaches 
to drug control at all levels for maximum 
effectiveness.22 It is questionable whether alternative 
development should continue to be seen almost solely 
in terms of supply reduction, as defined in 1998 by the 
General Assembly at its twentieth special session 
(Assembly resolution S-20/4 E). If a more 
comprehensive definition is to be considered, it would 
also be important to take a closer look at rural, peri-
urban and urban communities in terms of their 
development-oriented drug control needs. Like the 
challenges facing those involved in reducing illicit 
drug supply and demand, the challenges facing those 
communities should be seen as a continuum whose 
different parts are strongly interlinked. Poverty, despair 
and lack of prospects are some of the reasons why 
people have become involved in drug abuse and other 
drug-related activity. Most importantly, the 
geographical scope of development-oriented drug 
control would be much broader than that of alternative 
development, which is currently limited to only part of 
the world’s illicit crop cultivation areas. 
41. The alternative development projects that have 
been implemented to date do not have links at the 
micro- or macrolevel and at the regional and global 
levels, which would increase their effectiveness. To 
rectify this, alternative development should be taken 
out of the confines of the “project-by-project” 
approach and be seen as a cross-cutting issue, 
involving a multitude of players at the local, national 
and international levels. What is needed in areas more 
seriously affected by drug problems and in countries 
dominated by the illicit drug economy are overall 
development approaches that take such problems more 
fully into account. In other words, there is a need to 
follow overall development approaches that fully 
integrate into the mainstream the principles and 
practices of alternative development, including 
coordination with law enforcement agencies, whether 
in a rural or an urban context. 
42. Alternative development programmes are more 
effective as an integrated part of a comprehensive and 
sustained national development programme, aimed at 
raising the economic and social well-being of the entire 
population. The issue of illicit drug crops has been 
mentioned in the poverty reduction strategy papers for 
Bolivia, as well as for the Lao People’s Democratic 
Republic (which has made efforts to address problems 
related to addiction to opium and amphetamine-type 
stimulants).23 
43. With the integration of drug supply and demand, 
the boundaries of alternative development need to be 
redefined in terms of “alternative livelihoods”. In more 
recently planned programmes, the focus has been on 
alternative livelihoods as, with the inherent 
understanding of the interactions from household to 
policy levels, this concept is broader than alternative 
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development and lends itself better to mainstreaming. 
The newly adopted drug control strategy of 
Afghanistan, for example, includes alternative 
livelihoods as one of the main areas for intervention. 
Bolivia, Colombia, Ecuador, Peru and Venezuela 
(Bolivarian Republic of), have recently adopted a plan 
for sustainable alternative livelihoods as part of a 
regional approach to combating illicit crop cultivation. 
44. Legitimate alternative livelihoods should be 
considered not only in rural areas where illicit drug 
crops are cultivated, but also in areas, both rural and 
urban, where illicit drugs are abused. In many cases, 
producers and local communities no longer have the 
traditional structure for assisting producers and abusers 
of illicit drugs in coping with socio-economic 
problems. In particular, illicit drug users are often 
marginalized, living under difficult circumstances such 
as in the slums of large cities, and may require special 
development efforts to overcome their problems. 
Members of marginalized communities in urban areas 
may also be forced by violent gangs into drug dealing 
at the street level. The street-level dealers themselves 
are often addicts, requiring access to prevention, 
education and treatment programmes. In such 
situations, there may be almost no opportunities for 
earning legitimate income. In such cases, well-defined 
policies—including input from the affected groups—
are needed to help reduce drug problems, including 
drug-related crime. 
45. In today’s globalized society, donor countries can 
no longer afford to pay attention only to drug abusers 
on their own territory. If demand does indeed influence 
supply, then local demand (in countries where illicit 
drugs are produced) as well as international demand, 
may also influence drug production. The implication 
for the international community is that it is not enough 
for alternative development or development-oriented 
drug control to be seen in the framework of only 
limited circles of supply and demand within a single 
country or region. 
46. Bearing in mind the goals set in the Political 
Declaration adopted by the General Assembly at its 
twentieth special session, it is doubtful that alternative 
development can be effective if it is conceived as only 
being relevant mainly at the individual and community 
levels. As mentioned above, there are many national 
and international factors that play a role in local 
economies, including illicit drug economies. It is 
necessary to look at international terms of trade, for 
example. Are adequate concessions made to the 
growers of alternative crops to ensure that their 
produce receives a fair price? Are international markets 
open enough to allow unhindered access of alternative 
development crops and products? The Commission on 
Narcotic Drugs, in its resolution 45/14, reiterated the 
necessity to encourage access to international markets 
for products and produce from alternative development 
areas. In its resolution 2003/37 of 22 July 2003, the 
Economic and Social Council called upon the 
international community and Member States to 
promote an economic environment favourable to 
products from alternative development and facilitating 
the access of such products to international markets as 
an effective and efficient means of eliminating the 
illicit economy. Are domestic markets established in a 
such a way as to give advantages to produce and 
products from alternative development areas? Given 
the strength of illicit market mechanisms, it is of 
crucial importance to ensure that licit market 
mechanisms are made as favourable as possible to 
produce and products from alternative development 
areas. The private sector has an important role to play 
in this regard, through opening markets to products 
made as part of the implementation of alternative 
development programmes.  
 
 
 G. Conclusion and recommendations 
 
 
47. Alternative development as conceived and 
practised over the past 15-20 years has, in some case, 
played a role in achieving a reduction of illicit 
cultivation of opium poppy, and, to a lesser extent, 
coca bush, while at the same time bearing in mind 
humanitarian considerations vis-à-vis the crop growers.  
48. In addition, there is increasing recognition that 
the focus of alternative development, as it has 
generally been practised, needs to be broadened, 
paying greater attention to the needs of marginalized 
and neglected populations in both rural and urban 
areas. Governments, international organizations and 
the other parties concerned need to ensure that the 
relevant communities—not just communities growing 
illicit drug crops but all communities affected by the 
illicit drug economy—are provided with legitimate 
livelihoods that are both viable and sustainable in the 
long term. This includes programmes of economic and 
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social policy that will generate and promote lawful, 
sustainable socio-economic options for the 
communities and populations that have engaged in 
illicit drug activities, as well as measures of security 
created by effective, community-oriented law 
enforcement. 
49. In order to assist Governments in meeting the 
goals set for 2008 in the Political Declaration adopted 
by the General Assembly at its twentieth special 
session, the Board recommends the following: 
 (a) Governments and regional bodies should 
make more comprehensive analyses of the dynamics of 
the illicit drug economy in both individual countries 
and regions, in order to understand the impact it has on 
different aspects of the local economy and to ensure 
that each alternative livelihood strategy is suited to the 
area concerned. Governments should enhance joint 
strategies to strengthen alternative development 
programmes, including by providing training, 
education and technical assistance, with the aim of 
eliminating illicit crop cultivation and fostering 
economic and social development; 
 (b) Governments, the United Nations and other 
organizations of the United Nations system, including 
the World Bank and the International Monetary Fund, 
should integrate alternative development into their 
broader development programmes. The current 
“project-by-project” approach to alternative 
development should be changed, with commitment 
being made towards long-term strategies for the 
provision of legitimate alternative livelihoods. For 
example, cannabis-producing countries in sub-Saharan 
Africa should include the issue of cannabis plant 
cultivation in future revisions of their poverty 
reduction strategies;  
 (c) Governments should formulate their 
domestic and international trade policies, in particular 
policies regarding access to markets for products and 
services from alternative development areas, with a 
view to helping to reduce the illicit drug economy, 
wherever it exists;  
 (d) Governments and civic bodies should 
increase their alertness and anticipate changes in drug 
abuse and drug trafficking patterns, in order to 
maintain a proactive stance on strategies for providing 
legitimate livelihoods; 
 (e) Governments should ensure that law 
enforcement activities in illicit crop cultivation areas 
contribute to the building of trust between the local 
communities and the authorities and should promote 
the greater involvement of communities in the 
formulation of policies to deal with the various aspects 
of the drug problem. In order to be effective, law 
enforcement should be considered a supportive factor 
in the context of overall socio-economic development. 
Governments should be called upon to ensure that law 
enforcement officials who work with communities 
affected by the illicit drug economy are sufficiently 
trained in the principles of alternative development. 
Illicit crop eradication programmes and programmes 
for the provision of legitimate alternative livelihoods 
must be conducted simultaneously to ensure synergy;  
 (f) As part of alternative development 
strategies, Governments should ensure that adequate 
public services, such as schooling, health care and 
basic infrastructure, are provided to local communities. 
In rural areas, the farming population should be 
assisted and protected in the areas of land security and 
sustainable land development; 
 (g) Governments should promote the greater 
involvement of local women and men, as well as non-
governmental organizations and other members of civil 
society, in developing and proposing solutions to the 
different aspects of the drug problem affecting their 
daily lives; 
 (h) Governments and other members of the 
international community should consider more 
supportive national and/or international policy changes 
to help reduce the illicit drug economy wherever it may 
exist. This especially includes domestic and 
international trade policy and openness of markets to 
products and services from alternative development 
areas; 
 (i) Governments and other members of the 
international community should consider the fact that, 
since illicit crop production areas generally represent 
marginalized areas, more efforts are required to 
develop them. That development may be under a 
programme for providing alternative livelihoods or 
under a programme for promoting socio-economic 
development and achieving the Millennium 
Development Goals; 
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 (j)  Governments should identify population 
groups that are vulnerable to drug abuse wherever they 
may be and determine which policy and development 
measures would be most beneficial to them in 
providing legitimate livelihoods; 
 (k) Governments and other relevant 
institutions, including intergovernmental organizations, 
should share and disseminate their experiences with 
alternative development, ensuring the involvement of 
both local communities and academic and research 
institutions in that process, with a view to expanding 
the knowledge base of alternative development 
programmes; 
 (l)  In keeping with the Board’s 
recommendations of 2004, Governments and other 
members of the international community should move 
away from the traditional separation of “supply and 
demand” in terms of defining drug problems and their 
solutions and ensure their integration at all levels, 
including in the context of alternative development. 
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 II. Operation of the international drug control system 
 
 
 A. Narcotic drugs 
 
 
  Status of adherence to the Single Convention on 
Narcotic Drugs of 1961 
 
50. On 1 November 2005, the number of States 
parties to the Single Convention on Narcotic Drugs of 
1961,24 or to that Convention as amended by the 
1972 Protocol,25 stood at 183; 180 of those States were 
parties to that Convention as amended by the 
1972 Protocol.24 Since the publication of the report of 
the Board for 2004, Angola, Bhutan and Cambodia 
have become parties to the 1961 Convention as 
amended by the 1972 Protocol and Nicaragua has 
become a party to the 1972 Protocol amending the 
1961 Convention.26 Afghanistan, Chad and the 
Lao People’s Democratic Republic continue to be 
parties to the 1961 Convention in its unamended form 
only. 
51. A total of nine States have not yet become parties 
to the 1961 Convention: one State in Africa (Equatorial 
Guinea), two in Asia (the Democratic People’s 
Republic of Korea and Timor-Leste), one in Europe 
(Andorra) and five in Oceania (Kiribati, Nauru, Samoa, 
Tuvalu and Vanuatu). 
 
  Cooperation with Governments 
 
  Submission of annual and quarterly statistics on 
narcotic drugs 
 
52. The majority of States regularly submit the 
mandatory annual and quarterly statistical reports. By 
1 November 2005, a total of 171 States and territories 
had submitted to the Board annual statistics on narcotic 
drugs for 2004, in conformity with the provisions of 
article 20 of the 1961 Convention. That accounts for 
81 per cent of the 210 States and territories required to 
furnish such statistics. A total of 188 States and 
territories provided quarterly statistics of imports and 
exports of narcotic drugs for 2004; that figure 
represents 90 per cent of the 210 States and territories 
requested to furnish those data. The rate of submission 
was similar to that of the previous year. 
53. The Board urges all Governments to furnish in a 
timely manner all statistical reports required under the 
1961 Convention. In 2005, the Board noted an 
improvement in the furnishing of statistical data by 
Cameroon, Côte d’Ivoire, Ghana, Pakistan, Romania, 
the Russian Federation, Uruguay and Zimbabwe. In 
addition, after not furnishing annual statistical reports 
for several years, Bosnia and Herzegovina, Guinea, 
Micronesia (Federated States of) and Nauru resumed 
the submission of those reports. The Board will 
continue to monitor the situation closely in countries 
whose Governments do not regularly submit the 
required reports. The Board is ready to assist 
Governments with a view to facilitating their 
compliance with their obligations under the 
1961 Convention. 
54. Parties to the 1961 Convention are obliged to 
submit annual statistical reports on narcotic drugs to 
the Board not later than on 30 June following the year 
to which they relate. The Board continues to be 
concerned that several States, including some that are 
major manufacturers, importers, exporters or users of 
narcotic drugs, did not comply with that requirement in 
2005. The late submission of reports makes it difficult 
for the Board to monitor the manufacture of, trade in 
and consumption of narcotic drugs and hampers the 
Board’s analysis. The Board urges all States that 
experience difficulties in complying in a timely manner 
with their reporting obligations to take all measures 
necessary to ensure the observance of the deadline set 
in the 1961 Convention for the submission of annual 
reports. 
 
  Estimates of requirements for narcotic drugs 
 
55. The Board wishes to remind all Governments that 
the universal application of the system of estimates is 
indispensable for the functioning of the control system 
for narcotic drugs. Lack of adequate national estimates 
is often an indication of deficiencies in the national 
control mechanism and/or health system of a country. 
Without proper monitoring and knowledge of the 
actual requirements for narcotic drugs, there is a risk, 
if estimates are too low, that narcotic drugs available 
for medical treatment may be insufficient. If estimates 
are too high, there is a risk that drugs traded in a 
country may be in excess of medical needs and may be 
diverted into illicit channels or used inappropriately. A 
well-functioning health and regulatory system is 
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necessary to assess the actual requirements of narcotic 
drugs in every country. 
56. By 1 November 2005, a total of 168 States and 
territories had furnished their annual estimates of 
narcotic drug requirements for 2006. That number, 
which represents 80 per cent of the total of 210 States 
and territories required to furnish such estimates, is 
slightly lower than the number of States and territories 
that had provided, by 1 November 2004, estimates for 
2005. The Board is concerned that several States and 
territories failed to provide their estimates in time for 
examination by it, in spite of being reminded to do so. 
The Board had to establish estimates for those States 
and territories in accordance with article 12, 
paragraph 3, of the 1961 Convention. 
57. The estimates established by the Board are based 
on the estimates and statistics furnished in the past by 
the respective Governments. In some cases, when such 
statistics and estimates had not been received for 
several years, the estimates were lowered considerably 
in order to reduce the risk of diversion. As a result, the 
States and territories concerned may experience 
difficulties in importing in a timely manner the 
quantities of narcotic drugs required to meet their 
medical needs. The Board urges the Governments 
concerned to take all the necessary measures to 
establish their own estimates of narcotic drug 
requirements and to furnish those estimates to the 
Board as soon as possible. The Board is ready to assist 
those Governments by providing clarifications on the 
provisions of the 1961 Convention relating to the 
system of estimates. 
58. The Board examines the estimates received, 
including supplementary estimates, with a view to 
limiting the use of narcotic drugs to the amount 
required for medical and scientific purposes and to 
ensuring adequate availability of those drugs for such 
purposes. The Board contacted several Governments 
prior to confirming estimates for 2006, since those 
estimates, according to information available, appeared 
to be inadequate. The Board is pleased to note that, in 
2005, as in previous years, most Governments 
provided explanations promptly or corrected their 
estimates.  
59. The Board notes that the number of 
supplementary estimates furnished by Governments in 
accordance with article 19, paragraph 3, of the 
1961 Convention increased in 2005. A total of 432 
supplementary estimates had been received by 1 
November 2005, compared with fewer than 250 in 
2001. The Board reiterates its request to Governments 
to calculate their annual medical requirements as 
accurately as possible so that it will be necessary to 
submit supplementary estimates only in cases of 
unforeseen circumstances.  
 
  Shortcomings in reporting estimates and statistics 
of narcotic drugs 
 
60. The Board examines the statistical data and 
estimates submitted by Governments and contacts the 
competent authorities, as necessary, in order to clarify 
inconsistencies identified in their reports that may 
indicate shortcomings in national control systems 
and/or the diversion of drugs into illicit channels. The 
Board is concerned that some Governments continue to 
experience difficulties in providing complete statistical 
reports and estimates because of deficiencies in their 
national monitoring and reporting systems. The Board 
urges all Governments concerned to strengthen their 
domestic monitoring and reporting systems to ensure 
accurate reporting to the Board. 
61. In order to help Governments to overcome 
difficulties in reporting, the Board posted on its 
website explanations of the reporting requirements for 
narcotic drugs, including a list of the most frequent 
problems identified in the estimates and statistical data 
submitted in the past. Governments are invited to use 
those explanations, or contact the Board for further 
clarification, if they experience problems in reporting 
on narcotic drugs. 
 
  Modifications to the Board’s technical report on 
narcotic drugs 
 
62. Every year, the Board publishes a technical report 
on narcotic drugs.27 The report is used for control 
purposes by Governments and serves the needs of 
researchers, enterprises and the general public. The 
data in the report are based on information furnished 
by Governments to the Board in accordance with the 
relevant provisions of the 1961 Convention. In 2004 
and 2005, the Board carried out a survey to assess the 
needs of users of its technical reports on narcotic drugs 
and psychotropic substances. Information from users 
was obtained, inter alia, by means of a questionnaire 
sent to the competent authorities of all States and 
territories, selected pharmaceutical companies and 
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other users, including international organizations and 
associations of professionals.  
63. Based on the information gathered through the 
survey, the Board decided to make some modifications 
to the technical report on narcotic drugs. The notes on 
the use of various sections and tables were amended to 
provide more detailed explanations on the information 
contained in the publication. Three additional tables 
were included in the report, in view of the new 
developments in the manufacture and use of opiate raw 
materials. The table on world trade was redesigned to 
reflect three-year data series. 
 
  Prevention of diversion into the illicit traffic 
 
  Diversion from international trade 
 
64. In 2005, as in recent years, no cases involving 
diversion of narcotic drugs from licit international 
trade into the illicit traffic were detected, in spite of the 
very large quantities of substances and the large 
number of transactions involved. The system of control 
measures laid down in the 1961 Convention provides 
effective protection of international trade in narcotic 
drugs against attempts at their diversion into illicit 
channels.  
65. Effective prevention of the diversion of narcotic 
drugs from international trade requires the 
implementation by Governments, in cooperation with 
the Board, of all control measures for those drugs, as 
provided for in the 1961 Convention. While most 
Governments are fully implementing the system of 
estimates and the import and export authorization 
system, in 2004 and 2005 a few Governments 
authorized exports of narcotic drugs from their 
countries in excess of the corresponding total of the 
estimates of the respective importing countries. The 
Board reminds the Governments concerned that such 
exports are contrary to the provisions of article 31 of 
the 1961 Convention and could result in the diversion 
of narcotic drugs into illicit channels if falsified import 
authorizations are used by drug traffickers. The Board 
has urged the Governments in question to ensure 
compliance with the provisions of article 31 of the 
1961 Convention when authorizing exports of narcotic 
drugs in the future. The Board advised the 
Governments concerned to consult the annual estimates 
of requirements for narcotic drugs for each importing 
country and territory, which are published by the Board 
in its technical report on narcotic drugs, as well as the 
monthly updates of the list of estimates. 
 
  Diversion from domestic distribution channels  
 
66. Contrary to international trade, the diversion of 
pharmaceutical preparations containing narcotic drugs 
from domestic distribution channels and the abuse of 
those preparations have continued in many countries. 
The Board included in its report for 2004 information 
obtained by means of a questionnaire, sent to the 
Governments of selected countries, on the diversion 
and abuse of such preparations and on action taken to 
counter such activities.28 During 2005, a few 
additional Governments replied to that questionnaire; 
some of the information provided is summarized 
below.  
67. The diversion and abuse of pethidine continue to 
pose problems in several countries, as confirmed by 
reports in Bangladesh, China, Uganda and Zimbabwe. 
In those countries, pethidine was stolen from 
pharmacies or hospitals or abuse of prescriptions for 
pethidine was facilitated by medical or related 
professionals. In China, stricter controls for dispensing 
and administering drugs in hospitals have been applied 
with a view to preventing such diversions.  
68. In several countries, the diversion and abuse of 
narcotic drugs involve preparations for which certain 
control measures (such as a prescription requirement) 
are not mandatory under the 1961 Convention. In 
China, where cases involving the diversion and abuse 
of cough syrups containing codeine have been 
detected, a prescription requirement for those 
preparations has been introduced to counter such illicit 
activities. In India, the Government has established 
additional control measures for such preparations 
containing codeine and dextropropoxyphene; the 
measures include reducing the amount of the active 
ingredient in such preparations and introducing a quota 
system for their distribution. 
69. The Board welcomes the action taken by 
Governments to prevent the diversion and abuse of 
narcotic drugs in the form of pharmaceutical 
preparations. At the same time, the Board is concerned 
that the Governments of some countries in which 
problems with the diversion of pharmaceutical 
preparations containing narcotic drugs were identified 
in the past, such as Egypt and Pakistan, have not 
replied to the above-mentioned questionnaire. The 
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Board urges the Governments concerned to establish a 
mechanism for collecting information on the problem, 
so that, if necessary, measures against such diversion 
and abuse can be taken promptly.  
70. The diversion of pharmaceutical preparations 
containing narcotic drugs from domestic distribution 
channels and the abuse of such preparations continue 
to pose problems in several other countries where the 
availability of those products for legitimate medical 
purposes has increased (see paras. 102-103). 
71. In Australia, a nationwide survey undertaken in 
2004 by the Australian Institute of Health and Welfare 
indicated that the extent of abuse of opioid analgesics 
was similar to that of methylenedioxymeth-
amphetamine (MDMA, commonly known as Ecstasy) 
and other amphetamines. Opioid analgesics are 
considered twice as easy to obtain as cannabis and 
easier to obtain for abuse than tranquillizers. About 3.1 
per cent of the population aged 14 years and over 
reported recent abuse of such drugs. Eight per cent of 
the population aged 14 years and over considered the 
non-medical use of opioid painkillers to be acceptable. 
The Board trusts that, based on the survey, the 
Government of Australia will implement measures to 
prevent the diversion and abuse of pharmaceutical 
preparations containing opioid analgesics, including 
measures to educate the public on the dangers of 
abusing opioid analgesics. 
72. In the United States of America, the abuse of 
pharmaceutical preparations containing opioid 
analgesics has been rising in recent years. According to 
the 2004 National Survey on Drug Use and Health, 
there were 4.4 million regular abusers of narcotic pain-
relievers in 2004, and there was an increase in lifetime 
prevalence of non-medical use of narcotic pain-
relievers in the age group 18-25, from 22 per cent in 
2002 to 24 per cent in 2004. Among the narcotic drugs 
that continue to be diverted and abused in the United 
States are hydrocodone, oxycodone and methadone. 
The methods of diversion range from forged 
prescriptions to theft from manufacturers and 
wholesalers or retailers. The abuse of those drugs is 
also facilitated by poor practices on the part of some 
doctors and pharmacists. The Board notes with 
appreciation that the Government is taking action to 
prevent diversion and abuse of pharmaceutical 
preparations (see paras. 349-350). At the same time, 
the Board urges the Government to review, in 
particular, the controls of preparations containing 
hydrocodone with a view to increasing their 
effectiveness, because the diversion and abuse of that 
narcotic drug have posed serious problems in the 
United States for many years. 
73. The Board urges other Governments to regularly 
collect information on the extent of the diversion and 
abuse of pharmaceutical preparations containing 
narcotic drugs, with a view to developing 
countermeasures, where appropriate. Those measures 
might include, inter alia, raising the awareness of the 
public regarding the risks involved in abusing 
prescription drugs; launching programmes to monitor 
prescriptions in order to identify and prevent cases of 
inappropriate prescribing; collecting and analysing 
information on the dispensing and use of 
pharmaceuticals; training health-care providers; 
monitoring licit distribution channels more carefully to 
prevent and detect theft; and strengthening cooperation 
by law enforcement agencies, for example, by 
reporting on relevant seizures. Furthermore, the Board 
encourages all Governments to draw the attention of 
medical personnel to the good prescribing and 
dispensing practices as recommended by the World 
Health Organization (WHO).  
74. For some narcotic drugs, the risk of diversion 
may be increased when they become available in larger 
single dosages that are more liable to abuse. That was 
the case with controlled-release tablets containing high 
doses of oxycodone that were introduced in 2000. 
Abusers attempt to circumvent the time-release 
properties of the tablets by chewing or crushing them. 
In Canada and the United States, increasing numbers of 
cases involving the diversion and abuse of fentanyl in 
the form of transdermal patches have been reported. 
Abusers were able to remove the full dose of fentanyl 
from the patch (see para. 373 below). The Board 
invites all Governments, in cooperation with the 
pharmaceutical industry and health professionals, to 
monitor carefully cases involving the diversion and 
abuse of narcotic drugs available in controlled-release 
preparations and to take action against their abuse. 
75. Cases involving the diversion and abuse of 
opioids, in particular methadone and buprenorphine, 
when prescribed for substitution treatment, have been 
identified in many countries. The Board requests the 
Governments of countries where opioids are used for 
substitution treatment to take measures such as 
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supervised consumption, short dispensing intervals and 
central registration of all opioids prescribed for 
medical use, in order to prevent their diversion into 
illicit channels. The quantities of opioids used for 
substitution treatment are increasing in many countries 
(see paras. 103 and 138 below). The Board requests the 
Governments concerned to establish a mechanism for 
the systematic collection of information on the 
diversion and abuse of such drugs with a view to 
strengthening control measures to prevent their 
diversion, where appropriate.  
 
  Control measures 
 
  Export of poppy seeds from countries prohibiting 
opium poppy cultivation 
 
76. In its resolution 1999/32 of 28 July 1999, the 
Economic and Social Council called upon Member 
States to take measures to fight the international trade 
in poppy seed from countries where no licit cultivation 
of opium poppy is permitted. Several States have taken 
measures to prevent imports of poppy seed from such 
countries. The Board notes with appreciation that, in 
January 2005, the Government of Azerbaijan, after 
consultation with the Board, prevented 500 tons of 
poppy seed originating in Afghanistan from transiting 
through its territory. Strict control measures for 
international trade in poppy seed were implemented in 
India. Similarly, the authorities of Myanmar and 
Pakistan have adopted measures against trade in poppy 
seed from illicit sources. In Myanmar, over 163 tons of 
poppy seed have been voluntarily surrendered by 
opium poppy growers to the authorities and destroyed 
since 2002. In Mexico, more than 2 tons of poppy seed 
were seized in 2004. 
77. The Board notes with appreciation that the 
Government of Afghanistan agreed to the Board’s 
request to adopt legislative measures to prohibit the 
exportation of poppy seed. The Board trusts that the 
legislation will be adopted and implemented as soon as 
possible. 
78. Some countries that are involved in international 
trade in poppy seed have not yet adopted measures that 
would enable them to prevent imports of poppy seed 
from countries where no licit cultivation of opium 
poppy exists. The Board requests the Governments 
concerned to implement Economic and Social Council 
resolution 1999/32. 
 
  Cannabis used for medical or scientific purposes  
 
79. Cannabis is included in Schedules I and IV of the 
1961 Convention. Substances in Schedule IV are those 
considered particularly liable to abuse and to produce 
ill effects. For a few years there has been increased 
interest in the therapeutic usefulness of cannabis or 
cannabis extracts, as evidenced by the continuing 
scientific research in progress in several countries, 
including Canada, Germany, the Netherlands, 
Switzerland, the United Kingdom of Great Britain and 
Northern Ireland and the United States. The results of 
such research regarding the potential therapeutic 
usefulness of cannabis have so far been limited. 
80. The Board reiterates its concern that, without 
having reported conclusive research results to WHO, 
the Governments of Canada (in 2001) and the 
Netherlands (in 2003) authorized the use of cannabis 
for medical purposes. The Board is also concerned that 
cannabis is used for medical purposes in some 
jurisdictions of the United States without having 
definitive proof of its efficacy. The Board notes that 
the Supreme Court of the United States confirmed in 
June 2005 the right of the Government to enforce the 
prohibition of the use of cannabis in a state that 
removed state-level criminal penalties on the use, 
possession and cultivation of cannabis for medical 
purposes (see para. 338 below). The Board confirms 
that it welcomes sound scientific research on the 
therapeutic usefulness of cannabis, as stated in 
previous reports,29 and invites all Governments 
concerned to share the results of such research, when 
available, with the Board, WHO and the international 
community. 
81. Articles 23 and 28 of the 1961 Convention 
provide for a national cannabis agency to be 
established in countries where the cannabis plant is 
cultivated licitly for the production of cannabis, even if 
the cannabis produced is used for research purposes 
only. The Board notes that since the last report of the 
Board was published, the Government of the United 
Kingdom has established a national cannabis agency. 
82. The Board notes with concern that Governments 
of some countries where research on the use of 
cannabis or cannabis extracts for medical purposes is 
taking place or which authorized the use of cannabis 
for medical purposes have failed to furnish in a timely 
manner relevant estimates or statistical reports on their 
production, imports, exports, consumption and stocks 
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of cannabis or cannabis extracts, as required by the 
1961 Convention. The Board reminds the Governments 
concerned that those treaty provisions must be 
implemented and reiterates its request to them to 
ensure their compliance with those treaty obligations. 
 
  Ensuring the availability of drugs for medical 
purposes 
 
  Demand for and supply of opiates 
 
83. Pursuant to the 1961 Convention and relevant 
Economic and Social Council resolutions, the Board 
examines on a regular basis issues affecting the supply 
of and demand for opiates used for medical and 
scientific purposes and endeavours, in cooperation with 
Governments, to maintain a lasting balance between 
supply and demand. A detailed analysis of the current 
situation with regard to the supply of and demand for 
opiates for medical and scientific purposes worldwide 
is contained in the 2005 technical report of the Board 
on narcotic drugs.30  
 
  Monitoring of the global situation of supply of 
opiate raw materials 
 
84. The Board notes that in 2004 production of opiate 
raw materials, both those rich in morphine and those 
rich in thebaine, declined in relation to 2003. For 
opiate raw materials rich in morphine, it was the first 
decline since 2001, resulting in the production of 
447 tons expressed in morphine equivalent. For opiate 
raw materials rich in thebaine, for which total 
production had started to decrease in 2003, the decline 
continued during 2004, reaching 76 tons in thebaine 
equivalent. The advance data submitted by the main 
producing countries indicate that global production of 
opiate raw materials rich in morphine is expected to 
decline further in 2005, to 353 tons in morphine 
equivalent, and it is anticipated that global production 
of opiate raw materials rich in morphine will be less 
than the global demand, which is about 400 tons in 
morphine equivalent. Production of raw materials rich 
in thebaine is expected to rise substantially in 2005, to 
an estimated 105 tons in thebaine equivalent, and is 
expected to exceed global demand (90 tons in thebaine 
equivalent). 
85. The Board recommends that global stocks of 
opiate raw materials be maintained at a level sufficient 
to cover global demand for about one year, in order to 
ensure the availability of opiates for medical needs in 
case of an unexpected shortfall of production and to 
reduce the risk of diversion associated with excessive 
stocks. Global stocks of opiate raw materials rich in 
morphine have increased steadily since 2000; at the 
end of 2004 the stocks held in producing countries 
could have covered global demand for two years. Since 
the estimated production of raw materials rich in 
morphine will decline in 2005 to a level below that of 
global demand, it is expected that stocks of those raw 
materials will drop; however, they will still be 
sufficient to cover global demand for more than one 
and a half years. Global stocks of opiate raw materials 
rich in thebaine increased sharply until 2003 and were 
slightly depleted in 2004; at the end of 2004, they were 
sufficient to cover the annual global demand for those 
raw materials. It is anticipated that the overproduction 
of opiate raw materials rich in thebaine in 2005 will 
result in an increase in stocks of those raw materials. 
86. The Board notes that for 2006 most Governments 
are planning to maintain in their countries the total area 
to be cultivated with opium poppy so that it is well 
below the record figure during the expansion of 2002 
or 2003. According to the data available, the levels of 
production of both types of opiate raw material are 
expected to be below global demand in 2006. However, 
in view of the high level of stocks of raw materials 
held in producer countries, the total supply of opiate 
raw materials (production and stocks) will be sufficient 
to cover the expected demand. 
87. The Board requests the Governments of all 
producer countries to submit relevant estimates in a 
timely manner, to maintain cultivation within the limits 
of the estimates confirmed by the Board or to furnish 
supplementary estimates to the Board, if necessary, and 
to report in a timely and accurate manner the amounts 
of raw materials produced, as well as the alkaloids 
obtained from them. 
88. In the past, the Board has brought to the attention 
of the international community the fact that the levels 
of consumption of opioid analgesics for the treatment 
of moderate to severe pain were low in several 
countries. The Board welcomes Economic and Social 
Council resolution 2005/25 of 22 July 2005, entitled 
“Treatment of pain using opioid analgesics”, in which 
the Council called upon Member States to remove 
barriers to the medical use of such analgesics, taking 
fully into account the need to prevent their diversion 
for illicit use. The Board also appreciates that WHO is 
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currently developing a global cancer control strategy, 
which is to have as one of its priorities the promotion 
of pain relief and palliative care. The Board requests 
all Governments to promote the rational use of narcotic 
drugs for medical treatment, including the use of 
opioid analgesics, in accordance with the pertinent 
recommendations of WHO. 
89. With regard to the production levels of opiate raw 
materials, the Board requests all producer countries to 
maintain their future production of opiate raw 
materials at a level that conforms to the actual 
requirements for such raw materials worldwide and to 
avoid keeping excessive stocks, since they might be a 
source of diversion if they are not adequately 
controlled. A global increase in the production of 
opiate raw materials should follow as the countries 
develop programmes for gradually increasing their 
demand to the level of their medical needs for narcotic 
analgesics. 
 
  Prevention of the proliferation of production of 
opiate raw materials 
 
90. Pursuant to the relevant Economic and Social 
Council resolutions, the Board calls upon all 
Governments to contribute to the maintenance of a 
balance between the licit supply of and demand for 
opiate raw materials and to cooperate in preventing the 
proliferation of sources of production of opiate raw 
materials. Most recently, in its resolution 2005/26 of 
22 July 2005, the Council urged Governments of 
countries where opium poppy had not been cultivated 
for the licit production of opiate raw materials, in the 
spirit of shared responsibility, to refrain from engaging 
in the commercial cultivation of opium poppy, in order 
to avoid the proliferation of supply sites. 
91. The Board wishes to remind Governments that 
narcotic drugs and opiate raw materials are not 
ordinary commodities and that therefore market 
economy considerations should not be the factors 
determining whether or not to permit opium poppy 
cultivation. The Board appeals to all Governments to 
comply with Economic and Social Council 
resolution 2005/26. 
 
  Informal consultation on supply of and demand 
for opiates for medical and scientific purposes 
 
92. At the request of the Governments of India and 
Turkey and pursuant to Economic and Social Council 
resolution 2004/43 of 21 July 2004, the Board 
convened an informal consultation on the supply of 
and demand for opiates for medical and scientific 
purposes during the forty-eighth session of the 
Commission on Narcotic Drugs. All major producers 
and importers of opiate raw materials participated in 
the informal consultation. The Board has convened 
such informal consultations on a yearly basis since 
1992 to enable the participating Governments to be 
informed of recent developments affecting the global 
production of and demand for opiate raw materials. 
The information obtained during such consultations 
allows the Governments of producing countries to 
adjust the production of opiate raw materials to the 
demand for the opiates derived from them and 
facilitates monitoring of the situation by the Board. 
The consultations therefore contribute to the continued 
availability of opiates for medical purposes while 
preventing oversupply of the raw materials. 
 
  Technical study on the relative merits of different 
methods of producing opiate raw materials 
 
93. On the recommendation of the Commission on 
Narcotic Drugs at its forty-fifth session, the Economic 
and Social Council adopted resolution 2002/20 of 
24 July 2002, in which it urged Governments of all 
countries producing opiate raw materials to adhere 
strictly to the provisions of the 1961 Convention, to 
take effective measures to prevent illicit production, or 
diversion of opiate raw materials to illicit channels, 
especially when increasing licit production, and to 
adopt, after due technical study by the Board of the 
relative merits of different methods, the best method in 
that respect.  
94. Pursuant to that resolution, the Board studied the 
relative merits of different production methods, taking 
into account the following aspects:  
 (a) Relative safety: lower risks for diversion, 
lower regulatory and enforcement overheads;  
 (b) Flexibility: responsiveness to national and 
global needs;  
 (c) Productivity and efficiency;  
 (d) Adaptability to local conditions (agronomic, 
socio-economic, existing technology). 
95. With respect to relative safety, the Board found 
that both raw material production systems (for opium 
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and for poppy straw) have inherent potential for 
diversion and abuse. However, for illicit uses, opium 
continues to be more attractive than poppy straw, and 
the relative risks in opium production tend to be higher 
than in poppy straw production. Opium is relatively 
easy to transport and to store over extended periods of 
time. It is an ideal raw material for the illicit 
manufacture of morphine and heroin, since both can be 
obtained under simple conditions and with 
unchallenging technology.  
96. In general terms, the risk factors for the diversion 
of both products are higher: (a) at the crop production 
level than at the transportation or processor/industry 
level; (b) the longer the product is in the custody of the 
crop growers or at the collection area; and (c) with 
increased numbers of crop growers or others involved 
in production. In contrast, the risk factors for diversion 
appear to decrease with increased mechanization of 
production and transportation. 
97. With regard to other aspects, there is no globally 
acceptable best method of production that can be 
identified. There are only options to be considered in 
the context of the socio-economic, commercial, 
cultural and historical background, as well as the 
infrastructure and control systems, of the countries 
involved.  
98. The Board noted that a number of countries that 
had previously produced opium for licit purposes 
stopped such production or converted their production 
system from opium to poppy straw technology. The 
advantages of such a change are reduced potential for 
diversion and faster responsiveness to changes in 
national or global needs due to a more flexible 
production system.  
99. The Board also concluded that there is currently a 
need for some opium in medicine, which is likely to 
continue. To meet that need, an appropriate amount of 
opium should continue to be available. There is also 
demand for opium as a raw material for the extraction 
of some alkaloids that are not currently extracted from 
poppy straw (such as noscapine), although in the future 
the need for such alkaloids could possibly be met by 
poppy straw, through the development of alternative 
poppy varieties. 
100. With respect to (a) security measures to prevent 
diversion, (b) cultivation practices and (c) research, the 
Board found that improvements are possible in each 
producing country. The Board therefore invites all 
producing countries to review their own production 
systems and to adopt the best practices to achieve 
improvements. In particular, the Board calls upon all 
producing countries, regardless of the production 
method used, to examine their control measures 
applied to the production of opiate raw materials with a 
view to strengthening them, in order to prevent 
diversion from licit cultivation of opium poppy into 
illicit channels, in fulfilment of their treaty obligation. 
101. A summary of the findings of the Board was 
brought to the attention of the Commission on Narcotic 
Drugs at its forty-eighth session, in March 2005. The 
comprehensive background study was made available 
to the Governments of countries producing opiate raw 
materials for medical and scientific purposes. 
 
  Consumption of narcotic drugs 
 
102. Governments should be aware that increased 
availability of narcotic drugs for legitimate medical 
purposes may raise the risk of diversion and abuse of 
those drugs. In the United States, the most frequently 
diverted and abused pharmaceutical preparations of 
narcotic drugs are those containing hydrocodone and 
oxycodone (see para. 72 above). In 2004, the United 
States accounted for 99 per cent and 85 per cent of 
global consumption of hydrocodone and oxycodone, 
respectively. The medical consumption of hydrocodone 
and oxycodone increased by about 60 per cent and 
80 per cent, respectively, in the United States during 
the five-year period 2000-2004. The medical use of 
hydrocodone reached almost 16 defined daily doses for 
statistical purposes (S-DDD) per 1,000 inhabitants per 
day and that of oxycodone 4 S-DDD in 2004. The 
Board invites all Governments to closely monitor 
trends in the consumption of pharmaceutical 
preparations containing narcotic drugs and to adopt 
measures against their diversion and abuse, as 
necessary. 
103. Global consumption of methadone has increased 
by almost three and one half times during the last 
decade. Methadone is used in several countries for the 
treatment of pain, but the upward trend in its medical 
consumption is mainly attributable to its growing use 
in maintenance treatment related to opioid dependency. 
The main countries consuming methadone include (in 
descending order) the United States, Spain, Germany, 
the United Kingdom, Italy, the Islamic Republic of 
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Iran, Canada and Australia. Those countries together 
accounted for more than 86 per cent of global 
consumption of methadone in 2004. The Board 
requests the competent authorities of all countries 
concerned to be vigilant with regard to diversion of, 
trafficking in and abuse of methadone and to take 
countermeasures, if necessary (see para. 75 above). 
 
 
 B. Psychotropic substances 
 
 
  Status of adherence to the Convention on 
Psychotropic Substances of 1971 
 
104. On 1 November 2005, the number of States 
parties to the Convention on Psychotropic Substances 
of 197131 stood at 179. Since the report of the Board 
for 2004 was issued, four States (Angola, Bhutan, 
Cambodia and Honduras) have become parties to that 
convention. 
105. Of the 13 States that have yet to become parties 
to the 1971 Convention, there are 2 in Africa 
(Equatorial Guinea and Liberia), 1 in the Americas 
(Haiti), 3 in Asia (the Democratic People’s Republic of 
Korea, Nepal and Timor-Leste), 1 in Europe (Andorra) 
and 6 in Oceania (Kiribati, Nauru, Samoa, Solomon 
Islands, Tuvalu and Vanuatu). Some of those States 
(namely, Andorra, Haiti and Nepal) have already 
become parties to the 1988 Convention. 
 
  Cooperation with Governments 
 
  Submission of annual statistics 
 
106. By 1 November 2005, a total of 158 States and 
territories had submitted to the Board annual statistical 
reports on psychotropic substances for 2004 in 
conformity with the provisions of article 16 of the 
1971 Convention. That accounts for 75 per cent of the 
States and territories required to furnish such statistics.  
107. The Board continues to be concerned by the fact 
that some main manufacturing and exporting countries 
do not submit annual statistical reports on psychotropic 
substances on a regular basis and in a timely manner. 
That creates difficulties for international control. 
Statistical information on manufacture, imports and 
exports of psychotropic substances from those 
countries is needed to prepare a reliable analysis of 
global trends in manufacture and international trade of 
psychotropic substances. Missing or inaccurate details 
on exports and imports hinder identification of 
discrepancies in trade statistics, thereby impeding 
international drug control efforts. The Board urges the 
authorities of the countries concerned to examine the 
situation and to cooperate with the Board, in particular 
by providing annual statistics on psychotropic 
substances within the deadline, as required under the 
1971 Convention.  
 
  Quarterly reports for substances in Schedule II of 
the 1971 Convention 
 
108. In accordance with Economic and Social Council 
resolution 1981/7 of 6 May 1981, Governments of 
countries manufacturing, exporting or importing 
substances in Schedule II of the 1971 Convention 
provide voluntarily to the Board quarterly statistics on 
their imports and exports of those substances. A total 
of 172 governments (of 156 countries and 
16 territories) submitted quarterly statistical reports for 
the year 2004. Methylphenidate is the most commonly 
traded substance. Other substances that are traded are 
from the group of substances called amphetamines 
(amphetamine, dexamphetamine and meth-
amphetamine). 
 
  Assessments of requirements for psychotropic 
substances 
 
109. Assessments of annual domestic medical and 
scientific requirements (simplified estimates) have 
been submitted to the Board by Governments pursuant 
to Economic and Social Council resolution 1981/7 with 
respect to substances in Schedule II of the 
1971 Convention and Council resolution 1991/44 of 
21 June 1991 with respect to substances in 
Schedules III and IV of that Convention. The 
assessments are communicated to the competent 
authorities of all States and territories that are required 
to use them as guidance when approving exports of 
psychotropic substances. Pursuant to Council 
resolution 1996/30 of 24 July 1996, in 1997 the Board 
established assessments for 57 Governments that had 
failed to furnish such information by that time. Since 
then, those Governments have submitted their own 
assessments or communicated modifications to the 
assessments established by the Board. By 
1 November 2005, the Governments of all countries 
except Somalia had submitted to the Board at least 
once their assessments of annual medical requirements 
for psychotropic substances.  
  21 
 
 E/INCB/2005/1
110. The Board has recommended that Governments 
review and update the assessments of their annual 
medical and scientific requirements for psychotropic 
substances at least every three years. While the 
majority of Governments submit modifications from 
time to time, many have started submitting revised 
assessments every year, as is the case with regard to 
estimates for narcotic drugs. In January 2005, all 
Governments were asked to review and update, if 
necessary, the assessments of their annual medical and 
scientific requirements for psychotropic substances. By 
1 November 2005, 102 Governments had submitted to 
the Board a full revision of the assessments of their 
requirements for psychotropic substances and 172 had 
communicated modifications to previous assessments 
for one or more substances. 
111. The Board is concerned that, for several years, a 
number of Governments have not updated the 
assessments of their requirements for psychotropic 
substances. Those assessments may no longer reflect 
their actual medical and scientific requirements for 
psychotropic substances in the countries and territories 
concerned. Assessments that are lower than the actual 
legitimate requirements may delay the importation of 
psychotropic substances urgently needed for medical or 
scientific purposes in the country in question, owing to 
the need to verify the legitimacy of import orders. 
Assessments that are significantly higher than the 
actual legitimate needs may open the door for 
diversion of psychotropic substances into illicit 
channels. The Board encourages all Governments to 
ensure that their assessments are regularly updated and 
that it is informed of any modifications.  
 
  Prevention of diversion of psychotropic 
substances into the illicit traffic 
 
  Diversion from international trade 
 
112. Licit international trade in psychotropic 
substances in Schedule I of the 1971 Convention has 
been limited to a small number of transactions 
involving quantities of only a few grams, given the 
very limited use of such substances. While there have 
been isolated attempts over the years to divert 
substances in Schedule I, no diversion to illicit 
channels has ever taken place, mostly because of the 
strict international control mechanism for those 
substances. With regard to use of substances in 
Schedule I, article 7 (a) of the 1971 Convention states 
that parties to the Convention shall prohibit all use of 
substances in Schedule I except for scientific and very 
limited medical purposes. No industrial use of those 
substances is foreseen by the Convention.  
113. The above-mentioned provision of the 
1971 Convention had been respected by all countries 
for many years. However, in November 2004, the 
Board was informed of the use of methcathinone, a 
substance in Schedule I of the 1971 Convention, for 
the manufacture of pseudoephedrine by a Japanese 
company. The company had obtained large amounts of 
methcathinone in 2001, without the required special 
import authorization, from India. The Japanese 
authorities have examined the matter and referred it to 
the prosecutor’s office and have also issued a warning 
notice to the domestic association of pharmaceutical 
and chemical industries to review and reinforce 
compliance with the rules. The Board wishes to remind 
all Governments of the restrictions in place for the 
trade in and use of psychotropic substances in 
Schedule I of the 1971 Convention and calls upon them 
to remain vigilant and ensure that their industries, as 
well as authorized traders, are fully aware of all 
restrictions concerning trade in and use of those 
substances. 
114. The only substances included in Schedule II of 
the 1971 Convention that are manufactured and traded 
in large quantities are amphetamine, dexamphetamine 
and methylphenidate, which are used mostly in the 
treatment of attention deficit disorder (ADD) and, in 
the case of the amphetamines, for the manufacture of 
non-controlled substances. In the past, the diversion of 
substances in Schedule II from licit international trade 
was one of the main methods used to supply illicit 
markets. However, implementation of control 
measures, coupled with additional measures 
recommended by the Board and endorsed by the 
Economic and Social Council, such as assessments and 
quarterly statistical reports, have virtually eliminated 
the diversion of those substances in Schedule II. 
Preparations containing hallucinogens, fenetylline and 
methaqualone, which are found on illicit markets in 
various regions of the world, are almost exclusively 
from clandestine manufacture, while amphetamine, 
dexamphetamine and methylphenidate found on illicit 
markets are believed to have been diverted from 
domestic distribution channels. Other major sources of 
substances in Schedule II found on the illicit market 
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are illegally operating Internet pharmacies (see 
paras. 219-236 below). 
115. Licit international trade in psychotropic 
substances in Schedules III and IV of the 
1971 Convention consists of thousands of individual 
transactions each year. The Board analyses data on 
international trade in those substances and as 
appropriate initiates the investigation by Governments 
of suspicious transactions. The Board notes with 
satisfaction that such investigations indicate that, in 
recent years, there has been a significant decrease in 
the number of cases involving the diversion of 
substances in Schedules III and IV from licit 
international trade into illicit channels. Until 10 years 
ago, such diversion had occurred frequently and 
involved quantities of up to several thousands of 
kilograms; nowadays, however, almost all attempted 
diversions from international trade are discovered and 
the very rare successful diversions only involve minor 
quantities. That appears to have been the result of the 
implementation by Governments of the treaty 
provisions for substances listed in those schedules and 
of the additional controls over international trade (the 
import and export authorization system, the assessment 
system and the detailed reporting system) 
recommended by the Board and endorsed by the 
Economic and Social Council (see paras. 109-111 
above and 128-135 below). 
116. However, attempts to divert substances in 
Schedules III and IV of the 1971 Convention still 
continue. The method used most frequently in attempts 
to divert psychotropic substances from licit 
international trade is the falsification of import 
authorizations. The Board invites all Governments to 
continue to be vigilant with respect to orders for 
psychotropic substances and, if necessary, to confirm 
with the Governments of importing countries the 
legitimacy of such orders prior to approving the export 
of such substances. The Board continues to be at the 
disposal of Governments to facilitate such 
confirmation. Diversion attempts relate in all cases to 
substances identified many years ago as target 
substances for specific illicit drug markets. The 
substances targeted most frequently by drug traffickers 
have included stimulants (amfepramone, fenetylline, 
phentermine and pemoline), benzodiazepines 
(diazepam, flunitrazepam and temazepam), 
phenobarbital and buprenorphine.  
117. The Board notes with appreciation that exporting 
countries use the assessments of requirements for 
psychotropic substances published by the Board to 
verify the legitimacy of trade transactions. Such 
verification is especially important in the case of 
orders placed by companies in the few countries that 
have not yet introduced mandatory import 
authorizations for all psychotropic substances. Trade 
transactions identified as suspicious because the import 
orders exceed the established assessments are either 
verified with the Board or brought to the attention of 
the importing country. That process facilitates the 
identification of diversion attempts. For example, 
during the past year, two attempts at illegally importing 
into Afghanistan buprenorphine, an opioid analgesic in 
Schedule III of the 1971 Convention, were successfully 
prevented as a result of the vigilance of the exporting 
country. In both cases, the imports were ordered from 
companies in the Netherlands. The authorities of the 
Netherlands, noting that no assessment had been 
established for buprenorphine and that the import 
certificate to support the transaction was of unknown 
format, alerted the authorities in Kabul through the 
Board and were informed that the companies in 
question were not licensed or authorized to import 
buprenorphine.  
118. The Board also appreciates receiving information 
from Governments about new and emerging trends in 
diversion attempts, as well as about procedures not in 
line with international and national control measures. 
For example, the Board was recently informed by the 
Turkish authorities about cases where the import of 
minor quantities of psychotropic substances had been 
carried out using couriers and through the mail without 
the required authorization documents. The Ministry of 
Health of Turkey subsequently took the necessary 
measures to warn the importing Turkish companies 
against such importation. The Board requests national 
authorities of all countries to be aware that such 
practices may also occur in their countries and to take 
measures against such importations.  
119. Pharmaceutical preparations containing psycho-
tropic substances found on the illicit market are, 
however, not necessarily always diverted from licit 
manufacture and trade. In some cases, increased 
demand on illicit markets for a specific pharmaceutical 
product containing a psychotropic substance has led to 
the illicit manufacture of counterfeit preparations. As 
diversion from manufacture and international trade is 
  23 
 
 E/INCB/2005/1
no longer an important source for the illicit market, 
illegal manufacture, including counterfeiting of brand 
products, has become a major source of supply for 
illicit trade. Such counterfeits are not restricted to the 
traditionally illegally manufactured substances in 
Schedule I of the 1971 Convention, such as MDMA, or 
in Schedule II, such as amphetamines and fenetylline. 
Pharmaceutical products containing psychotropic 
substances in all the Schedules have become major 
drugs of abuse.  
120. In addition to the considerable demand for such 
products on the illicit market, the professional 
expertise of operators of clandestine laboratories has 
increased. In some countries, this is attributed to 
economic problems that have resulted in the loss of 
jobs by specialists in the chemical or pharmaceutical 
industry. Raw materials for the manufacture of 
psychotropic substances can be obtained from 
countries with insufficient control, or may even be 
ordered over the Internet, and are then professionally 
processed by those working for traffickers.  
121. Another source of illicit supply is clandestine 
operations carried out by some established chemical 
and pharmaceutical companies in addition to their 
legitimate manufacturing activities. The phenomenon 
of a business enterprise having both legal and illegal 
operations, commonly called “night shifts” or “the 
front and back offices”, can be found not only in 
manufacturing companies, but also at the retail level, 
that is, in pharmacies. Such dual operations, legal and 
illegal, conduced by the same establishment are often 
the source supplying illicitly operating Internet 
pharmacies. 
122. One example of such ongoing counterfeit 
operations is the illicit manufacture of counterfeit 
Captagon, a pharmaceutical preparation that, in its licit 
form, contains fenetylline. Numerous diversions of 
licitly manufactured Captagon and/or the base 
substance fenetylline occurred in the late 1980s. Since 
the beginning of the 1990s, increased control measures 
have succeeded in stopping such diversions. As 
fenetylline can no longer be obtained from licit 
sources, traffickers have resorted to the use of illicitly 
manufactured fenetylline, in addition to substituting 
other stimulants for that substance. In recent years, 
most seized Captagon tablets have been found to 
contain amphetamines, in addition to stimulants not 
under international control.  
123. Counterfeiting is not restricted to the strictly 
controlled substances in Schedule II of the 
1971 Convention. For example, Rohypnol, a 
pharmaceutical preparation containing flunitrazepam, 
is increasingly being counterfeited for the illicit 
market. Flunitrazepam, a benzodiazepine used as 
sedative-hypnotic in Schedule III, is one of the most 
frequently abused benzodiazepines. After diversion 
from international trade had been successfully stopped 
in the 1990s, diversion from domestic distribution 
channels became the preferred method of supplying 
illicit markets. In response, several countries, including 
major manufacturers and importers of the substance, 
adopted strict control policies for flunitrazepam, in 
close cooperation with the pharmaceutical industry. In 
recent years, counterfeit tablets have constituted a 
sizeable portion of all seized Rohypnol tablets, at least 
in Scandinavian countries.  
124. Information from the Swedish customs 
authorities indicates that almost all Rohypnol tablets 
seized are of counterfeit origin. Lithuanian authorities 
confirm the smuggling of significant amounts of 
counterfeit tablets from Lithuania into Scandinavian 
countries. In Norway, most of the 360,000 Rohypnol 
tablets seized in 2004 were counterfeit. The Board 
warns national authorities that reliable information on 
the proportion of counterfeits depends to a large extent 
on the priority accorded by law enforcement to the 
problem of Rohypnol abuse and the willingness of 
authorities to test seized drugs. The illicit manufacture 
of counterfeit tablets often uses diverted raw materials, 
such as those obtained from China and India over the 
Internet.  
 
  Diversion from domestic distribution channels 
 
125. Diversions from domestic distribution channels 
continue, in some cases, involving, relatively large 
quantities. Reports in various countries on the abuse 
and seizure of psychotropic substances indicate that the 
diversion of pharmaceutical products containing such 
substances from licit domestic distribution channels is, 
together with illegally operating Internet pharmacies, 
the most important source used by illicit drug 
suppliers. The methods used by drug traffickers to 
divert those products include theft from factories and 
wholesalers; pretended export; falsified prescription; 
and the supply of substances by pharmacies without 
the required prescriptions. The diverted drugs are not 
only destined for personal use, but are also trafficked 
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within the country of diversion or smuggled into other 
countries.  
126. Illicit demand for pharmaceuticals containing 
controlled substances is growing. In a number of 
countries, the abuse of such pharmaceuticals is second 
only to the abuse of cannabis. The two most abused 
groups of psychotropic substances are benzodiazepines 
and amphetamine-type stimulants. The Board calls on 
Governments to monitor consumption levels of 
prescription drugs containing psychotropic substances 
and to raise awareness about the consequences of the 
abuse of such drugs.  
127. Recently, trafficking in gamma-hydroxybutyric 
acid (GHB), a sedative-hypnotic included in 
Schedule IV of the 1971 Convention in 2001, and its 
abuse, have increased. The illicit manufacture of GHB 
and trafficking in GHB kits and gamma-butyrolactone 
(GBL), a precursor of GHB, have also become serious 
problems in a number of countries. The Board 
therefore calls on the competent authorities of all 
countries concerned to increase their vigilance as 
regards diversion, the illicit manufacture and abuse of 
and trafficking in GHB and to inform the Board of 
developments in that area. The Board strongly 
encourages Governments to consider developing 
appropriate programmes for drug abuse prevention that 
take into account the abuse of GHB. 
 
  Control measures 
 
  Assistance to Governments in verifying the 
legitimacy of import transactions 
 
128. Many exporting countries request the assistance 
of the Board in verifying the legitimacy of import 
authorizations for psychotropic substances purportedly 
issued by the authorities of importing countries. In 
order to assist Governments in the verification of the 
authenticity of import documents for narcotic drugs, 
psychotropic substances and precursor chemicals, the 
Board maintains a collection of sample copies of 
official import certificates and authorizations in current 
use by national administrations. By maintaining an 
updated collection of sample records, the Board seeks 
to diminish the possibility of narcotic drugs and 
psychotropic substances being diverted into illicit 
channels. The Board calls on all countries that have not 
yet provided such samples to the Board to do so 
without further delay.  
129. The Board notes with concern that, in certain 
cases, responses to its inquiries for confirmation of 
legitimacy of import orders have taken months. The 
Board is concerned that failure to cooperate with it 
may hinder the investigation of diversion attempts 
and/or may cause delays in legitimate trade in 
psychotropic substances. The Board would like to draw 
the attention of the Governments of several countries 
(Bosnia and Herzegovina, Iraq, Kenya, Myanmar, 
Senegal, Somalia and the Syrian Arab Republic) to the 
importance of responding in a timely manner to the 
Board’s requests, in order to avoid delays in imports, 
which may impede the availability of psychotropic 
substances for legitimate purposes. 
 
  National control measures regarding international 
trade 
 
130. The Board is aware of recent cases in which the 
import of controlled substances was carried out 
through the post, cargo or couriers without the required 
import authorization documents having been issued by 
the authorities of the importing country. The Board 
draws the attention of the countries concerned to the 
fact that those practices are not in line with the relevant 
Economic and Social Council resolutions and that 
exporting countries must respect national legislation of 
the importing countries (see paras. 237-242 below, on 
smuggling by mail). 
131. The Board notes with appreciation that in 2005 
Costa Rica, Ethiopia, Maldives and Timor-Leste 
extended the system of import and export authorization 
for substances in Schedules III and IV of the 1971 
Convention. At present, export and import 
authorizations are required by national legislation for 
all substances in Schedules III and IV in more than 150 
countries and territories. In approximately 20 
additional countries and territories, import and export 
authorizations are mandatory for at least some of those 
substances. 
132. The Board requests the Governments of all 
countries that do not yet control the import and export 
of all psychotropic substances by the system of import 
and export authorizations to introduce such controls. 
As confirmed by past experience, countries that are 
centres of international commerce but do not have such 
controls are at particular risk of being targeted by 
traffickers. The Board urges all other countries 
concerned, whether they are parties to the 
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1971 Convention or not, such as Andorra, the 
Bahamas, Bhutan, Brunei Darussalam, Burkina Faso, 
the Congo, Equatorial Guinea, Gabon, Guinea-Bissau, 
Ireland, Lesotho, the Libyan Arab Jamahiriya, 
Myanmar, the Niger, Singapore and Zimbabwe, to also 
introduce such controls for all substances controlled 
under the 1971 Convention. 
133. The Board notes that the Government of India has 
removed its prohibition on the importation of 
bromazepam, clorazepate, nimetazepam, phentermine 
and temazepam, for which article 13 of the 
1971 Convention had been invoked. 
134. In 2004, several exporting countries received 
import authorizations for quantities of psychotropic 
substances in excess of the assessments established by 
the authorities of the importing countries. The Board 
notes that the number of countries issuing such 
authorizations for quantities above assessments has 
declined in recent years. In 2004, more than 
15 countries issued import authorizations for 
substances in Schedule IV, at least for quantities 
between 1 kg and 150 kg, without established 
assessments for the substances concerned. The Board 
appreciates the support received from some major 
exporting countries, including France, Germany, India 
and Switzerland, which have consistently reminded 
importing countries of any failure to comply with the 
assessment system. The Board reiterates its request to 
all Governments to establish a mechanism to ensure 
that their assessments are in line with their actual 
legitimate needs and that no imports exceeding the 
assessments are authorized. 
 
  Voluntary submission of details on trade in 
substances in Schedules III and IV of the 
1971 Convention 
 
135. In accordance with Economic and Social Council 
resolutions 1985/15 of 28 May 1985 and 1987/30 of 
26 May 1987, Governments should, in their annual 
statistical reports, provide the Board with details of 
trade in substances in Schedules III and IV of the 
1971 Convention. Such details should include the 
identification of countries of origin for imports and 
countries of destination for exports. Complete details 
concerning trade movements were submitted for 2004 
by 124 Governments, or 79 per cent of all submissions 
of annual statistical reports for 2004. With few 
exceptions, all the major manufacturing and exporting 
countries furnished such information. However, some 
23 parties to the 1971 Convention failed to provide that 
information, which may indicate certain deficiencies in 
their national reporting systems. The Board encourages 
the Governments of the countries concerned to 
improve their data collection systems to ensure the 
submission of details of trade in their future reports to 
it. 
 
  Prohibition of advertising of controlled 
substances 
 
136. The Board welcomes the decision of the 
Government of New Zealand in 2005 to ban direct-to-
consumer advertising of prescription drugs, including 
medicines that contain controlled substances, in line 
with article 10 of the 1971 Convention. That decision 
was based on the advice of health professionals and 
consumer groups. The Board calls on countries that 
allow direct-to-consumer advertising to adopt similar 
measures. 
137. In accordance with the provisions of article 10, 
“advertisement” refers not only to public 
announcements in newspapers and magazines destined 
for the general public, but also to broadcasts on 
television or radio and the Internet. The Board notes 
that announcements in technical journals, commercial 
literature published exclusively for members of the 
medical profession or for pharmacists or other licensed 
traders in psychotropic substances should be aimed at 
the education of health professionals. The Board also 
draws the attention of Governments to the fact that 
media used for direct-to-consumer advertising, such as 
magazines and, increasingly, the Internet, are available 
and accessible globally. Such advertisements are 
therefore not restricted to consumers in countries that 
allow advertising of controlled substances, but also 
target consumers in countries where such direct-to-
consumer advertising is prohibited (see para. 139 on 
consumption of stimulants for ADD, and paras. 219-
236 on misuse of the Internet). 
 
  Ensuring the availability of psychotropic 
substances for medical purposes 
 
  Consumption of buprenorphine 
 
138. Buprenorphine is a potent opioid analgesic that 
has been included in Schedule III of the 1971 
Convention since 1989. For many years, its main use 
has been as an analgesic. Due to its mixed 
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agonist/antagonist properties, buprenorphine in higher 
doses has lately been used for the detoxification and 
substitution treatment of persons dependent on opiates. 
Since new preparations containing high doses of 
buprenorphine (Subutex®) or buprenorphine with 
naloxone (Subuxone®) have been introduced in several 
countries for the treatment of drug addicts, global 
manufacture and consumption of buprenophine have 
increased substantially in recent years. During the five-
year period 2000-2004, global consumption of 
buprenorphine nearly tripled, from 660 million S-DDD 
to 1.7 billion S-DDD. The more buprenorphine is made 
available for the treatment of addiction as part of 
primary health care in many countries, the more cases 
of diversion are reported. In France, which has 
considerable experience in dispensing buprenorphine 
for the treatment of persons addicted to opiates, there 
has been significant diversion of preparations 
prescribed to opiate addicts registered in substitution 
treatment programmes. In some countries, such as 
Finland, buprenorphine has become the most important 
illicitly used substitute for opiate addicts; in some 
illicit markets, it has almost totally replaced heroin. 
The Board notes that in several countries 
buprenorphine continues to be diverted from licit 
distribution channels and that opiate addicts are used 
as couriers, travelling from one country to another to 
obtain medical prescriptions for the substance. 
 
  Use of stimulants for the treatment of attention 
deficit disorder 
 
139. The Board notes the continuing increase in the 
medical use of stimulants in Schedule II of the 
1971 Convention. The Board recognizes the usefulness 
of stimulants in the treatment of ADD when prescribed 
on the basis of careful and appropriate diagnosis and 
proper treatment evaluation. However, the significant 
increase in the use of stimulants for ADD treatment in 
many countries raises the question of possible 
overdiagnosis and overprescription. The high 
prescription level of stimulants used for the treatment 
of ADD has increased the availability of those 
substances on the illicit market. As a result, the 
non-medical use of prescription stimulants is a growing 
problem, particularly among young adults and college 
students in the United States and in other countries 
where the consumption level of stimulants in 
Schedule II is high. The Board continues to be 
concerned about this trend and urges Governments to 
take steps to prevent overprescription, diversion and 
abuse of stimulants in Schedule II. The Board requests 
the competent authorities of the countries concerned to 
remind health-care professionals of the need for proper 
diagnosis of ADD and appropriate prescription 
practice, in accordance with article 9, paragraph 2, of 
the 1971 Convention, as well as the need for secure 
storage and distribution of such substances. In 
addition, the Board urges the Government of the 
United States to prohibit public advertisement of 
psychotropic substances, including stimulants in 
Schedule II used for the treatment of attention deficit 
disorder, in accordance with article 10 of the 
1971 Convention. 
 
  Stimulants used as anorectics 
 
140. During the 1990s, the highest level of 
consumption of stimulants in Schedule IV of the 
1971 Convention was recorded in the Americas. The 
Board has regularly requested the Governments 
concerned to devote adequate attention to those 
elevated consumption levels. Consequently, Argentina 
and Chile, two of the countries with the highest 
consumer consumption levels, introduced special 
control measures against the inappropriate use of 
stimulants, which resulted in a significant decrease in 
the use of stimulants. 
141. In the United States, there was also a significant 
reduction in the consumption levels of anorectics, 
mainly phentermine; that reduction lasted only for the 
short period 1997-1999. After 2000, the consumption 
of phentermine in that country again rose, though it 
was still 56 per cent less in 2004 (8.6 S-DDD per 1,000 
inhabitants per day) than in the peak consumption year 
1996, (19.5 S-DDD per 1,000 inhabitants per day). 
142. A steady downward trend in the consumption of 
stimulants in Schedule IV has been noted in a number 
of European countries such as (in descending order) 
France, Ireland, Malta, Italy, Denmark and Portugal; 
however, in other countries, in particular in Australia, 
Brazil, Singapore and the Republic of Korea, per capita 
consumption of anorectics has risen significantly.  
143. The Board is concerned that the increasing 
availability of stimulants in the Republic of Korea 
(from 9 million S-DDD in 2002 to 139 million S-DDD 
in 2004) may lead to conditions that are conducive to 
their abuse and diversion. The Board strongly 
recommends that the authorities in that country 
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monitor the situation closely to rule out any possible 
overprescribing of anorectics while ensuring adequate 
measures of control over domestic distribution 
channels. 
 
 
 C. Precursors 
 
 
  Status of adherence to the United Nations 
Convention against Illicit Traffic in Narcotic 
Drugs and Psychotropic Substances of 1988 
 
144. On 1 November 2005, a total of 177 States, as 
well as the European Community (extent of 
competence: article 12), were parties to the 
1988 Convention. Seven States have become parties to 
the 1988 Convention since the report of the Board for 
2004 was issued: Angola, Cambodia, Cook Islands, 
Democratic Republic of the Congo, Liberia, Samoa and 
Switzerland.  
145. With the accession of Switzerland, all major drug 
and chemical manufacturing, exporting and importing 
countries are now parties to the 1988 Convention. Of 
the remaining 16 States that have not yet become 
parties, 4 are in Africa (Equatorial Guinea, Gabon, 
Namibia and Somalia), 2 are in Asia (the Democratic 
People’s Republic of Korea and Timor-Leste), 2 are in 
Europe (the Holy See and Liechtenstein) and 8 are in 
Oceania (Kiribati, the Marshall Islands, Nauru, Palau, 
Papua New Guinea, Solomon Islands, Tuvalu and 
Vanuatu). 
 
  Cooperation with Governments 
 
  Annual submission of information on substances 
frequently used in the illicit manufacture of 
narcotic drugs and psychotropic substances 
 
146. Reporting information on substances frequently 
used in the illicit manufacture of narcotic drugs and 
psychotropic substances on form D is an obligation 
under article 12 of the 1988 Convention. By 
1 November 2005, such information had been 
submitted for 2004 by a total of 127 States, territories 
and the European Community (on behalf of its 
25 member States). Several States, including Morocco, 
New Zealand, the Republic of Moldova and 
Turkmenistan, have resumed their submission to the 
Board of information on form D. 
147. The Board remains concerned that there are still 
five States parties that have never submitted form D: 
Albania, Burundi, Gambia, Serbia and Montenegro and 
Yemen. The Board urges those States to comply with 
their treaty obligations without delay. It also calls upon 
the non-parties that have not yet done so to furnish the 
required information. 
 
  Annual submission of information on the licit 
trade in and uses of substances in Tables I and II 
of the 1988 Convention 
 
148. Since 1995, in accordance with Economic and 
Social Council resolution 1995/20 of 24 July 1995, the 
Board has been requesting Governments to provide on 
form D, on a voluntary basis, data on licit trade in, uses 
of and requirements for scheduled substances. It is 
crucial for all Governments to be well informed of 
trade in and licit requirements for substances in 
Tables I and II of the 1988 Convention, in order to be 
able to identify unusual transactions at an early stage 
and thus prevent the diversion of those substances. 
Some 79 per cent of all Governments that submitted 
form D for 2004 to the Board provided data on licit 
trade in substances in Tables I and II, while 74 per cent 
were able to provide information on licit uses of and 
requirements for those substances. 
149. Most of the major importing and exporting 
countries now provide data on licit trade. The Board 
notes that the Islamic Republic of Iran has reported 
imports and licit requirements of some substances in 
Table I, including potassium permanganate and 
pseudoephedrine, for 2002 and 2003. However, 
Pakistan, a country that imports large quantities of 
substances in Table I, including acetic anhydride, 
ephedrine, potassium permanganate and pseudo-
ephedrine, still does not provide data on its licit trade 
and requirements. The major exporting countries and 
territories continued to provide information on 
individual exports through pre-export notifications 
pursuant to article 12, paragraph 10 (a), of the 
1988 Convention and in compliance with the terms of 
reference of the international initiatives Operation 
Purple, Operation Topaz and Project Prism.32  
150. The Board is pleased to note that, over the years, 
an increasing number of countries and territories have 
provided information on imports, exports and licit uses 
of precursors of amphetamine-type stimulants. 
Reporting on those substances continued to be highest 
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for ephedrine and pseudoephedrine. Although the 
information on trade in other precursors of 
amphetamine-type stimulants, such as safrole, 
1-phenyl-2-propanone (P-2-P) and 3,4-
methylenedioxyphenyl-2-propanone (3,4-MDP-2-P), 
remains limited, the number of countries providing 
relevant information is increasing. The Board 
encourages all countries and territories to strengthen 
their capacity to monitor and report on trade in 
precursors of amphetamine-type stimulants. 
 
  Prevention of diversion of precursors into the 
illicit traffic 
 
151. The most effective way to prevent the diversion 
of precursors into illicit channels continues to be the 
rapid exchange of information on both licit trade and 
trafficking in precursors. The provision of pre-export 
notifications for the exportation of precursor chemicals 
has proved to be an efficient tool for that purpose. The 
Board has continued to play an active role as the 
international focal point for the exchange of such 
information in the international initiatives Operation 
Purple, Operation Topaz and Project Prism. The Board 
is pleased to note that many countries have already 
designated central national authorities for Project 
Prism, which will facilitate the exchange of operational 
information.  
152. An adequate legislative basis or system of control 
is necessary for successful action against the diversion 
of precursors into illicit channels. The Board is pleased 
to note that, in 2005, many Governments introduced 
new or strengthened existing, controls over precursors. 
In particular, new European Union legislation33 
entered into force in August 2005, strengthening the 
monitoring of exports and introducing import controls 
over precursors. 
153. Full details on the activities undertaken by 
Governments and by the Board in precursor control are 
contained in the 2005 report of the Board on the 
implementation of article 12 of the 1988 Convention.34  
 
  Use of ephedrine and pseudoephedrine for illicit 
drug manufacture 
 
154. Trends in trafficking in precursors used in the 
illicit manufacture of amphetamine-type stimulants 
have changed over the past few years. Traffickers in 
North America have increasingly been attempting to 
divert pseudoephedrine raw material through brokers 
in Europe, whereas the pharmaceutical products 
containing the precursor are usually diverted from 
Asia. Furthermore, trafficking networks have appeared 
in Oceania that often smuggle the precursor by 
employing the same method usually used for 
smuggling the drug itself.  
155. Pseudoephedrine is the key precursor used for the 
illicit manufacture of methamphetamine, which is 
abused mainly in the United States and in countries in 
South-East Asia. While pseudoephedrine is listed in 
Table I of the 1988 Convention, the control measures 
provided for in article 12 of that convention do not 
apply to pharmaceutical preparations containing the 
substance. As a result, and as more and more countries 
have strengthened their controls over the raw material, 
traffickers are increasingly taking advantage of that 
loophole in the international drug control regime.  
156. In the period 2000-2001, large quantities of 
pharmaceutical preparations containing pseudo-
ephedrine that had been licitly manufactured by 
Canadian companies were diverted by traffickers for 
use in illicit methamphetamine manufacture in the 
United States. The Government of Canada, with the 
assistance of the Board, was able to remedy that 
situation by establishing a mechanism for the 
comprehensive monitoring and control of precursors in 
Canada, applying control measures also to 
pharmaceutical preparations containing precursors. 
That route having been effectively closed, traffickers 
appear to be turning, once again, to a previous route, 
namely, via Mexico. There is some concern that 
pseudoephedrine, in the form of both raw material and 
a preparation, is again being diverted from licit trade 
and distribution channels in Mexico for use in the 
illicit manufacture of methamphetamine.  
157. The Board calls upon Governments to estimate 
their licit requirements for precursors, which may be 
used in the illicit manufacture of amphetamine-type 
stimulants, and to submit those data to the Board. The 
Board reiterates its recommendation to Governments to 
control pharmaceutical preparations containing 
scheduled substances in the same way as they control 
the scheduled substances that those preparations 
contain. Furthermore, exporting countries are 
encouraged to provide pre-export notifications for 
exports of ephedrine and pseudoephedrine, including 
the pharmaceutical preparations containing those 
substances, to the authorities of importing countries. At 
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the same time, Governments are encouraged to take 
measures, as appropriate, to limit the availability of 
ephedrine and pseudoephedrine for medical purposes 
by improving measures for the monitoring and control 
of domestic distribution channels, where necessary.  
 
  Project Prism 
 
158. As a series of suspicious shipments of 
pseudoephedrine destined for Mexico were identified 
and subsequently stopped,35 the major exporting, 
importing and trans-shipment countries agreed, under 
Project Prism, on several voluntary measures to 
prevent the diversion of pseudoephedrine, including 
the sending, by certain key exporting countries, of 
pre-export notifications for pseudoephedrine 
preparations destined for North America and the 
development of a framework for a subregional 
assessment of licit pseudoephedrine requirements by 
Canada, Mexico and the United States. The Mexican 
authorities have also taken steps to reduce imports of 
the substance into Mexico on the basis of a rough 
estimate of the country’s legitimate requirements for 
pseudoephedrine. 
159. Several diversion attempts were uncovered under 
Project Prism during 2005 involving ephedra, the plant 
material from which ephedrine and pseudoephedrine 
are extracted and which is currently not under 
international control. The 15 shipments involved in the 
attempted diversions, totalling 933 tons, originated in 
China and were destined for companies in Germany, 
Mexico, the Netherlands and Sweden. As in all those 
cases the authorities of China had provided pre-export 
notifications to the authorities of the importing 
countries, it was possible to stop the shipments in time. 
The Government of Mexico has prohibited all imports 
of ephedra into that country. Furthermore, all 
authorities participating in Project Prism were alerted 
to the attempted diversions.  
160. The Board has taken note of the efforts under 
Project Prism to gather information on exports of 
safrole-rich oils from South-East Asia. In view of the 
role of such oils in the illicit manufacture of MDMA, 
whether as a direct precursor or as a “pre-precursor” 
(for instance, in the illicit manufacture of 3,4-MDP-2-
P), the UNODC Regional Office in Bangkok will 
conduct a regional survey to determine the extent of 
the cultivation, harvesting and marketing of the 
safrole-rich oils in South-East Asia. Governments of 
countries in East and South-East Asia are encouraged 
to cooperate with that important initiative. 
161. The concept of directing Project Prism through a 
task force, with members36 from each major geo-
graphical region, appears to be a sound approach. The 
Board is pleased to note that the Government of 
Australia has joined the Project Prism Task Force as 
the regional representative of Oceania. The experience 
gained by the Australian authorities in intercepting 
smuggled consignments of precursors will be of value 
to the Task Force and will be useful in similar 
operations launched in other regions. 
 
  Project Cohesion (Operation Purple and 
Operation Topaz) 
 
162. The Board notes that, upon its recommendation, 
the steering committees of Operation Purple and 
Operation Topaz held a meeting in Mexico City in 
October 2005 to examine and evaluate the activities 
that had been undertaken. The Board welcomes the 
decision of the meeting to launch a new phase of the 
combined operations, named Project Cohesion, which 
builds upon the successes achieved, for example, 
through the use of pre-export notifications. The new 
project introduces a regional approach to operational 
work and time-limited regional activities and provides 
for the exchange of real-time information, 
intelligence-gathering and backtracking investigations. 
The project also foresees the regular evaluation of 
activities. 
163. In view of the changes in the trends in licit trade 
and trafficking in potassium permanganate that have 
taken place since Operation Purple began, it is 
necessary to ensure that diversions of that substance, 
which is a precursor of cocaine, are prevented and that 
the illicit manufacture of cocaine is disrupted. For 
example, while both the number of shipments and the 
volume of potassium permanganate imported into the 
Andean subregion have declined since Operation 
Purple began in 1999, the Colombian authorities 
effected their largest seizures ever of that substance in 
2004, totalling over 170 tons. 
164. During the period from 1 November 2004 to 
31 October 2005, the Board was informed of 
824 shipments of potassium permanganate, amounting 
to 27,200 tons, which had been sent to 87 importing 
countries or territories. In addition to those licit 
shipments in international trade, a further 36 shipments 
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of potassium permanganate, totalling over 1,500 tons, 
were stopped, as there was concern over the legitimacy 
of the orders. As one of the principal aims of Operation 
Purple is to identify and intercept attempted diversions 
of potassium permanganate and to discover front 
companies and suspect persons, Governments need to 
thoroughly investigate stopped shipments of the 
substance. Furthermore, steps will have to be taken to 
improve the exchange of information on seizures and 
stopped shipments of potassium permanganate and to 
initiate backtracking investigations to identify and 
dismantle the networks concerned.  
165. During the period from 1 November 2004 to 
31 October 2005, the authorities of 14 exporting 
countries provided 1,300 pre-export notifications for 
shipments of acetic anhydride to 48 importing 
countries or territories. The total amount of acetic 
anhydride monitored was 331,000 tons. The 
monitoring of international trade under Operation 
Topaz resulted in the identification of six suspicious 
shipments in 2004, with a total of 556 tons. Those 
shipments were stopped as there was reason to doubt 
the legitimacy of the orders. There is, however, some 
concern that not all countries have appropriate 
mechanisms in place to enable them to rapidly report 
seizures of acetic anhydride. While nine countries 
reported 36 individual seizures of the substance in 
2004 under Operation Topaz, only four seizure reports 
were received in 2005. 
166. In Turkey, seizures of acetic anhydride have 
fallen for the third year in a row, which may indicate 
that traffickers are using new methods or routes of 
diversion. The authorities of the Russian Federation 
reported their largest seizures ever of the substance, 
totalling over 53 tons in 2004. No major seizures have 
been reported in Afghanistan or its neighbouring 
countries since 2003, when 11 tons of acetic anhydride 
were seized in Afghanistan near that country’s border 
with Pakistan. While acetic anhydride was seized each 
year in Pakistan between 1991 and 1998, no seizures of 
that substance have been reported in that country since 
2001. 
167. Governments of countries in West Asia are urged 
to develop counter-trafficking activities focusing on 
the substances used in the illicit manufacture of heroin 
and on acetic anhydride in particular. Furthermore, 
those Governments are invited to make use of the 
mechanism established under Project Cohesion to 
enable countries in that region to receive support in 
investigations through advice, guidance and on-site 
practical assistance. 
 
 
 D. Special topics 
 
 
  Evaluation of overall treaty compliance by 
Governments 
 
168. Pursuant to its mandate under the international 
drug control treaties, the Board regularly selects 
several countries and reviews these countries’ overall 
compliance with the provisions of the international 
drug control conventions. The review covers various 
aspects of drug control, including the functioning of 
national drug control administrations, the adequacy of 
national drug control legislation and policy, measures 
taken by Governments in combating drug abuse and 
illicit trafficking, and Governments’ fulfilment of their 
reporting obligations as required under the 
international drug control treaties.  
169. The findings of the review, as well as the Board’s 
recommendations for remedial action, are conveyed to 
the Governments concerned, as part of an ongoing 
dialogue between the Board and Governments to 
ensure that the provisions of the international drug 
control conventions are implemented.  
170. The Board, while reviewing the drug control 
situation in various countries, adopts, when necessary, 
positions on particular drug control issues. Those 
positions are conveyed to the Government concerned 
and, when appropriate, made public by the Board 
through its annual report. Showing respect for the 
views is an important aspect of cooperating with the 
Board. 
171. In 2005, the Board reviewed the drug control 
situation in a number of countries, including Albania, 
Bosnia and Herzegovina, and Romania, as well as 
measures taken by the Governments of those countries 
to address their respective drug problems. The three 
countries are on the Balkan route, the main route used 
for smuggling heroin from Afghanistan into Europe, 
and for many years have faced serious drug trafficking 
problems. 
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  Albania 
 
172. The Government of Albania has made some 
progress in recent years, in particular in the area of law 
enforcement, and seizures of illicit drugs have 
increased since 1999. Drug control legislation in 
Albania is by and large adequate. In 2004, the 
Government adopted a drug control strategy covering 
the years 2004-2010, together with an action plan for 
its implementation.  
173. However, resources provided for drug control 
efforts by the Government are insufficient. Though an 
interministerial committee to coordinate drug control 
policy exists, the committee has not been able to 
function adequately because of a lack of resources. In 
addition, resources allocated for drug control within 
the relevant government agencies in Albania are 
inadequate.  
174. Cooperation with the Board has proved to be 
problematic in several respects. Despite several 
requests since 2003 for a progress report on the 
implementation of the Board’s recommendations 
pursuant to its 2002 mission to Albania, the 
Government could not provide comprehensive 
information until late 2005. In addition, Albania, 
despite being a party to the 1988 Convention, has 
never provided to the Board any of the required 
information on precursors. 
175. In November 2005, the Board invited a 
delegation of the Government of Albania to its session, 
as part of the ongoing dialogue with the Government. 
The delegation reported to the Board on recent 
measures taken in the field of drug control and assured 
the Board that the Government was committed to drug 
control and that cooperation with the Board would 
improve. The Board trusts that those assurances will be 
realized and looks forward to closer cooperation with 
the Government of Albania.  
 
  Bosnia and Herzegovina 
 
176. There remains an almost complete lack of 
coordination in the area of drug control between the 
two entities comprising Bosnia and Herzegovina: the 
Federation of Bosnia and Herzegovina; and Republika 
Srpska. There is no legislation at the national level to 
ensure the implementation of the provisions of the 
international drug control treaties and no national 
entity responsible for coordinating drug control efforts. 
As a result, Bosnia and Herzegovina has been unable 
to fulfil its treaty obligations and has failed to provide 
the Board with the required data regarding narcotic 
drugs and psychotropic substances.  
177. The Board sent a mission to Bosnia and 
Herzegovina in October 2000. The mission found that 
the Government had, with the assistance of UNODC, 
prepared a comprehensive draft bill on drug control. 
The draft bill would have established a national agency 
responsible for coordinating drug control policy. 
However, subsequent to the mission, the draft bill was 
rejected by the parliament of Bosnia and Herzegovina 
and remained pending for years.  
178. In August 2005, the President and the Secretary 
of the Board met with the High Representative for the 
Implementation of the Peace Agreement on Bosnia and 
Herzegovina. All parties agreed that the adoption of 
comprehensive legislation on drug control should be a 
priority of the Government. In late 2005, a revised 
version of the draft bill was passed in the lower house 
of parliament and was scheduled for debate in the 
upper house. The Board expects that the draft bill will 
be adopted as scheduled.  
179. The drug abuse situation in Bosnia and 
Herzegovina is worsening, especially among young 
persons. Again, lack of coordination in the Government 
has hampered efforts to gather data on the drug abuse 
situation in the country and to establish adequate 
facilities for the treatment of drug addicts.  
180. The Board urges the Government of Bosnia and 
Herzegovina to make the adoption and implementation 
of comprehensive drug control legislation matters of 
priority and to renew its efforts to ensure adequate 
coordination between the Federation of Bosnia and 
Herzegovina and Republika Srpska in the area of drug 
control.  
 
  Romania  
 
181. After years of dialogue with the Board, the 
Government of Romania has made significant progress 
in responding to the Board’s concerns. For many years, 
legislation in the area of drug control was inadequate 
and administrative structures were weak. That had led 
to Romania being increasingly used as a drug 
trafficking hub along the Balkan route.  
182. In recent years, the Government of Romania has 
taken numerous measures to strengthen drug control. 
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New laws were adopted with the assistance of 
UNODC, bringing national legislation into conformity 
with the provisions of the international drug control 
treaties. An interministerial committee was established 
to coordinate government efforts in drug control; and 
recently, a new agency, the National Anti Drug Agency, 
became operational. The cooperation of the 
Government with the Board has also improved 
significantly.  
183. The National Anti-Drug Agency of Romania has, 
on a regular basis, conducted comprehensive 
evaluations of the implementation of the national drug 
control strategy. Those evaluations indicate that, while 
progress has been made in the reduction of illicit drug 
supply, activities involving demand reduction and drug 
abuse prevention and treatment remain underfunded.  
184. The Board welcomes the progress made in 
Romania and trusts that the Government will continue 
its efforts to strengthen drug control. The Board also 
urges the Government to ensure that programmes in the 
areas of demand reduction and treatment receive 
adequate resources, in order to be effective in dealing 
with the increasing drug abuse problem in Romania. 
 
  Evaluation of implementation by Governments 
of recommendations made by the Board 
subsequent to its country missions 
 
185. The Board conducts an average of 20 country 
missions a year to review the drug control situation in 
various countries and Governments’ compliance with 
the international drug control treaties. The country 
missions generally result in a series of observations 
and recommendations, which are conveyed formally to 
the Government concerned.  
186. As part of its ongoing dialogue with 
Governments, the Board also conducts an annual 
evaluation of the implementation of its 
recommendations pursuant to those missions. Selected 
countries are invited to provide information on 
progress made in the implementation of the Board’s 
recommendations and to inform the Board of any 
achievements and difficulties in that regard.  
187. In 2005, the Board selected a number of countries 
and one territory to which it had sent missions in 2002 
and requested their governments to provide 
information. The selected countries included 
Kazakhstan, Kenya, Namibia and the former Yugoslav 
Republic of Macedonia; the selected territory was the 
Netherlands Antilles. 
188. The Board expresses its appreciation for the 
information provided by the Governments of Namibia 
and the former Yugoslav Republic of Macedonia, as 
well as by the government of the Netherlands Antilles. 
That information enabled the Board to conduct a 
meaningful assessment of the drug control situations in 
those countries or areas. The Board notes with concern, 
however, that no information was received from the 
Governments of Kazakhstan and Kenya. 
189. The Board underlines the importance of the 
review of its country missions and requests the 
Governments of Kazakhstan and Kenya to ensure that 
the required information is provided to it without 
further delay. The full support and cooperation of 
Governments are essential to the efforts by the Board 
to achieve the aims of the international drug control 
treaties. 
 
  Namibia 
 
190. The Government of Namibia has made progress 
in some of the areas of drug control, pursuant to the 
recommendations of the Board. In October 2004, the 
Government adopted a national drug control master 
plan. 
191. There are, however, a number of issues that still 
need to be addressed in Namibia. In particular, no 
significant progress has been made with regard to the 
adoption of certain draft bills related to drug control. 
The Board urges the Government of Namibia to take 
the steps necessary to ensure that those bills are 
adopted as soon as possible, in order to bring the 
national legislation into full conformity with the 
provisions of the international drug control treaties. 
Measures need to be taken with regard to the control of 
precursor chemicals, before the relevant legislation is 
put in place.  
192. The Board wishes to emphasize the importance of 
conducting a rapid assessment of the drug abuse 
situation in Namibia, in order to ensure that the 
growing problem of drug abuse is dealt with in a more 
effective manner. 
 
  Netherlands Antilles 
 
193. The government of the Netherlands Antilles has 
adopted new legislation on psychotropic substances, 
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bringing under control the substances in Schedules III 
and IV of the 1971 Convention. The legislation in force 
in the territory is now in compliance with the 
1971 Convention. Furthermore, cooperation and 
coordination in law enforcement activities have been 
enhanced, and the government has been successful in 
addressing the problem of cocaine “body packers”37 
departing from the territory for countries in Europe.  
194. Legislation on the implementation of article 12 of 
the 1988 Convention, however, is still pending 
discussion by the Parliament of the Netherlands 
Antilles. Moreover, there has been little or no progress 
in developing a comprehensive national drug control 
strategy to combat the drug problem. The Board urges 
the government to take additional steps to ensure that 
progress is made in those areas.  
195. The Board also urges the government of the 
Netherlands Antilles to implement other 
recommendations of the Board, in particular to take 
concrete measures to deal with the problems of the 
illicit sale of controlled substances via Internet 
pharmacies and the related diversion of narcotic drugs 
and psychotropic substances and to conduct a rapid 
assessment of the drug abuse situation in the territory.  
 
  The former Yugoslav Republic of Macedonia  
 
196. Noticeable progress has been achieved in drug 
control in the former Yugoslav Republic of Macedonia. 
In particular, the Government has undertaken a 
comprehensive reform of the criminal codes and has 
adopted a new law on precursor control. 
197. Coordination among government agencies, as 
well as the cooperation of the Government of the 
former Yugoslav Republic of Macedonia with the 
Governments of other countries in the region, has also 
improved. The statistical information provided by the 
Government indicates a considerable increase in the 
volume of seized drugs in recent years. Furthermore, 
the Ministry of Health has taken a number of measures 
with regard to the control of pharmacies, as well as the 
treatment of drug addicts, in accordance with the 
recommendations of the Board.  
198. The Government of the former Yugoslav 
Republic of Macedonia has set objectives in the area of 
drug control, to be accomplished by the end of 2005, as 
part of its action plan for European partnership. The 
Board expects to receive from the Government 
information regarding any progress that has been made 
and difficulties that have been encountered in 
achieving those objectives. 
 
  Measures to ensure the implementation of the 
international drug control treaties 
 
  Action of the Board taken pursuant to article 14 of 
the 1961 Convention and article 19 of the 
1971 Convention 
 
199. Article 14 of the 1961 Convention and article 19 
of the 1971 Convention describe measures that the 
Board may take to ensure the implementation of the 
provisions of those conventions. In 1997, the Board 
invoked article 14 of the 1961 Convention and 
article 19 of the 1971 Convention with respect to 
several States, in view of their persistent failure to 
bring national control measures in conformity with the 
respective conventions, to submit information to the 
Board as required under those conventions and to 
respond to enquiries of the Board, despite the various 
forms of communications available, the reminders sent 
and the technical assistance provided to them in the 
area of drug control. The objective of the Board has 
been to promote compliance with those conventions 
when other means failed. After having what amounted 
to in some cases a lengthy dialogue with the Board 
pursuant to article 14 of the 1961 Convention and 
article 19 of the 1971 Convention, most of the States 
took remedial measures. Consequently, the Board 
decided to terminate any action pursuant to those 
articles vis-à-vis those States.  
200. The Board notes with concern, however, that one 
State in Africa, with respect to which the Board 
invoked in 1997 article 14 of the 1961 Convention and 
article 19 of the 1971 Convention, has made no 
substantial progress in drug control, despite the 
Board’s ongoing dialogue with that State. While 
acknowledging the difficulties the Government may 
have encountered, the Board urges it to take speedy 
action to remedy the situation. Measures taken 
pursuant to article 14 of the 1961 Convention and 
article 19 of the 1971 Convention consist of 
increasingly severe steps, and continuous failure to 
remedy the situation may result in the Board deciding 
to take further action pursuant to those articles, which 
could include the Board proposing to the Economic 
and Social Council to impose an embargo on the State 
concerned. The Board will continue its consultations 
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with the State pursuant to those articles to ensure that 
progress is made in its compliance with the 
international drug control treaties.  
 
  Consultation with the Government of Afghanistan 
pursuant to article 14 of the 1961 Convention 
 
201. The Board, having determined that the situation 
in Afghanistan had seriously endangered the aims of 
the 1961 Convention as amended by the 1972 Protocol, 
invoked article 14 of the 1961 Convention in 2000 with 
respect to Afghanistan. Since then, the Board has 
followed closely the development of the drug control 
situation in Afghanistan and has maintained an ongoing 
dialogue with the Afghan authorities pursuant to 
article 14 of the 1961 Convention. 
202. The Board notes that the Government of 
Afghanistan remains fully committed to drug control, 
as evidenced by the recent statements of the President 
of Afghanistan in which he reiterated the Government’s 
determination to pursue the fight against drug abuse 
and illicit trafficking on all fronts. Despite many 
obstacles, the Government of Afghanistan, with the 
assistance of the international community, has 
undertaken a number of major institutional and policy 
changes, aimed at reaching its counter-narcotics 
objectives. In particular, the Government has 
established the Counter Narcotics Ministry, with a 
view to strengthening the coordination of drug-related 
activities at the national level, and has created the 
Central Poppy Eradication Force to address the 
problem of illicit opium poppy cultivation. The 
Government has also recently created a committee, 
headed by the President, to intensify the efforts to 
eradicate opium poppy. The committee, which includes 
cabinet ministers and representatives of donor 
countries, is expected to launch a number of campaigns 
providing farmers with an alternative livelihood, 
preventing opium poppy cultivation, destroying opium 
poppy cultivation sites, establishing a new mechanism 
for dealing with drug cases, rehabilitating drug addicts 
and promoting regional cooperation.  
203. Progress continues to be made in law 
enforcement. Several particularly effective law 
enforcement operations took place in 2005, resulting in 
a number of significant drug seizures and the 
dismantling of opium bazaars and illicit drug 
laboratories. The increasing operations of the newly 
trained Afghan Special Narcotics Force on illicit drug 
activities in different parts of the country displayed a 
more significant role in the Government’s counter-
narcotics efforts. Furthermore, the Counter Narcotics 
Criminal Justice Task Force, established in 
January 2005, has become operational. The Board 
encourages the Government to continue its efforts to 
ensure that the Task Force also operates in provinces in 
order to bring to justice quickly those engaged in drug-
related crime.  
204. The Board, while welcoming the above-
mentioned positive developments, is seriously 
concerned that, despite the efforts of the Government 
and the international community, opium poppy 
cultivation and illicit drug trade continue to be among 
the greatest threats to establishment of the rule of law 
and effective governance in Afghanistan. Opium 
production in 2005 was estimated at about 4,100 tons, 
only 100 tons less than the record harvest of 2004, 
although there was a decline of 21 per cent in the total 
area under opium poppy cultivation. Afghanistan thus 
remains the largest source of illicit opium production, 
accounting for 87 per cent of the world total in 2005. 
Over one half of the national income continues to be 
generated from illicit drug-related activities; that 
situation poses a continuous threat to peace, security 
and development, not only in Afghanistan, but also in 
other countries. 
205. The varying situation with regard to the 
eradication of opium poppy cultivation in Afghanistan 
in 2005 is a clear indication that the ban on opium 
production issued by the Afghan authorities in 2002 
has so far not adequately been implemented. This 
reveals a lack of commitment towards law enforcement 
on the part of some officials in the provinces of the 
country. The Board reiterates that achieving peace, 
security and development in Afghanistan is closely 
linked with the solving of the drug control problem, 
and that failure to address the current drug control 
situation could undermine the political progress, 
economic growth and social development in 
Afghanistan. The Board urges the Government to take 
firm measures to ensure that the situation is remedied, 
thus responding to the Board’s invoking of article 14 of 
the 1961 Convention.  
206. The Board notes with concern that drug abuse 
continues to increase in Afghanistan. The most 
commonly abused substances include not only heroin, 
opium and cannabis, but also a wide variety of 
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pharmaceutical products such as analgesics, hypnotic-
sedatives and tranquillizers, which can easily be 
obtained in pharmacies without a prescription. One 
matter of particular concern is opium abuse among 
women and the exposure of very young children to 
opium, as well as the rapid spread of drug-related 
HIV/AIDS infection. 
207. There appears to be no significant progress in this 
area, due to the lack of institutional arrangements for 
the planning and coordination of demand reduction 
programmes. The Board urges the Government of 
Afghanistan to pursue its action plan on demand 
reduction in order to achieve the targets identified in 
various areas of demand reduction, including a public 
awareness campaign, training, treatment and 
rehabilitation.  
208. The Board expresses its concern regarding the 
recent advocacy by a non governmental organization of 
legalization of opium poppy cultivation in Afghanistan. 
The idea that legalizing opium poppy cultivation would 
somehow enable the Government to obtain control over 
the drug trade and exclude the involvement of criminal 
organizations is simplistic and does not take into 
account the complex situation in the country. On the 
contrary, implementation of such an idea would make 
drug control in Afghanistan more difficult. The Board 
believes that at present a ban on opium poppy 
cultivation in Afghanistan is the most suitable and 
important measure to eliminate the drug problem in the 
country. The Board is in full agreement with the 
Government, which has rejected this proposal and has 
reiterated its determination to continue strengthening 
drug control, in compliance with its obligations under 
the international drug control treaties. 
209. While recognizing the need to provide the 
Government with technical assistance, the Board, in 
cooperation with UNODC, has developed an overall 
training programme for Afghanistan on the control of 
licit activities related to narcotic drugs, psychotropic 
substances and precursors. The purpose of the 
programme is to increase the Government’s capacity to 
implement the provisions of the international drug 
control treaties. The Board expects that UNODC will 
allocate the necessary funds to ensure that the 
programme is implemented as soon as possible.  
210. The Board welcomes the various activities that 
are being implemented by UNODC to assist the 
Government in strengthening drug control. The Board 
trusts that UNODC will continue to provide assistance 
to the Government and that the international 
community will provide adequate funds for that 
purpose. In particular, the Board notes that the 
production of opium remains high, despite a reduction 
in the area of illicit opium poppy cultivation, and 
requests UNODC to focus on measures to address that 
issue.  
211. In its report for 2001,38 the Board, under the 
authority granted to it under article 14, paragraph 1 (d), 
of the 1961 Convention, called the attention of the 
parties to that convention, the Economic and Social 
Council and the Commission on Narcotic Drugs to the 
drug control situation in Afghanistan. The Board notes 
with appreciation the continued commitment of the 
international community to assisting Afghanistan in 
implementing the ban on opium production, providing 
legitimate livelihoods to opium poppy growers and 
bringing counter-narcotics measures into the 
mainstream of overall development assistance.  
212. The Board underlines that addressing the drug 
control situation in Afghanistan is a matter that 
requires the continuous and long-term support and 
cooperation of the international community. The Board 
urges the international community to renew its efforts 
to combat opium production in Afghanistan and the 
corruption associated with that activity, so that the 
goals in the national drug control strategy, as set out by 
the Government of Afghanistan in cooperation with the 
international community, may be achieved within the 
established time schedule.  
213. The Board reiterates that the Government of 
Afghanistan has the ultimate responsibility of 
addressing the drug problem and fulfilling its treaty 
obligations under the international drug control 
treaties. The elimination of illicit drug activities, in 
particular the illicit cultivation of opium poppy, should 
be of the utmost importance to the Government of 
Afghanistan. The Board will continue to monitor 
developments in drug control in Afghanistan, as well as 
the Government’s progress, pursuant to article 14 of 
the 1961 Convention. The invoking of article 14 will 
remain in force until such time as the Board is satisfied 
that Afghanistan has complied fully with the provisions 
of the 1961 Convention. 
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  Provisions regarding travellers under treatment 
involving the use of medical prescriptions 
containing controlled substances 
 
214. The Commission on Narcotic Drugs, in its 
resolutions 45/5 and 46/6, encouraged States parties to 
the 1961 Convention, that Convention as amended by 
the 1972 Protocol and the 1971 Convention to notify 
the Board of restrictions currently applicable in their 
territory to travellers under medical treatment with 
drugs containing narcotic drugs or psychotropic 
substances under international control. The Board has 
requested Governments to provide specific information 
on legal provisions or administrative measures adopted 
in their countries for travellers under medical 
treatment. Such information should include restrictions 
and conditions that need to be met by travellers 
entering or leaving their territory and carrying medical 
preparations containing controlled substances for 
personal use. The Board calls on all Governments that 
have not yet done so to submit the relevant legal 
provisions and administrative measures without delay. 
The Board will ensure the wide dissemination of the 
information so that Governments will be able to advise 
travellers on the requirements needed in the country of 
destination. Whenever appropriate, the Board 
encourages Governments, when developing or updating 
a regulatory framework for travellers carrying medical 
preparations containing controlled substances, to 
consult the guidelines for national regulations 
concerning travellers under treatment with 
internationally controlled drugs, which has been made 
available in the six official languages of the United 
Nations on the website of the Board (www.incb.org). 
215. By 1 November 2005, the Governments of 
71 countries had provided the requested information to 
the Board. In all of the responding countries, travellers 
were allowed to carry medical preparations containing 
narcotic drugs and/or psychotropic substances for their 
personal use in the amount indicated in their medical 
prescriptions and for the length of treatment prescribed 
by their doctors, provided that the travellers possessed 
supporting documents. The diverse laws and 
regulations, including administrative procedures and 
practical measures, provided by Governments are 
being consolidated in a standard format and will be 
made available on a yearly basis in the technical 
publications of the Board and on the website of the 
Board. That information should be considered 
indicative of the requirements that travellers should be 
aware of prior to entering the countries in question. 
International travellers should be encouraged to obtain 
more details from the competent national authorities or 
through other authorized channels such as the 
diplomatic missions of countries of destination. 
 
  Requirement for drug reference standards 
 
216. Reference standards of narcotic drugs, 
psychotropic substances and/or precursors are required 
for the proper and reliable identification and analysis 
of controlled drugs and precursors, whether simple 
screening tests are used or more sophisticated methods 
are performed for the qualitative and quantitative 
analysis of drugs in biological samples. The reference 
standards are an essential element of laboratory 
routines. The Board draws the attention of 
Governments to the value and importance of drug 
testing and to the fact that, without reference standards, 
laboratories cannot provide essential support services 
to national criminal justice systems and law 
enforcement and health authorities. 
217. When reference standards of controlled 
substances are not available in a country and must be 
imported, authorized national laboratories are required 
to submit original import certificates issued by the 
national competent authority under the international 
drug control treaties. As some national drug testing 
laboratories have experienced difficulties in obtaining 
reference standards, the Board encourages 
Governments to review the adequacy of existing 
national legislation and regulations, where appropriate, 
in order to ensure that they do not hinder bona fide 
drug testing laboratories in their efforts to obtain 
reference standards or test samples containing 
controlled substances.  
218. The Board encourages national competent 
authorities to consider as a matter of priority requests 
for import and export certificates for reference 
standards or test samples containing controlled 
substances for use by drug testing laboratories and to 
take all steps to ensure the timely issuance of the 
authorizations required under the international drug 
control treaties. Governments should be aware of and 
recognize the critical importance of the reference 
standards and other materials required by drug testing 
laboratories in providing a reliable service in support 
of national drug control efforts. Governments should 
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also bring to the attention of laboratories the 
requirements and obligations for licensing. 
 
  Misuse of the Internet 
 
219. Since 1996, the Board has devoted increasing 
attention to the problem of internationally controlled 
substances, including the most strictly controlled 
substances, being illegally sold by Internet pharmacies. 
Narcotic drugs in Schedules I and II of the 
1961 Convention that are illegally sold by such 
pharmacies include fentanyl, hydrocodone, oxycodone, 
methadone, codeine and dextropropoxyphene, all of 
which are known to be widely abused by drug addicts. 
Psychotropic substances that are illegally sold by such 
pharmacies include stimulants in Schedule II 
(methylphenidate, dexamphetamine, amphetamine) and 
Schedule IV of the 1971 Convention (amfepramone, 
phentermine), analgesics in Schedule III (pentazocine) 
and benzodiazepines in Schedule IV (alprazolam, 
bromazepam, chlordiazepoxide, diazepam, nitrazepam, 
temazepam etc.). Those substances are also frequently 
diverted to be sold on the illicit market and abused by 
drug addicts. 
220. While Internet pharmacies can easily be relocated 
and can operate from any region in the world, some 
countries are more frequently used as the base for 
illegal Internet activities. In the Americas, the United 
States is not only the biggest consumer country for 
Internet pharmacies but also the country from where 
many illegal Internet pharmacies operate. Countries in 
the Caribbean and Mexico are often found to be source 
countries. In Asia, China, India, Pakistan and Thailand 
are most often identified as countries from where 
illegal Internet pharmacies operate. China has also 
been identified as a country from where the raw 
material used for counterfeiting internationally 
controlled substances is sold illegally via the Internet. 
In Europe, the Netherlands has been frequently 
identified as a country from where illegal Internet 
pharmacies are operating. While illegally operating 
Internet pharmacies cater to all countries, the majority 
of the consumers are citizens of the United States or 
countries in Europe. 
221. The extremely volatile and flexible Internet 
pharmacy market makes a systematic assessment of the 
scope of the problem difficult. Extensive Internet 
searches, supported by other information such as 
seizure data, can provide an indication of the volume 
of illegal transactions. According to seizure data, the 
number of transactions carried out by an illegally 
operating Internet pharmacy is significantly higher 
than that of a traditional, legally operating pharmacy. 
In some cases, the Internet pharmacies averaged 450 
sales transactions involving prescription drugs per day; 
95 per cent of the transactions involved internationally 
controlled substances. According to seizure data from 
the United States, in the case of one illegally operating 
Internet pharmacy, the turnover for only two 
substances, diazepam and hydrocodone, totalled about 
6 million dosages per year. According to the United 
States Postal Inspection Service, 10 million shipments 
of prescription drugs enter the United States illegally 
each year—and that figure does not include domestic 
shipments from illegally operating Internet pharmacies 
based in the United States. Taking into account that 
each illegal shipment often contains a significant 
quantity of such drugs (several thousand tablets, 
according to reports of parcels seized by Thai and 
United States authorities), the profits to be gained are 
an incentive for organized criminal groups to engage in 
such activities. Based on the above-mentioned figures, 
the estimated value of the illegal transactions is 
probably in hundreds of millions of United States 
dollars.  
222. The quantities involved, the advertisements of the 
illegally operating Internet pharmacies and their sales 
procedures indicate that customers misusing and 
abusing such drugs are the target group. For example, 
emphasis on the possibility of purchasing prescription 
drugs without a prescription, references to discreet 
shipments and to delivery by mail or to a post office 
box are signs that the pharmacy in question is an 
illegally operating Internet pharmacy.  
223. Customers of illegally operating Internet 
pharmacies are using the services for purposes not 
related to the availability or price of the drugs. 
Prescriptions for controlled substances can easily be 
obtained if the substances are required for medical 
treatment, and at a much lower price. According to the 
prices listed on the websites of such pharmacies, the 
substances offered on the Internet are in fact much 
more expensive, sometimes nearly 18 times more 
expensive than the same substance purchased through a 
health or social security insurance scheme or any 
private health insurance scheme. Even in cases where 
customers are not insured, legally operating Internet 
pharmacies with cheaper prices, even for substances 
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requiring prescriptions, would be preferred over 
illegally operating Internet pharmacies.  
224. Excluding customers with legitimate medical 
reasons and excluding the cost factor, the availability 
of prescription drugs without prescriptions remains the 
only reason for using an illegally operating Internet 
pharmacy. In the case of internationally controlled 
substances, this implies that the customers are only 
those who cannot legally obtain prescriptions for 
narcotic drugs and psychotropic substances, as they are 
solely intended for drug abuse and drug trafficking.  
225. Some of those prescription drugs contain narcotic 
drugs and psychotropic substances with habit-forming 
properties similar to illicit drugs such as heroin and 
cocaine. Demand is high for some of those controlled 
pharmaceuticals, which are often abused by drug 
addicts as their first drug of choice. Another concern is 
the “discreetness” of illegal Internet pharmacies, which 
allow customers to remain anonymous. In the case of 
online consultations, personal details to be given by the 
customer, including information concerning his or her 
age, are not verified. Such anonymity poses a serious 
problem in terms of ensuring the protection of children 
and youth against drug abuse. The ease with which 
controlled substances can be obtained through Internet 
pharmacies constitutes encouragement of their abuse 
and a serious threat to children and adolescents. 
226. Part of the supply of illegal Internet pharmacies is 
provided through the diversion of pharmaceutical 
preparations containing controlled substances from 
licit manufacture and trade. As mentioned in 
paragraph 121 above, the Board has received several 
reports from law enforcement authorities on companies 
and establishments engaged in both legal and illegal 
manufacture and trade. Another part is illegal 
manufacture of the products in question (counterfeit) 
by the use of either diverted raw material or illicit 
manufacture of raw materials. Customers of illegally 
operating Internet pharmacies need to be aware that 
their chances of receiving the authentic product is low. 
In the United States, for example, it is estimated that 
only 50 per cent of customers ordering through 
illegally operating Internet pharmacies receive the 
genuine product; in particular, pharmaceutical products 
containing controlled substances and known to be 
subject to abuse are difficult to divert in the required 
quantities and are therefore likely to be counterfeit.  
227. In one particular case of an illegally operating 
Internet pharmacy, the United States authorities 
detected the sale of counterfeit Xanax (alprazolam), 
Valium (diazepam) and Ritalin (methylphenidate), all 
from one single counterfeiter in Belize. Similarly, 
Swedish authorities have reported the appearance of 
counterfeit Rohypnol tablets that had been 
manufactured by using raw material illegally obtained 
on a website operating from China.  
228. Similarly, precursors of psychotropic substances 
are bought via the Internet to be used to clandestinely 
manufacture those substances. In one such case in the 
Netherlands, the vigilance of a courier service was 
crucial in the detection of the illegal sale of GBL on a 
large scale by a website owner from the Netherlands, 
who was selling the precursors necessary for the 
manufacture of GHB, providing the recipe for the 
illicit manufacture of GHB and actively promoting the 
use of GHB, all via the Internet. The Board notes with 
appreciation this example of teamwork involving, 
among others, law enforcement agencies at the national 
and international levels, the chemical industry and 
courier services, which has led to the closing down of 
the illegal Internet operation. 
229. Websites may go up, be moved or be taken down 
in a short period of time, making it difficult for 
authorities to track, monitor or shut down sites that are 
operating illegally and making it easier for the site 
owners to avoid impending or suspected law 
enforcement action. Having closed down, they can 
immediately relocate to another site and start up the 
business again. It appears that illegally operating 
Internet pharmacies routinely relocate, without any real 
reason, just as a precaution. Replicating web searches 
show the rapid changes and replacements within the 
business. In a number of cases, an automatic 
connection from a closed down site redirects the 
Internet user to a new site that most likely belongs to 
the same owner as it has practically the same layout 
and wording.  
230. So far, only a limited number of countries have 
adopted specific legal measures to prevent such misuse 
of the Internet. Even in countries where such 
legislation exists, different laws and regulations in 
other countries make it difficult to consistently 
identify, investigate and ultimately prevent misuse of 
the Internet. Isolated legal measures in individual 
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countries can therefore have only a limited impact 
without concerted, supportive international action.  
231. Counteracting illegal Internet pharmacies 
requires more diverse investigative resources, at the 
national level and the international level. Close 
cooperative working relationships between the 
different agencies involved needs to be established at 
the national level. In addition to efforts at the national 
level, increased international cooperation and 
networking are required. Specialized units in various 
countries are already doing screening exercises. In 
order to avoid duplication, set complementary action 
and use resources responsibly, authorities should know 
about each other’s activities. International cooperation 
and exchange of information with regard to operations 
of illegal Internet pharmacies are currently very 
limited. 
232. The Board notes with appreciation the various 
initiatives undertaken by authorities in the Netherlands, 
Sweden and the United States that include cooperation 
with international organizations, authorities of other 
countries, Internet service providers and service 
industries. The Board encourages the countries and 
international organizations concerned to actively 
participate in such activities or to initiate such joint 
efforts if required. The Board urges international 
organizations, in particular the Universal Postal Union 
(UPU), the International Criminal Police Organization 
(Interpol), the Customs Cooperation Council (also 
called the World Customs Organization) and UNODC, 
to confront the problems of illicitly operating Internet 
pharmacies and smuggling controlled drugs by mail in 
their respective areas of responsibility and to share 
their experiences with the Board. 
233. Authorities encounter difficulties in finding 
partners in other countries with whom to cooperate in 
ongoing operations. In a number of cases, there has 
been no response to requests for cooperation. The 
Board appeals to the Governments of all countries to 
handle such requests seriously, to provide all the 
necessary support to investigative efforts and to 
instigate immediate criminal procedures against 
offenders. The Board calls on Governments to 
undertake efforts to increase the awareness of law 
enforcement, regulatory and drug control authorities 
regarding the need to counteract the activities of 
illegally operating Internet pharmacies. In addition, 
awareness-raising campaigns should alert the public to 
the potential dangers of illegally operating Internet 
pharmacies. Furthermore, national authorities need to 
ensure that legislation, as well as the application of 
laws and sanctioning by courts, is stricter with regard 
to the diversion of pharmaceuticals in general and the 
illegal operations of Internet pharmacies in particular. 
At present, in many countries the judiciary does not 
accord sufficient importance to such cases. With regard 
to support required from Internet service providers, the 
Board wishes to remind Governments to fully utilize 
existing legislation, or in cases in which such 
legislation is lacking, to introduce such legislation. 
National authorities may also seek the cooperation of 
service industries essential to Internet business 
operations, such as credit card companies, other 
financial services facilitating monetary transactions 
and courier services. They can provide important 
support not only during investigations, but also in 
identifying such illegal activities (see para. 228 above). 
234. Not all illegally operating Internet pharmacies 
provide prescription drugs without a prescription. 
Some offer the possibility of online consultations; 
however, in most cases such consultations are only an 
attempt to mask the illegal nature of the transaction. In 
most cases, such online consultations rely on a 
questionnaire to be filled out by the customer. The 
information provided by the customer is not verified. 
On the basis of such bogus consultations, online 
prescriptions are then provided by medical doctors 
working for the illegally operating Internet pharmacies. 
The procedure does not provide a meaningful doctor-
patient relationship but is used as a front for illegal 
transactions. 
235. The authorities of the Netherlands and the United 
States, having recognized the above-mentioned 
problem, have issued or are in the process of issuing 
guidelines and legislation to counteract such illegal 
activities. In response to a request by the authorities of 
the Netherlands, the professional organization of 
physicians in that country released guidelines for 
online doctor-patient contact in January 2005 that 
cover all online contact between doctor and patient. 
The guidelines are similar to the amendment to United 
States legislation that is currently being discussed, the 
Ryan Haight Internet Pharmacy Consumer Protection 
Act of 2005. Once adopted, the Act will require 
Internet pharmacy websites to display information 
identifying the business, pharmacist and physician 
associated with the website; will bar the selling or 
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dispensing of a prescription drug solely on the basis of 
an online questionnaire; and will allow a state 
attorney-general to shut down a rogue site across the 
country, instead of only barring transactions involving 
consumers in his or her own state. The Board requests 
the Governments of all other countries that have 
adopted guidelines or legislation on prescription 
practices for Internet pharmacies to provide it with the 
relevant information. 
236. The Board, in an attempt to strengthen 
international cooperation to counteract illegally 
operating Internet pharmacies, has informed all 
Governments of the dangers of such illicit activities, 
requested them to identify focal points for all activities 
related to such Internet pharmacies and to provide 
details of legislation and regulations related to Internet 
services and sites, as well as on the use of the mail for 
individual shipments of controlled drugs. The Board 
calls on those Governments which have not yet 
provided that information to do so without delay, so 
that requests for support can be appropriately dealt 
with and international collaborative efforts will not be 
hindered. Governments are also requested to provide to 
the Board all other information on illegally operating 
Internet pharmacies, so that other Governments can be 
alerted. 
 
  Smuggling drugs by mail 
 
237. The smuggling of drugs, both illicit drugs and 
those licitly manufactured and subsequently diverted, 
by mail constitutes a major threat for law enforcement. 
According to the World Customs Organization, over 
the last five years every region of the world has 
experienced an increase in such illicit activity. For 
example, in the United States, where 200 billion pieces 
of mail are handled every year, authorities arrested 
more than 11,000 suspects during 2003, of whom more 
than 15 per cent were linked to the smuggling of 
narcotic drugs, psychotropic substances or precursors 
through the mail. Such cases have in turn led to a 
heavy burden being placed on authorities to detect 
suspicious shipments and to identify sources of illicit 
supply.  
238. The Board notes that other Governments are also 
enhancing their efforts to intercept illicit drug 
shipments by mail, and those improvements have 
contributed to the increase in the number of 
interceptions of smuggled drug consignments in recent 
years. In Bangkok, for example, Thai authorities seized 
in 2004 more than half a million (526,272) diazepam 
tablets and capsules in 12 different cases. The 
individual quantities seized ranged from 28 tablets (a 
package size) to 40,000 tablets, the main destinations 
for the consignments being the United Kingdom and 
the United States. Other psychotropic substances 
seized by the authorities included alprazolam, 
clonazepam, loprazolam and phenobarbital. 
Furthermore, in addition to diverted and/or counterfeit 
pharmaceutical preparations containing controlled 
substances, illicit drugs of abuse, such as MDMA and 
GHB, and precursors are also smuggled by mail. 
239. While some of the seized consignments may have 
been destined for abuse by the recipients, the large size 
of some the seizures indicates that traffickers are 
obtaining such substances for distribution on the illicit 
market. Governments that have not yet done so 
therefore need to take into account that smuggling by 
mail has become an important means of supplying 
illicit markets and that regular and thorough searches 
of the mail for illicit drug consignments should become 
a routine law enforcement procedure in all countries.  
240. At the same time, the Board recognizes that it is 
practically impossible to constantly screen all mail and 
that searches of the mail continue to rely on risk 
assessments and profiling. Therefore, as in all activities 
to counter trafficking, close national and international 
cooperation is required. In particular, standard 
procedures for conducting investigations into seizures 
of controlled substances smuggled by mail should be 
developed, including the collecting of information 
required for further investigation and analysis. The 
Africa mail project, initiated by UPU and UNODC 
with the support of Interpol and the World Customs 
Organization, provides examples of best practices in 
the area and demonstrates how such activities can be 
carried out in a coordinated manner.  
241. In the absence of such an operational approach, 
the Board encourages Governments to provide all 
available information on seizures of drugs smuggled 
through the mail to the authorities of the countries of 
destination, as well as to international entities such as 
the Board, UPU, Interpol and the World Customs 
Organization, in order to contribute to the development 
of concerted international action. 
242. In order to counteract smuggling of drugs by 
mail, the Board encourages every Government to 
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ensure that its national legislation provides for the 
possibility to effectively control and screen all routes 
of international mail leading into and out of the 
country, including private premises of international 
mail courier companies. Such control measures should 
include cooperative arrangements between the various 
national authorities responsible for the processing and 
screening of international mail and with privately 
owned companies. Experience has shown that such 
efforts can be greatly helped by limiting the number of 
entry points for parcels, thereby allowing for more 
efficient control of such consignments. Governments 
must also ensure adequate training of staff and provide 
the technical aid required for drug identification, such 
as X-ray machines, ion scan technology and sniffer 
dogs. Governments should encourage their law 
enforcement services to develop intelligence or 
information centres to support their front-line drug law 
enforcement operations. 
 
  Supply of controlled substances in emergency 
situations 
 
243. The Board wishes to emphasize the importance of 
ensuring the availability of essential narcotic drugs, 
including opioid analgesics, and psychotropic 
substances in emergency situations, such as natural 
disasters, epidemics and conflicts, in which the health 
conditions of a group of individuals are seriously 
threatened. In December 2004, immediately following 
the tsunami in the Indian Ocean, the Board granted 
expeditiously requests for additional supplies of 
narcotic drugs to be shipped to the countries 
concerned. The Board contacted the Governments of 
major exporting countries and advised them of the 
simplified export-import control procedures in 
emergency situations, in accordance with the model 
guidelines for such situations, which were developed 
jointly by WHO and the Board. In situations of similar 
natural and other types of emergencies, Governments 
should follow the guidelines to ensure the proper 
provision of essential narcotic drugs and psychotropic 
substances to people in disaster-stricken areas. 
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III. Analysis of the world situation 
 
 
 A. Africa 
 
 
  Major developments 
 
244. The main illicit drug of abuse in Africa is 
cannabis, which is abused by over 34 million people in 
the region. The cannabis plant is illicitly cultivated 
throughout Africa, and cannabis is smuggled within the 
region and beyond, mainly into Europe and North 
America. While cannabis herb is illicitly produced in 
all subregions of Africa, Morocco continues to be one 
of the world’s largest suppliers of cannabis resin. It is, 
therefore, encouraging to note that, as a result of 
intervention by the Government, both the total area 
under illicit cannabis plant cultivation and the total 
potential production of cannabis resin in Morocco 
decreased by 10 per cent in 2004 over the previous 
year. 
245. Drug traffickers are increasingly using West 
African countries along the Gulf of Guinea for 
smuggling cocaine from Latin America into Europe 
and, to a lesser extent, into North America, as 
evidenced by the record seizures that have been 
effected in that subregion during the past two years. 
Moreover, two recent seizures of cocaine in Kenya, 
totalling over 1 ton, may indicate that cocaine 
traffickers have also begun using Eastern Africa as a 
transit area. While cocaine continues to be abused 
mainly in cities and tourist centres in Southern and 
Western Africa, there is concern that the increased 
trans-shipment of illicit drugs through the area of the 
Gulf of Guinea might have a spillover effect, resulting 
in increased drug abuse in countries in those 
subregions. 
246. Although the abuse of opiates has remained 
limited in Africa, the increasing abuse of such drugs, 
including by injection, is becoming a cause for 
concern, particularly in African countries along the 
Indian Ocean. 
247. In Africa, the continued availability of illicitly 
manufactured and diverted pharmaceutical products 
containing narcotic drugs and psychotropic substances 
in unregulated markets has, for many years, been a 
major problem for national regulatory authorities in 
ensuring the safety and efficacy of medicine. At the 
same time, controlled substances for legitimate medical 
purposes, in particular opiates for the treatment of 
pain, are often not available. 
248. In Southern Africa, one recent worrying 
development is the rapidly emerging abuse of 
methamphetamine in South Africa, particularly in the 
Western Cape area. While the substance is mainly 
smuggled from China, some of it is also illicitly 
manufactured in laboratories in South Africa, as 
evidenced by the increasing number of illicit 
methamphetamine laboratories dismantled in that 
country. While the abuse of MDMA (Ecstasy) has so 
far been largely confined to South Africa, there is some 
concern that the uncovering of an MDMA laboratory in 
Egypt in late 2004 might indicate the emergence of 
illicit MDMA manufacture in Northern Africa. 
249. As mechanisms for the monitoring and control of 
precursor chemicals are being tightened in many 
countries of the world, traffickers have started to take 
advantage of weaker mechanisms for precursor control 
in African countries. That development is reflected in 
the increased number of reported attempts to divert 
precursor chemicals in Africa. In 2005, a number of 
multi-ton shipments of controlled precursor chemicals 
destined for African countries, for diversion into illicit 
markets, were stopped. 
 
  Treaty adherence 
 
250. In October 2005, Angola became a party to the 
1961 Convention as amended by the 1972 Protocol, the 
1971 Convention and the 1988 Convention. 
Furthermore, the Democratic Republic of the Congo 
and Liberia acceded to the 1988 Convention in October 
2005 and September 2005, respectively. 
251. Equatorial Guinea remains the only State in 
Africa that is not yet a party to any of the three main 
international drug control treaties. In addition, Chad 
has not yet acceded to the 1972 Protocol amending the 
1961 Convention, Liberia is not yet a party to the 
1971 Convention and Gabon, Namibia and Somalia are 
not yet parties to the 1988 Convention. 
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  Regional cooperation 
 
252. The Board notes with appreciation that the 
African Union takes drug control issues very seriously. 
The African Union has assigned to the Economic, 
Social and Cultural Council, an advisory body of the 
Union established in Addis Ababa in March 2005, the 
responsibility of advising it on drug-related matters 
while promoting the economic, social and cultural 
development of African States. The Board notes that 
the second Ministerial Conference on Drug Control in 
Africa, the theme of which was “Mainstreaming drug 
control in socio-economic development into Africa”, 
was held in Grand Baie, Mauritius, in December 2004. 
The Conference was attended by African experts from 
28 African Union member States and representatives of 
relevant international and regional organizations. 
Subsequently, the Sixth Ordinary Session of the 
Executive Council of the African Union, held in Abuja, 
in January 2005, adopted a decision in which it 
requested those African Union member States which 
had not yet submitted reports on the implementation of 
the Plan of Action on Drug Control in Africa: 2002-
2006 to do so without delay. 
253. A regional meeting of the International Drug 
Enforcement Conference was held in Abuja in 
February 2005. The meeting, which was hosted by the 
National Drug Law Enforcement Agency of Nigeria 
and attended by representatives of a number of 
countries in Europe and the Middle East, formulated a 
common position on money-laundering, international 
drug trafficking organizations and the control of 
precursor chemicals. 
254. The Fifteenth Meeting of Heads of National Drug 
Law Enforcement Agencies, Africa, was held in 
Ouagadougou in March 2005. The Meeting formulated 
recommendations on regional and subregional 
cooperation; the threat posed by illegal cannabis 
production in Africa; and the protection of witnesses in 
investigating and prosecuting crime syndicates. 
255. The Government of Algeria hosted the 
seventeenth Summit of the League of Arab States in 
Algiers in March 2005. The members of the League of 
Arab States may use their meetings as an opportunity 
to, inter alia, share their experiences in fighting drug 
abuse and illicit trafficking, with a view to 
harmonizing their policies and strategies related to 
countering illicit drug trafficking in the region.  
256. A regional youth network of non-governmental 
organizations focusing on drug abuse prevention was 
established in eight countries in Eastern Africa in 2004. 
Non-governmental organizations from Ethiopia, 
Kenya, Madagascar, Mauritius, Rwanda, Seychelles, 
Uganda and the United Republic of Tanzania 
participated in the first regional workshop of the youth 
network, on the elaboration of networking and 
collaboration, which was held in Mombasa, Kenya, in 
April 2005. 
257. An operational meeting on drugs for Eastern 
African heads of criminal investigation departments 
and anti-narcotic units was held in Kigali in May 2005 
with a view to strengthening collaboration in drug law 
enforcement between the member States (Ethiopia, 
Kenya, Rwanda, Uganda and the United Republic of 
Tanzania) in the area of drug law enforcement. 
258. In June 2005, the Arab Conference for Protecting 
Youth from Drug Abuse was held in Cairo. Delegations 
from Northern Africa and the Middle East, comprising 
high-level government officials, heads of drug control 
agencies and representatives of civil society, 
participated in the Conference. The Conference 
formulated the Cairo Action Plan, containing 
recommendations on enhancing coordination among 
participating Arab countries in drug abuse prevention. 
On the occasion of the Conference, the Government of 
Egypt launched a new national strategy on protecting 
youth against drugs. 
259. The Board notes that, for the first time in Africa, 
a subregional workshop on precursor control was held. 
Regulatory and law enforcement authorities from 
11 countries in Eastern Africa, as well as 
representatives of trade and industry, attended the 
workshop, which was organized in Mombasa, Kenya, 
in July 2005 by UNODC, in cooperation with the 
Board. The workshop participants discussed the 
inadequate controls over precursors in Eastern Africa 
and developed measures to prevent the diversion of 
precursors into illicit channels. 
260. The seventh meeting of the Eastern Africa Police 
Chiefs Cooperation Organization, aimed at enhancing 
collaboration among its member States, was held in 
Mombasa, Kenya, in August 2005. A model 
subregional train-the-trainer workshop for 
pharmaceutical inspectors was held in Dar es Salaam 
in September 2005. The participants discussed ways to 
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improve the monitoring and surveillance of national 
drug distribution channels. 
261. A Round Table for Africa was hosted by the 
Government of Nigeria and organized by UNODC in 
Abuja in September 2005. The Round Table, which 
was attended by government representatives of African 
countries and development partners, adopted a 
programme of action for the period 2006-2010, aimed 
at integrating a drug control dimension into official 
development assistance policies and practices. 
262. A number of African countries have undertaken 
further initiatives against money-laundering. In 
Northern Africa, Algeria, Egypt, Morocco and Tunisia 
have joined the Middle East and North Africa Financial 
Action Task Force, established in November 2004 to 
promote best practices in combating money-laundering 
and terrorist financing in those subregions. The 
Economic Community of West African States 
(ECOWAS) has stepped up action against money-
laundering: in May 2005, its Groupe 
intergouvernemental d’action contre le blanchiment 
d’argent en Afrique de l’Ouest (GIABA)39 met in 
Abuja to work out an integrated approach to countering 
money-laundering, as experience has shown that 
money-laundering kingpins are moving away from 
countries with rigorous legislation against money-
laundering, such as Nigeria, to countries in Western 
and Central Africa where action against such criminal 
activity is deemed weak.  
 
  National legislation, policy and action 
 
263. National drug control master plans have been 
adopted by Algeria and South Africa. The Government 
of Algeria has also set up a secretariat under the office 
of the Prime Minister to implement the plan. 
Furthermore, in December 2004, Algeria promulgated 
a new law on the prevention and repression of the use 
of and illicit traffic in narcotic drugs and psychotropic 
substances together with a law specifically on 
preventing and fighting money-laundering and the 
financing of terrorism. In Morocco, the national 
strategy against drugs drafted by the National 
Committee on Narcotics is expected to be adopted in 
2005. 
264. In March 2005, the Government of Lesotho 
prepared a comprehensive programme framework for 
drug abuse prevention in the country. The Government 
of Malawi has taken several important initiatives to 
address drug control issues in the country, such as the 
completion of a UNODC-funded rapid situation 
assessment on drug abuse, the drafting of a drug abuse 
bill and the conducting of a survey of cannabis abuse. 
265. The Board notes that the authorities of the Libyan 
Arab Jamahiriya have taken measures to enhance 
programming and implementation capacities in the area 
of drug demand reduction, with a view to developing a 
national prevention programme in schools, covering all 
aspects related to drug abuse, including HIV/AIDS. 
266. The Board calls upon the Government of the 
United Republic of Tanzania to implement without 
delay the precursor control law enacted in 2004. In 
Kenya, in response to a series of attempted diversions 
of ephedrine (see para. 280 below), the Government 
appointed a precursor control steering committee 
within the Ministry of Health in May 2005 to address 
the inadequate controls over precursors and to draft 
appropriate precursor control legislation. The Board 
appreciates those efforts and encourages the 
Government of Kenya to put in place as soon as 
possible an adequate mechanism for monitoring and 
controlling precursors. 
267. The Board notes with appreciation the measures 
taken by the Government of Tunisia to reduce illicit 
drug demand through awareness-raising programmes in 
schools and welcomes the steps taken to establish a 
national rehabilitation centre for drug addicts. The 
Board also notes that legal and law enforcement 
measures taken against corruption have helped to curb 
illicit drug abuse and trafficking in Tunisia. 
268. A number of Governments have taken further 
legislative and administrative measures to combat 
money-laundering. In Egypt, the Anti-Narcotics 
General Administration has opened a special office for 
investigating financial crime and combating money-
laundering. The Board notes that, in 2004, as a result 
of this and other measures taken to counter money-
laundering, Egypt was removed from the list of 
countries and territories considered by the Financial 
Action Task Force on Money Laundering to be “non-
cooperative” in efforts to counter money-laundering or 
to have critical deficiencies in their systems for 
countering money-laundering. The Kenyan Cabinet 
approved in February 2005 a bill against money-
laundering that is before Parliament; once passed, the 
legislation will enable the identification, tracing and 
freezing, seizure and potential confiscation of proceeds 
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of crime, including drug trafficking and corruption. 
The Government of Morocco has prepared a draft law 
against money-laundering that is now before 
Parliament. In Nigeria, the Money Laundering Act was 
revised and updated in 2004 to facilitate asset recovery. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
269. Cannabis continues to be the most widely grown, 
trafficked and abused drug in the African region. Africa 
is the world’s second largest producer of cannabis herb 
(after North America), accounting for approximately 
12,000 tons, or 28 per cent of global production. In 
Morocco, illicit cannabis plant cultivation decreased by 
10 per cent in 2004 compared with the level of the 
previous year. More than 40 per cent of the world’s 
cannabis resin is produced in Morocco. In addition, 
Morocco is the source of 80 per cent of the cannabis 
resin abused in Europe, the world’s largest market for 
cannabis resin. Illicit trafficking in cannabis resin 
continues to be a major problem in the Rif area. The 
Board notes with appreciation that the Government of 
Morocco launched a cannabis plant eradication 
campaign in the Rif area in early May 2005. Of the 
approximately 1,500 tons of cannabis resin seized 
throughout the world in 2004, 87 tons were seized in 
Morocco. Weak control measures at seaports and land 
border crossings and inadequate drug control 
legislation have continued to contribute to the 
trafficking problem in that country. The Board 
commends the Government of Morocco for its efforts 
and calls upon it to continue its efforts to achieve the 
total eradication of cannabis plant cultivation on its 
territory. At the same time, the Board calls upon the 
international community to support the efforts of the 
Government of Morocco where possible. 
270. Cannabis herb production is taking place in all 
subregions in Africa. In Egypt, where cannabis plants 
continue to be illicitly cultivated in the northern Sinai, 
there has been an alarming increase in the seizure of 
cannabis herb; seizures of cannabis herb increased in 
2004 by 40 per cent over the 2003 level. The increase 
in cannabis production was accompanied by an upsurge 
in the abuse of cannabis herb. In countries in Western 
and Central Africa (Cameroon, Ghana, Nigeria, Togo 
and Senegal), seizure data suggest that cannabis plants 
continue to be cultivated for commercial purposes. 
Cannabis plants are also cultivated in most countries in 
Eastern Africa, not only fuelling local demand but also 
constituting a significant commercial crop, especially 
in the Comoros, Ethiopia, Kenya, Madagascar, Uganda 
and the United Republic of Tanzania. The largest 
producers of cannabis herb in Southern Africa are (in 
decreasing order) South Africa, Malawi, Lesotho and 
Swaziland. According to data published by UNODC, 
cannabis herb was the most commonly seized drug in 
Africa in 2003, the most recent year for which such 
data are available. Also in that year, the bulk of all 
demand for drug abuse treatment in Africa (64 per 
cent) was linked to cannabis. 
271. The African region, particularly Western and 
Northern Africa, continues to be used for smuggling 
cocaine from South America into North America and 
Europe. In 2004, the total amount of cocaine seized 
while being transported through countries in Western 
Africa (mainly Nigeria and other countries in the area 
of the Gulf of Guinea) exceeded 14 tons. In the first 
half of 2005, authorities in Spain seized a total of 
5.5 tons of cocaine originating in South America and 
destined for Europe: one single seizure of 2.5 tons of 
cocaine was made on a vessel off the coast of Ghana 
that had been registered in that country. Furthermore, 
in September 2005, 3 tons of cocaine were seized on a 
vessel off the coast of Cape Verde. Since the beginning 
of 2004, seizures of cocaine totalling some 40 tons 
have been effected on the high seas on ships coming 
from Western Africa. Ghana, Guinea and Nigeria 
reported having seized cocaine bound for illicit 
markets in the United States of America. Investigations 
made in conjunction with those seizures reveal the 
presence in Western African countries of foreign 
criminal networks from Europe and Latin America, 
giving rise to speculation about Western Africa being 
used not just as a transit area but as a stockpiling 
logistics base for drug trafficking. Cocaine destined for 
Spain is also smuggled through the islands off the coast 
of Mauritania and Senegal, mainly Cape Verde. The 
shift in the traditional trafficking routes leading to 
Western Africa is attributed to tightened controls in the 
Netherlands and Spain (see also para. 599 below). 
Other developments in Africa relate to increased 
interdiction of cocaine (shipped from Brazil) in South 
Africa and, most recently, on the eastern coast of 
Africa, where Kenyan authorities seized a total of over 
1 ton of cocaine in two seizures: one in the coastal 
town of Malindi and the other in Nairobi. The two 
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seizures in Kenya were made possible by operational 
information received from Belgium; the seized 
cocaine, believed to be of Colombian origin, was 
destined for illicit markets in Europe. 
272. Despite the increase in the volume of cocaine 
seized in Africa, the level of abuse is still relatively 
low. Cocaine abuse in Africa seems to be confined 
mainly to Nigeria, Senegal and South Africa, where it 
continues to be abused in the form of crack cocaine. 
There is some concern, however, that, as cocaine 
trafficking routes evolve and new routes emerge, there 
will be a spillover effect and cocaine abuse will spread. 
As a result of the growing illicit trafficking in Nigeria 
and Togo, for instance, the cost of cocaine has already 
dropped significantly in those countries. Also, 
according to data provided by the South African 
Community Epidemiology Network on Drug Use 
(SACENDU), demand for cocaine abuse treatment 
increased in the period 2002-2004 in South Africa. 
273. In Africa, heroin interdiction rates remained low. 
In Western Africa, according to reports on heroin 
seizures made in 2005, heroin continued to be sent 
mainly in small quantities on couriers and in mail 
parcels. In Eastern Africa, however, significant 
seizures of heroin were made at the international 
airports in Nairobi, Dar es Salaam, Addis Ababa and, 
to a lesser extent, Zanzibar City. As countermeasures 
are being taken in those airports, heroin traffickers 
appear to be shifting their operations to airports near 
large cities in other African countries, including 
Malawi (Lilongwe), Rwanda, (Kigali), Uganda 
(Entebbe) and Zambia (Lusaka). From there, the heroin 
is often smuggled back into Kenya and the United 
Republic of Tanzania through the inadequately 
controlled land borders and subsequently into countries 
in Europe and North America. The quality of the heroin 
transiting Kenya has increased markedly in recent 
years, from (lower-quality) “brown heroin” to “white 
heroin”. As heroin is increasingly becoming available 
at affordable prices in the United Republic of Tanzania, 
heroin abuse is also increasing in that country. 
274. The abuse of heroin continues to be at a low level 
in Africa. According to the available data, the annual 
prevalence of abuse of opiates (mostly heroin) in 
Africa was 0.2 per cent among persons aged 15-64 in 
the period 2002-2004, which is below the global 
average of 0.3 per cent. The abuse of opiates increased 
in Eastern and Southern Africa. In Eastern Africa, the 
increase in heroin abuse was particularly significant in 
Kenya, Mauritius and the United Republic of Tanzania 
(countries where drug abuse by injection also 
increased), as well as in Rwanda, Somalia and Uganda. 
According to the SADC Epidemiology Network on 
Drug Use (SENDU), high levels of heroin abuse by 
injection were reported by patients in Mauritius (94 per 
cent), South Africa (28-55 per cent in selected sites), 
the United Republic of Tanzania (29 per cent) and 
Mozambique (23 per cent in Maputo). In Nigeria, a 
survey revealed that there was growing drug abuse by 
injection, as well as higher HIV/AIDS prevalence 
among persons who abuse drugs by injection, in big 
cities such as Kano and Port Harcourt. In Northern 
Africa, there is significant heroin abuse in Egypt, 
where the total number of heroin addicts is estimated at 
20,000-30,000 and the practice of needle-sharing has 
been reported. 
 
  Psychotropic substances 
 
275. In most African countries, it is possible to 
purchase drugs in unregulated markets. A wide range 
of licit narcotic drugs and psychotropic substances are 
sold both by licensed pharmacies without a 
prescription and on street markets following their 
diversion from licit into illicit channels. Those 
substances include sedatives, codeine-based syrups and 
phenobarbital, which are also used in combination with 
other products to enhance the effects of cannabis and 
alcohol, including locally brewed alcoholic drinks. In 
Northern Africa, the abuse of benzodiazepines, such as 
diazepam, clonazepam (Rivotril), lorazepam (Temesta), 
clorazepate (Tranxene), and the opioid analgesic 
buprenorphine (Subutex) has gained in popularity, as 
those preparations are relatively cheap and easily 
obtainable. Several countries in Western and Central 
Africa have reported that there is growing concern 
about the smuggling into their territories of fake and 
counterfeit medical products. In Southern Africa, the 
abuse of over-the-counter and prescription medicines, 
such as slimming tablets, analgesics and 
benzodiazepines (diazepam and flunitrazepam), 
continues to be a matter of concern. 
276. The availability of controlled substances in 
unregulated markets and the circulation of counterfeit 
medicines create serious public health problems, 
including the abuse and misuse of drugs, and 
undermine public confidence in health services and in 
drug control and drug law enforcement regimes. The 
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Board calls upon all the Governments concerned to 
take remedial action by strengthening mechanisms for 
the monitoring and control of licit narcotic drugs and 
psychotropic substances, including licensing systems, 
record-keeping, the collection and reporting of 
statistical data, the import and export authorization 
regime, inspections and sanctions. The Board also 
urges the Governments concerned to assess their real 
needs for controlled drugs, as well as constraints that 
contribute to those drugs not being available for 
medical purposes in sufficient quantities. The outcome 
of such an assessment could be beneficial in addressing 
the non-availability of those drugs for medical 
purposes. WHO and international and bilateral donors 
would then be in a better position to assist African 
countries in implementing their strategies for the 
rational use of controlled drugs. 
277. The illicit manufacture of amphetamine-type 
stimulants, mainly cathinone, methcathinone, MDMA 
(Ecstasy) and methamphetamine, continues to take 
place in South Africa. There has been a rapid increase 
in laboratories for the illicit manufacture of cathinone 
and methcathinone during the past few years: while 
one such laboratory was detected in 2001, that number 
rose to over 30 by 2003. Of particular concern is the 
emergence of abuse of methamphetamine (commonly 
called “tic”) in South Africa’s Cape Town area. 
According to SACENDU, a dramatic increase in the 
demand for treatment for methamphetamine abuse was 
noted in Cape Town: 1 out of 5 patients reported that 
methamphetamine had been their primary or secondary 
drug of abuse and 41 per cent reported having used the 
drug daily in 2004. Almost 60 per cent of patients 
seeking treatment for methamphetamine abuse during 
the second half of 2004 were under 20 years of age. 
278. Despite vigorous law enforcement efforts by the 
South African police, the abuse of methaqualone 
(Mandrax) has continued unabated in South Africa, 
where most of the world’s illicitly supplied 
methaqualone is abused. Methaqualone is also abused 
in other countries in Southern Africa, but to a lesser 
extent. Methaqualone is smuggled out of India and 
China and transported along the coast of Eastern Africa 
and, to some extent, Western Africa to countries in 
Southern Africa. Some methaqualone is also 
manufactured in South Africa. In 2004, as a result of 
intensified police efforts, the total volume of 
methaqualone seizures rose sharply in South Africa, 
reaching the record level of 12 tons. In the same year, 
15 illicit methaqualone laboratories were dismantled in 
South Africa. 
279. Some abuse of MDMA (Ecstasy) is taking place 
in South Africa. While most of the MDMA (Ecstasy) is 
smuggled into that country, some is illicitly 
manufactured locally. For the first time ever, an 
MDMA laboratory was uncovered and dismantled in 
Egypt in late 2004; four persons were arrested and the 
chemicals and equipment were seized. While illicit 
manufacture of amphetamine-type stimulants (under 
the brand name Maxim forte) had reportedly taken 
place in Egypt some years ago, the discovery of an 
MDMA laboratory in that country is a matter of 
concern, since it might indicate a shifting of the illicit 
manufacture of MDMA to Northern Africa. 
280. African countries are increasingly being used by 
traffickers to divert precursor chemicals. Following an 
attempt in early 2004 to divert to Kenya 6 tons of 
ephedrine, a precursor of amphetamine-type 
stimulants, two further attempts to divert to that 
country large amounts of ephedrine (500 kg and 
800 kg) were prevented in 2005. There were other 
attempts to divert large amounts of precursors to 
African countries in 2005: one involved several multi-
ton consignments of potassium permanganate destined 
for Egypt; another attempt involved almost 7 tons of 
acetic anhydride destined for Nigeria; and two others 
involved large consignments of pseudoephedrine 
destined for Angola (1.2 tons) and the Democratic 
Republic of the Congo (26 tons). The Board calls upon 
the Governments of all countries in Africa to take the 
measures necessary to adequately control the precursor 
chemicals listed in Tables I and II of the 
1988 Convention. The Board also calls upon UNODC 
to provide technical assistance, including in the form 
of training, to the African countries at risk. 
 
  Substances not under international control 
 
281. The Board notes with concern that the abuse of 
khat, a substance currently not under international 
control that is cultivated in several countries in Eastern 
Africa, is becoming a serious threat to reconstruction 
efforts in Somalia. In that country, which has suffered 
many years of civil strife and is one of the poorest 
countries in the world, the abuse of khat is widespread; 
as a result, the family structure is deteriorating and a 
large portion of the family income is used to buy khat. 
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  Missions  
 
282. The Board sent a mission to Cape Verde in 
September 2005. The Board commends the 
Government of Cape Verde for its political will and 
commitment to address the drug problem in its country, 
as exemplified by the national drug and crime control 
strategy adopted in October 2004. 
283. Over the past two years, Cape Verde has emerged 
as part of a major transit route for consignments of 
cocaine originating in South America en route to 
Europe. It is estimated that each year several tons of 
cocaine pass through the archipelago of Cape Verde, 
which is situated off the coast of Senegal. The Board 
expresses appreciation to the Government of Cape 
Verde for its determination in addressing the smugglers 
of cocaine through its territory and encourages the 
Government to continue its work on strengthening the 
interdiction capabilities of its national drug law 
enforcement agencies. The Government should 
continue to seek international cooperation and 
assistance in that matter. 
284. Drug abuse appears to have increased in Cape 
Verde. However, the actual extent, patterns and trends 
of drug abuse are not known, since no nationwide 
survey or even a rapid assessment of the drug abuse 
situation has ever been conducted. The Board therefore 
urges the Government to carry out, as a matter of 
priority, an assessment of the drug abuse situation, 
including the collection and analysis of data on the 
incidence, prevalence and other characteristics of drug 
abuse. 
285. The consumption of narcotic drugs for medical 
purposes is considerably lower in Cape Verde than in 
other small island developing countries in Africa. The 
Board calls on the authorities of Cape Verde to 
continue their efforts to improve the access of the 
population to essential narcotic drugs, inter alia, by 
providing training to health-care professionals. The 
WHO guidelines on achieving balance in national 
opioid control policy can be used as a guide for that 
purpose. 
286. The Board sent a mission to Ghana in 
January 2005. The Board notes with appreciation the 
firm commitment of the Government to the objectives 
of the international drug control treaties and its efforts 
to further develop the existing national drug control 
mechanisms with a view to vigorously combating the 
drug menace. The Board welcomes the 
multidisciplinary approach taken by the Government, 
as reflected in the establishment of the interministerial 
Narcotics Control Board of Ghana, which guides and 
coordinates all drug-related activities of the various 
authorities and bodies responsible for drug control 
matters and directs their efforts towards achieving the 
common objective of fighting drug abuse and 
trafficking. 
287. While the drug control legislation currently in 
place in Ghana provides a measure of control over 
substances scheduled under the 1961 Convention and 
the 1971 Convention, that legislation still requires 
updating. In addition, there is still no legislation on 
precursor control and no designated competent 
authority for the implementation of the provisions of 
article 12 of the 1988 Convention. The Board therefore 
encourages the Government to give priority to updating 
legislation on narcotic drugs and psychotropic 
substances and drafting adequate legislation on the 
control of precursor chemicals, as well as to establish 
an adequate mechanism for the monitoring and control 
of precursor chemicals, in order to prevent the country 
from being used for the diversion of those substances 
into illicit channels. 
288. The Board notes the efforts by the law 
enforcement authorities of Ghana to combat the 
smuggling of drugs through their country, as well as 
the measures taken by the Government to eradicate 
cannabis plants and realize an integrated alternative 
development programme. In view of the increasing 
number and volume of seizures of illicit drugs, in 
particular cocaine, in Ghana and in its neighbouring 
countries, Ghana appears to be at risk of being used as 
a transit country by illicit drug traffickers, a 
development that could have a spillover effect, 
resulting in increased drug abuse. The Board therefore 
encourages the Government to continue its efforts and 
to elaborate appropriate programmes for drug abuse 
prevention and demand reduction, targeting young 
people in particular. The Board calls upon UNODC to 
provide assistance to the Government to enable it to 
further strengthen the capacity of its law enforcement 
authorities to intercept illicit drug consignments. 
289. In August 2005, the Board sent a mission to 
Lesotho for the first time to review the drug control 
situation and the Government’s compliance with the 
international drug control treaties. The Board notes the 
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efforts made by the Government in drug control and 
encourages it to continue to strengthen those efforts. 
290. In Lesotho, current drug control legislation 
contains the relevant provisions for the control of licit 
and illicit drug movements. Two new bills are in the 
process of being drafted to replace the outdated 
legislation. The new legislation will include provisions 
to control precursor chemicals and equipment used in 
the illicit manufacture of drugs. The Board notes the 
efforts of the Government to update existing drug 
control legislation and encourages it to establish and 
implement the necessary precursor control legislation 
as soon as possible. 
291. The Board notes the efforts of the law 
enforcement authorities of Lesotho to eradicate 
cannabis plant cultivation and combat drug trafficking. 
The Board urges the Government of Lesotho to 
strengthen its efforts to eradicate cannabis plant 
cultivation and to introduce alternative development 
programmes, with the assistance of international 
donors. 
292. The Board notes that the Government of Lesotho 
has established a national focal point for drug control. 
The Board encourages the Government to allocate 
adequate resources to ensure that the focal point is able 
to carry out its functions effectively and efficiently. 
Staff at all levels of government involved in drug 
control require adequate training. 
293. A drug abuse treatment centre and resource centre 
are providing invaluable services to Lesotho and have 
the potential to provide similar services to 
neighbouring countries. The Board urges the 
Government to pursue its efforts to provide a 
comprehensive drug abuse prevention and treatment 
programme. 
294. The Board sent a mission to Swaziland in August 
2005 to review the progress made by the Government 
in implementing the Board’s recommendations 
following its mission to that country in 1985. In 
Swaziland, legislation currently being used to control 
the licit and illicit movement of drugs dates back to the 
1920s. The Board notes that a new drug bill is 
currently before the parliament. It encourages the 
Government of Swaziland to adopt the bill without 
delay and to take measures for its speedy 
implementation, incorporating the provisions required 
to deal with the current drug control problems facing 
the country. The Board notes with concern that there is 
currently no relevant legislation controlling precursor 
chemicals in Swaziland. The Board urges the 
Government to establish, adopt and implement as soon 
as possible the measures necessary to control precursor 
chemicals. 
295. Despite the efforts by law enforcement officials, 
cannabis plants continue to be illicitly cultivated 
throughout Swaziland. The Board notes with concern 
that there is an ongoing privately sponsored national 
campaign aimed at the legalization of cannabis plant 
cultivation in Swaziland. The Board wishes to remind 
the Government that cannabis, as it is considered 
particularly liable for abuse, is in Schedule IV of the 
1961 Convention, which requires Governments, 
pursuant to article 2, paragraph 5, of that convention, 
to adopt special measures having regard to the 
dangerous properties of that drug. Therefore, the Board 
urges the Government to continue to take a strong 
stand against the legalization of cannabis plant 
cultivation and, at the same time, to strengthen its 
eradication efforts and to introduce alternative 
development programmes. 
296. Both cocaine abuse and heroin abuse have 
emerged as major problems in the city of Manzini, the 
industrial centre of Swaziland. The Board encourages 
the Government to conduct a rapid assessment survey 
of drug abuse in that city and its surrounding areas and 
to put into place programmes for reducing illicit drug 
abuse in the country. The Board notes with concern 
that there are currently no facilities in Swaziland that 
provide specialized treatment for drug abusers. The 
Board encourages the Government to establish such 
facilities as soon as possible. 
297. The Board sent a mission to Zambia in 
August 2005 to review the progress made by the 
Government in implementing the Board’s 
recommendations following its mission to that country 
in 1996. The Board notes with appreciation the 
continued commitment and efforts of the Government 
in combating drug abuse and trafficking in Zambia. 
298. The legislation currently in force in Zambia 
contains provisions on control over the licit and illicit 
movement of drugs. The current legislation is in the 
process of being amended to include provisions on the 
control of precursor chemicals. The Board urges the 
Government to establish, adopt and implement as soon 
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as possible the measures necessary to control precursor 
chemicals. 
299. Cannabis plants continue to be illicitly cultivated 
throughout Zambia, despite efforts by law enforcement 
officials. The Board encourages the Government to 
strengthen its efforts to eradicate the illicit cultivation 
of cannabis plants and to introduce alternative 
development programmes in cooperation with other 
countries in the region and international donors. The 
Board notes with concern that there are currently no 
treatment facilities in Zambia for drug abusers and 
encourages the Government to establish such facilities 
as soon as possible. The Board also encourages the 
Government to provide the drug law enforcement and 
pharmaceutical regulatory bodies in Zambia with 
adequate resources to enable them to carry out their 
functions properly. 
300. As there is a particularly high prevalence of 
HIV/AIDS and drug abuse in Lesotho, Swaziland and 
Zambia, the Board is concerned that the current 
situation could be further exacerbated by insufficient 
drug abuse prevention programmes and urges the 
Governments concerned to take appropriate preventive 
measures to address those problems. 
 
 
 B. Americas 
 
 
  Central America and the Caribbean 
 
 
  Major developments 
 
301. The region of Central America and the Caribbean 
continues to be used as a major trans-shipment point 
for consignments of drugs, mainly cocaine, originating 
in South America and destined for the United States 
and countries in Europe. While extensive coastal areas 
and difficult terrain may to some extent explain the 
situation, persistent negative social factors, such as 
high unemployment and institutional weaknesses, have 
played a major role as well. It is estimated that a large 
part of the 300 tons of cocaine entering the United 
States each year has passed through Central America 
and the Caribbean. 
302. Several countries in Central America and the 
Caribbean have signed the Central America Free Trade 
Agreement (CAFTA), a free trade agreement with the 
United States that would liberalize interregional 
commerce and remove barriers to trade in most goods. 
The Board urges the Governments concerned not to 
weaken existing controls over drugs once CAFTA 
enters into force. 
303. In its report for 2004, the Board expressed its 
concern over the link between drug trafficking and 
organized crime perpetrated by youth gangs in several 
Central American and Caribbean countries.40 The 
Board welcomes the Meeting on Transnational 
Criminal Youth Gangs: Characteristics, Importance and 
Public Policies, organized in Tapachula, Mexico, in 
June 2005 by the Inter-American Drug Abuse Control 
Commission (CICAD) of the Organization of American 
States. The Board urges the Governments concerned to 
step up their efforts to fight that problem, while 
maintaining respect for human rights. 
 
  Treaty adherence 
 
304. All States in Central America and the Caribbean 
are parties to the 1961 Convention and the 
1988 Convention and, with the exception of Haiti, to 
the 1971 Convention. The Board calls on Haiti to 
accede to the 1971 Convention without delay. The 
Board welcomes the ratification by Nicaragua of the 
1972 Protocol amending the 1961 Convention and the 
ratification by Honduras of the 1971 Convention. 
 
  Regional cooperation 
 
305. In 2004, the CICAD Group of Experts on 
Pharmaceutical Products developed the Model 
Reference Guide for Health Professionals: Prevention 
and Detection of Abuse of Narcotics and Controlled 
Substances and Their Diversion to Illicit Channels and 
the Model Guide for Manufacturers to Control 
Pharmaceutical Products. The Group also analysed 
different mechanisms to enhance inspections, control 
measures and coordination, including with regard to 
the sale of pharmaceutical products on the Internet.  
306. In October 2004, the Caribbean Epidemiology 
Centre (CAREC), with the support of UNODC and 
CICAD, established drug information networks to 
guide the development of efforts to reduce illicit drug 
supply and demand in the Caribbean. 
307. CICAD is working together with the Inter-
American Development Bank to create and/or 
strengthen financial intelligence units throughout 
Central America and the Caribbean. The Caribbean 
Financial Action Task Force and the Financial Action 
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Task Force of South America against Money 
Laundering (GAFISUD) are also providing support in 
that endeavour. 
308. An operation involving the cooperation of law 
enforcement agencies in Central America and the 
Caribbean and in the United States has resulted in 
354 arrests and the seizure of a total of 26.5 tons of 
cocaine and about US$ 86 million in currency and 
other assets. The operation was terminated at the end 
of 2004. 
309. In October 2004, Operation Escandalo, conducted 
by United States law enforcement agencies, 
successfully dismantled an important cocaine 
smuggling network in Haiti involving several high-
level officials of the previous Government. 
310. The Fourteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and 
the Caribbean, held in Mexico City from 11 to 
15 October 2004, recommended that central law 
enforcement databases and standardized reporting 
should be encouraged and that Governments should 
consider the posting of judicial liaison officers in their 
diplomatic missions to ensure proper adherence to 
required legal procedures and the speedy gathering of 
prosecution evidence (see para. 399 below). 
 
  National legislation, policy and action 
 
311. Almost all of the countries in Central America 
and the Caribbean have designed national plans to deal 
with the drug problem; at the same time, however, 
almost all of those countries have experienced 
difficulties in implementing the plans, mainly because 
of lack of human and financial resources. 
312. Most countries in Central America and the 
Caribbean have no epidemiological studies on drug 
abuse among the general population, which makes it 
difficult to estimate the prevalence of the abuse of 
psychoactive substances at the national level, to 
determine trends in drug abuse and to assess the 
effectiveness of policies to reduce illicit drug supply 
and demand. 
313. Measures for the control of pharmaceutical 
preparations, including rules regarding the 
prescription, distribution and sale of such products, 
need to be enhanced in Central America and the 
Caribbean. The need for stringent control measures has 
increased as pharmaceuticals, including substances 
such as pseudoephedrine, amphetamine-type 
stimulants, phentermine, hydrocodone and oxycodone, 
are being sold over the Internet.  
314. To deal with the growing problem of youth gangs 
in El Salvador, the Government is implementing the 
Super Mano Dura plan (super heavy hand plan) and the 
Mano Amiga plan (friendly hand plan). The Super 
Mano Dura plan established punitive measures against 
gang members, while the second plan established 
rehabilitation assistance for former gang members. The 
Super Mano Dura plan has been criticized by civil 
society and has led to protests and riots in prisons in 
El Salvador. Prison inmates have demanded more 
rehabilitation programmes to replace the severe 
penalties provided for in current legislation. 
315. In Honduras, the implementation of drug control 
legislation by the judicial system appears to be 
hampered by, among other things, corrupt practices. 
The National Assembly in that country has not yet 
adopted legislation that would remove the immunity 
privileges of high-level officials, thereby allowing for 
them to be prosecuted (the Constitution was amended 
in 2004 to make that possible). The National Assembly 
has yet to adopt legislation to reform the statute that 
covers illegal drugs and to make money-laundering a 
crime. 
316. In Costa Rica, the Government has promulgated 
decree No. 31684, aimed at strengthening drug control 
in the country. Costa Rica is the depositary of the 
multilateral Agreement concerning cooperation in 
Suppressing Illicit Maritime and Air Trafficking in 
Narcotics Drugs and Psychotropic Substances in the 
Caribbean Area, which was signed in 2003. The Board 
urges the parties to the Agreement to ratify it without 
delay. 
317. In Cuba, operations Coraza Popular and Aché III 
resulted in a reduction in smuggling of narcotic drugs 
in 2004. In addition, Interpol has resumed its 
operations in Cuba. 
318. In June 2004, the Government of the Bahamas 
signed a comprehensive maritime agreement that 
would provide law enforcement officers with a 
comprehensive framework for their work in the area of 
fighting maritime drug trafficking. The Government 
also launched its first national drug control plan. The 
Board notes, however, that national legislation to 
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improve the control of substances in the schedules of 
the 1988 Convention has not yet been approved. 
319. In 2004, the Government of Jamaica launched 
Operation Kingfish, which targets the increasing drug-
related crime and violence in that country (see also 
para. 598 below). That has led to disruption of the 
cocaine traffic; at the same time, however, other crimes 
have increased, as drug traffickers have turned to other 
sources of income. The Government has drafted 
several new laws to deal with the situation. The Board 
is concerned that illegal use of Ecstasy (MDMA), 
which is regulated by the Food and Drugs Act of 
Jamaica, is subject to light penalties. The Board 
encourages the Government of Jamaica to pursue its 
efforts to include Ecstasy in the list of drugs covered in 
the Dangerous Drugs Act, so that applying stricter 
penalties would apply in cases involving the use of that 
drug. 
320. Despite the efforts of the United Nations, the 
situation in Haiti remains precarious, which means that 
the conditions are ideal for organized criminal 
activities, including drug trafficking, money-
laundering and gang violence. However, some 
improvements appear to have been made. For example, 
a joint information coordination centre, a Maritime 
Interdiction Task Force and an anti corruption unit 
have been established. The Board encourages the 
interim Government to make full use of those bodies to 
fight drug trafficking. 
321. The Government of the Dominican Republic 
implemented the revised criminal procedural code in 
2004 that modified the country’s penal system. The 
new system is expected to improve the administration 
of justice in the country. In addition, a new guideline 
on the prevention and treatment of drug abuse was 
issued. The new guideline is based on a CICAD 
recommendation.  
322. The Government of Barbados has not yet placed 
under national control all the substances listed in the 
1988 Convention. There are also some weaknesses in 
the national control measures; for example, no special 
licences or permits are required to prescribe certain 
drugs. The Board urges the Government to completely 
fulfil its international obligations and to strengthen 
control measures in the country. 
323. Drug traffickers are taking advantage of the dire 
unemployment situation in Nicaragua by paying 
members of the local population to illegally distribute 
drugs. The situation appears to have led to an increase 
in the number of addicts among the population. 
324. The government of the Netherlands Antilles 
enacted two ministerial decrees on 28 January 2005 
classifying as controlled substances all psychotropic 
substances in the schedules of the 1971 Convention. 
With the enactment of the new legislation, the 
government has complied with the provisions of the 
1971 Convention. The requirement of import 
authorizations for substances in Schedules III and IV 
went into effect on 1 April 2005. Legislation on the 
implementation of article 12 of the 1988 Convention is 
still waiting to be enacted by the parliament.  
325. In December 2004, the Government of Belize 
enacted new legislation concerning the coast guard and 
implemented measures to strengthen drug abuse 
prevention programmes at all levels of the school 
system in order to deal with the growing drug problem 
and the problems associated with it, including drug-
related criminal activities. The Government, however, 
lacks funding to implement its programmes. 
326. In Costa Rica, a 2004 study on drug-related 
crime, showed that 33 per cent of the crimes 
committed in the country were linked to some violation 
of the Law on Psychotropic Substances; furthermore, 
34 per cent of the persons interviewed in the study 
admitted that they had committed crimes while under 
the influence of drugs and 22 per cent reported that 
they had committed crimes in order to obtain drugs.  
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
327. The total amount of cocaine seized in Central 
America and the Caribbean each year continues to be 
high (about 30 tons). Panama continued to account for 
the largest total quantity of cocaine seized in the region 
(7 tons). The most significant increase in total cocaine 
seizures was registered in Nicaragua (6.2 tons seized in 
2004, compared with 1.1 tons in the previous year). 
Total cocaine seizures also increased in Belize, Costa 
Rica and El Salvador. The total amount of cocaine 
seized was reported to have decreased in Guatemala 
and Honduras. 
328. Cocaine traffickers appear to be targeting 
countries in Central America more than countries in the 
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Caribbean, as reflected in seizure data for 2004. There 
are indications that new routes are being used to 
transport consignments of drugs, mainly cocaine, to 
Europe, for the most part through Western Africa but 
also through South America. 
329. The total volume of cannabis seized has increased 
in Central America but declined in the Caribbean. In 
2004, the largest total volume of cannabis seized 
(1,700 tons) was reported by Trinidad and Tobago. 
330. Cannabis is produced in Central America and the 
Caribbean but on a small scale, mainly for local 
consumption. Jamaica continues to be the main country 
in the region that is producing and exporting cannabis 
on a larger scale.  
331. To deal with the problem of opium poppy 
cultivation in Guatemala, the Government 
implemented during 2004 a successful eradication 
programme, eliminating more than 5.4 million opium 
poppy plants. Pharmaceutical preparations containing 
narcotic drugs have been diverted from licit 
distribution channels in Guatemala for illicit use; in 
addition, significant quantities of pharmaceutical 
preparations from El Salvador, Honduras and Mexico 
have been smuggled into Guatemala. In El Salvador 
and Guatemala, the trafficking in heroin appears to be 
on the increase. 
332. Although the rate of cocaine abuse is low in 
Central America and the Caribbean as a whole, the 
abuse of cocaine and crack is reported to have 
increased in Costa Rica, Honduras, Jamaica and 
Nicaragua. Cannabis abuse has continued to rise in the 
region. 
 
  Psychotropic substances 
 
333. In 2004, cases involving Ecstasy from the 
Netherlands were reported in Costa Rica and the 
Dominican Republic; in the Dominican Republic, 
about 50 per cent of the Ecstasy was seized while it 
was on its way to the United States. 
 
 
  North America 
 
 
  Major developments 
 
334. The abuse of, trafficking in and illicit 
manufacture of drugs are major problems in North 
America, which is comprised of Canada, Mexico and 
the United States. The Governments of all three of the 
countries in the region remain committed to the fight 
against drug abuse and drug trafficking. All three 
countries devote substantial resources to counteracting 
the drug problem within and beyond their borders. The 
excellent regional cooperation, particularly in the area 
of law enforcement, has yielded significant results 
mostly with regard to dismantling major drug 
trafficking operations. 
335. The abuse of prescription drugs is a major 
problem in all three countries in North America, in 
particular the United States, where the abuse of 
prescription drugs is increasing despite numerous 
initiatives by the Government and is reported to be 
taking place among persons in all age groups, 
including schoolchildren. The sale of controlled drugs 
from illegally operating Internet pharmacies is part of 
the problem. 
336. Because of its geographical position, Mexico has 
long been used as a major transit country for illicit 
drug consignments destined for the United States. That 
has been one of the main areas of emphasis of its drug 
control efforts. The transit traffic has had a spillover 
effect: Mexico is no longer only a transit country but 
has also become a consumer country for illicit drugs 
and even a producer country for drugs such as 
cannabis, heroin and amphetamine-type stimulants. 
Should that trend continue, Mexico could become a 
major source country for illicit drugs. The Board 
acknowledges the efforts of the Government of Mexico 
in countering drug trafficking and illicit drug 
production and in fighting corruption and encourages 
the Government to pursue the implementation of its 
policies in those areas. 
337. The Board is concerned that in Canada draft 
legislation on cannabis (Bill C-17), which would 
provide for the issuing of a ticket for possession of up 
to 30 grams of cannabis and the imposing of an 
administrative penalty instead of imprisonment for 
cannabis plant cultivation, may send the wrong 
message, particularly in view of the increase in 
cannabis abuse in the country. 
338. The Board notes that the Supreme Court of the 
United States ruled in June 2005 that all use of 
cannabis, including its use for medical purposes, was 
illegal throughout the territory of the United States. 
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  Treaty adherence 
 
339. All three States in North America are parties to 
the three international drug control treaties. 
  Regional cooperation 
 
340. The excellent cooperation between the three 
countries in North America has continued, resulting in 
a number of effective measures being implemented 
against drug trafficking and organized crime. 
341. The Canada-United States Cross-Border Crime 
Forum is the principal bilateral cooperative initiative 
between the two countries in the area of fighting cross-
border crime. The Forum announced in October 2004 
the establishment of four new intelligence exchange 
sites to support the International Border Enforcement 
Team programme. 
342. The Governments of Mexico and the United 
States have further improved cooperation in law 
enforcement matters. Anti-corruption initiatives and 
institutional reforms in Mexico have contributed to the 
sharing of information, the conducting of joint 
investigations and the extradition of fugitives to the 
United States. 
343. A number of joint law enforcement operations 
have been successfully conducted by law enforcement 
authorities of Canada, Mexico and the United States. In 
January 2005, Operation Candy Box, a two-year 
operation involving cooperation between Canada and 
the United States and targeting a criminal organization 
illicitly manufacturing MDMA and supplying 15 per 
cent of the Ecstasy on the illicit market in the United 
States, culminated in the extradition of the 
organization’s kingpin to the United States. In April 
2005, Operation Cyber Chase, a one-year investigation 
targeting international Internet pharmaceutical 
traffickers, was successfully concluded; using more 
than 200 websites, the traffickers involved had, since 
July 2003, distributed each month approximately 
2.5 million dosage units of controlled substances, 
including hydrocodone (a narcotic analgesic sold under 
the brand name Vicodin), anabolic steroids and 
amphetamines. 
344. Operation Cold Remedy and Operation Aztec Flu, 
conducted in cooperation with law enforcement 
agencies of Mexico and the United States, as well as 
the Hong Kong Special Administrative Region of 
China, resulted in the seizure of 67.26 million 
pseudoephedrine tablets between September 2003 and 
December 2004. Operation Money Clip, a one-year 
investigation ending in December 2004, resulted in the 
dismantling of a money-laundering and poly-drug 
trafficking organization based in Mexico, the arrests of 
90 persons involved and the seizure of 
US$ 5.2 million, in addition to significant seizures of 
cocaine, methamphetamine, cannabis and heroin. 
345. Operation United Eagles, an ongoing effort to 
apprehend Consolidated Priority Organization Targets, 
is being carried out by a “fugitive apprehension team” 
comprising Mexican and United States law 
enforcement officers. A number of other initiatives are 
being carried out jointly by Mexico and the United 
States at the south-west border of the United States to 
disrupt and dismantle poly-drug trafficking 
organizations based in Mexico, as well as their 
associates based in Colombia. However, a number of 
obstacles have been encountered during such 
operations because of legal provisions in Mexico. The 
requirement of approval of the Attorney General of 
Mexico for undercover operations complicates the 
implementation of such operations. Moreover, the 
Government of Mexico has not yet established a 
reliable routine procedure for seeking and obtaining 
court authorization for undercover operations. 
Furthermore, controlled deliveries are not permitted by 
Mexican law. The Board urges the Government of 
Mexico to take appropriate steps to remedy the 
situation. 
346. All three countries in North America are 
members of the Financial Action Task Force on Money 
Laundering and of CICAD. 
 
  National legislation, policy and action 
 
347. The Government of Mexico is currently involved 
in efforts to introduce legal reforms relating to the 
smuggling of small quantities of narcotic drugs and 
psychotropic substances; the amendment of the federal 
law against organized crime; and the reform of laws 
related to national security and penal justice. Legal 
reform to strengthen measures aimed at preventing and 
punishing money-laundering was undertaken in 2004 
and new laws have been adopted by the Government of 
Mexico and five states in that country. The laws are in 
compliance with the recommendations of the Financial 
Action Task Force. 
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348. The National Drug Control Strategy of the United 
States Administration includes plans for increased drug 
abuse prevention and treatment efforts, such as support 
for student drug-testing programmes, assistance to 
local educational agencies for drug abuse prevention 
and school safety programmes, support for community 
coalitions’ civic action for preventive efforts and 
increased drug abuse treatment resources through the 
Access to Recovery voucher programme and the 
Screening, Brief Intervention, Referral and Treatment 
initiative, which emphasizes early intervention aimed 
at non-dependent drug users. 
349. Other priorities of the National Drug Control 
Strategy of the United States include support for drug 
court programmes. The total number of drug courts in 
the country increased significantly during the past year 
to 1,621. The Strategy also addresses the abuse of 
prescription drugs, which ranks second only to 
cannabis abuse in the United States. Prescription drug 
monitoring programmes at the state level have taken a 
leading role in detecting and deterring the diversion of 
popular prescription drugs. 
350. In the United States, the Drug Intelligence Fusion 
Center, under the programme of the Organized Crime 
and Drug Enforcement Task Forces, provides member 
agencies with a comprehensive data warehouse with 
access to investigative drug and related financial 
information. One highly successful investigation 
conducted by the Task Forces, Operation Cotton 
Candy, focused on the illegal distribution of pain 
medication containing controlled substances, including 
oxycodone, by 60-80 doctors, pharmacists and patients. 
One of the main traffickers involved, a doctor who had 
prescribed up to 1,600 oxycodone tablets each day that 
were subsequently trafficked, was sentenced in April 
2005 to 25 years of imprisonment and a fine of 
$1 million after having been convicted on charges of 
illegal drug distribution. 
351. Canada is faced with a similar problem with 
regard to the abuse of prescription drugs. A task force 
in Atlantic Canada found that a small number of 
physicians were responsible for writing prescriptions 
for large quantities of OxyContin, an oxycodone-based 
drug, and other controlled substances such as 
benzodiazepines. The electronic monitoring and 
tracking of prescriptions are considered to be 
promising tools for reducing the abuse of prescription 
drugs. To date, five Canadian provinces have 
implemented programmes for tracking multiple-copy 
prescriptions in an effort to reduce the diversion of 
drugs that are at a high risk of being diverted and 
abused. 
352. The Board notes that Canada published in 
November 2004 the Canadian Addiction Survey, 
initiated in December 2003 to provide information 
about prevalence rates and trends in drug abuse. Since 
the renewal of its Drug Strategy in May 2004, Canada 
has established an accountability and evaluation 
framework to enable the progress made in achieving 
the objective of the Strategy to be monitored, 
documented and evaluated. In April 2005, the Drug 
Strategy Community Initiatives Fund was launched to 
provide funds for conducting activities for the 
reduction of illicit drug demand and the prevention of 
drug abuse. 
353. The Government of Canada has recently initiated 
consultations with federal, provincial and municipal 
law enforcement agencies to discuss and develop a 
collaborative and strategic approach to enforcement of 
the Precursor Control Regulations. The consultations 
led to the identification of a collaborative action plan 
to improve the controls related to precursor chemicals 
used in the illicit manufacture of drugs. 
354. In accordance with a recommendation made by 
the Board in 1996, the Government of Mexico has 
increased the resources to be set aside for control of 
narcotic drugs and psychotropic substances. Measures 
to interdict the illicit sale of controlled substances 
through Internet pharmacies will be carried out in 
cooperation with relevant agencies at the national 
level, such as consumer protection services, and with 
the Governments of the United States and other 
countries concerned. 
355. In Mexico, a pilot project to study the use of 
remote sensing technology to assess the extent of illicit 
crop cultivation and to estimate illicit production from 
the identified cultivation is being planned with the help 
of UNODC. A satellite monitoring system is under way 
and preliminary results are expected to be available by 
December 2005. The Board welcomes that initiative of 
the Government of Mexico, as reliable data on the 
extent of illicit drug crop cultivation in Mexico are 
urgently needed and long overdue. 
356. In addition to eradicating illicit crop cultivation, 
seizing illicit drugs and arresting the criminals 
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involved, the Government of Mexico has also been 
fighting corruption at all levels. Almost 
30,000 persons, including high-ranking officials, have 
been arrested for corruption since 2003. Additional 
efforts will be required to further fight corruption, 
including in the area of law enforcement and in the 
correction system. Of particular concern are reports of 
drug gang violence and violent challenges to police 
efforts to deal with drug trafficking in several cities in 
northern Mexico. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
357. The Board notes the declining rates of abuse of 
cannabis, cocaine and Ecstasy in the United States, 
particularly among adolescents and youth. However, 
that positive development is partly counteracted by an 
increase in the abuse of prescription drugs, in 
particular painkillers, among young adults and an 
increase in the abuse of inhalants among youth. The 
Board is also concerned about reports that 
methamphetamine manufacture, trafficking and abuse 
seem to be on the rise, particularly in rural areas. The 
Board notes the recent announcement of an anti-
methamphetamine initiative by the Government of the 
United States in response to this trend. 
358. In the United States, a little less than 8 per cent of 
the population aged 12 and above are current (past 
month) users of illicit drugs; the main drug of abuse is 
cannabis, followed by prescription drugs and cocaine. 
The prescription drugs that are abused are, to a large 
extent, diverted from domestic distribution channels or 
illegally operating Internet pharmacies. Most of the 
cocaine and much of the heroin, cannabis and 
methamphetamine available on the illicit drug markets 
in the United States are smuggled into the country over 
the Mexican border in the south-west. Despite 
concerted efforts by the Government of Mexico to 
counter illicit drug manufacture and trafficking, 
Mexico continues to be the primary transit country for 
the cocaine and one of the main manufacturers of the 
heroin, methamphetamine and cannabis found on illicit 
markets in the United States. 
359. The smuggling of drugs over the border between 
Canada and the United States has declined 
considerably; however, cannabis and meth-
amphetamine continue to be smuggled into the United 
States, while heroin and cocaine continue to be 
smuggled into Canada. Trafficking in and use of 
controlled synthetic drugs have become firmly 
entrenched in the drug culture in Canada. While the 
rave phenomenon served as the primary vehicle for the 
proliferation of Ecstasy trafficking and use, it also led 
to the introduction of other drugs associated with clubs 
and the resurgence of the abuse of established illicit 
synthetic drugs, notably methamphetamine. The illicit 
market for synthetic drugs has evolved from a 
relatively small market to a huge profit-making 
opportunity, enticing major organized crime networks 
to participate in the illicit manufacture of and 
trafficking in such drugs. 
 
  Narcotic drugs 
 
360. Cannabis continues to be the most abused drug in 
all three countries in North America. In Canada and 
Mexico cannabis abuse is still increasing, while in the 
United States the rate for cannabis use in the past year 
for almost all age groups, in particular for adolescents, 
has been declining since the late 1990s. 
361. Despite this positive trend, cannabis is readily 
available throughout the United States, and varieties of 
cannabis with higher potency have become more 
prevalent over the last 10 years. Domestic cannabis 
production appears to be increasing in part because of 
large-scale cannabis production by criminal groups. 
Tentative estimates indicate that approximately 
10,000 tons of cannabis are produced each year in the 
United States. 
362. Mexican cannabis is the principal type of foreign-
produced cannabis available in the United States. The 
illicit cultivation of cannabis plants in Mexico is 
concentrated in the least developed parts of the 
country, predominately in the west. 
363. While Canada is not a primary source of cannabis 
in the United States, exportation of cannabis to the 
United States has continued: Canada is the source of 
approximately 2 per cent of all cannabis seized on 
United States borders. In Canada, cannabis plant 
cultivation has continued to spread throughout the 
country due to the significant demand for cannabis, 
particularly among youth. For the last five years, 
Canadian law enforcement agencies have seized each 
year an average of 1.1 million cannabis plants, a 
sixfold increase since 1993. Operations with thousands 
of cannabis plants are no longer uncommon.  
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364. In the United States, it is estimated that 
2.3 million persons are current users of cocaine. The 
Board considers it to be encouraging that, among 
adolescents, the overall trend in cocaine abuse, like 
that of cannabis abuse, has been downward since 1999. 
In Canada, the annual prevalence of cocaine abuse 
increased during the period 1994-2004 from 0.7 to 
1.9 per cent. Cocaine is the second most widely abused 
illicit drug in Canada and Mexico. 
365. In the past, of the cocaine found in the United 
States, more than 70 per cent had entered the country 
through the corridor of Central America and Mexico, 
less than 30 per cent had entered the country through 
the Caribbean and about 1 per cent had been imported 
directly from the source country. Recently, the volume 
of cocaine passing through the corridor of Central 
America and Mexico to the United States has 
increased, accounting for 92 per cent of the total 
volume of cocaine entering the United States. 
366. Most of the cocaine available on the illicit market 
in Canada is supplied by commercial trucks passing 
through the United States. There is a close relationship 
between the smuggling of cocaine from the United 
States into Canada and the smuggling of Canadian 
cannabis to the United States. 
367. In the United States, current users of heroin 
represent 0.1 per cent of the population. The rate for 
heroin use in the past year appears to be relatively 
stable in the United States, but the rate for heroin use 
among adolescents is below the peak rates of the late 
1990s. The most prevalent types of heroin in the 
United States continue to be Colombian and Mexican 
heroin, although the share of the heroin market 
accounted for by South-West Asian heroin may be 
increasing. 
368. Despite the relatively small share of global opium 
production that it accounts for (less than 5 per cent), 
Mexico is currently the second largest supplier of 
heroin to the illicit market in the United States. About 
60 per cent of the trafficked heroin is reportedly 
smuggled out of Colombia through Mexico, the 
remainder being manufactured in Mexico itself. Illicit 
cultivation of opium poppy in Mexico (like the illicit 
cultivation of cannabis plant) is concentrated in the 
least developed parts of the country, largely in the 
west. The Government of Mexico estimates that about 
80 per cent of the illicit opium cultivation in the 
country has been eradicated. 
369. While most of the heroin available on the illicit 
market in Canada continues to originate in South-East 
Asia and South-West Asia, heroin of Latin American 
origin is being encountered more frequently. South-
East Asian, South-West Asian and other criminal 
organizations continue to be largely responsible for 
heroin importation and heroin trafficking activities in 
Canada. 
370. All three countries in North America have 
experienced a significant increase in the abuse of 
pharmaceutical preparations containing narcotic drugs. 
In Mexico, the abuse of pharmaceutical preparations is 
nearly as frequent as cocaine abuse. In Canada, an 
illegal street market for many prescription drugs has 
been confirmed, reportedly with large profit margins in 
the street value of various drugs.  
371. In the United States, the results of national 
surveys indicate that the non-medical use of all major 
groups of prescription drugs has been increasing over 
the past 10 years and now rivals the abuse of all other 
drugs except cannabis. Most pharmaceuticals abused in 
the United States are diverted through forged 
prescriptions, theft or “doctor shopping” (individuals 
obtaining considerably more prescriptions than 
clinically necessary in the course of a year). Law 
enforcement agencies report that illegal sale of 
prescription drugs via the Internet, often through 
Internet-based pharmacies, has increased sharply since 
the late 1990s. 
372. In 2004, approximately one out of five teenagers 
(18 per cent) in the United States was reported to have 
abused Vicodin (hydrocodone) in the past year and one 
out of 10 teenagers was reported to have abused 
OxyContin (oxycodone) in the past year; that 
represents a significant increase compared with the 
figures for 2002. A task force in Atlantic Canada found 
that a growing number of young people were abusing 
OxyContin. 
373. In the United States, transdermal patches 
containing a slow-release dose of fentanyl are 
increasingly being used for recreational purposes. As a 
result, there has been an increase in overdoses: 
115 deaths by overdose were attributed to the fentanyl 
patch in 2004. Some of the victims had removed the 
entire three-day supply of the drug from the patch and 
then injected, ingested or smoked it; others had used 
several patches at once. 
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  Psychotropic substances 
 
374. In the United States, it is estimated that there are 
over 3 million persons abusing prescription drugs 
containing psychotropic substances, mostly 
tranquillizers, stimulants and, to a lesser extent, 
sedatives. The rate of abuse of those drugs has 
remained fairly stable during the past two years. The 
abuse of sedatives among adolescents increased for a 
decade before levelling for the first time in 2003, a 
development welcomed by the authorities. Due to the 
high prescription level of stimulants used for the 
treatment of ADD (called attention deficit/ 
hyperactivity disorder (ADHD) in the United States), 
the preparations are also found on the illicit market. 
One out of 10 teenagers has used prescription 
stimulants (Ritalin® and/or Adderall®) without a 
doctor’s prescription. 
375. In Mexico, the abuse of tranquillizers is higher 
and is growing faster among women than among men. 
There continue to be cases in which flunitrazepam is 
diverted not to be abused but to be used to commit 
“date rape” (drug-facilitated sexual assault); 
consequently, the substance has been reclassified in 
order to strengthen control over it. 
376. GHB has become a matter of particular concern 
to United States law enforcement and public health 
agencies because of its increasing availability, the 
sharp increase in the frequency with which it was 
mentioned in emergency room cases since the mid-
1990s and its use in the commission of drug-facilitated 
sexual assault. In Canada, GHB has become a 
prominent law enforcement problem. Organized 
criminal groups in Quebec and Ontario engage in 
cross-border trafficking in GHB kits (including the 
precursor chemical GBL), selling the kits over the 
Internet and mailing them to customers in the United 
States and other countries throughout the world. 
Clandestine GHB laboratories, particularly in western 
Canada, provide supplies for traffickers. 
377. In Mexico, the seizure of a total of 30.6 million 
tablets of psychotropic substances in the period 2000-
2004 and the fact that the abuse of such substances is 
reflected in various surveys are indications that the 
problem is growing. In 2004 alone, over 40 tons of 
stolen medicaments were seized in Mexico, including 
some psychotropic substances, mainly in the form of 
medical samples, indicating that there is a sizeable 
illicit market for such products in that country. 
378. In the United States, the availability of MDMA 
has decreased nationwide. Moreover, data on illicit 
drug demand show that the rate of use of MDMA in the 
past year peaked for most age groups in 2001 and has 
declined significantly since then. A considerable 
increase in the perceived risks involved in using 
Ecstasy no doubt accounts for most of the turnaround.  
379. According to Health Canada, the demand for 
MDMA in Canada is increasing; the drug appears to be 
the preferred drug of abuse among adolescents and 
young adults. The total volume of MDMA seized each 
year at Canadian ports of entry soared from thousands 
of tablets in the 1990s to nearly 6 million tablets in 
2003. Contributing to that increase was a shift towards 
the importation of large shipments of MDMA in 
powder form from Western Europe to be pressed into 
tablets in Canada. Clandestine synthetic drug 
laboratories have become larger and more 
sophisticated. 
380. In the United States, the rate of use of 
phencyclidine (PCP), as well as lysergic acid 
diethylamide (LSD), in the past year has decreased to a 
very low level. In Canada, psilocybine, PCP and LSD 
continue to be available on the illicit market in small 
quantities. 
381. While the declining abuse of methamphetamine 
among adolescents in the United States is an 
encouraging sign, the overall increase in such abuse, 
particularly in rural areas, remains a matter of grave 
concern. Moreover, the number of methamphetamine 
laboratories detected and dismantled in the United 
States increased from over 9,000 in 2002 to more than 
17,000 in 2004. In Canada, the percentage of persons 
who have used “speed” (methamphetamine) in their 
lifetime increased from 2.1 per cent in 1994 to 6.4 per 
cent in 2004.  
382. It appears that the illicit drug markets in the 
United States are increasingly being supplied with 
methamphetamine manufactured in Mexico, the largest 
foreign source of the methamphetamine found in the 
United States. The manufacture and distribution of a 
form of methamphetamine commonly called “ice” (it 
has a higher purity level and is therefore more 
addictive) by Mexican criminal groups have increased 
sharply over the past two years. Pseudoephedrine was 
previously diverted mainly in bulk quantities for use in 
the illicit manufacture of methamphetamine; however, 
pseudoephedrine obtained from crushed 
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pharmaceutical preparations (tablets) is now being 
used for such manufacture. The majority of the 
clandestine methamphetamine laboratories detected 
and dismantled in Mexico were in the north of the 
country, close to the border of the United States. 
383. The illicit manufacture of and trafficking in 
methamphetamine have dramatically increased in 
Canada and the abuse of that substance is reported to 
have greatly increased in some parts of the country. 
The bulk of the methamphetamine available on the 
illicit market in Canada has been manufactured in that 
country. Seizure data indicate that illicitly 
manufactured methamphetamine from Canada is being 
smuggled into other countries, in particular the United 
States and, to a small extent, Japan. 
384. The Government of Mexico is monitoring the 
movement of precursor chemicals used in the illicit 
manufacture of narcotic drugs and psychotropic 
substances. Pseudoephedrine has been moved to a 
different schedule to allow stricter control over its sale. 
Several national training workshops on the control of 
precursor chemicals have been held in Mexico since 
2003 to inform industry of relevant control measures 
and of the need to remain vigilant with regard to 
attempts to divert such chemicals. 
 
  Substances not under international control 
 
385. Ketamine abuse has been reported in all three 
countries in North America. The rate of use of 
ketamine in the past year has declined among 
adolescents and young adults in the United States. In 
Canada, ketamine is among the more popular drugs 
that have been introduced in the “rave” and “clubbing” 
subcultures. Because of problems in the past involving 
its diversion and abuse, stricter controls over ketamine 
have been implemented in Mexico. 
386. Inhalants abused in Mexico and the United States 
are easily accessible in the form of household and 
office products, including glue, shoe polish, gasoline 
(petrol), aerosols, butane, paint thinner and nail polish 
remover. After 1995, there was a long and substantial 
decline in the abuse of inhalants among adolescents in 
the United States that was related to a media campaign 
against the abuse of such substances conducted by the 
Partnership for a Drug-Free America; then, in 2004, 
inhalant abuse in that country increased again. The 
proportion of young people who believe it is dangerous 
to abuse inhalants has declined over the past three 
years, which could explain the resurgence in the abuse 
of such substances. 
387. In the United States, one out of 11 teenagers has 
abused over-the-counter cough medications containing 
the active ingredient dextromethorphan (DXM). The 
recently reported deaths of five teenagers in that 
country may be associated with the consumption of 
DXM in capsule form. Though DXM abuse is not a 
new phenomenon, there has been a disturbing new 
development involving the sale of pure DXM in 
powder form. Such pure DXM is often put into 
capsules by the dealer before being sold on the street. 
 
  Missions 
 
388. The Board sent a mission to Mexico in January 
2005. The Board notes the significant efforts made by 
the Government of Mexico in combating illicit drug 
production, manufacture, trafficking and abuse. 
However, the Board is concerned that, despite 
important law enforcement successes, the trafficking 
organizations remain powerful and continue to strongly 
impede drug control efforts in Mexico and beyond. The 
Board urges the Government to curb the influence of 
organized criminal organizations on the Government 
and to fight corruption at all levels. With regard to 
illicit cultivation of cannabis plant and opium poppy, 
the Board recommends that the Government adopt 
effective means to prevent the resurgence of such 
cultivation, for example, by providing legitimate 
sources of livelihood for the farmers in question, in 
addition to intensifying law enforcement action. 
389. The Board notes the changes of the legislative 
basis for drug control introduced or planned to be 
introduced to better combat trafficking in and misuse 
of narcotic drugs, psychotropic substances and 
precursors and encourages the Government of Mexico 
to ensure concerted action involving the authorities at 
the federal level and the state level. In view of the 
continued diversion of psychotropic substances and 
precursor chemicals in Mexico, the Board requests the 
Government to investigate all cases of diversion and 
attempted diversion, with a view to identifying new 
trends and detecting and arresting the traffickers 
involved. With respect to demand reduction, the Board 
notes that the competent authorities ascertain regularly 
the extent and pattern of drug abuse and have improved 
the situation with regard to the prevention of drug 
abuse and the treatment and rehabilitation of drug 
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abusers. Although the extent of drug abuse in Mexico 
is small compared with the situation in other countries 
in the region, it has increased in recent years. The 
Board encourages the Government to continue to 
expand drug abuse prevention and treatment activities. 
 
 
  South America 
 
 
  Major developments 
 
390. In South America, the level of illicit coca bush 
cultivation remained significantly lower in 2004 than 
in the peak year of 2000, although it increased in 2004 
compared with 2003. The Board notes that intensified 
eradication and law enforcement efforts by the 
Government of Colombia have led to a decrease in 
illicit coca bush cultivation in that country; however, 
cultivation is increasing in other countries in the 
region, in particular in Bolivia and Peru. The 
Governments of most countries in the region have 
continued to be successful in their efforts to suppress 
trafficking in drugs, mainly cocaine, as evidenced by 
reports of record drug seizures, the dismantling of 
increased numbers of cocaine laboratories and 
increases in seizures of precursor chemicals. 
391. In 2004, coca bush cultivation in South America 
increased by 3 per cent compared with 2003 and 
continued to spread to areas that were previously not 
affected by such cultivation. Authorities identified 
extensive areas that had been newly cultivated with 
coca bush, including areas with high levels of 
insecurity and violence and in national forests and 
parks. Coca bush is also illicitly cultivated on small 
plots of land in Ecuador and Venezuela (Bolivarian 
Republic of). Cocaine manufacture and drug 
trafficking have continued to spread in the region 
despite intensified interdiction efforts. The Board notes 
with concern that the consistently high volume of 
seizures of cocaine, both in the region and elsewhere, 
and of coca paste and the precursor chemicals needed 
to manufacture cocaine have not yet led to a reduction 
in the availability of cocaine worldwide. 
392. Illicit cultivation of opium poppy and trafficking 
in heroin have not diminished in South America. The 
abuse of narcotic drugs and psychotropic substances 
has increased in most countries in the region. There are 
signs that the international syndicates involved in drug 
trafficking in the region are also becoming involved in 
trafficking in amphetamine-type stimulants and are 
experimenting with the illicit manufacture of such 
drugs. Money-laundering and corruption seriously 
affect most countries in South America and may reduce 
the impact of drug control efforts in the region. 
393. Political and social tension increased in many 
countries in South America, including in countries that 
had previously been less affected by it. In Bolivia and 
Peru, the Governments did not succeed in enforcing the 
law because of resistance on the part of coca bush 
growers; in both countries, the total area under coca 
bush cultivation has increased, although the 
transitional measures regarding the licit cultivation of 
coca bush and consumption of coca leaf under the 
1961 Convention ended a long time ago and it is a 
known fact that coca leaf harvested in the areas 
concerned is used in the illicit manufacture of cocaine. 
In addition, studies have been undertaken or will be 
undertaken in Peru and Bolivia, respectively to assess 
the demand for coca leaf used for local consumption. 
394. The Board is concerned that the Governments of 
some countries in South America, in view of the 
perceived difficulties in fighting illicit crop cultivation 
and drug trafficking, are considering ways to reduce 
their efforts in those areas, thereby sending the wrong 
message to the public. The Board urges all 
Governments to ensure that the provisions of the 
1961 Convention concerning illicit crop cultivation and 
illicit drug production and trafficking are fully 
implemented. 
395. At the same time, the Board believes that 
measures to alleviate poverty, accompanied by 
sustained law enforcement efforts to prevent the re-
emergence of illicit crop cultivation, are essential to 
the achievement of a lasting reduction in the 
production of coca or other narcotic drugs in South 
America. 
 
  Treaty adherence 
 
396. All States in South America are parties to the 
1961 Convention as amended by the 1972 Protocol, the 
1971 Convention and the 1988 Convention. 
 
  Regional cooperation 
 
397. South American countries continue to participate 
actively in multilateral cooperation mechanisms of 
CICAD for countries in the Americas. CICAD is 
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assisting those countries in the preparation of reports 
under the Multilateral Evaluation Mechanism and the 
development of the Inter-American Observatory on 
Drugs. CICAD also carries out, among other things, 
drug supply reduction and control activities and 
provides guidance in the development of the integrated 
drug treatment system. Together with UNODC, CICAD 
is establishing a drug information network to ensure 
common standards among countries and comparability 
of national drug abuse surveys (see para. 409 below). 
Regional cooperation related to drug control also 
includes Operation Andes II, a regional tracking 
initiative for precursors carried out in collaboration 
with Interpol and the World Customs Organization, and 
joint activities carried out by the member States 
(Argentina, Brazil, Paraguay and Uruguay) and 
associated States (Bolivia and Chile) of the Common 
Market of the Southern Cone (MERCOSUR). 
398. In addition, multilateral and bilateral agreements 
on drug control between States with common 
geographical traits or shared borders continue to be 
upheld. For example, an intelligence centre 
coordinated by the Federal Police of Brazil was created 
in 2005 in the border area where the borders of 
Argentina, Brazil and Paraguay meet. To assist law 
enforcement agencies of Colombia in establishing 
connections with their counterparts in the Caribbean, in 
collaboration with the Office central de répression du 
trafic illicite des stupéfiants of France, two meetings 
were organized in Fort-de-France, the capital of 
Martinique, in March and May 2005. 
399. The Fourteenth Meeting of Heads of National 
Drug Law Enforcement Agencies, Latin America and 
the Caribbean, held in Mexico City in October 2004, 
recommended that Governments should examine the 
possibility of sharing the proceeds from the forfeiture 
of illegally acquired assets upon the conclusion of 
investigations of drug trafficking activity undertaken in 
multiple jurisdictions, to facilitate the prosecution of 
persons involved in illicit activities. 
400. Leaders of drug control agencies from 
70 countries held a conference in Santiago in April 
2005 to strengthen international cooperation in the 
fight against drug trafficking and money-laundering. 
One of the main issues discussed was the increased use 
of the Internet by drug traffickers. 
401. The United States and countries in Europe 
continue to provide resources for drug control in South 
America through bilateral and multilateral agreements 
in a variety of areas such as law enforcement, criminal 
and fiscal investigation and judiciary matters, 
alternative development assistance, and programmes 
for drug abuse prevention. Recent examples include 
the agreement between Colombia and the United States 
and the agreement between Bolivia and the United 
States to maintain in 2006 the assistance provided for 
alternative development, strengthening institutions and 
creating social infrastructure, as well as the Lima 
Declaration, on strengthening cooperation between 
regions to reduce the supply of and demand for illicit 
drugs, agreed on during the VII High-Level Meeting of 
the Coordination and Cooperation Mechanism on 
Drugs between the European Union and Latin America 
and the Caribbean, held in Lima in June 2005. 
 
  National legislation, policy and action 
 
402. The Government of Argentina approved in 
January 2005 the Federal Plan for Integral Prevention 
of Drug Abuse and Drug Trafficking for the period 
2005-2007, which provides for reduction of illicit drug 
demand and supply; control measures; strengthening of 
institutions; and evaluation programmes. In Brazil, the 
Chamber of Deputies of the National Congress 
approved in February 2004 a new law amending Act 
No. 6368 of 21 October 1976, on measures for the 
prevention and suppression of the illicit traffic in and 
abuse of narcotic drugs or those substances which 
cause physical or psychic dependence; the new law is 
still awaiting approval by the Senate. In the Bolivarian 
Republic of Venezuela, a revised law on narcotic drugs 
and psychotropic substances (including the control of 
precursor chemicals) is still awaiting approval. The 
Board urges the Governments of those countries to take 
all the steps necessary to ensure that the new laws are 
enacted as soon as possible.  
403. In Ecuador, a new national drug strategy for the 
period 2004-2008 and its implementation plan came 
into effect in 2004. The Strategy includes provisions to 
strengthen the legal framework and institutional 
capacities to address drug trafficking. The first 
agreement to establish joint customs and police port 
control in Guayaquil, Ecuador, was achieved under a 
container control pilot programme aimed at reducing 
drug trafficking and increasing port safety without 
hampering legitimate container trade. 
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404. The Government of Guyana published in 
June 2005 the long-awaited five-year drug control 
strategy for the period 2000-2005. The strategy should 
lead to improvement in coordination by various 
agencies and a balanced approach to reducing the illicit 
supply of and demand for drugs; key elements are 
increased resources for law enforcement and greater 
bilateral cooperation with neighbouring countries, 
together with training of judges and magistrates on 
laws relating to drug control, improved facilities for 
the prosecution of drug cases and a revision of the 
Narcotic Drugs and Psychotropic Substances (Control) 
Act of Guyana, to provide for speedier forfeiture of 
assets related to drug trafficking. 
405. A multi-year criminal justice reform project 
continues to be implemented in Chile. In Colombia, a 
new criminal prosecution system with adversarial, oral 
and public trial features was initiated in January 2005, 
to be implemented gradually until December 2008. In 
Peru, the new code of criminal procedure will 
implement a similar accusatory system commencing in 
early 2006. The Board invites other countries 
experiencing similar problems with their criminal 
justice system to take appropriate measures to allow 
proper sentencing of drug-related crimes. For example, 
in Ecuador, drug traffickers appeared to operate with 
impunity following the dismissal of the Supreme Court 
in December 2004. In several remote regions of 
Ecuador and Peru, drug-related crimes go unpunished 
as there is no government presence and no public 
prosecutors. 
406. The Board notes that Colombia continued to 
strengthen its efforts in the area of law enforcement, in 
particular against the powerful drug trafficking 
organizations in that country. In late 2004 and early 
2005, Colombia extradited several high-ranking drug 
traffickers to the United States. 
407. New legislation against money-laundering was 
approved in Uruguay in September 2004. Draft 
legislation against money-laundering is to be approved 
in Ecuador and Paraguay (see also para. 432 below) by 
the congress of each of those countries. The Board 
urges the Government of Ecuador to expedite the 
approval and entry into force of the proposed 
legislation. The Board urges the Government of the 
Bolivarian Republic of Venezuela to approve the 
Organized Crime Bill, which has been ready since 
2002 and which would address the problems of money-
laundering and corruption and foster judicial 
cooperation; the Government is reviewing its 
agreement on drug control cooperation with the United 
States. 
408. In South America, activities aimed at combating 
the illicit use of chemicals in the manufacture of 
cocaine and heroin continued under Operation Seis 
Fronteras, a regional initiative involving Bolivia, 
Brazil, Colombia, Ecuador, Peru and Venezuela 
(Bolivarian Republic of), as well as the United States. 
The Parliament of Chile adopted in November 2004 a 
law that includes strengthened measures for the control 
of precursor chemicals. In Peru, where a new chemical 
precursor law was enacted in July 2004, a draft 
regulation on the implementation of the new law is 
before the congress. The Board invites Suriname, the 
only country in the region without legislation on 
precursor control, to enact such legislation as soon as 
possible. The Board urges all Governments in the 
region to strengthen their cooperation with a view to 
preventing the diversion of precursor chemicals across 
their borders and to identifying the attempted diversion 
of such chemicals. 
409. The Board welcomes the fact that during 2004 
and 2005 a comprehensive survey of drug abuse among 
school-aged persons was conducted with the assistance 
of CICAD and UNODC in Argentina, Bolivia, Chile, 
Ecuador, Peru, Suriname and Uruguay, using common 
methodologies and procedures to enable comparisons 
to be made between countries. The Board notes that 
programmes for the prevention and treatment of drug 
abuse in some countries in South America appear to be 
inadequate to deal with the increasing drug abuse in 
those countries. The Board invites Governments of 
countries in the region to increase their activities for 
reducing illicit drug demand and to strengthen their 
programmes for the treatment and social reintegration 
of drug abusers, as necessary. Governments should 
establish appropriate policies in this regard and provide 
adequate resources for such activities.  
 
  Cultivation, production, manufacture, 
trafficking and abuse  
 
  Narcotic drugs 
 
410. Illicit cultivation of cannabis destined mainly for 
local or regional markets continues to be detected in 
most countries in South America, as evidenced by 
increasing seizures of cannabis. For example, cannabis 
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plants are cultivated in northern and north-eastern 
Brazil, where eradication efforts are ongoing. Paraguay 
continues to be the principal source of the cannabis 
resin found in the region. In Paraguay, the good soil 
and high prices for cannabis and for cannabis resin on 
the illicit markets are ideal conditions for the illicit 
cultivation of cannabis plant and trafficking in 
cannabis. Only 10 per cent of the cannabis cultivated in 
Paraguay is abused locally; most of the rest is destined 
for markets in Argentina, Brazil and Chile. More than 
5,000 tons of cannabis were destroyed in Paraguay 
with the assistance of Brazilian authorities. Seizures of 
cannabis were reported to have increased in 2004 in 
Bolivia, where they rose by 250 per cent (to over 28 
tons) compared with 2003, and in Colombia. 
411. The illicit cultivation of cannabis plant, like the 
illicit cultivation of other drug crops in South America, 
is concentrated in areas where poverty prevails. 
Although a small number of countries in the region are 
experiencing serious problems with illicit cannabis 
plant cultivation, until now, sustainable legitimate 
livelihood programmes have been practically non-
existent in areas where cannabis plant is cultivated. 
The Board urges those countries to carry out 
sustainable legitimate livelihood programmes in 
conjunction with eradication and other effective law 
enforcement measures in areas that are already affected 
and those likely to be affected by illicit cannabis plant 
cultivation. 
412. Cannabis abuse is the driving force behind illicit 
crop cultivation and drug trafficking in South America. 
A comparative study of drug abuse in Bolivia between 
1992 and 2005 showed that cannabis continued to be 
the most frequently abused narcotic drug and that the 
abuse of cannabis was growing faster than the abuse of 
other internationally controlled substances. The Board 
urges the countries concerned to take cannabis abuse 
into account when considering measures to reduce the 
illicit demand for drugs. 
413. In 2004, the total area cultivated with coca bush 
in Bolivia, Colombia and Peru, after having decreased 
for three years, increased by 3 per cent (to 
158,000 hectares) over 2003, and coca bush cultivation 
continued to spread to areas previously not affected by 
it. Whereas the total area under coca bush cultivation 
in Colombia continued to decrease, from 
86,000 hectares in 2003 to 80,000 hectares in 2004, 
about 60 per cent of the coca bush fields identified in 
that country were new. Significant replanting of coca 
bush was reported in Colombia at the end of 2004; that 
has not yet been included in the coca bush cultivation 
survey for 2004. In 2004, crop spraying reached a 
record level in Colombia for the fourth consecutive 
year, contributing to the continued decrease in coca 
bush cultivation. However, the vegetation cover of 
some of the sprayed coca bush fields had time to grow 
back. In addition to crop spraying, manual eradication 
of coca bush fields is also taking place in Colombia. 
414. In Peru, which continues to be a major producer 
of coca leaf, the total area under coca bush cultivation 
was estimated in 2004 at 50,300 hectares, an increase 
of 14 per cent over 2003. More than 10,000 hectares of 
coca bush were eradicated in 2004 and a further 
8,000 hectares are expected to be eradicated in 2005; 
however, opposition to illicit crop eradication is 
growing. Almost one quarter of the total area cultivated 
with coca bush in Peru in 2004 was in national parks 
and other areas where the conditions are not suitable 
for agriculture. In 2004, studies on coca leaf yields 
revealed that field management practices had 
improved. The many coca bush seedlings and newly 
prepared fields, in particular in areas with high levels 
of insecurity and violence, where eradication is 
difficult, indicate that coca bush cultivation in Peru 
could increase further in 2005. Moreover, in 2005, 
several local governments issued ordinances that, in 
effect, legalized the cultivation of coca bush for 
traditional purposes, such as chewing and making 
infusions. Those ordinances have been vigorously 
rejected by the Government of Peru, as they are 
deemed to be unconstitutional and in breach of Peru’s 
international drug control commitments and 
responsibilities. The Board is concerned that that 
action could serve as a precedent if it is allowed to 
stand. 
415. In Bolivia, political and social tension has 
severely limited the ability of the Government to deal 
with the increasing coca bush cultivation; moreover, 
the eradication policy has been undermined by short-
term agreements with coca growers. UNODC estimates 
that in Bolivia a total of 27,700 hectares were under 
coca bush cultivation in 2004, which represents an 
increase of 17 per cent over the total for 2003; 41 per 
cent of the total area under illicit coca bush cultivation 
was in national parks. A total of 8,437 hectares of coca 
bush were eradicated in Bolivia in 2004, less than the 
amount eradicated in any of the three previous years.41 
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The increase in coca bush cultivation in Bolivia took 
place mainly in Chapare, where coca leaf yields were 
estimated to be more than twice as high as elsewhere in 
the country; more than 50 per cent of the increase took 
place at the expense of forest areas. 
416. In addition, the illicit cultivation of coca bush 
continues to be reported in Ecuador and Venezuela 
(Bolivarian Republic of), near those countries’ borders 
with Colombia, although it is very limited and sporadic 
compared with such cultivation in the major producing 
countries. In both Ecuador and Venezuela (Bolivarian 
Republic of) the first surveys of illicit crops were 
launched in mid-2005, focusing on provinces in those 
countries adjacent to the Colombian border; the results 
of those surveys are expected in December 2005. The 
Board hopes that the Governments of those two 
countries will take vigorous action against illicit coca 
bush cultivation so that it can be stopped before it 
spreads and becomes much more difficult to eliminate. 
417. The Board wishes to re-emphasize that the 
continued success of efforts to reduce illicit crop 
cultivation, as well as interdiction efforts, will depend 
on the political will of Governments to enforce a 
policy of not tolerating illicit crop cultivation and drug 
trafficking even in times of difficult circumstances 
such as social and political tension. However, that 
policy should be accompanied by programmes offering 
sustainable legitimate livelihood to farmers in the 
producing countries. 
418. Based on the estimated total area under coca bush 
cultivation, the potential total manufacture of cocaine 
in 2004 was estimated at 687 tons, an increase of 2 per 
cent compared with the total in 2003 (674 tons). That 
estimate is less reliable than the estimated total area 
under coca bush cultivation, in the absence of hard data 
on agricultural yields and also on the yields from 
processing coca leaf into cocaine. As noted by the 
Board already in its report for 2004, there are 
indications that coca leaf yields in some countries, as 
well as the assumed cocaine manufacture, might have 
increased considerably more than estimated, due to 
improved methods;42 moreover, better agricultural 
techniques, including irrigation, have been used. It is 
also believed that the manufacture of cocaine from 
coca leaf has become more effective since the late 
1990s, as traffickers have become more experienced in 
the use of precursor chemicals. The relatively stable 
prices of coca base and cocaine in South America, 
despite the success of efforts to reduce illicit coca bush 
cultivation, as well as law enforcement efforts, support 
the view that actual illicit manufacture of cocaine 
might have been substantially higher than estimated. 
419. The bulk of the cocaine in the world continued to 
be manufactured in Colombia, but the illicit 
manufacture of cocaine is known to have taken place in 
recent years also in all other countries in South 
America except Paraguay (even in countries not 
previously affected by illicit cocaine manufacture, such 
as Argentina and Uruguay). For example, in the 
northern border area of Ecuador, a large laboratory for 
processing cocaine was found in February 2005. In 
Colombia, intensified law enforcement efforts resulted 
in an increase in the volume of detected and dismantled 
clandestine laboratories for cocaine manufacture 
during 2003 and 2004, as well as an increase in the 
total volume of seizures of coca base and cocaine 
hydrochloride. In May 2005, more than 15 tons of 
cocaine hydrochloride were seized at an illegal storage 
location near Tumaco, Colombia, the largest single 
seizure of that substance ever made in that country; 
during the same operation, precursor chemicals, 
speedboats and firearms were also seized and a centre 
for controlling drug trafficking activities throughout 
the country was destroyed. 
420. Drug traffickers responded to intensified 
interdiction efforts in Colombia by gradually shifting 
the illicit manufacture of cocaine to other countries and 
by using new and diverse trafficking routes. 
International criminal groups involving Colombian and 
Mexican nationals are involved in drug trafficking 
throughout South America. Criminal organizations that 
previously focused their activities on trafficking only 
in either cannabis, cocaine or heroin are now 
trafficking in all of those drugs. There are some new 
trends in the smuggling of cocaine into Europe: the 
cocaine shipments involved are increasingly being 
transported through Southern Africa and, in particular, 
Western Africa; and the operations are often organized 
by criminal groups from Western Africa. In Ecuador, 
international trafficking networks with links to 
criminal groups in Lebanon and countries in Northern 
Africa have been identified as being involved in 
smuggling cocaine and heroin into the United States 
and have used corrupt airport officials for that purpose. 
421. In Bolivia, the low prices of coca leaf and other 
illicit drugs noted in the last few months could have 
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led to Colombian and Mexican drug gangs being 
attracted to that country. According to information on 
law enforcement efforts in Bolivia during 2004 and the 
first half of 2005 and in Peru during 2004, there 
continues to be a large volume of seizures of cocaine 
base and precursor chemicals, as well as a large 
number of dismantled clandestine laboratories for 
large-scale cocaine manufacture; despite those 
successes, the low prices of cocaine in the streets in 
Peru indicate that cocaine is readily available in that 
country. 
422. Although the abuse of cocaine is a problem in 
South America, the cocaine that is smuggled in the 
region continues to be mainly destined for the United 
States or, increasingly, countries in Europe. Brazil, 
Ecuador, Suriname and Venezuela (Bolivarian 
Republic of) are the countries in the region that are 
most affected by cocaine trafficking, although other 
countries, such as Argentina and Chile, have 
experienced growing transit traffic. In Chile, for 
example, in the second half of 2004, two consignments 
of cocaine were seized, each exceeding 1 ton. Other 
significant seizures of cocaine in 2004 were reported 
by Brazil, Peru and Venezuela (Bolivarian Republic of) 
(7 tons each). 
423. Traffickers continue to attempt to circumvent the 
controls put in place within the framework of 
Operation Purple, the international tracking 
programme for the prevention of the diversion of 
potassium permanganate, the key chemical for the 
purification of cocaine. In 2004, 19 clandestine 
laboratories for the manufacture of potassium 
permanganate were detected and dismantled in 
Colombia (more than twice the number detected and 
dismantled in that country in 2003), and 3 clandestine 
laboratories for the manufacture of precursor chemicals 
were dismantled in Bolivia. In Colombia, the total 
volume of seizures of precursor chemicals for the 
manufacture of cocaine increased in 2004 compared 
with 2000. 
424. The precursor chemicals smuggled in South 
America continue to be mainly from the region. For 
example, in Ecuador, law enforcement investigations in 
2004 and 2005 confirmed a major incident involving 
transnational organized crime: the large-scale, 
systematic diversion through theft of petroleum ether 
for use as a precursor in Colombia. Progress is being 
made towards finding effective solutions to prevent 
such theft in the future. Strengthened precursor control 
in Paraguay resulted in the seizure of 10,000 litres of 
toluene, a solvent used in the manufacture of cocaine, 
in November 2004. In the Bolivarian Republic of 
Venezuela, theft of precursor chemicals is reported to 
the Government. The Board urges each Government in 
the region to remain vigilant and strengthen its controls 
over the distribution and use of precursors on its 
territory. 
425. The Government of Colombia estimates that 
almost 4,000 hectares were used for the illicit 
cultivation of opium poppy in 2004, similar to the total 
area under such cultivation in that country in 2003. It is 
assumed that the total area under such cultivation in 
that country has not changed much in recent years, 
despite crop spraying. Total potential heroin 
manufacture in Colombia in 2004 was estimated at 
5 tons. The illicit cultivation of opium poppy continues 
to take place in Peru, where the Government has 
continued its eradication efforts. According to 
estimates by the Government of Peru, in 2004, a total 
of 1,400 hectares were cultivated with opium poppy; 
that area had the potential of yielding approximately 
1 ton of heroin. In 2004, Peru reported the seizure of 
450 kilograms of opium.43 In the Bolivarian Republic 
of Venezuela, opium poppy is illicitly cultivated; there 
are plans to begin an eradication programme once the 
results of the survey of the extent of that cultivation are 
known. 
426. Heroin manufacture continues to take place 
mainly in Colombia and, to a lesser degree, in Peru. 
Eight clandestine laboratories for heroin manufacture 
were dismantled in Colombia during 2004. Most of the 
heroin manufactured in South America is destined for 
the United States. The Bolivarian Republic of 
Venezuela, one of the main countries in South America 
used as a transit country for heroin shipments bound 
for the United States, cooperated in the dismantling of 
a heroin smuggling organization in 2004. 
427. Cannabis and cocaine, in that order, continue to 
be the main narcotic drugs abused in South America; 
however, the extent of the abuse of those drugs varies 
from country to country. For example, the level of drug 
abuse is fairly low in Paraguay (see para. 433 below): a 
survey released in August 2004 revealed that only 
0.7 per cent of the surveyed population had tried 
cocaine in their lifetime. In contrast, surveys 
undertaken in Peru in 2004 showed that abuse of drugs 
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had increased among men and women, especially 
among young people, that the abuse of cocaine base 
and cannabis had nearly doubled between 2002 and 
2004, and that about 4 per cent of the surveyed 
population over 12 years of age had used cocaine at 
least once. 
428. The abuse of morphine and heroin is not a major 
problem in South America; however, in Argentina and 
some Andean countries, the abuse of those drugs is 
reported to be increasing, especially among youth. The 
Board urges the Governments concerned to alert their 
population about the risks associated with the abuse of 
such drugs. 
 
  Psychotropic substances 
 
429. According to reports, the illicit manufacture of 
psychotropic substances in South America remains 
limited. Seizures of illicitly manufactured stimulants, 
still smuggled mainly out of Europe, continue to be 
effected in countries in the region. However, in 
September 2005, Colombian police dismantled for the 
first time a clandestine laboratory used for the 
manufacture of methamphetamine. In Colombia, some 
of the Ecstasy smuggled out of Europe is pressed into 
tablets and there are trafficking organizations 
specializing in Ecstasy. The availability and abuse of 
Ecstasy are increasing in Colombia and Venezuela 
(Bolivarian Republic of). Ecstasy is also becoming 
more readily available in Ecuador and Peru. In 
Suriname, the volume of seizures of Ecstasy rose 
sharply in 2004. 
430. The diversion and overprescription of a variety of 
pharmaceuticals containing psychotropic substances 
have continued. For example, the latest drug abuse 
surveys conducted in Argentina, Chile and Uruguay 
show that the rate of abuse of sedatives 
(benzodiazepines) is ranked second after cannabis 
abuse and that the rate of abuse of stimulants (such as 
femproporex) is similar to or even higher than that of 
cocaine. The Board reiterates its appeal to 
Governments to strengthen their control over 
prescriptions for controlled pharmaceuticals and to 
inspect records on relevant sales (see, for example, the 
report of the Board for 2003).44 
 
  Substances not under international control 
 
431. Ketamine, a substance currently under review by 
WHO to determine whether it should recommend that 
it be placed under the control of the 1971 Convention, 
is readily available in Peru on the illicit market and 
therefore abused extensively, despite the fact that 
officially its sale is restricted to hospitals. The abuse of 
ketamine has also been detected in Uruguay. 
 
  Missions  
 
432. The Board sent a mission to Paraguay in April 
2005. The Board notes the commitment of the 
Government of Paraguay in combating illicit drug 
production, trafficking and abuse. The mission found 
that in Paraguay the legislative basis for the control of 
drugs in general and for the control of narcotic drugs 
and psychotropic substances in particular was 
adequate. Nevertheless, the Board notes that the 
resources for drug control remain inadequate and 
coordination and cooperation between the agencies 
involved are still lacking. The Board recommends that 
the Government provide more human resources, 
training and equipment with a view to making more 
effective the agencies involved in drug control. The 
Board urges the Government to continue to implement 
its policy of zero tolerance of corruption and to 
increase the effectiveness and transparency of the law 
enforcement and judicial systems by providing 
appropriate human resources and training. In addition, 
the Board encourages the Government to take all steps 
necessary to ensure that changes to be introduced into 
the national legislation against money-laundering will 
be implemented as soon as possible. 
433. The Board advises the Government of Paraguay 
to keep a balanced approach in its overall drug control 
policy, ensuring the reduction of both the demand for 
and the supply of illicit drugs. The Board notes that the 
Government has recently undertaken surveys to 
ascertain the extent and pattern of drug abuse, which 
have shown that there is relatively little abuse of 
psychotropic substances and cannabis in the country, 
and is planning drug abuse prevention activities. The 
Board notes the measures already taken in Paraguay, as 
well as those planned to be taken, to suppress the illicit 
cultivation of cannabis plant and trafficking in 
cannabis and other drugs and encourages the 
Government to maintain its efforts in those areas. 
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 C. Asia 
 
 
  East and South-East Asia 
 
 
  Major developments 
 
434. The total area under illicit opium poppy 
cultivation in the Lao People’s Democratic Republic 
declined considerably. Although illicit opium poppy 
cultivation has continued to decline in Myanmar, that 
country remains the main source of illicit opium in 
East and South-East Asia. 
435. The Lao People’s Democratic Republic has now 
joined Thailand and Viet Nam as countries that are no 
longer significant suppliers of opiates on the world’s 
illicit markets. However, there are indications that it 
may be emerging as a transit country used for 
smuggling amphetamine-type stimulants and heroin. 
436. The illicit manufacture of, trafficking in and 
abuse of amphetamine-type stimulants continue to be a 
problem in East and South-East Asia. In countries such 
as Brunei Darussalam, Cambodia, the Lao People’s 
Democratic Republic, the Philippines and Thailand, 
methamphetamine is reported to be the drug of choice. 
Large seizures of amphetamine-type stimulants 
continued to be reported in most countries in the 
region, including Cambodia, China, Indonesia, Japan, 
Myanmar, Thailand and Viet Nam. The illicit 
manufacture of methamphetamine is concentrated in 
China and Myanmar, but has been increasingly 
detected in Indonesia, Malaysia and the Philippines. 
Significant amounts of MDMA (Ecstasy) continued to 
be seized not only in countries such as Indonesia and 
Japan, but also in the Hong Kong Special 
Administrative Region (SAR) and the Macao SAR of 
China. 
437. Opiates, followed by amphetamine-type 
stimulants, continued to be the main drugs of abuse in 
East and South-East Asia. Heroin was the most 
commonly abused drug in the majority of countries in 
the region, with the exception of Myanmar, where 
opium was the main drug of abuse, and Japan, the 
Philippines, the Republic of Korea and Thailand, 
where methamphetamine was the main drug of abuse. 
Heroin is the drug of choice in China (including the 
Hong Kong SAR and the Macao SAR of China), 
Indonesia, Malaysia and Viet Nam. HIV infection 
continues to be a major problem in many of the 
countries where heroin is the preferred drug among 
persons who abuse drugs by injection. 
 
  Treaty adherence 
 
438. The Board welcomes the accession of Cambodia 
to the three international drug control treaties in April 
2005. 
439. The Board notes that the Democratic People’s 
Republic of Korea and Timor-Leste have not yet 
become a party to any of the international drug control 
treaties. The Board calls on those States to ratify the 
treaties without further delay.  
440. The Board calls on the Lao People’s Democratic 
Republic to become a party to the 1972 Protocol 
amending the 1961 Convention without further delay. 
 
  Regional cooperation 
 
441. The Board notes that, in May 2005, the 
signatories of the 1993 memorandum of understanding 
on drug control between the countries in the Mekong 
area (Cambodia, China, the Lao People’s Democratic 
Republic, Myanmar, Thailand and Viet Nam) adopted 
the Siemreap Declaration. The Declaration focuses on 
collaboration in a wide range of areas, including the 
control of precursor chemicals and amphetamine-type 
stimulants, the treatment and prevention of drug abuse, 
the development of a comprehensive package of 
interventions related to drug abuse and HIV/AIDS, 
sustainable alternative development and technical and 
financial assistance. 
442. The Eleventh United Nations Congress on Crime 
Prevention and Criminal Justice was held in Bangkok 
from 18 to 25 April 2005. The Congress adopted the 
Bangkok Declaration on Synergies and Responses: 
Strategic Alliances in Crime Prevention and Criminal 
Justice,45 which calls for an integrated approach, 
including measures against illicit drug trafficking, 
money-laundering and terrorism. 
443. The Seventh International Congress on AIDS in 
Asia and the Pacific was held in Kobe, Japan, in July 
2005. The Congress noted the lack of access to 
prevention services for persons who abuse drugs by 
injection. 
444. The second International Association of 
Southeast Asian Nations (ASEAN) and China 
Cooperative Operations in Response to Dangerous 
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Drugs (ACCORD) Congress was held in Beijing in 
October 2005. The main objective of the Congress was 
to review the ACCORD Plan of Action, endorsed by 
the Congress in 2000, and to update it to reflect the 
current drug control needs and responses of the region. 
445. Within the framework of ACCORD, the Drug 
Abuse Information Network for Asia and the Pacific 
was established in 2004. The 11 ACCORD partner 
countries electronically submit their national drug 
control data in quarterly and annual reports; those data 
appear in a common database. 
446. Thailand hosted the Seminar on Illicit Traffic by 
Waterways for ACCORD Partner Countries in June 
2005. The United States Coast Guard, the Australian 
Federal Police, the Japan Coast Guard and the Royal 
Thai Navy also participated in the Seminar, which was 
held in Phuket, Thailand. Effective drug control 
approaches related to waterway interdiction and 
investigations were presented at the Seminar. 
447. Cooperation in the form of joint drug control 
operations in East and South-East Asia continued to 
yield good results. In February 2005, Japanese 
authorities seized 80 kg of “crystal” methamphetamine 
and 250,000 MDMA (Ecstasy) tablets and arrested 
three suspects following an investigation carried out 
jointly by law enforcement agencies of Japan and the 
Hong Kong SAR of China. In March 2005, authorities 
in China arrested four suspects and seized 7 kg of 
heroin as a result of a law enforcement operation 
carried out in cooperation with the Hong Kong SAR of 
China. 
 
  National legislation, policy and action 
 
448. China announced that it would launch a three-
year nationwide “war against drugs” starting in 2005. 
The objective of the campaign is to reduce illicit drug 
supplies, drug-related harm and the number of new 
drug abusers. 
449. China has adopted a new law on narcotic and 
psychotropic substances, as well as a new law on 
precursor chemicals, both of which went into effect on 
1 November 2005. The laws are intended to further 
strengthen control over narcotic drugs, psychotropic 
substances and precursor chemicals. 
450. Japan continues to place high priority on drug 
control in its national planning, which remains focused 
on the strengthening of drug control measures to 
combat drug smuggling and on the prevention of drug 
abuse by organizing awareness-raising campaigns and 
providing support for the rehabilitation of drug 
abusers. 
451. In March 2005, Viet Nam approved a national 
drug control master plan for the period up to 2010. The 
master plan is aimed at reducing the number of drug 
abusers by at least 20 per cent compared with the 
figure for 2001 and to significantly reduce the number 
of the communes, city wards, townships, workplaces, 
schools and armed force units affected by drug 
problems, as well as to increase treatment services for 
drug addicts. 
452. In December 2004, Cambodia approved a drug 
control master plan for the period 2005-2010. The plan 
is focused on reducing illicit drug supply and demand, 
strengthening law enforcement, reducing the risk of 
drug abuse and strengthening international cooperation 
in drug control. 
453. The Board notes that in February 2005, the 
Democratic People’s Republic of Korea established an 
interministerial committee to ensure effective 
coordination of drug control activities and adequate 
implementation of drug control legislation. The Board 
expects that this positive development will enable the 
Government to take swift action to ratify the 
international drug control treaties. In order to 
strengthen the capacity of the Government of the 
Democratic People’s Republic of Korea for carrying 
out drug control activities, the Board encourages the 
Government to allocate sufficient resources to such 
activities. 
454. Viet Nam has approved a plan to combat cross-
border drug trafficking in the period 2005-2010. The 
plan includes measures for tightening the inspection of 
suspected goods, means of transport and people along 
border areas, including along road, air and sea routes 
and in the postal services. The plan also includes the 
introduction of punishment for administrators who 
have allowed drug abuse and trafficking. 
455. During a period of several months beginning in 
June 2005, nine countries in East and South-East Asia 
(Cambodia, China, Indonesia, the Lao People’s 
Democratic Republic, Malaysia, Myanmar, the 
Philippines, Thailand and Viet Nam) each held a 
national workshop focusing on building a partnership 
between the Government and the chemical and 
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pharmaceutical industries to prevent the diversion of 
precursor chemicals from licit trade. As a result of the 
workshops, it was agreed to establish partnership 
committees; the priority tasks to be undertaken 
included educating the industries, drafting a code of 
conduct and promoting cooperation between the 
industries and the Government.  
456. Several countries in East and South-East Asia 
have implemented policies to provide employment 
opportunities for rehabilitated drug addicts. In the 
Philippines, non-governmental organizations are 
involved in providing jobs in the service industry to 
former drug addicts. More than 10,200 rehabilitated 
addicts in Viet Nam have been given jobs under a 
project on organizing and managing vocational training 
and job creation. Over 90 enterprises, cooperatives and 
individuals are participating in the initiative. The 
beneficiaries are involved in the garment, wood 
product and food processing industries, in fine arts and 
handicrafts, and in agricultural production and animal 
husbandry. 
457. The Board is pleased to note that Indonesia and 
the Philippines have been removed from the list of 
countries and territories considered by the Financial 
Action Task Force on Money Laundering to be “non-
cooperative” in efforts to counter money-laundering or 
to have critical deficiencies in their systems for 
countering money-laundering. The Board notes with 
concern that Myanmar remains on that list. The Board 
encourages Myanmar to put in place the relevant 
legislation and administrative structures to prevent 
money-laundering, which play an important role in 
efforts to fight drug trafficking. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
 
  Narcotic drugs 
 
458. The illicit cultivation of cannabis plants has 
continued throughout East and South-East Asia. 
Several countries in the region have continued to seize 
substantial quantities of cannabis. Indonesia, Japan, 
Myanmar and the Republic of Korea reported for 2004 
a large increase in the volume of cannabis seized. 
Malaysia reported having made its largest seizure of 
cannabis in recent years. 
459. The Government of the Lao People’s Democratic 
Republic succeeded in further reducing illicit opium 
poppy cultivation, from 6,600 hectares in 2004 to 
1,800 hectares in 2005. As a result of continued 
eradication efforts by the Government of Myanmar, 
illicit opium poppy cultivation declined to 
32,800 hectares in 2005, a decrease of 26 per cent 
compared with the figure for 2004. 
460. The Lao People’s Democratic Republic has 
succeeded in virtually eliminating illicit opium poppy 
cultivation. However, it is faced with problems 
involving other drugs. The illicit cultivation of 
cannabis plant and trafficking in cannabis are matters 
of great concern to the Government of the Lao People’s 
Democratic Republic; cannabis is grown on a large 
scale in certain areas of the country. The Lao People’s 
Democratic Republic is also emerging as a transit 
country used for trans-shipping consignments of heroin 
originating in Myanmar and destined for Cambodia, 
China, Viet Nam and Thailand. 
461. In 2004, several countries in East and South-East 
Asia, such as Indonesia and Malaysia, reported a 
significant increase in the volume of opium seized. 
Myanmar, which usually reports having seized a large 
quantity of opium every year, reported having seized a 
total of only 1 ton of opium in 2004. 
462. In many countries in East and South-East Asia 
(China, Myanmar, Malaysia, Thailand and Viet Nam) 
the total quantity of heroin seized continued to be 
large. Although Singapore had seized significant 
amounts of heroin in the past, the quantity of such 
seizures had recently decreased dramatically. During a 
raid on the largest drug cartel in Viet Nam in August 
2005, police arrested dozens of suspects and seized 
highly specialized equipment designed for the large-
scale manufacture of heroin. On numerous occasions in 
2004, the police in Viet Nam seized large amounts of 
heroin. In 2004, Malaysia reported having dismantled 
six clandestine laboratories for the manufacture of 
heroin. 
463. Recent seizures in East and South-East Asia 
indicate an increase in drug trafficking using water 
routes. In July 2004, authorities of Myanmar seized 
over 592 kg of heroin in the Andaman Sea; eight 
months later, in March 2005, Thai authorities seized in 
the Gulf of Thailand 522 kg of heroin and 10,000 
methamphetamine tablets destined for the Hong Kong 
SAR of China. Furthermore, Cambodian authorities 
reported having seized in September 2004 
600,000 methamphetamine tablets along the Mekong 
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near their country’s northern border with the Lao 
People’s Democratic Republic and Thailand. 
464. Authorities in East and South-East Asia 
continued to report the seizure of small quantities of 
cocaine. In the Hong Kong SAR of China, a significant 
amount of cocaine was seized in 2004 (compared with 
the figure for the previous year) and five clandestine 
cocaine laboratories were dismantled. 
465. Some countries are making progress in 
preventing the abuse of opium; for example, a survey 
of villages in the Lao People’s Democratic Republic 
showed that there has been a decrease of 32 per cent in 
the abuse of opium since 2003.  
466. Although the abuse of cannabis is not widespread 
in East and South-East Asia, the Hong Kong SAR of 
China reported a new trend: the abuse of cannabis 
buds. 
467. The transmission of HIV infection through drug 
abuse by injection continues to be a major problem in 
many of the countries in East and South-East Asia. 
Heroin is the drug of choice among persons who abuse 
drugs by injection in countries such as China 
(including the Hong Kong SAR and the Macao SAR of 
China), Indonesia, Myanmar, Thailand and Viet Nam. 
In China, the provinces of Sichuan and Yunnan and the 
autonomous region of Xinjiang have reported a high 
prevalence of HIV infection transmitted through drug 
abuse by injection. In 2004, there were 1.6 million 
registered drug abusers in China, the majority of whom 
were abusers of heroin; over 41 per cent of the 89,000 
reported HIV cases involved drug abusers. The Macao 
SAR of China reported an increase in the percentage of 
females and youth among newly reported HIV cases. 
HIV infection among persons who abuse drugs by 
injection in the Macao SAR increased dramatically 
from 0.7 per cent in 2003 to 6.5 per cent in 2004; in 
order to combat the epidemic, the government 
announced that it would introduce substitution 
treatment for drug abusers in 2005. Persons who abuse 
drugs by injection account for approximately 30 per 
cent of all new cases involving HIV infection in 
Myanmar and 20 per cent of such cases in Thailand. 
Drug abuse by injection continues to be one of the 
main routes of HIV transmission in Viet Nam; over 
56 per cent of new HIV cases involve persons who 
abuse drugs by injection and have adopted the practice 
of needle-sharing. 
 
  Psychotropic substances 
 
468. The illicit manufacture of amphetamine-type 
stimulants continued to take place mainly in China and 
the border area between China and Myanmar and, to a 
lesser extent, in Indonesia, Malaysia and the 
Philippines. Drug dealers in Viet Nam have been 
known to be involved in the illicit manufacture of 
tablets of amphetamine-type stimulants using 
amphetamine powder and crystal methamphetamine 
from other countries. Some of those tablets also 
contain caffeine, paracetamol and ketamine. 
469. Many countries in East and South-East Asia, 
including Cambodia, China, Indonesia, Japan, 
Myanmar and Thailand, again reported the seizure of a 
large volume of amphetamine-type stimulants. In 
April 2005, a clandestine laboratory with the capacity 
to produce 7.5 million MDMA (Ecstasy) tablets a 
month was dismantled in Indonesia; the police arrested 
several suspects in connection with that case and 
seized a considerable amount of MDMA tablets, 
precursor chemicals and equipment. In 2004, Malaysia 
reported the dismantling of three clandestine 
methamphetamine laboratories. The Hong Kong SAR 
of China dismantled in 2004 two laboratories involved 
in the illicit manufacture of methamphetamine. 
Contrary to the upward trend implied by the above-
mentioned reports in the region, preliminary data for 
2004 indicate a decline in global seizures of 
amphetamine-type stimulants. In China the total 
volume of seizures of amphetamine-type stimulants 
declined from about 6 tons in 2003 to 3 tons in 2004. 
470. Some countries in East and South-East Asia 
reported having seized a significant quantity of 
sedatives and hallucinogens in 2004. Japan seized 
310 kg of benzodiazepines and Indonesia seized over 
1 million tablets of hallucinogens. 
471. In East and South-East Asia, sizeable quantities 
of MDMA (Ecstasy) continued to be seized in 
Indonesia (251,000 tablets) and Japan 
(469,000 tablets), as well as in the Hong Kong SAR of 
China (284,000 tablets). In Viet Nam, police arrested 
the leaders of the country’s largest MDMA trafficking 
ring and seized a large amount of that drug. Those 
arrests were the result of police interdiction following 
the arrest of their accomplices and the seizure of a 
considerable quantity of MDMA tablets and ketamine. 
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472. Although over half of the methamphetamine 
smuggled into the Republic of Korea originates in 
China, the Philippines is rapidly emerging as a 
significant source. The Lao People’s Democratic 
Republic is emerging as a transit country for 
consignments of amphetamine-type stimulants 
originating in Myanmar and destined for Cambodia, 
China, Thailand and Viet Nam. 
473. Pseudoephedrine and ephedrine, precursors 
frequently used in the illicit manufacture of 
methamphetamine, continued to be seized in East and 
South-East Asia. In August 2004, 90 kg of ephedrine 
were seized in Myanmar. In 2004, the authorities in the 
Philippines dismantled 11 clandestine laboratories and 
seized over 4 tons of ephedrine. In addition, those 
chemicals are being diverted from East and South-East 
Asia to other regions. In August 2005, 400 kg of 
ephedrine concealed in statues from Viet Nam were 
seized in Australia, the country of destination. That is 
an indication that, as controls over those precursor 
chemicals become increasingly stringent, traffickers 
are turning to methods of concealment previously used 
in smuggling illicit drugs. Furthermore, traffickers are 
increasingly attempting to divert preparations 
containing pseudoephedrine. In February 2005, for 
example, capsules containing a pseudoephedrine-based 
product originating in the Hong Kong SAR of China 
were seized in New Zealand. In November 2004, 
authorities in New Zealand seized over 240,000 
capsules containing pseudoephedrine originating in 
China. In 2004, Malaysia reported the diversion of 
456,000 tablets containing pseudoephedrine. 
474. The second most commonly abused group of 
drugs in East and South-East Asia (after opiates) 
continues to be amphetamine-type stimulants. Most 
countries in the region reported increases in the abuse 
of methamphetamine and MDMA (Ecstasy). The abuse 
of amphetamine-type stimulants is increasing in the 
Lao People’s Democratic Republic, in part because of 
their increased availability in the country since it has 
become a transit country for such stimulants.  
475. In Japan, the majority of methamphetamine 
abusers are persons who abuse drugs by injection. 
Although HIV infection through drug abuse by 
injection remains low (0.5 per cent), the Government 
continues to promote nationwide awareness-raising 
campaigns in order to prevent an HIV epidemic. 
Among high-risk groups in Thailand, HIV prevalence 
is highest (50 per cent) among persons who abuse 
drugs by injection, the majority of whom abuse heroin. 
In the Lao People’s Democratic Republic, people who 
used to grow opium poppy are reportedly being 
recruited as traffickers of amphetamine-type stimulants 
and are becoming infected with HIV through drug 
abuse by injection. 
 
 
  South Asia  
 
 
  Major developments 
 
476. The drug trafficking and abuse problems in South 
Asia continue to be both serious and multifaceted. 
Owing to its proximity to opium poppy cultivation 
areas in West Asia and in South-East Asia, where most 
of the world’s illicit production of opiates takes place, 
there continue to be significant trafficking in and abuse 
of opiates, in particular heroin, in South Asia. Despite 
the strict controls that are in place, some diversion 
from licit opium poppy cultivation in India continues 
to take place. Some of the diverted opium is abused, 
either as opium or in the form of heroin, in India and 
some is smuggled into other countries. Cannabis plants 
are illicitly cultivated (and widely abused) in the 
region as well. 
477. In South Asian countries, in particular 
Bangladesh, India and Nepal, lapses in the control of 
pharmaceutical preparations containing narcotic drugs 
and psychotropic substances have led to widespread 
abuse of such preparations among all segments of the 
population. Those pharmaceuticals are generally 
diverted from domestic distribution channels and are 
sold without prescription in pharmacies and other retail 
outlets in the region. 
478. Drug abuse by injection is becoming one of the 
driving forces of the increase in the HIV/AIDS 
infection rate in countries in South Asia, in particular 
in India and Nepal. 
479. The Board welcomes the resumption of talks 
between India and Pakistan, which has given impetus 
to efforts to combat drug trafficking, particularly along 
the border between the two countries.  
 
  Treaty adherence 
 
480. All six States in South Asia are parties to the 
1988 Convention. In August 2005, Bhutan acceded to 
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the 1961 Convention and the 1971 Convention, thereby 
becoming a party to all three international drug control 
conventions. As Nepal is not yet a party to the 1971 
Convention, the Board urges it to take speedy action to 
become a party to that convention.  
 
  Regional cooperation 
 
481. In June 2005, the Drug Advisory Programme of 
the Colombo Plan for Cooperative Economic and 
Social Development in Asia and the Pacific published a 
guidebook on minimum standards of treatment and 
rehabilitation programmes for drug abusers in Asia. 
The guidebook provides practitioners with informative 
and practical information on strengthening capacity for 
the treatment and rehabilitation of drug abusers. 
482. In Maldives, the Drug Advisory Programme of 
the Colombo Plan also organized the Second South 
Asian Law Enforcement Training Course on Counter 
Narcotics in Male in November and December 2004. 
Law enforcement officials from seven South Asian 
countries attended training courses on a large number 
of subjects, ranging from drug identification and 
testing to controlled deliveries. 
483. The South Asian Association for Regional 
Cooperation organized the second meeting of the 
Coordination Group on Drug Law Enforcement 
Agencies in South Asia in Male in August 2004. The 
participants discussed joint efforts against drug 
trafficking and ways to ensure effective cooperation 
between law enforcement agencies in the region. 
484. In August 2005, the Governments of India and 
Pakistan agreed that their drug control agencies should 
enter into a memorandum of understanding to intensify 
mutual cooperation and liaison on drug control issues. 
Other efforts at strengthening cooperation between the 
two countries have been made. For example, the 
Governments of India and Pakistan agreed in May 
2005 to establish a formal channel of communication 
between the coast guard of each of the two countries 
for the exchange of information on various issues, 
including drug trafficking. Moreover, border officials 
of India and Pakistan held a meeting in April 2005 to 
discuss a proposal on joint border patrols and ways to 
combat drug trafficking on both sides of the border 
between the two countries. 
485. At a meeting held in June 2005, the foreign 
ministers of China, India and the Russian Federation 
agreed to strengthen coordination in efforts to counter 
drug trafficking, terrorism and other cross-border 
crimes. The foreign ministers issued a statement in 
which they emphasized that their Governments would 
continue to cooperate in combating new threats and 
meeting challenges. 
486. In April 2005, a major international trafficking 
organization involved in illegally distributing 
pharmaceuticals via the Internet was dismantled in a 
joint operation conducted by Indian law enforcement 
authorities in cooperation with the authorities of 
Canada, Costa Rica and the United States. According 
to the United States authorities, the organization had 
used more than 200 websites to illegally distribute 
pharmaceuticals worldwide and had been repackaging 
controlled substances from India and other countries 
that had been smuggled into the United States. 
 
  National legislation, policy and action 
 
487. It continues to be easy to obtain many 
pharmaceuticals without a prescription in South Asia. 
In 2005, the Government of India imposed strict 
measures to control the sale of medicines in retail and 
wholesale establishments. Arguing that the stricter 
control measures constituted harassment, retail and 
wholesale pharmacists subsequently threatened to stop 
stockpiling drugs, including many drugs commonly 
used for medical treatment. While the Government has 
since amended the relevant rules by simplifying 
documentation to facilitate the transport of medical 
preparations containing psychotropic substances, the 
Board hopes that that step will not lead to a weakening 
of control measures or an increase in drug abuse. 
488. With the assistance of UNODC, the Government 
of India plans to integrate drug abuse prevention 
elements into school curricula and textbooks in several 
parts of the country. 
489. Legislation adopted in 2002 to prevent money-
laundering entered into force in India in July 2005. The 
legislation defines a number of acts as offences and 
establishes a multidisciplinary unit for gathering 
intelligence on suspicious financial transactions and 
connections with criminal activities. 
490. Drug control legislation in Nepal needs 
strengthening in a number of areas. Nepal is the only 
country in South Asia with no legislation to regulate 
precursors. That is a cause for particular concern, 
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especially considering that the country is situated 
between China and India, two large manufacturers of 
precursors. In addition, current national legislation in 
Nepal does not criminalize money-laundering and is 
not adequate to deal with complicated financial crimes. 
The Board urges the Government of Nepal to adopt and 
implement legislation in both of those areas. 
491. In June 2005, the Government of Sri Lanka 
announced that the capabilities of its coast guard would 
be extended to include patrolling coastal areas where 
there was a high incidence of drug trafficking. The lack 
of maritime interdiction capacity has long hindered the 
efforts of Sri Lanka to counter drug trafficking, as 
large amounts of heroin from India are smuggled into 
Sri Lanka by sea, mainly in small boats. The 
Government of Sri Lanka also announced that controls 
would be strengthened at the international airport in 
that country through measures such as the introduction 
of sniffer dogs. 
492.  In Bangladesh, work continued to expand 
significantly the capacity of the main centre for the 
treatment of drug abuse, operated by the Government. 
The Board notes, however, that drug abuse treatment 
facilities in the region in general continue to be 
inadequate. The Board urges the Governments 
concerned to take remedial measures in that area. The 
Board notes that treatment programmes for female 
addicts are lacking in some countries in the region, 
such as Bangladesh, and urges the Governments 
concerned to take female addicts into account when 
formulating measures in the area of drug abuse 
treatment. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
493. In South Asia, illicit cannabis plant cultivation 
and cannabis abuse continue. Cannabis plants also 
grow wild in several countries in the region, including 
India and Sri Lanka. Illicit cannabis plant cultivation 
takes place on a large scale in India and in some 
provinces in Sri Lanka. 
494. The cannabis plant also grows wild in Nepal, 
mainly in areas where the terrain makes its eradication 
difficult. Cannabis resin is produced in large quantities 
in the country. Cannabis resin, in addition to being 
abused locally, is smuggled into other countries, 
primarily India. According to Nepalese law 
enforcement authorities, the production of cannabis 
resin in Nepal has risen in recent years. 
495. The total volume of cannabis seized in Sri Lanka 
decreased in 2004 (for the second time in recent years) 
to the level for the entire period since 1998; the current 
cannabis seizure level in Sri Lanka is one of the 
highest levels among the countries in South Asia. In 
Bangladesh, the decrease in the volume of cannabis 
seizures in 2004 was offset by a significant increase in 
trafficking in heroin and buprenorphine. 
496. According to a national household survey 
conducted in India, there are approximately 8.7 million 
cannabis abusers in the country. 
497. Most of the illicit heroin laboratories dismantled 
in India were near opium poppy cultivation areas. The 
Government of India continues to take stringent 
measures against the diversion of licitly cultivated 
opium poppy. Measures currently under consideration 
by the Government include the issuing of cards with 
microchips to opium poppy growers so that relevant 
information can be easily retrieved, with a view to 
ensuring the effective control and monitoring of opium 
poppy crops. In addition, the use of satellite imagery to 
estimate the area under opium poppy cultivation is to 
be expanded further. The total area under licit opium 
poppy cultivation in India decreased in 2004 as a result 
of self-imposed restrictions by the Government. 
498. Large quantities of heroin of West Asian origin 
are increasingly being seized in India. Significant 
quantities of heroin manufactured in India also 
continue to be seized in that country. Heroin 
consignments seized in India had been destined for 
illicit markets not only in that country but also in Sri 
Lanka and countries in other regions, including 
Europe. The number of heroin manufacturing facilities 
dismantled by the Government of India in recent years 
has been small. The Board urges the Government to 
strengthen its law enforcement efforts in that area. 
499. Low-quality heroin base known as “brown sugar” 
continues to be abused widely in India. It is also 
abused in Bangladesh, Maldives, Nepal and Sri Lanka. 
After declining for several years, the volume of heroin 
seized along the border between India and Pakistan 
appears to be increasing again. 
500. There appears to have been a shift in drug abuse 
patterns in India in recent years, from inhaling to 
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injecting drugs (mainly heroin and buprenorphine). 
Though the national household survey of India 
indicated a lifetime prevalence of drug abuse by 
injection among adult males of 0.1 per cent, the Board 
notes that household surveys generally have had 
difficulty assessing the situation in marginalized 
communities, where drug abuse by injection is more 
likely to occur. The Board calls on the Government to 
include such communities in future household surveys. 
501. The Government of Maldives is concerned about 
growing social disorder caused by young drug abusers 
in some areas of the country. Drug-related offences 
have increased significantly in Maldives in recent 
years and have become the most frequent problem 
faced by the criminal courts in that country. This is a 
matter of particular concern, especially considering 
that the majority of drug abusers in Maldives are 
between 16 and 30 years of age and that over one half 
of the national population is under 16 years of age. In 
response to that situation, the Government, with the 
assistance of UNODC, is formulating a national drug 
control master plan. 
502. Data regarding seizures of heroin in Sri Lanka 
and in neighbouring countries indicates that Sri Lanka 
continues to be used as an important trans-shipment 
point for heroin consignments from Afghanistan and 
India destined for countries in other regions, in 
particular Europe. The Board urges the Government of 
Sri Lanka to continue strengthening its efforts against 
drug trafficking. 
503. In South Asia, drug abuse by injection has been 
an important contributing factor in the spread of 
HIV/AIDS infection. Though HIV prevalence among 
adults is not high in India (0.8 per cent), the HIV/AIDS 
prevalence rate in the different parts of the country 
varies widely. In some north-eastern states in India, 
drug abuse by injection is the predominant mode of 
transmission of HIV/AIDS infection and the HIV 
infection rate among persons who abused drugs by 
injection was as high as 56 per cent in 2003, the last 
year for which data are available. In many urban areas 
with a large number of persons who abuse drugs by 
injection, the HIV/AIDS prevalence rate among the 
general population is around the critical level of 5 per 
cent.  
504. In Nepal, HIV/AIDS infection among persons 
who abuse drugs by injection has increased 
dramatically in recent years. In 2002, the last year for 
which data on the subject are available, HIV 
prevalence among males who inject drugs by injection 
in Nepal ranged from 22 to 68 per cent. Many of those 
drug abusers were under 25 years old. 
505. The HIV prevalence rate among persons who 
abuse drugs by injection in Bangladesh continues to be 
relatively low (estimated at 4.4 per cent) and the rate 
has not changed in recent years. According to a recent 
study, however, the HIV prevalence rate among 
persons who abuse drugs by injection in central Dhaka 
is 8.9 per cent. 
506. Approximately 8-10 per cent of the over 
12,000 inmates in the largest prison in India are 
addicted to drugs, mainly heroin. Many of the inmates 
had been addicted to heroin before they were 
incarcerated. 
507. The abuse of pharmaceutical preparations 
containing narcotic drugs and psychotropic substances 
diverted from licit channels continues to be one of the 
main drug control issues in South Asia. India is a major 
manufacturer of pharmaceuticals, accounting for 
approximately 10 per cent of global pharmaceutical 
manufacture. Despite strict controls exercised by the 
authorities, pharmaceuticals continue to be diverted in 
India and subsequently smuggled into countries in 
South Asia and other regions. Trafficking in such 
substances, in particular codeine-based cough syrups, 
dextropropoxyphene and buprenorphine, in India is a 
major concern for its neighbouring countries, such as 
Bangladesh, Nepal and Sri Lanka. There is also 
evidence of pharmaceuticals from India being 
smuggled into Myanmar, Pakistan (via Dubai), and 
States members of the Commonwealth of Independent 
States. Diazepam and nitrazepam are also being 
diverted, to be abused in India or smuggled into other 
countries. 
508. There are indications that drug abuse is 
increasing in Bhutan, particularly in Thimphu, the 
capital. The main drugs of abuse include cannabis and 
pharmaceutical preparations containing narcotic drugs 
(in particular dextropropoxyphene and codeine 
phosphate) and psychotropic substances (in particular 
nitrazepam). 
 
  Psychotropic substances 
 
509. India remains the main illicit manufacturer of 
methaqualone. Most of the methequalone illicitly 
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manufactured in India is not abused in that country but 
is smuggled into other countries, primarily South 
Africa, the main consumer of methaqualone. In 2004, 
authorities in India dismantled a laboratory in the 
southern part of the country that had been 
manufacturing methaqualone on a large scale. Drug 
trafficking organizations in India may be using acetyl 
chloride for the illicit manufacture of methaqualone. 
Using acetyl chloride, which is currently not under 
international control, as a substitute chemical makes it 
more difficult for the authorities to identify illicit 
methaqualone manufacturers. 
510. The Board notes the growing illicit trade in the 
substance commonly called “synthetic heroin” in India. 
“Synthetic heroin” is a drug prepared by crushing 
tablets of phenobarbital, a psychotropic substance in 
Schedule IV of the 1971 Convention. While “synthetic 
heroin” is much cheaper to manufacture than 
organically derived heroin, it is sold by drug traffickers 
in India at approximately the same price as heroin. It is 
believed that “synthetic heroin” is manufactured 
mainly in cities in the north of the country. The Board 
urges the Government of India to take measures to 
combat this development. 
 
  Missions of the Board 
 
511. A mission of the Board visited Bangladesh in 
April 2005. The Board notes that, in spite of the 
dedication of its individual officers, the Department of 
Narcotics Control of Bangladesh, within the Ministry 
of the Interior, did not appear to be receiving sufficient 
resources from the Government. The Board also notes 
that cooperation between government agencies 
involved in drug control in Bangladesh is not adequate 
and that, as a result, the Department has been unable to 
perform its coordinating function. The Board urges the 
Government of Bangladesh to take immediate steps to 
address those issues and to ensure that the Department 
has the necessary resources to play a lead role in drug 
control in Bangladesh. 
512. The Board notes that, despite efforts by the 
Government of Bangladesh to expand the main drug 
abuse treatment centre, near Dhaka, treatment facilities 
for drug addicts in the country continue to be 
inadequate. The Board encourages the Government to 
take measures to continue strengthening its capacity in 
the area of drug abuse treatment and to conduct at the 
earliest opportunity a survey to assess the scope of the 
drug addiction problem in the country.  
513. The Board also urges UNODC to provide 
assistance to the Government of Bangladesh to enable 
it to strengthen drug control in that country and to 
fulfil its obligations under the international drug 
control treaties. 
 
 
  West Asia  
 
  Major developments 
 
514. Figures released in September 2005 show that, 
though progress is being made in the eradication of 
illicit opium poppy cultivation in Afghanistan, much 
work remains to be done. Afghanistan continues to be 
the main producer of illicit opium poppy, accounting 
for 87 per cent of global production in 2005. Moreover, 
Afghanistan’s share of the illicit manufacture of 
opiates, mainly heroin, has been increasing since the 
1990s, indicating that Afghanistan continues to be a 
supplier of illicit morphine and heroin, as well as illicit 
opiate raw materials. 
515. In Afghanistan, the abuse of drugs, not only 
opiates but also prescription drugs smuggled into the 
country in the absence of proper licit control 
mechanisms, continues to be on the increase, creating a 
further obstacle on that country’s path to stability. 
516. The Islamic Republic of Iran, Pakistan and 
countries in Central Asia continue to be the main 
countries used as transit points for consignments of 
Afghan heroin, destined for illicit markets primarily in 
Europe but also in North America. Despite the best 
efforts of the Governments of the Islamic Republic of 
Iran and Turkey to halt that trade, an estimated 60 per 
cent of Afghan opiates pass first through the Islamic 
Republic of Iran and then Turkey before reaching illicit 
markets in Europe. Approximately 20 per cent of 
Afghan opiates pass through countries in Central Asia, 
in particular Tajikistan, with 20 per cent being 
smuggled through Pakistan. The increased availability 
of heroin and opium continue to fuel the abuse of 
narcotic drugs in West Asia and beyond.  
517. In Central Asia, drug abuse has contributed to the 
spread of HIV/AIDS infection. In the Islamic Republic 
of Iran, the incessant flow of Afghan opiates has 
increased the level of drug abuse many times over. 
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518. Illicit opium poppy cultivation has continued in 
Pakistan, although not on the same scale as in 
Afghanistan. The persistence of illicit opium poppy 
cultivation in Pakistan is believed to be associated with 
the displacement of trafficking organizations from 
Afghanistan to Pakistan. 
519. On the Arabian peninsula, the drug problem has 
generally consisted of the transit traffic in illicit drugs 
such as cannabis destined for European markets. The 
Board is concerned about the apparent increase in drug 
trafficking, notably along the border of Iraq with 
Jordan and Kuwait, as evidenced by the fact that 
seizures of cannabis and psychotropic substances in 
West Asia have recently increased to unprecedented 
levels. 
520. The southern Caucasus is emerging as an 
important transit area for drug trafficking. The Board is 
concerned that the continuing lack of funding, 
technical equipment and human resources may hinder 
the effectiveness of border control. Recent 
epidemiological surveys conducted in Azerbaijan and 
Georgia have revealed a significant increase in drug 
abuse in those countries. 
 
  Treaty adherence 
 
521. All States in West Asia are parties to all three 
international drug control treaties. However, 
Afghanistan has not yet acceded to the 1972 Protocol 
amending the 1961 Convention. The Board encourages 
the Government of Afghanistan to take immediate 
steps to accede to the 1972 Protocol.  
 
  Regional cooperation 
 
522. The fight against trafficking of Afghan opiates 
has remained central to cooperation between countries 
in West Asia and other countries. For example, at the 
third annual Afghanistan Development Forum, the 
annual meeting of the Government of Afghanistan and 
donors to review the country’s development priorities, 
held in Kabul in April 2005, particular emphasis was 
placed on the development of legitimate alternative 
livelihoods in rural areas in Afghanistan. 
523. At the sixth annual meeting of the parties to the 
Memorandum of Understanding on Subregional Drug 
Control Cooperation, held in Moscow in December 
2004, the Governments of Azerbaijan, Kazakhstan, 
Kyrgyzstan, the Russian Federation, Tajikistan, 
Turkmenistan and Uzbekistan reiterated their 
commitment to make further efforts to strengthen drug 
control security belts around Afghanistan and to 
suppress the supply of precursors used for the illicit 
manufacture of heroin.  
524. Under the auspices of the Paris Pact,46 a 
consultative mechanism for countries affected by 
trafficking in opiates from Afghanistan, three round-
table meetings of experts were held in 2005: in 
Islamabad, in Istanbul and in Tehran. The meetings 
brought together representatives of donor countries and 
assistance agencies and government representatives to 
review the current patterns of smuggling drugs into and 
across West Asia and to discuss priorities in border 
control, as well as drug and precursor control.  
525. The Economic Cooperation Organization (ECO) 
organized several activities to assist its member States 
in strengthening drug control. ECO organized two 
workshops in 2005 on the reduction of illicit drug 
demand: one in Baku and the other in Ankara. A 
meeting of national focal points and liaison officers of 
the Drug Control Coordination Unit, established in 
1999 as part of the ECO secretariat, was held in 
Almaty, Kazakhstan, in June 2005. 
526. The Financial Action Task Force on Money 
Laundering has established the Middle East and North 
Africa Financial Action Task Force as a mechanism for 
coordinating efforts to fight money-laundering and 
other forms of financial crime. 
527. The Board is concerned that the regional 
cooperation among the countries in the southern 
Caucasus continues to be inadequate, as there is no 
comprehensive framework that includes all countries in 
the area. The Board stresses the need for concerted 
regional and international cooperation against drug 
trafficking. 
528. In 2005, Governments of countries in West Asia 
entered into a number of bilateral agreements to 
combat drug trafficking. In 2005, the Government of 
Turkey entered into agreements with the Governments 
of Bosnia and Herzegovina, Kazakhstan and Kuwait to 
strengthen efforts against drug trafficking, terrorism 
and organized crime. In May 2005, the Governments of 
the Islamic Republic of Iran and the United Arab 
Emirates signed a memorandum of understanding to 
combat drug trafficking. Jordan and the Syrian Arab 
Republic concluded a security agreement that provided 
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for the redrawing of their common border and resulted 
in the seizure of large quantities of illicit drugs along 
that border. 
529. The States of Central Asia plan to establish the 
Central Asian Regional Information and Coordination 
Centre, which is to promote the sharing of border 
intelligence, training and effective coordination of 
supply reduction measures in Central Asia in the 
forthcoming months. The heads of States members of 
the Collective Security Treaty Organization (CSTO), 
including some Central Asian States, decided, during a 
meeting held in Moscow in June 2005, to establish a 
centre for coordinating mechanisms for combating 
organized criminal groups engaged in drug trafficking 
in CSTO member States. 
530. In 2005, Turkmenistan participated in various 
regional cooperation mechanisms and activities. Of 
particular interest was its participation in a UNODC- 
funded precursor control project for Central Asia, as 
well as the exchange of drug seizure statistics. The 
competent national authorities of Turkmenistan 
attended several regional meetings and conferences on 
the problems of drug addiction, HIV/AIDS and drug 
abuse by injection. Turkmenistan continued to be 
involved in bilateral and multilateral project activities 
in the areas of reducing illicit drug supply and sharing 
information (setting up databases and mechanisms for 
the exchange of information). 
 
  National legislation, policy and action 
 
531. Upon his inauguration in December 2004, the 
President of Afghanistan declared a “holy war” against 
the growing influence of Afghan drug lords. The 
President described the illicit cultivation of opium 
poppy as a dishonour to the country and urged the 
people of Afghanistan to recover their dignity by 
ridding the country of the illicit drug trade. 
532. The Board notes that there have been proposals 
for legalizing opium poppy cultivation in Afghanistan 
as a solution to the current drug trafficking situation in 
that country. As noted in paragraph 208 above, the 
Board is encouraged by the Government’s strong 
stance against those proposals. The Board trusts that 
the Government will continue to stand by its policies 
and swiftly implement the existing programmes.  
533. The Government of Afghanistan has continued to 
strengthen its administrative structures in the area of 
drug control. Following the establishment of the new 
Ministry of Counter-Narcotics in late 2004, the Cabinet 
Sub-Committee on Counter-Narcotics was formed. One 
of the key tasks of the Sub-Committee in 2005 was the 
preparation of the alternative livelihood development 
plan, in which key areas requiring urgent assistance 
were identified.  
534. The Board notes that the Government of 
Afghanistan has also created the Counter-Narcotics 
Trust Fund, administered by the United Nations 
Development Programme (UNDP). The Fund will give 
priority to support for legitimate alternative livelihoods 
for opium poppy growers, in accordance with priorities 
identified in the Alternative Livelihood Development 
plan. 
535. The Government has also strengthened its efforts 
in supply reduction, as evidenced by the effective 
operation of the newly established Counter-Narcotics 
Police of Afghanistan. The Government created the 
Counter-Narcotics Criminal Justice Task Force, 
composed of specialized investigators, prosecutors and 
judges, so that criminal cases involving narcotic drugs 
can be dealt with quickly within the criminal justice 
system.  
536. The Government of Afghanistan is in the process 
of revising its legislative framework to strengthen drug 
control in the country, with the assistance of UNODC. 
The Board trusts that the revision will take place with 
the involvement of all relevant players within the 
Government and that any revision will take due 
account of the international drug control treaties. 
537. In March 2005, the North Atlantic Treaty 
Organization (NATO) began a comprehensive 
expansion of its peacekeeping forces in western 
Afghanistan. NATO reportedly plans to create 
provincial reconstruction teams, aimed at extending the 
authority of the Government and helping with 
reconstruction efforts in the country. The United States 
more than tripled its funding for drug control efforts in 
Afghanistan in 2005, to US$ 780 million. The Board 
reiterates its call to the international community to 
provide assistance to the Government of Afghanistan 
so that the provisions of the international drug control 
treaties will be adhered to fully. 
538. The Board welcomes the commitment of the 
Government of Iraq to fight illicit drug trafficking and 
other criminal activities. The Iraqi authorities have 
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established a national drug control committee, chaired 
by the Ministry of Health, and are working to develop 
a national drug control plan. The Board also notes with 
concern numerous media reports of increasing abuse of 
drugs, including heroin, in the country, and urges the 
Government to ensure that adequate measures in the 
area of demand reduction are implemented. The Board 
calls upon UNODC and the international community to 
provide assistance to the Government in that area.  
539. In Kyrgyzstan, the parliament is reviewing a draft 
law that would amend the national law on narcotic 
drugs, psychotropic substances and precursors. Once 
adopted, the amended law will enhance drug control, 
the prevention of drug abuse and the treatment of drug 
abusers.  
540. The Board notes that Turkmenistan has not yet 
implemented the provisions of the new drug control 
law that came into force in November 2004. The Board 
urges the competent national authorities of 
Turkmenistan to adopt national regulations to ensure 
the implementation of all provisions of the 
international drug control treaties without delay.  
541. In Israel, the Money Laundering Prohibition 
Authority, a unit specialized in investigating cases 
involving money-laundering, was established in the 
Ministry of Justice, and a unit for countering money-
laundering was established within the intelligence 
branch of the Israeli Police. In Uzbekistan, the national 
law against money-laundering, which had been enacted 
at the end of 2004, entered into force on 1 January 
2005. The Board notes that current legislation in 
Armenia, Georgia and Turkmenistan is insufficient to 
deal with the problem of money-laundering; the Board 
urges the Governments of those countries to remedy 
the situation without delay. In September 2005, the 
Government of Kyrgyzstan established a financial 
intelligence unit to combat crime involving money- 
laundering. 
542. The Board welcomes the assistance being given 
to the Palestinian authorities by UNODC in 
strengthening the interdiction capabilities of the 
Palestinian Anti-Narcotics General Administration and 
the legal framework for drug control. UNODC is also 
exploring ways to establish a working framework for 
cooperation between the Palestinian and Israeli drug 
control authorities.  
543. The Government of Jordan maintains an 
extensive drug abuse prevention programme, targeting 
children and young adults throughout the education 
system and modernizing treatment centres and 
hospitals, with the aim of strengthening the country’s 
capacity to deal with drug abuse. In April 2005, the 
Government of Tajikistan endorsed the national 
programme for the prevention of drug abuse and the 
related HIV/AIDS epidemic among persons who abuse 
drugs by injection, enhancing the drug abuse treatment 
system for the period 2005-2010. 
544. In the United Arab Emirates, police in Dubai 
have started an awareness campaign called “Bravery” 
where specially trained officers regularly visit schools 
in order to raise awareness among youth about the 
consequences of drug abuse. Drug demand reduction 
campaigns are also taking place in Lebanon, and the 
Government is developing a national action plan on 
drug demand reduction. 
545. The Board notes that some countries in West 
Asia, including Bahrain, Israel and the United Arab 
Emirates, have adopted legislative and/or 
administrative measures to allow travellers carrying 
prescribed medical preparations containing narcotic 
drugs or psychotropic substances to enter their 
territory. The measures are in compliance with the 
guidelines for national regulations concerning 
travellers under treatment with internationally 
controlled drugs, which, as noted in paragraph 214 
above, were developed jointly by the Board, UNODC 
and WHO in 2002. The Board urges the Governments 
of countries in the region that have not yet done so to 
take appropriate measures to adopt such control 
measures for travellers entering their territory. 
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
546. According to a UNODC survey released in 
September 2005, the total area under illicit opium 
poppy cultivation in Afghanistan decreased by 21 per 
cent, from 131,000 hectares in 2004 to 
104,000 hectares in 2005. Nevertheless, increased crop 
yields meant that the actual production of opium 
remained at almost the same level. Afghanistan 
continued to supply the overwhelming majority of the 
world’s illicit opium, accounting for 87 per cent of the 
world’s supplies in 2004.  
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547. Together, the central and provincial governments 
of Afghanistan were able to eradicate 5 per cent of 
illicit poppy crops in 2005. There were varying levels 
of decline in the area under opium poppy cultivation in 
the 34 provinces of Afghanistan, indicating that not all 
provincial governments were committed to the 
eradication efforts. According to the Government of 
Afghanistan, the failure to provide alternative 
livelihoods for opium poppy growers, the security 
situation in the country and the involvement of several 
provincial officials in drug trafficking are the main 
reasons for the continuation of illicit opium poppy 
cultivation in the country.  
548. Illicit opium poppy cultivation in Pakistan, while 
not on the same scale as in Afghanistan, has also 
increased in recent years. In Pakistan, the total area 
under illicit opium poppy cultivation was reduced 
dramatically in 1996, to under 1,000 hectares, and was 
further reduced in the years that followed. In 2003, 
however, the total area under such cultivation rose 
sharply, to 2,500 hectares. Illicit opium poppy 
cultivation remained at that level in 2004, and there are 
indications that it could increase again in 2005. The 
Board urges the Government of Pakistan to intensify 
its eradication efforts before the country becomes a 
major source of supply. 
549. The illicit cultivation of cannabis plant and, on a 
much smaller scale, opium poppy takes place in 
Lebanon, despite the Government’s eradication efforts 
and public information campaigns. In 2004, more than 
6.7 hectares of opium poppy and more than 
13.0 hectares of cannabis plant were eradicated. 
550. In several countries in Central Asia, opium poppy 
continues to be cultivated on a small scale, and ephedra 
and cannabis plants continue to grow wild. The Board 
welcomes the fact that, in the last decade, government 
eradication campaigns have virtually eliminated the 
risk of such cultivation gaining importance in those 
countries. 
551. In West Asia, the United Arab Emirates has 
become a trans-shipment point for heroin consignments 
coming from South Asia and South-West Asia and 
destined for Europe. Some of the heroin consignments 
are smuggled through Africa before being transported 
further to Europe. Cannabis, heroin and opium 
shipments originating in Afghanistan pass through the 
Islamic Republic of Iran and Pakistan and are then sent 
overland through Oman and the United Arab Emirates 
to countries in Europe.  
552. Turkmenistan, whose extensive borders with 
Afghanistan, the Islamic Republic of Iran, Kazakhstan 
and Uzbekistan are inadequately controlled, continues 
to be used as a transit country by traffickers of Afghan 
opiates. The Afghan opiates are smuggled not only by 
land (in trucks and cars), but also by sea (on vessels 
from neighbouring countries passing through the 
Caspian Sea) and by air (on cargo planes passing 
through Azerbaijan and Turkey). In 2004, the total 
quantity of drugs seized in Turkmenistan reached 
1.3 tons, almost tripling the figure for the year before. 
The seizures of heroin (266 kg) and opium (656 kg) 
each represented a fourfold increase over the figures 
for 2003.  
553. Uzbekistan continues to be an important transit 
country for consignments of Afghan opiates destined 
for Europe; the consignments are smuggled mainly by 
road and rail through Kyrgyzstan and Tajikistan, as 
well as directly from Afghanistan. The total quantity of 
heroin seized in Uzbekistan almost doubled, from 
336 kg in 2003 to 670 kg in 2004. 
554. Analysis of the seizure data for countries 
neighbouring Afghanistan shows that there has been an 
increase in the illicit manufacture of heroin and 
morphine in Afghanistan since the 1990s. In 2003, 
77 per cent of all opiates seized in South-West Asia 
and Central Asia was in the form of either morphine or 
heroin (compared with 40 per cent in 1995). In 2004, 
that proportion decreased to 64 per cent. Equipment 
used for the illicit manufacture of heroin and morphine 
is brought from China, Pakistan and Uzbekistan. 
555. In Afghanistan, illicit heroin manufacture is 
taking place on such a large scale that it requires a 
large amount of the precursor acetic anhydride. 
However, as noted in paragraph 166 above, 
investigating the routes used for smuggling that 
substance into the country continues to be extremely 
difficult. Afghanistan has no licit requirements for 
acetic anhydride and no licit imports of the substance, 
indicating that the precursor is trafficked into the 
country and not diverted from licit sources in that 
country. Nevertheless, no seizures of acetic anhydride 
have been reported in the countries neighbouring 
Afghanistan since 2001. 
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556. Pakistan remains the country with the largest 
seizures of opiates (which include opium and all of its 
derivatives); in 2003, seizures of opiates in Pakistan 
amounted to 34.7 tons, or 31 per cent of global 
seizures. However, seizures of heroin in Pakistan 
decreased significantly in 2004, from 6.4 tons in 2003 
to 3.5 tons. Seizures of opiates in Turkey almost 
tripled, from 5.7 tons in 2003 to 14.7 tons in 2004. 
557. In 2004, seizures of opium in the Islamic 
Republic of Iran increased to 174 tons, nearly twice the 
high figure recorded in 2003 (98 tons). The Islamic 
Republic of Iran is the country with by far the largest 
volume of seized opium. In 2003, the last year for 
which data on global seizures of opiates are available, 
the Islamic Republic of Iran accounted for 73 per cent 
of global seizures of opium. 
558. The drug abuse situation in the Islamic Republic 
of Iran appears to be worsening. The official estimate 
is that, out of a total population of 68 million, 2 million 
persons abuse drugs regularly; and of the 2 million 
drug abusers, 1.2 million are classified as addicts. 
However, those figures are based on a survey 
conducted in 1999, and the Board is concerned 
regarding the lack of more recent information. Some 
officials estimate that the number of drug abusers in 
the country is now at least 3 million. Though opiates 
are the main drug of abuse, reports indicate that the 
abuse of crystalline methamphetamine and MDMA 
(Ecstasy) also appears to be increasing. The Board 
urges the Government to take measures to accurately 
assess the current state of drug abuse in the country.  
559. In countries in Central Asia, the drug abuse 
problem continues to worsen. The main drug of abuse 
has shifted from cannabis and opium to heroin. Needle-
sharing remains one of the main modes of transmission 
of HIV in Central Asian countries, Kazakhstan being 
the worst hit of those countries. In 2004, over 70 per 
cent of new HIV/AIDS cases in Kazakhstan were 
persons who abused drugs by injection. 
560. In Turkmenistan, the total number of officially 
registered HIV/AIDS cases is reported to be 
unchanged: two cases. The Board is concerned that that 
low official figure brings into question the accuracy of 
that information, especially in view of the persistent 
reports about the spread of HIV/AIDS in the country. 
The Board urges the Government of Turkmenistan to 
take immediate steps to make an assessment of the 
extent of drug abuse and HIV/AIDS infection in the 
country.  
561. Cannabis remains the main drug of abuse in 
countries on the Arabian peninsula, many of which 
continue to be used as transit countries for 
consignments of cannabis, as well as opiates, destined 
for Europe. 
562. Although the volume of drug seizures remains 
low in the countries in the southern Caucasus, drug 
abuse is increasingly becoming a problem. In 2003, 
there were over 17,000 registered drug abusers in 
Azerbaijan, opiates being the main drugs of abuse. 
About one half of the persons infected with HIV/AIDS 
in Azerbaijan are persons who abuse drugs by 
injection. In Georgia, official estimates indicate that 
there are 275,000 drug abusers in the country, an 
increase of 80 per cent compared with the figure for 
2003; that increase is mainly attributed to the import 
and illegal sale of buprenorphine tablets.  
563. The abuse of cocaine is not a major issue in West 
Asia. The Board has no information regarding the 
illicit manufacture of that drug in the region. However, 
the Board has noted in recent years that a 
disproportionately large amount of potassium 
permanganate continues to be imported into the Islamic 
Republic of Iran. A large number of firms appear to be 
involved in that activity, making control and 
monitoring of the industry difficult and increasing the 
possibility of that substance being diverted. The Board 
requests the Government of the Islamic Republic of 
Iran to conduct a thorough assessment of the licit 
requirements for potassium permanganate and to 
remain vigilant regarding possible attempts to divert 
the substance to certain countries in Latin America, 
where it could be used to manufacture cocaine.  
 
  Psychotropic substances 
 
564. The abuse of pharmaceuticals, in particular 
pharmaceuticals containing benzodiazepines, continues 
to be of concern in West Asia. Controlled substances 
are often easily available without prescription in 
pharmacies in many countries in the region. That is 
particularly the case in Afghanistan, where the licit 
control framework has yet to recover from decades of 
civil war and a wide range of pharmaceuticals are 
available without prescription in pharmacies, other 
retail outlets and even roadside stalls. Many of those 
drugs are adulterated or outdated and were illicitly 
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manufactured in India or Pakistan before being 
smuggled into Afghanistan. One survey has indicated 
that, in the eastern part of Afghanistan, pharmaceutical 
drugs are abused regularly by 10 per cent of the adult 
population. 
565. In Israel, a recent survey indicated that 6.1 per 
cent of students in secondary schools abuse 
pharmaceuticals, a figure higher than the figure for 
cannabis or heroin. Since the results of the survey were 
made available, the Government of Israel has shortened 
the period of validity of prescriptions for 
pharmaceuticals. According to the Israeli authorities, 
there are 20,000-30,000 drug addicts in the country, 
and they are in every segment of society. 
566. Fenetylline (Captagon) continues to be widely 
abused in countries on the Arabian peninsula. As the 
licit manufacture of Captagon has ceased, the 
substance is manufactured clandestinely, primarily in 
the southern part of Europe, and trafficked into the 
Arabian peninsula through the Syrian Arab Republic 
and Jordan. Large seizures of Captagon tablets took 
place in 2005 at the borders of Jordan with Iraq and the 
Syrian Arab Republic, as well as in the United Arab 
Emirates. 
 
  Missions 
 
567. In September 2005, the Board sent a mission to 
Saudi Arabia to assess the drug control situation and 
the progress made by the Government in implementing 
the recommendations of the Board pursuant to its 1992 
mission to that country. The Board notes the 
commitment of the Government to drug control, 
reflected in its adoption of a new national drug control 
strategy in 2005. The Board was informed that the 
Government is reviewing the text of draft legislation 
on drug control that would introduce comprehensive 
controls over the licit movement of narcotic drugs, 
psychotropic substances and precursor chemicals, in 
line with the provisions of the international drug 
control treaties. 
568. The Board notes that in Saudi Arabia mechanisms 
for the collection and sharing of data, in particular 
those relating to statistics on drug seizures and abuse, 
as well as the Government’s performance with regard 
to the provision of data to the Board, as required under 
the international drug control treaties are in need of 
improvement. The Board urges the Government to take 
immediate measures in those areas, in order to ensure 
that Saudi Arabia fully meets its obligations under the 
international drug control treaties. 
 
 D. Europe  
 
 
  Major developments 
 
569. Cannabis remains the most commonly abused 
drug in Europe. About 30 million people in the member 
States of the European Union and in Iceland, 
Liechtenstein, Norway and Switzerland have used 
cannabis during the past year. About 15 per cent of 
15-year-old students in the European Union member 
States use cannabis more than 40 times a year. The 
European countries with high prevalence for cannabis 
abuse include the Czech Republic, France, Ireland, 
Switzerland and the United Kingdom. 
570. The total amount of cocaine seized in Europe 
continues to increase, indicating that there may be 
widespread abuse of the substance. Increased demand 
for treatment of cocaine abuse in Western Europe also 
indicates that the abuse of that substance may be 
widespread; however, it is difficult to say with 
certainty if that is the case because, unfortunately, 
trends in the abuse of cocaine have not been monitored 
consistently—there have been few national surveys on 
the abuse of that drug and, in some cases, the sample 
sizes have been small. 
571. Almost all of the heroin encountered on the illicit 
market in Europe is from Afghanistan. The smuggling 
of Afghan heroin into the Russian Federation increased 
significantly. The total volume of heroin seized in that 
country reached a record level of 3.8 tons in 2004. 
Despite the increased availability of heroin in Europe 
as a whole, the abuse of that substance is reported to be 
stable or declining in most countries in Western 
Europe.  
572. The Board notes the commitment of the 
Government of the Russian Federation to addressing 
the problems of drug abuse and trafficking. While the 
number of registered drug abusers is about 500,000, 
the total number of drug abusers in the Russian 
Federation is estimated to be as high as 6 million, or 
4 per cent of the total population. About 2 million of 
the drug abusers are adolescents and people under the 
age of 24. However, as no systematic nationwide 
survey on drug abuse has been conducted in the 
Russian Federation, the reliability of those estimates is 
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uncertain. Persons who abuse drugs by injection 
continue to account for most cases involving HIV 
infection although the percentage of such persons 
among new cases of HIV infection is declining. 
573. A number of countries in Europe continue to 
supply the world with MDMA. It is estimated that up 
to 80 per cent of the MDMA abused worldwide is 
illicitly manufactured in laboratories in European 
countries. MDMA from Europe is smuggled into 
Australia, Canada, Japan and South Africa. After a 
temporary decline, seizures of MDMA have been 
increasing again. The illicit manufacture of 
amphetamine also appears to be expanding, the main 
source of that substance being the Netherlands, 
followed by Poland and Belgium. The illicit 
manufacture and abuse of methamphetamine, on the 
other hand, continue to be limited throughout Europe. 
574. The Board welcomes the adoption of Council of 
the European Union regulation No. 111/2005, laying 
down rules for the monitoring of trade between the 
European Community and third countries in drug 
precursors. The regulation, which entered into force in 
August 2005, strengthens control procedures for 
precursors. 
 
  Treaty adherence 
 
575. Switzerland, which signed the 1988 Convention 
in November 1989, ratified that convention in 
September 2005. The Board urges the Holy See and 
Liechtenstein to become parties to the 
1988 Convention.  
576. Andorra remains the only State in Europe that is 
not a party to the 1961 Convention or the 
1971 Convention. In September 2005, the Government 
of Andorra informed the Board that both conventions 
would be submitted to the forthcoming session of the 
parliament for approval.  
 
  Regional cooperation 
 
577. In December 2004, the Council of the European 
Union endorsed the European Union Drugs Strategy 
for the period 2005-2012. The new strategy builds on 
the final evaluation of the European Union Drugs 
Strategy and Action Plan on Drugs for the period 2000-
2004 and is complementary to national drug control 
strategies in the European Union. Confirming the 
European Union’s integrated, multidisciplinary and 
balanced approach to drugs, the strategy focuses on the 
reduction of illicit drug supply and demand, as well as 
on international cooperation and research, information 
and evaluation. It also emphasizes the importance of 
making optimal use of existing legal instruments and 
the need to ensure adequate consultation with a broad 
group of partners, including scientific centres and 
professionals, non-governmental organizations, local 
communities and other members of civil society. The 
eight-year strategy will provide the umbrella for two 
consecutive four-year European Union action plans on 
drugs. The strategy foresees annual progress reviews 
by the European Commission on the status of 
implementation of activities set out in the action plans, 
an impact assessment in 2008 (with a view to 
proposing a second plan of action for the period 2009-
2012) and a final overall evaluation of the European 
Union Drugs Strategy and Action Plan on Drugs in 
2012. 
578. In June 2005, the Council of the European Union 
endorsed the European Union Action Plan on Drugs for 
the period 2005-2008. The Action Plan covers the four 
priority areas of the new strategy: demand reduction, 
supply reduction, international cooperation and 
research, information and evaluation. It lists specific 
measures to be implemented by the European Union 
and its member States by the end of 2008. Assessment 
tools and indicators, responsibility for implementation 
and deadlines are clearly indicated for each action.  
579. The Board notes that the eighth European 
Conference on Drugs and Infections Prevention in 
Prison was held in Budapest from 7 to 9 July 2005. At 
the Conference, representatives of 41 countries, as well 
as WHO and the European Monitoring Centre for 
Drugs and Drug Addiction, exchanged practical and 
scientific knowledge and expertise on the prevention 
and treatment of drug dependence and infectious 
diseases in prisons. All participants agreed to continue 
to work together to respond to that challenge. 
580. In July 2005, the Netherlands and the United 
States signed an agreement outlining areas for future 
collaboration in drug demand reduction. The agreement 
includes provisions on the exchange of information on 
drug abuse prevention programmes and the 
coordination of research, particularly on the health 
risks of cannabis with a high tetrahydrocannabinol 
(THC) content. 
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581. In May 2005, the Council of the European Union 
adopted a decision on the exchange of information, the 
assessment of risks and the control of new 
psychoactive substances, which allows the European 
Union to take steps regarding psychoactive substances 
that appear in States members of the European Union 
and that may pose health or social risks similar to those 
posed by substances already controlled under the 
international drug control treaties. In order to ensure 
that substances that could constitute public health and 
social problems are placed under international control, 
the Board calls on States members of the European 
Union, pursuant to their obligations under the 
1961 Convention and the 1971 Convention, to notify 
the Secretary-General of the substances scheduled 
under the new procedure so that they may be placed 
under international control as soon as possible. 
 
  National legislation, policy and action 
 
582. In November 2004, the Parliament of Romania 
adopted legislation to reduce the penalty for possessing 
or cultivating drugs for personal use, from a maximum 
of five years to 6-24 months in prison. Under the new 
law, persons arrested for possession of illicit drugs may 
be released if they agree to undergo treatment.  
583. In April 2005, the Drugs Act 2005 entered into 
force in the United Kingdom. The Act gives new 
powers to drug law enforcement agencies to test 
arrested persons for cocaine and heroin and to make 
drug trafficking near schools or involving children as 
drug couriers an aggravating factor in sentencing. The 
Act also facilitates action against suspected “drug 
swallowers”47 by remanding them in custody for up to 
eight days. 
584. In Ukraine, the Cabinet of Ministers has proposed 
amending the list of scheduled drugs to reclassify 
methadone as a prohibited substance, thus barring its 
use for therapeutic purposes. Pursuant to article 39 of 
the 1961 Convention, a Government may adopt stricter 
measures than those provided for in the Convention. 
Nevertheless, the Board notes that WHO included 
methadone in its Model List of Essential Medicines in 
June 2005. 
585. The Board calls on the Parliament of Bosnia and 
Herzegovina to urgently adopt draft drug control 
legislation in order to facilitate action to address the 
situation with regard to drug and precursor trafficking 
in that country. The geographical location of Bosnia 
and Herzegovina and the lack of adequate national 
legislation, a central control structure and trained 
personnel make that country an easy target for 
international criminal organizations.  
586. In the Netherlands, a new regulation introduced 
in 2005 requires air passengers and aircraft arriving 
from South America and the Caribbean to be subject to 
thorough controls. As a result, more than 1 ton of 
cocaine has been seized, which underlines the 
importance of those routes to traffickers sending 
cocaine to Europe. The Board welcomes effective 
action taken in the Netherlands on that matter.  
587. In September 2005, the Government of the 
Russian Federation adopted a national programme for 
the prevention of drug abuse and drug trafficking for 
the period 2005-2009, which is aimed at, inter alia, 
reducing significantly the extent and consequences of 
drug abuse by 2010. The Board urges the Government 
to ensure that sufficient funds are available to carry out 
the programme.  
588. Several Governments of European countries are 
in the process of reviewing or evaluating their drug 
control strategies. In 2005, the Mid-term Review of the 
National Drugs Strategy 2001-2008 of Ireland was 
published. Portugal has been undertaking a 
comprehensive review of its drug control strategy for 
1999 and action plan on drugs for the period 2001-
2004, evaluating their consistency, efficiency and 
effectiveness. According to the European Monitoring 
Centre for Drugs and Drug Addiction, the 
Governments of the majority of European Union 
member States now evaluate implementation of their 
actions, and the Governments of some of those States 
(France, Ireland, Portugal and Spain) even evaluate the 
effectiveness of their policy regarding the drug 
problem. The Board calls on all Governments of all 
countries in Europe to make it a priority to evaluate 
national drug control strategies, programmes and 
action plans.  
589. The Government of Spain has launched an action 
plan for the period 2005-2008 as part of the 
implementation of its national drug control strategy for 
the period 2000-2008. The action plan encompasses a 
number of measures to be completed in a set time 
frame. The measures incorporated in the action plan 
cover various areas of drug control such as 
international cooperation, the prevention of drug abuse, 
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the social reintegration of drug abusers and the 
provision of measures to control illicit drug supply. 
590. The Board reiterates its position that drug 
injection rooms or other facilities, where persons may 
abuse drugs acquired illicitly, facilitate the illicit use of 
internationally controlled substances and violate the 
provisions of the international drug control treaties. 
Drug injection rooms contravene the major principle of 
the treaties, namely that the use of drugs should be 
limited to medical and scientific purposes. The Board 
therefore deeply regrets the opening of a drug injection 
room in Norway in January 2005 and urges the 
Government to take immediate and necessary steps to 
ensure full compliance with the international drug 
control treaties. 
591. In the United Kingdom, the National Treatment 
Agency for Substance Misuse in England launched in 
June 2005 a new strategy to improve the effectiveness 
of drug abuse treatment for adults for the period 2005-
2008. One of the objectives of the strategy is to ensure 
that, for persons voluntarily seeking drug abuse 
treatment, the waiting time for such treatment does not 
exceed three weeks; another objective is to ensure 
faster access for priority groups.  
592. In the United Kingdom, Operation Crackdown, a 
three-month campaign by 33 police forces in England 
and Wales aimed at addressing the problem of drug 
trafficking, has led to the closure of 170 crack houses, 
as well as the seizure of 123 kg of cocaine, 3.4 kg of 
crack cocaine, 119.8 kg of heroin and 86,059 MDMA 
tablets.  
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
593. The cannabis plant continues to be cultivated in 
several European countries, in particular Albania and 
the Netherlands. In the Netherlands, the number of 
shops where cannabis seeds can be purchased 
increased to over 300 in 2004. The Government of the 
Netherlands estimates that the cannabis industry in that 
country consists of 1,200 retail businesses, employing 
about 4,600 people. While the total revenue of the 
cannabis industry in the Netherlands is not known, the 
annual turnover of outlets where cannabis is sold and 
used (so-called “coffee shops”) is estimated by the 
Government to be between €211 million and 
€283 million. The number of so-called “coffee shops” 
continued to decline, from 1,179 in 1997 to 737 in 
2004. The Board encourages the Government of the 
Netherlands to pursue its policy towards the 
elimination of those outlets. 
594. Morocco continues to be a major source of 
cannabis resin abused in Western and Central Europe; 
other major sources of that drug are Afghanistan and 
Pakistan, as well as countries in Central Asia. Cannabis 
resin from Albania can be found on the illicit markets 
of Greece and various countries in the Balkans. Large 
amounts of cannabis resin are smuggled through 
Portugal, as indicated by a single seizure in France of 
4.7 tons of that drug arriving from Portugal. 
595. The European School Survey Project on Alcohol 
and Other Drugs (ESPAD) found that the lifetime 
prevalence of cannabis among secondary school 
students 15-16 years old rose by an annual average of 
almost 25 per cent between 1999 and 2003. In the 
Czech Republic, for example, 44 per cent of students 
have abused cannabis or cannabis resin. A high 
prevalence rate for cannabis abuse has also been 
reported in France, Ireland, Switzerland and the United 
Kingdom. Other European countries in which more 
than one fourth of the school population has abused 
cannabis include Belgium, Germany, Italy, the 
Netherlands, Slovakia and Slovenia. The lowest level 
of cannabis abuse has been reported in Cyprus, Greece, 
Romania and Sweden. The countries with the highest 
prevalence rate for cannabis abuse in the previous 
month include the Czech Republic, France, 
Switzerland and the United Kingdom. A report on the 
health of Irish students,48 containing the results of the 
College Lifestyle and Attitudinal National Survey, was 
published in April 2005. The Survey revealed that 
cannabis was the illicit drug most commonly used by 
students: 37 per cent of the students participating in the 
Survey stated that they had abused cannabis in the 
previous 12 months.  
596. The Board encourages the Government of the 
Netherlands to develop and implement an action plan 
to discourage cannabis abuse, an initiative that the 
Government announced in an inter-ministerial policy 
paper on cannabis in 2004.49 This is particularly 
important as research has shown that the concentration 
of THC in cannabis products from the Netherlands has 
increased significantly over the years, from an average 
of about 8 per cent in 1999 to 20.4 per cent in 2004. 
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597. The volume of cocaine seizures has increased, 
particularly in Western Europe. That is partly 
attributable to strengthened law enforcement measures 
in the Netherlands: the introduction of routine checks 
on flights from Latin America to the Netherlands 
resulted in the seizure of a total of 1,675 kg of cocaine 
and the arrest of 565 couriers. In addition, a total of 
1,545 kg of cocaine that had been concealed in air 
freight was seized in the Netherlands. The total volume 
of cocaine seized in the Netherlands increased from 
17.6 tons in 2003 to 21.4 tons in 2004. 
598. Most of the cocaine that is smuggled into Europe 
enters the region through Spain or the Netherlands, 
though the use of other countries (notably countries 
with airports that are not so well controlled) as entry 
points has also increased in recent years. Exceptionally 
large individual seizures of cocaine were made in 
Portugal and Spain in 2005. The largest single seizure 
of cocaine in 2005, 5.4 tons, was made in Spain in 
cooperation with the Greek authorities. Another seizure 
of almost 5 tons was made south-east of the Canary 
Islands. In the United Kingdom, seizures of cocaine 
totalling 12 tons were made as a result of Operation 
Kingfish, a joint operation involving law enforcement 
agencies in Jamaica and the United Kingdom. In 
Switzerland, the total volume of cocaine seized almost 
doubled, from 188.6 kg in 2003 to 361.4 kg in 2004. 
599. New trends in cocaine trafficking include the 
increasing importance of a trafficking route leading 
from the Andean subregion through Western Africa to 
Europe. That variation of the traditional trafficking 
route seems to be linked to better controls in the 
Netherlands and along the northern coast of Spain. 
Colombian trafficking groups are now shipping 
cocaine to Spain through the islands and countries off 
the coast of Mauritania and Senegal. 
600. Increased seizures of cocaine in Europe reflect 
increased abuse of that drug, which is evident from the 
fact that more Europeans are seeking treatment for 
cocaine-related problems. In the Netherlands and 
Spain, cocaine is now the second most commonly 
reported drug in specialist treatment centres after 
heroin. Surveys show that the annual prevalence rate 
for cocaine abuse has risen among young persons in 
Denmark, Germany, Spain and the United Kingdom, as 
well as in some areas in Austria, Greece, Ireland and 
Italy. 
601. In Europe, the illicit demand for heroin is 
estimated to be about 170 tons, about half of which is 
abused in Western and Central Europe. The bulk of the 
heroin entering Western Europe continues to be 
transported via the Balkan route to the Netherlands and 
from there, in smaller consignments, back to Germany 
and other Western European countries. Data analysed 
in 2004 indicate that there was an increase in the 
smuggling of heroin along the Balkan route, as well as 
through Italy. Most of the heroin continues to be 
smuggled in trucks. Analysis of seizures shows that the 
southern Balkan route (leading to Italy, via Greece, 
Albania or the former Yugoslav Republic of 
Macedonia) appears to be used as frequently as the 
northern Balkan route (via Turkey, Bulgaria, Romania, 
Hungary and Austria, in that order). 
602. Most of the heroin is seized in the United 
Kingdom, Italy, Germany, the Netherlands, France and 
the Russian Federation (in that order). In the Russian 
Federation, 240 kg of heroin were seized in a single 
operation in July 2005. Russian officials have termed 
the flow of heroin entering their country a threat to 
national security. Most of the heroin seized in the 
Russian Federation originates in Afghanistan. 
603. According to UNODC, in Europe the annual 
prevalence for the abuse of opiates is 0.8 per cent. In 
individual countries in Eastern Europe, the annual 
prevalence rate for the abuse of opiates is higher than 
the average for Europe as a whole; for example, in 
Estonia the rate is 1.2 per cent and in Latvia, 1.7 per 
cent. In the Russian Federation, the number is 
estimated to be about 1 million. The number of heroin 
abusers in Western and Central Europe is estimated at 
1.5 million, or 0.5 per cent of the population 
aged 15-64. Italy and the United Kingdom continue to 
report a high level of heroin abuse. 
604. In January 2005, there were 308,000 officially 
registered HIV/AIDS cases in the Russian Federation, 
an increase of 10 per cent over the figure of the 
previous year. (In 1999, only 10,000 cases of HIV 
infection were reported.) Drug abusers account for 
about 56 per cent of new HIV cases registered in 2004. 
605. The number of drug-related deaths appears to be 
declining in many European countries. According to 
the European Monitoring Centre for Drugs and Drug 
Addiction, drug-related deaths in Europe decreased 
from 8,838 in 2000 to 8,306 in 2001, representing a 
small but significant decline (6 per cent). According to 
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an annual report of the Ministry of Health of Germany, 
in 2004, the number of drug-related deaths in that 
country was at the lowest level since 1989. Similarly, 
in 2004, there were 1,372 drug-related deaths in the 
United Kingdom, the lowest level since 1997. 
 
  Psychotropic substances 
 
606. Europe remains the main source of MDMA 
abused in that region, as well as in the Americas and 
Asia. Most of the MDMA consignments seized by 
European drug law enforcement agencies is believed to 
originate in the Netherlands. German law enforcement 
authorities have reported that an increasing number of 
MDMA consignments are being intercepted on their 
way to countries in Southern and South-Eastern 
Europe. 
607. European countries account for a third of global 
MDMA abuse. The recently published results of 
ESPAD indicate that MDMA is the second most 
commonly abused drug in Europe after cannabis. A 
report on the health of Irish students,50 containing the 
results of the College Lifestyle and Attitudinal 
National Survey, revealed that MDMA was the second 
most commonly abused illicit drug among students in 
that country; it was followed by cocaine, “magic 
mushrooms” (psilocybin) and amphetamines. 
608. The main sources of the amphetamine found on 
the illicit markets in Europe are located in the region 
itself (Belgium, the Netherlands and Poland). In 
addition Bulgaria, Estonia and Lithuania also play an 
important role in the illicit manufacture of 
amphetamine. Although there is significant illicit 
manufacture of amphetamine in Bulgaria, it is not 
mentioned as a source country for the amphetamine 
seized in Western Europe, which indicates that the 
finished product is smuggled into countries outside of 
Europe. The precursor P-2-P, which is used for the 
manufacture of amphetamine, is being clandestinely 
manufactured in the Russian Federation and Ukraine; 
there are also some indications of the illicit 
manufacture of amphetamine in Lithuania and Poland. 
609. According to ESPAD, the countries in Europe 
with the highest percentage of students that have 
abused amphetamines (5-7 per cent each) are Estonia, 
Germany, Iceland, Lithuania and Poland. In 13 other 
countries, no more than 1 per cent of students reported 
that they had abused amphetamines.  
610. The illicit manufacture of methamphetamine in 
Europe continues to be limited to the Czech Republic 
and some of the Baltic States. In Germany, about 8 kg 
of crystal methamphetamine were seized in the area 
along that country’s border with the Czech Republic. 
611. While there has always been illicit demand for 
buprenorphine in those countries where there is licit 
demand for the substance (which is primarily used in 
drug substitution treatment), it appears that 
buprenorphine is being smuggled across borders in 
Europe. Preparations containing buprenorphine are 
being smuggled into Finland, mainly out of France. In 
2005, Estonia emerged as a significant source of the 
buprenorphine preparations found on illicit markets in 
Finland. In Estonia, such preparations can be easily 
obtained in pharmacies with prescriptions. Finnish 
drug law enforcement authorities seize more than 
30,000 tablets containing buprenorphine every year. 
612. In Europe, the country in which tranquillizers or 
sedatives are most commonly abused is Poland (17 per 
cent), followed by Lithuania, France and the Czech 
Republic. The lowest prevalence rate for the abuse of 
such substances is in Austria, Bulgaria, Germany, 
Ireland, Ukraine and the United Kingdom (2 per cent 
each). 
 
  Missions 
 
613. A meeting of the President of the Board, with the 
Secretary of the Board and the High Representative for 
the Implementation of the Peace Agreement on Bosnia 
and Herzegovina was held in August 2005. The High 
Representative expressed concern over current national 
drug control legislation and administrative 
mechanisms, which have turned the country into a safe 
haven for traffickers of illicit drugs and precursors. 
Outdated and fragmented legislation that is not 
applicable throughout the entire territory of Bosnia and 
Herzegovina and outdated lists of internationally 
controlled substances, as well as the lack of central 
administrative and control bodies, are some of the 
factors that have prevented effective action by the 
authorities. As a result, most of the narcotic drugs 
produced in or smuggled out of Bosnia and 
Herzegovina are able to make their way into Western 
Europe. Moreover, drug abuse is becoming a serious 
problem in Bosnia and Herzegovina itself. The Board 
welcomes the fact that the draft Law on the Prevention 
and Suppression of Narcotics Drugs, which will bring 
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national drug control legislation up to date and close 
gaps between the drug control laws of the entities of 
Republika Srpska and the Federation of Bosnia and 
Herzegovina, was approved by the constitutional 
committees of both houses of Parliament in September 
2005. The Board urges the Parliament to adopt the 
draft law as soon as possible. The Board commends the 
High Representative for his commitment to achieving 
the aims of the international drug control treaties, to 
which Bosnia and Herzegovina is a party. 
614. In June 2005, a mission of the Board visited 
Bulgaria. The Board notes that the Government of 
Bulgaria has the political commitment and the will to 
deal with drug abuse, drug trafficking and organized 
crime. Drug control policies, national drug control 
legislation and the institutional framework to carry out 
those policies and implement that legislation are well 
developed. The National Anti-Drug Strategy of the 
Republic of Bulgaria 2003-2008 is implemented on the 
basis of an action plan that links the Strategy to other 
key national reforms and strategies relevant to 
measures to reduce illicit drug supply and demand. 
Cooperation between drug regulatory authorities, 
police and customs is well established. However, the 
institutional framework is compromised by corruption. 
The Government of Bulgaria will therefore need to 
intensify its efforts to detect and counteract corruption 
among government officials at all levels.  
615. In Bulgaria, the annual prevalence rate for drug 
abuse is still lower than in most other European 
countries. Nevertheless, the high percentage of persons 
who abuse drugs by injection among both heroin 
abusers and amphetamine abusers is a cause for serious 
concern. The Board advises the Government of 
Bulgaria to focus its drug abuse prevention activities 
on both of those worrying trends and to devote 
increasing attention to the growing abuse of synthetic 
drugs by injection. 
616. In order to address the problem of large-scale 
smuggling of counterfeit Captagon tablets from illicit 
laboratories in Bulgaria into countries on the Arabian 
peninsula, the Board urges the Government of Bulgaria 
to initiate, together with other countries concerned and 
with the support of Interpol, a multilateral operation to 
investigate trafficking in counterfeit Captagon tablets, 
with a view to dismantling the international criminal 
groups involved. 
617. The Board sent a mission to the Russian 
Federation in May 2005 to review the drug control 
situation and the progress made by the Government 
following its mission to that country in 2000. The 
Board welcomes the fact that the Government 
continues to be strongly committed to addressing all 
aspects of the drug problem. The Board encourages the 
Government to provide additional resources for drug 
control and to constantly evaluate the effectiveness of 
the use of those resources. The Board notes with 
satisfaction that the creation of the Federal Drug 
Control Service has led to the strengthening of the 
institutional network for drug control in the Russian 
Federation. The Board encourages the Government to 
further improve coordination and cooperation among 
the drug control bodies and urges the Government to 
ensure the effective flow of information between them.  
618. The Board notes with concern the large extent of 
drug abuse in the Russian Federation. The Board 
requests the Government to facilitate the systematic 
collection and analysis of epidemiological data on drug 
abuse and to ensure the availability and quality of drug 
dependence treatment. The Board encourages the 
Government to ensure adequate coordination and 
cooperation between the services providing treatment 
for drug addicts and HIV/AIDS services. The Board 
urges the Government to provide adequate human 
resources and equipment to customs authorities and 
border guards to prevent drug smuggling. The 
Government should adopt effective measures to 
facilitate the confiscation of proceeds from drug-
related crime. 
619. The Board welcomes the continuous attention 
given by the Russian authorities to the control of 
precursors and encourages the Government to examine 
the present mechanism for their control with a view to 
further increasing its effectiveness. The Board urges 
the Government to strengthen cooperation among the 
various departments involved in the preparation of 
statistical reports for submission to the Board. The 
Government should promote the rational use of 
narcotic drugs and psychotropic substances for medical 
treatment, including the use of opioids for the 
treatment of pain. 
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 E. Oceania 
 
 
  Major developments 
 
620. The illicit cultivation and abuse of cannabis 
continue to be serious problems in most countries in 
Oceania, including Australia, Fiji, Micronesia 
(Federated States of), New Zealand, Papua New 
Guinea and Samoa. 
621. The illicit manufacture of amphetamine-type 
stimulants also continues to be a problem in Oceania. 
Australia and New Zealand have continued to detect 
and dismantle large numbers of clandestine 
laboratories. There is some evidence that clandestine 
laboratories are increasingly being used for the illicit 
manufacture of both methamphetamine and MDMA 
(Ecstasy), especially in Australia. 
622. There are indications that Oceania may be 
emerging as a transit area for consignments of 
“crystal” methamphetamine (commonly called “ice”); 
the abuse of that drug may also be increased in the 
region. Both Australia and New Zealand have reported 
a substantial increase in seizures of crystalline 
methamphetamine, mainly from China. 
623. Trafficking in and abuse of MDMA (Ecstasy) are 
becoming significant problems in countries in Oceania, 
in particular in Australia and New Zealand. In 
Australia, information gathered in an investigation of 
an attempt to smuggle a large amount of MDMA from 
Europe to Oceania indicates that the free flow of goods 
within the expanded European Union may present 
traffickers with new opportunities. 
 
  Treaty adherence 
 
624. The Board continues to be concerned that the rate 
of accession to the international drug control treaties is 
lower in Oceania than in all the other regions of the 
world. Of the 15 States in Oceania, only Australia, Fiji, 
Micronesia (Federated States of), New Zealand and 
Tonga are parties to all three of the treaties.  
625. The Board welcomes the accession of Samoa to 
the 1988 Convention and encourages it to accede to the 
1961 Convention and the 1971 Convention without 
delay. The Board also welcomes the accession of the 
Federated States of Micronesia to the 
1988 Convention; that State is now a party to each of 
the three international drug control treaties. 
626. The Cook Islands, Kiribati, Nauru, Niue, Tuvalu 
and Vanuatu are not parties to any of the international 
drug control treaties. The Solomon Islands is a party 
only to the 1961 Convention, while the Marshall 
Islands, Palau and Papua New Guinea are parties to 
both the 1961 Convention and the 1971 Convention. 
  Regional cooperation 
 
627. The Pacific Islands Forum continued to play a 
central role in promoting regional cooperation. At its 
annual meeting held in Auckland, New Zealand, in 
June 2005 the Regional Security Committee of the 
Pacific Islands Forum discussed various security 
issues, including the need to strengthen legislation to 
prevent illicit drug manufacture and trafficking. In 
Suva and Nadi, Fiji, in January 2005, the Forum hosted 
a seminar on terrorism, transnational crime and border 
security threats for frontline operational staff from 
customs, immigration and police officers from 
countries in Oceania. 
628. Police, customs and other law enforcement 
officials from 15 countries and organizations in 
Oceania attended the South Pacific Defence and 
Security Seminar in Trentham, New Zealand, in March 
2005. The officials discussed various regional issues, 
including drug-related transnational crime. 
629. Oceania continued to benefit from the support of 
key regional agencies such as the Oceania Customs 
Organization and South Pacific Chiefs of Police 
Conference. 
630. In 2004, the Australian and New Zealand police 
assisted the police and customs of Fiji in an operation 
that resulted in the dismantling of a clandestine 
laboratory used for the illicit manufacture of crystalline 
methamphetamine. The raid resulted in the seizure of 
large amounts of drugs and precursor chemicals, as 
well as the arrest of six suspects associated with an 
organized criminal group operating throughout South-
East Asia. 
 
  National legislation, policy and action 
 
631. New Zealand strengthened its precursor control 
legislation by passing the Misuse of Drugs Amendment 
Bill in June 2005. Under the new Bill, sanctions for 
existing offences related to the possession and supply 
of precursors were increased. Moreover, a new offence 
was added, making persons who import precursor 
chemicals “without reasonable excuse” liable for a 
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maximum penalty of one year in prison. An additional 
amendment of the new Bill enables law enforcement 
officers to carry out controlled deliveries in cases 
involving precursors. In addition, New Zealand has 
spent US$ 19 million on non-invasive inspection 
equipment, including mobile container inspection 
trucks, fixed site cargo inspection units and a 
“backscatter van”, which can scan moving vehicles. 
632. In 2005, New Zealand launched its Illicit Drug 
Monitoring System, a database containing information 
on drug abuse, illicit drug manufacture and drug 
trafficking that is to act as an early warning system for 
policymakers. Information collected during 2005 will 
be compared with data for 2006 and 2007. In addition, 
New Zealand announced that, in 2005, it would be 
testing a pilot version of its Arrestee Drug Abuse 
Monitoring programme, an international monitoring 
programme, the objective of which is to measure drug 
abuse among individuals who have recently been 
arrested. 
633. The Board is pleased to note that the Cook 
Islands and Nauru have been removed from the list of 
countries and territories considered by the Financial 
Action Task Force on Money Laundering to be “non-
cooperative” in efforts to counter money-laundering. 
The United States provided financial assistance to the 
Pacific Islands Forum secretariat to support activities 
to combat money-laundering in Oceania.  
 
  Cultivation, production, manufacture, 
trafficking and abuse 
 
  Narcotic drugs 
 
634. The illicit cultivation and abuse of cannabis 
continue to be prevalent in most countries in Oceania, 
including Australia, Fiji, Micronesia (Federated States 
of), New Zealand, Papua New Guinea and Samoa. 
Cannabis originating in Papua New Guinea has been 
seized in Australia and New Zealand. New Zealand has 
reported a new form of cannabis resin commonly 
called “ice hash”, which is manufactured from 
cannabis buds and smoked in pipes. Cannabis is often 
abused in combination with other drugs. In New 
Zealand, the majority of cannabis abusers are between 
15 and 24 years old. Cannabis continues to be the drug 
of choice among drug abusers throughout the region, 
due to its availability and low price. 
635. Both Australia and New Zealand reported 
increased seizures of cocaine. Australia reported 
having seized a larger volume of cocaine along its 
borders in 2004 than in 2003; the bulk of that increase 
was attributed to a single seizure of 100 kg of cocaine 
in August 2004. It appears that New Zealand is 
increasingly being used as a major transit area for 
illicit drugs destined for Australia and the United 
States. In New Zealand, over 18 kg of cocaine were 
seized in 2004, compared with only 7 kg in the 
previous year. Follow-up investigations indicate that 
most of the cocaine seized in New Zealand originated 
in Brazil or Chile and was destined for Australia. 
636. In Australia, authorities continued to seize heroin 
in small quantities. In 2004, the number of heroin 
detections increased, while there was a decline in the 
total amount of heroin seized. In April 2004, the Board 
was informed of the seizure by Australian law 
enforcement officials of an ocean freighter registered 
in the Democratic People’s Republic of Korea. The 
Australian Federal Police arrested eight suspects on 
charges of aiding and abetting the importation of 
150 kg of heroin into Australia. 
 
  Psychotropic substances 
 
637. Amphetamine-type stimulants continue to be 
illicitly manufactured in Oceania. In Australia, the 
authorities dismantled 358 clandestine laboratories 
during the period 2003-2004; the majority of those 
laboratories (221) had been used for the illicit 
manufacture of methamphetamine. In 2004, authorities 
in New Zealand dismantled 182 clandestine 
laboratories used for the illicit manufacture of 
methamphetamine; although that figure is slightly less 
than the figure for 2003 (202), it is still high compared 
with the figure for previous years. 
638. Australia made one of its largest seizures of 
crystalline methamphetamine in October 2004, when a 
consignment of 125 kg of that substance originating in 
China was seized. In New Zealand, while less than 
1 kg of crystalline methamphetamine was seized in 
2003, over 17 kg were seized in 2004 and 9.5 kg were 
seized already in the first half of 2005. Most of the 
seized crystalline methamphetamine originated either 
in China or Malaysia. In June 2004, six suspects were 
arrested and 5 kg of crystalline methamphetamine and 
700 litres of liquid methamphetamine and a large 
amount of precursor chemicals were seized. 
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639. In New Zealand, seizures of ephedrine and 
pseudoephedrine, precursor chemicals frequently used 
in the illicit manufacture of methamphetamine, 
continued to increase. Over 1.8 million capsules of 
ephedrine and pseudoephedrine were seized in 2004. 
Due to tightened controls over ephedrine and 
pseudoephedrine, there are indications that traffickers 
are finding it more difficult to procure those substances 
locally and are attempting to smuggle them instead. 
Furthermore, during November 2004, a large number 
of pseudoephedrine tablets were seized in a post office 
in New Zealand, which may signify that traffickers 
have turned to using the postal system to smuggle such 
precursors. 
640. Australia and New Zealand continued to seize 
substantial quantities of MDMA (Ecstasy), in line with 
a worldwide increase in seizures of MDMA and other 
hallucinogens in 2004. In April 2005, Australia 
arrested four suspects in connection with the attempted 
smuggling of over 1 ton of MDMA tablets (worth an 
estimated US$ 191 million) hidden in a shipping 
container of tiles from Italy. Australia reported a 
significant increase in seizures of MDMA in 2004. It 
seized over 800 kg of MDMA, which purportedly 
originated in Poland, in air cargo from Germany. Over 
45,000 tablets of MDMA were seized in New Zealand 
in 2004. The majority of the seized MDMA originated 
in China, in particular in the Hong Kong SAR of 
China. The amount of MDMA seized in New Zealand 
in 2004 fell compared with the figure for the previous 
year; authorities attribute the decline to several factors, 
including the use of more elaborate trafficking and 
concealment methods. Australia reported the lifetime 
prevalence rate for the abuse of MDMA was higher 
than the rate for all other drugs except cannabis and 
methamphetamine. 
641. Seizures of ketamine, GHB and GBL are also 
increasing in New Zealand. For example, while small 
amounts of GBL were seized in previous years, 
43 litres of GBL were seized in 2004. 
 
  Substances not under international control 
 
642. Increased seizures of khat (Catha edulis) were 
reported in New Zealand. Over 27 kg of khat was 
seized in 2004. The majority of the khat originated in 
Ethiopia and was sent through the international mail 
centre. 
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 IV. Recommendations to Governments, the United Nations and other relevant 
international and regional organizations 
 
 
643. The Board examines, on an ongoing basis, the 
functioning of the international drug control regime, 
identifies shortcomings in the implementation, by 
Governments, of the three main international drug 
control treaties, and formulates recommendations for 
further action addressed to national drug control 
agencies and relevant international and regional 
organizations. Those recommendations, which are 
aimed at assisting Governments in fully complying 
with their treaty obligations and at further developing 
the international drug control regime, are included 
every year in the annual report of the Board, for 
dissemination to all Governments. 
644. For its report for 2005, the Board has decided to 
select some of the key recommendations and proposals 
for further action and to highlight them in the present 
new chapter. The Board believes that this will assist 
Governments, relevant United Nations organizations 
and other international and regional organizations 
responsible for drug control issues in focusing their 
attention on the main recommendations and, at the 
same time, facilitating the implementation of the 
recommendations by all those concerned.  
 
 
 A. Recommendations to Governments 
 
 
645. The recommendations to Governments are 
grouped according to the following subject areas: 
treaty adherence; treaty implementation and control 
measures; prevention of diversion and abuse; 
availability and rational use of narcotic drugs and 
psychotropic substances for medical treatment; and the 
Internet and smuggling by mail.  
 
  Treaty adherence 
 
646. The 1961 Convention as amended by the 
1972 Protocol, the 1971 Convention and the 
1988 Convention form the basis of the international 
drug control system. The accession of all States to 
those treaties is a fundamental prerequisite for 
effective drug control worldwide.  
  Recommendation 1: The Board urges 
States that are not yet parties to any of the 
international drug control treaties to take prompt 
action to accede to them without further delay. 
 
  Treaty implementation and control measures 
 
647. Universal treaty adherence will, however, not be 
sufficient without effective and universal 
implementation of all the provisions of the three main 
international drug control treaties and the application 
of the necessary control measures by all Governments.  
  Recommendation 2: Provision of 
mandatory information to the Board is one of the 
key elements of the international drug control 
mechanism. The Board urges all Governments to 
furnish in a timely manner all statistical reports 
required under the three international drug 
control treaties. 
  Recommendation 3: The system of control 
measures laid down in the 1961 Convention 
provides effective protection against attempts at 
the diversion of narcotic drugs from international 
trade into illicit channels. The Board requests all 
Governments to implement fully the system of 
estimates and export authorizations and to ensure 
that no exports of narcotic drugs are authorized 
from their countries in excess of the 
corresponding total of the estimates of the 
respective importing country. 
  Recommendation 4: Strict restrictions are 
in place for the trade in and use of psychotropic 
substances in Schedule I of the 1971 Convention. 
The Board reminds all Governments of those 
restrictions and requests them to remain vigilant 
and ensure that those restrictions are observed by 
industry and authorized traders. 
  Recommendation 5: The Board wishes to 
emphasize the importance of ensuring the 
availability of essential narcotic drugs, including 
opioid analgesics, and psychotropic substances in 
emergency situations, such as natural disasters 
and other types of emergencies. The Board 
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requests Governments to apply, if appropriate, the 
simplified export-import control procedures to 
ensure the proper provision of essential narcotic 
drugs and psychotropic substances in 
disaster-stricken areas, in accordance with the 
model guidelines for the international provision 
of controlled medicines for emergency medical 
care, developed jointly by WHO and the Board 
for such emergency situations. 
  Recommendation 6: As an increasing 
number of countries and territories are already in 
a position to provide information on imports, 
exports and licit uses of precursors of 
amphetamine-type stimulants, in particular 
ephedrine and pseudoephedrine, the Board 
encourages Governments to monitor and report 
on trade in precursors of amphetamine-type 
stimulants. 
 
  Prevention of diversion and abuse 
 
648. One of the fundamental objectives of the 
international drug control treaties is to limit the use of 
controlled substances to legitimate purposes and to 
prevent their diversion into illicit channels and abuse.  
  Recommendation 7: As attempts to divert, 
by using falsified import authorizations, 
substances in Schedules III and IV of the 1971 
Convention from international trade have 
continued, the Board requests all Governments to 
be vigilant with respect to orders for psychotropic 
substances and, if necessary, to confirm with the 
Governments of importing countries the 
legitimacy of such orders prior to approving the 
export of such substances.  
  Recommendation 8: The diversion of 
pharmaceutical preparations containing narcotic 
drugs and psychotropic substances from domestic 
distribution channels and their abuse represent 
problems in many countries. The Board urges 
Governments to collect on a regular basis 
information on the extent of the diversion and 
abuse of pharmaceutical preparations containing 
controlled substances, with a view to developing 
countermeasures, where appropriate. 
  Recommendation 9: For some narcotic 
drugs and psychotropic substances, the risk of 
diversion may be increased when they become 
available in large single dosages, for example, in 
controlled-release preparations. The Board 
recommends that Governments, in cooperation 
with the pharmaceutical industry and health 
professionals, should monitor carefully cases 
involving the diversion and abuse of controlled 
substances available in controlled-release 
preparations and to take action against such 
diversion and abuse. 
  Recommendation 10: Cases involving the 
diversion and abuse of opioids, such as 
methadone and buprenorphine, when prescribed 
for substitution treatment, have been identified in 
many countries. The Board requests the 
Governments of countries where opioids are used 
for substitution treatment to take measures to 
prevent their diversion into illicit channels, such 
as supervised consumption, short dispensing 
intervals and central registration of all opioids 
prescribed for medical use. 
  Recommendation 11: Noting information 
from some countries on the increasing trafficking 
in and abuse of GHB, a sedative-hypnotic added 
to Schedule IV of the 1971 Convention in 2001, 
the Board calls upon the Governments of all 
countries concerned to increase their vigilance as 
regards the diversion, illicit manufacture and 
abuse of and trafficking in GHB and to inform 
the Board of developments in that area. The 
Board strongly encourages Governments to 
consider developing appropriate drug abuse 
prevention programmes that provide information 
on the consequences of GHB abuse. 
  Recommendation 12: To prevent traffickers 
from obtaining the precursor chemicals required 
for the illicit manufacture of amphetamine-type 
stimulants, the Board encourages Governments to 
estimate their licit requirements for the relevant 
precursors and to submit those data to the Board.  
  Recommendation 13: Furthermore, to 
prevent the diversion of precursors required for 
the illicit manufacture of amphetamine-type 
stimulants, the Board reiterates its 
recommendation to Governments: 
  (a) To control pharmaceutical 
preparations containing scheduled substances in 
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the same way as the scheduled substances they 
contain; 
  (b) To provide pre-export notifications for 
exports of ephedrine and pseudoephedrine, 
including the pharmaceutical preparations 
containing those substances, to the authorities of 
importing countries; 
  (c) To take measures, as appropriate, to 
regulate the availability of ephedrine and 
pseudoephedrine for medical purposes by 
improving the monitoring and control of domestic 
distribution channels, where necessary. 
  Recommendation 14: The system of 
assessment of annual requirements for 
psychotropic substances is essential for the 
identification of diversion attempts. The Board 
reiterates its request to all Governments that have 
not yet done so to establish a mechanism to 
ensure that their assessments are in line with their 
actual legitimate needs and that no imports 
exceeding the assessments are authorized. 
  Recommendation 15: The introduction by 
the majority of countries of the system of import 
and export authorizations for substances in 
Schedules III and IV of the 1971 Convention has 
significantly reduced the diversion of those 
substances from international trade. The Board 
requests the Governments of all countries that do 
not yet control the import and export of all 
psychotropic substances by the system of import 
and export authorizations to introduce such 
controls. 
 
  Availability and rational use of narcotic drugs 
and psychotropic substances for medical 
treatment 
 
649. Another objective of the international drug 
control treaties is to ensure the availability of narcotic 
drugs and psychotropic substances for medical 
treatment and to promote the rational use of controlled 
drugs.  
  Recommendation 16: To ensure appropriate 
medical use and availability of controlled 
substances, the Board requests all Governments 
to promote the rational use of narcotic drugs and 
psychotropic substances for medical treatment, 
including the use of opioids for the treatment of 
pain, in accordance with the pertinent 
recommendations of WHO. The Governments 
should include the topic of rational use of 
narcotic drugs and psychotropic substances, 
including substance misuse and abuse, in the 
curricula of the relevant faculties of health-care 
professions, such as doctors, pharmacists and 
nurses, and, as appropriate, in the curricula of the 
faculties of law and social and behavioural 
sciences. 
  Recommendation 17: Illicit demand for 
pharmaceuticals containing psychotropic 
substances, particularly amphetamine-type 
stimulants and benzodiazepines, is growing. The 
Board calls on Governments to monitor 
consumption levels of prescription drugs 
containing psychotropic substances and to raise 
awareness about the consequences of the abuse of 
such drugs. 
  Recommendation 18: The Board calls to the 
attention of Governments the problem of 
inappropriate promotion of medicines containing 
controlled substances, in particular through 
Internet pharmacies, and requests Governments to 
ensure that these medicines are prescribed and 
dispensed in accordance with sound medical 
practice.  
  Recommendation 19: The availability of 
controlled substances in unregulated markets, 
particularly in Africa, and the circulation of 
counterfeit medicines in many countries create a 
number of problems, including the abuse and 
inappropriate use of drugs, and undermine public 
confidence in health services and in drug control 
and law enforcement regimes. The Board calls 
upon all the Governments concerned to take 
remedial action by strengthening mechanisms for 
the monitoring and control of licit narcotic drugs 
and psychotropic substances, including licensing 
systems, record-keeping, inspections and 
sanctions. 
  Recommendation 20: The Board also urges 
the Governments concerned to assess their real 
needs for controlled drugs, as well as constraints 
that contribute to those drugs not being available 
in sufficient quantities for medical purposes. 
WHO and international and bilateral donors 
would then be in a better position to assist the 
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countries concerned in implementing their 
strategies for the rational use of controlled 
substances. 
 
  The Internet and smuggling by mail 
 
650. The Board notes that internationally controlled 
substances, including the most strictly controlled 
substances, are increasingly being illegally sold by 
Internet pharmacies. Furthermore, the smuggling of 
drugs by mail has become a major problem for drug 
law enforcement agencies. Appropriate action is 
therefore required to counteract such activities. 
  Recommendation 21: Smuggling of drugs 
by mail has become an important means of 
supplying illicit markets. The Board requests all 
Governments that have not yet done so to take the 
necessary measures to ensure that regular and 
thorough searches of the mail for illicit drug 
consignments become a routine law enforcement 
procedure on their territory. 
  Recommendation 22: The Board en-
courages Governments to enact legislation that 
allows the control and screening of all routes of 
international mail into and out of the country, 
including the private premises of international 
mail courier companies. Such control measures 
could include: 
  (a) Cooperative arrangements between the 
various national authorities responsible for the 
processing and screening of international mail 
and privately owned companies;  
  (b) Limiting the number of entry points 
for parcels;  
  (c) Provision of adequate training for 
staff; 
  (d) Provision of the required technical 
aids for drug identification;  
  (e) Development of intelligence or 
information centres by the law enforcement 
services to support their front-line drug law 
enforcement operations.  
  Recommendation 23: The Board notes the 
initiatives undertaken by the authorities of 
several countries against the illicit sale of 
internationally controlled substances by illegally 
operating Internet pharmacies, such as 
cooperation with international organizations, 
authorities of other countries, Internet service 
providers and service industries. The Board 
encourages the countries and relevant 
international organizations concerned to actively 
participate in such activities or to initiate such 
joint efforts, if required.  
  Recommendation 24: Noting that the 
authorities of some countries have issued or are 
in the process of issuing guidelines and 
legislation on prescription practices of Internet 
pharmacies, the Board requests the Governments 
of countries that have adopted such guidelines 
and/or legislation to provide the Board with the 
relevant information.  
  Recommendation 25: As authorities often 
encounter difficulties in finding partners in other 
countries with whom to cooperate in ongoing 
investigations of illegally operating Internet 
pharmacies, the Board appeals to the 
Governments of all countries to provide all 
necessary cooperation and support to 
investigative efforts and to initiate criminal 
procedures against offenders.  
  Recommendation 26: In an attempt to 
strengthen international cooperation to counteract 
illegally operating Internet pharmacies, the Board 
requested all Governments to identify focal 
points for all activities related to such Internet 
pharmacies and to provide to it details of 
legislation and regulations related to Internet 
services and sites. The Board calls on those 
Governments which have not yet provided that 
information to do so without delay, so that 
requests for support can be appropriately dealt 
with and international collaborative efforts will 
not be hindered.  
  Recommendation 27:  The Board calls on 
Governments to introduce further measures to 
counteract illegally operating Internet pharmacies 
including: 
  (a) To undertake efforts to increase the 
awareness of law enforcement, regulatory and 
drug control authorities regarding the need to 
counteract the activities of illegally operating 
Internet pharmacies;  
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  (b) To undertake awareness-raising 
campaigns to alert the public to the potential 
dangers of such pharmacies;  
  (c) To ensure that legislation, as well as 
the application of laws and sanctioning by courts, 
deals adequately with the diversion of 
pharmaceuticals in general and the illegal 
operations of Internet pharmacies in particular. 
  Recommendation 28:  In view of recent 
cases of importation of narcotic drugs and 
psychotropic substances by using couriers and 
through the mail without the required 
authorization documents, the Board requests 
Governments to be aware that such practices may 
also occur on their territory and to take measures 
against such importations.  
 
 
 B. Recommendations to the United 
Nations Office on Drugs and Crime 
 
 
651. In the implementation of their treaty-based 
obligations, States may require operational support 
from the United Nations and other relevant 
organizations. Therefore, as UNODC is the primary 
United Nations entity responsible for the provision of 
technical assistance in drug control issues, as well as 
coordination of such assistance provided by 
Governments and other organizations, the 
recommendations below are addressed to UNODC for 
appropriate action.  
  Recommendation 29: In view of the low 
level of accession to the international drug 
control treaties by States in Oceania and the 
problems those States have in reporting to the 
Board and UNODC, the Board reiterates its 
requests to UNODC to stimulate the accession of 
those States to the international drug control 
treaties and to assist them in establishing the 
necessary capacity to fulfil their reporting 
obligations, as required by the treaties. 
  Recommendation 30: Noting the persistent 
need for training of national drug control 
administrators in the administration of narcotic 
drugs, psychotropic substances and precursor 
chemicals in many countries, the Board wishes to 
draw the attention of UNODC to these needs and 
requests it to look into ways to facilitate such 
training activities on an ongoing basis, for 
instance, by establishing a specific training unit 
within UNODC. 
  Recommendation 31: Noting in Afghanistan 
the increasing problem of the abuse of drugs 
including not only opiates but also prescription 
drugs smuggled into the country in the absence of 
adequate control mechanisms, the Board urges 
UNODC to continue providing assistance to the 
Government in that area, in order to ensure the 
full compliance of Afghanistan with the 
international drug control treaties.  
  Recommendation 32: The Board urges 
UNODC to allocate the necessary funds to ensure 
speedy implementation of the overall training 
programme for Afghanistan on licit activities 
related to narcotic drugs, psychotropic substances 
and precursors, which was developed by the 
Board in cooperation with UNODC, to increase 
the Government’s capacity to implement the 
provisions of the international drug control 
treaties.  
  Recommendation 33: Welcoming the 
commitment of the Government of Iraq to fight 
illicit drug trafficking and other criminal 
activities and noting the efforts of the Iraqi 
authorities to develop a national drug control 
plan, the Board requests UNODC to provide 
assistance to the Government in that area.  
  Recommendation 34: Concerned about the 
continuing diversion of pharmaceutical 
preparations containing internationally controlled 
substances, the Board encourages UNODC to 
assist the Governments concerned in monitoring 
trends and preventing the diversion and abuse of 
such preparations. 
  Recommendation 35: In order to allow 
proper identification of trends in the diversion 
and abuse of psychotropic substances, the Board 
recommends that UNODC should use a more 
specific classification system for collecting 
reports on seizures of psychotropic substances. 
The Board is ready to provide support in the 
identification of an appropriate classification 
system.  
  Recommendation 36: Noting information 
on the increasing trafficking in and abuse of 
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GHB, a sedative-hypnotic added to Schedule IV 
of the 1971 Convention in 2001, the Board 
requests UNODC to include, in its drug abuse 
prevention programmes, the prevention of GHB 
abuse. (The same request is addressed to WHO in 
recommendation 50 below.) 
  Recommendation 37: The Board believes 
that measures to alleviate poverty, accompanied 
by sustained law enforcement efforts to prevent 
the re-emergence of illicit crop cultivation, are 
essential to the achievement of a lasting reduction 
in the production of narcotic drugs and 
recommends that UNODC should guide 
Governments on adopting a balanced approach in 
this regard. 
  Recommendation 38: In several countries, 
the levels of consumption of opioid analgesics 
are low. The Board requests UNODC to facilitate 
the preparation by WHO of a technical study to 
assess the medical needs of populations for 
opioids.  
  Recommendation 39: The Board believes 
that the UNODC African project to counter the 
smuggling of drugs by mail has been a good 
initiative. The Board recommends that UNODC 
should resume the project targeting African 
countries and extend the project to other regions 
and share its experiences with interested parties. 
  Recommendation 40: Noting that the 
southern Caucasus is emerging as an important 
transit area for drug trafficking and in view of a 
significant increase in drug abuse in that 
subregion, the Board wishes to draw the attention 
of UNODC to those negative developments and 
urges it to take active measures to assist the 
Governments of countries in that subregion in 
improving their national drug control systems, 
subregional cooperation and border control. 
  Recommendation 41: Misuse of the mail or 
illegal use of the Internet have become important 
means of obtaining drugs to supply illicit 
markets. The Board calls on UNODC to address 
the problems of illegally operating Internet 
pharmacies and the smuggling of controlled drugs 
by mail and to share its experiences with the 
Board. 
 Recommendation 42: In many countries in 
Africa, there is a lack of adequate precursor control 
legislation and monitoring, and mechanisms for the 
control of precursor chemicals are insufficient. As a 
consequence, drug traffickers are increasingly targeting 
countries in Africa in an attempt to divert the 
chemicals they require for illicit drug manufacture. The 
Board calls upon UNODC to offer technical assistance, 
including training, to the African countries at risk of 
such diversion. 
 
 
 C. Recommendations to the World Health 
Organization 
 
 
652. The treaty-based function of WHO in the 
international drug control system is to provide 
recommendations, based on scientific assessments, 
regarding changes in the scope of control of narcotic 
drugs under the 1961 Convention and the scope of 
control of psychotropic substances under the 
1971 Convention. Furthermore, WHO plays a key role 
in supporting the rational use of narcotic drugs and 
psychotropic substances worldwide and in giving 
guidance on the provision of adequate treatment for 
drug addicts.  
  Recommendation 43: Buprenorphine, a 
potent opioid included in Schedule III of the 
1971 Convention, continues to be diverted from 
domestic distribution channels in several 
countries. The Board reiterates its request to 
WHO to examine information on the misuse and 
diversion of buprenorphine when reviewing the 
control status of the substance and to consider 
reviewing the control status of other mixed 
agonist-antagonist opioid analgesics.  
  Recommendation 44: Noting the widespread 
abuse of ketamine in many countries, the Board 
urges WHO to expedite the review of this 
substance to determine whether it should be 
recommended to be placed under international 
control.  
  Recommendation 45: The Board notes with 
concern the abuse of khat (Catha edulis), which 
is currently not under international control, in 
countries in Eastern Africa and elsewhere. The 
Board calls upon WHO to expedite the review of 
this substance to determine whether it should be 
  97 
 
 E/INCB/2005/1
recommended to be placed under international 
control.  
  Recommendation 46: In view of difficulties 
experienced by several Governments in assessing 
their medical needs of populations for opioids, 
the Board calls upon WHO to prepare a technical 
study on the medical needs for opioids in order to 
facilitate the identification by Governments of 
appropriate quantities of opioids required for 
medical purposes.  
  Recommendation 47: With respect to the 
availability and use of narcotic drugs for the 
treatment of pain, the Board recommends that 
WHO systematically collect and analyse 
information on the different treatment methods 
used in countries worldwide.  
  Recommendation 48: Pursuant to Economic 
and Social Council resolution 2005/25 and the 
World Health Assembly resolution WHA 58.22, 
the Board calls upon WHO to examine the 
feasibility of a possible assistance mechanism 
that would facilitate the adequate treatment of 
pain using opioid analgesics. The Board stands 
ready to support WHO in responding to this 
request. 
  Recommendation 49: The Board requests 
WHO to continue to draw the attention of 
Governments to the risks of abuse or misuse of 
particular groups of psychotropic substances, 
such as benzodiazepines and stimulants used as 
anorectics, and to provide practical guidelines to 
States on the rational use of those substances. 
  Recommendation 50: Noting information 
on the increasing trafficking in and abuse of 
GHB, a sedative-hypnotic added to Schedule IV 
of the 1971 Convention in 2001, the Board 
requests WHO to include, in its drug abuse 
prevention programmes, the prevention of GHB 
abuse. (The same request is addressed to UNODC 
in recommendation 36 above.) 
 
 
 D. Recommendations to other relevant 
international and regional 
organizations  
 
 
653. In cases where States require additional 
operational support in specific areas, such as drug law 
enforcement, the Board addresses relevant 
recommendations pertaining to the specific spheres of 
competence of the relevant international and regional 
organizations, including Interpol, UNDP, UPU, the 
World Customs Organization and the European 
Commission. 
  Recommendation 51: The Board welcomes 
the participation of Interpol, the World Customs 
Organization and the European Commission as 
members of the task force of the newly 
established Project Cohesion (Operation Purple 
and Operation Topaz combined) and recommends 
that those organizations continue to actively 
support activities under that important initiative.  
  Recommendation 52: Noting operational 
activities undertaken by Interpol and the World 
Customs Organization, such as Project Novak and 
Operation Tamerlane, respectively, which target 
heroin trafficking from South-West Asia and 
Central Asia, the Board recommends that those 
organizations, in their function as task force 
members of Project Cohesion and Project Prism, 
consider including activities against precursor 
trafficking in those and similar projects.  
  Recommendation 53: In view of the 
increasing use of the mail for smuggling 
controlled substances, the Board recommends 
that Interpol and the World Customs Organization 
develop standard procedures for conducting 
investigations into seizures of controlled 
substances smuggled by mail, including the 
collection of information required for further 
investigation and analysis. The African mail 
project, initiated by the UPU and UNODC with 
the support of Interpol and the World Customs  
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 Organization, provides examples of best practices 
in the area and demonstrates how such activities 
can be carried out in a coordinated manner. The 
Board encourages the international organizations 
concerned to continue developing and 
participating in similar projects in the future. 
  Recommendation 54: In order to obtain a 
more comprehensive picture of the situation 
regarding seizures of psychotropic substances, 
the World Customs Organization, in its annual 
report entitled Customs and Drugs, should 
specify in a more detailed manner what kind of  
 psychotropic substances are reported as seized. 
The Board is ready to provide its support in 
identifying the appropriate classification for 
reporting.  
  Recommendation 55: The Board urges 
inter-national organizations, in particular UPU, 
Interpol and the World Customs Organization, to 
address the problems of illegally operating 
Internet pharmacies and the smuggling of 
controlled drugs by mail in their respective fields 
of responsibility and to share their experiences 
with the Board. (The same request is addressed to 
UNODC in recommendation 41 above.) 
  Recommendation 56: The Board notes with 
appreciation the cooperation and support it has 
regularly received from UNDP and recommends 
that that organization continue to actively 
cooperate with and support the Board in the 
following areas:  
  (a) Provision of support and assistance in 
arranging country missions of the Board, 
including the provision of substantive briefing to 
members of the mission;  
  (b) Provision of assistance in the 
launching of annual reports of the Board; 
  (c) Provision of assistance in the 
dissemination of findings of the Board;  
  (d) Inclusion of issues dealt with by the 
Board (for example, the relation between illicit 
drugs and economic development; the complex 
relationship between drug abuse, crime and 
violence at the community level; and the 
availability and rational use of controlled 
substances for medical purposes) in the future 
development programmes of UNDP.  
 
 
 
     (Signed)    (Signed) 
Hamid Ghodse Robert Jean Joseph Chrétien Lousberg 
     President    Rapporteur 
(Signed) 
Koli Kouame 
Secretary 
 
 
 
Vienna, 18 November 2005 
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Notes 
 1  In the Action Plan on International Cooperation on the 
Eradication of Illicit Drug Crops and on Alternative 
Development contained in General Assembly 
resolution S-20/4 E of 10 June 1998, the Assembly 
defined alternative development as a process to prevent 
and eliminate the illicit cultivation of plants containing 
narcotic drugs and psychotropic substances through 
specifically designed rural development measures in the 
context of sustained national economic growth and 
sustainable development efforts in countries taking 
action against drugs, recognizing the particular 
sociocultural characteristics of the target communities 
and groups, within the framework of a comprehensive 
and permanent solution to the problem of illicit drugs. 
 2  United Nations, Treaty Series, vol. 1582, No. 27627. 
 3  Report of the International Narcotics Control Board for 
2004 (United Nations publication, Sales No. E.05.XI.1), 
chap. I. 
 4  In 2001, Afghanistan experienced a temporary but 
drastic decline in opium poppy cultivation in areas under 
the control of the Taliban; however, that decline was 
attributable not to alternative development efforts but to 
a strictly enforced ban on such cultivation, accompanied 
by credible threats of violence against any persons who 
violated the ban. 
 5  “Third biennial report of the Executive Director on the 
world drug problem: Action Plan on International 
Cooperation on the Eradication of Illicit Drug Crops and 
on Alternative Development” (E/CN.7/2005/2/Add.2), 
paras. 2 and 3. 
 6  D. Mansfield, “Alternative development: the modern 
thrust of supply-side policy”, Bulletin on Narcotics, 
vol. LI, Nos. 1 and 2 (1999) (United Nations 
publication), pp. 19-43. 
 7  This does not mean that Governments have not made any 
alternative development efforts of their own in areas 
affected by cannabis plant cultivation. The Government 
of Ghana, for example, has been carrying out a project in 
support of alternative livelihoods for cannabis plant 
growers in a small area of the country. 
 8  In Commission on Narcotic Drugs resolution 45/14, it is 
stated that alternative development constitutes a 
medium- and long-term process. 
 9  “Report of the Secretary-General on the implementation 
of the outcome of the twentieth special session of the 
General Assembly devoted to countering the world drug 
problem together” (A/56/157), para. 37. 
 
 10  In its resolution 45/14, the Commission on Narcotic 
Drugs urged Member States to facilitate a rigorous and 
comprehensive thematic evaluation for determining best 
practices in alternative development by assessing the 
impact of alternative development on both human 
development indicators and drug control objectives and 
by addressing the key development issues of poverty 
reduction, gender, environmental sustainability and 
conflict resolution. 
 11  In its resolution 45/14, the Commission on Narcotic 
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more sustainable and socially and economically more 
appropriate than forced eradication of illicit crops. 
 12  Pursuant to Commission on Narcotic Drugs 
resolution 48/9, para. 1. 
 13  Ronald D. Renard, Opium Reduction in Thailand, 1970-
2000: a Thirty-year Journey (Chiang Mai, Thailand, 
Silkworm Books, 2001), p. 36. 
 14  Report of the International Narcotics Control Board for 
2004 ..., para. 368. 
 15  Ibid., para. 339. 
 16  See, for example, General Assembly resolution 57/174, 
section II, paragraph 12; see also Assembly 
resolution 58/141, section II, paragraph 11 (d), in which 
the Assembly calls upon States to provide, in accordance 
with the principle of shared responsibility, greater access 
to their markets for products of alternative development 
programmes, which are necessary for the creation of 
employment and the eradication of poverty. 
 17  According to UNODC, only 5 per cent of families in the 
Lao People’s Democratic Republic, Myanmar and Viet 
Nam and 23 per cent of families in Bolivia, Colombia 
and Peru have had access to alternative livelihood 
schemes. 
 18  L. Armstead, “Illicit narcotics cultivation and 
processing: the ignored environmental drama”, Bulletin 
on Narcotics, vol. XLIV, No. 2 (1992) (United Nations 
publication), pp. 9 ff. 
 19  Report of the International Narcotics Control Board for 
2003 (United Nations publication, Sales No. E.04.XI.1), 
para. 238. 
 20  Report of the International Narcotics Control Board for 
2004 ..., chap. I. 
 21  In its resolution 45/14, the Commission on Narcotic 
Drugs recognized that the world supply of and demand 
for illicit drugs had remained at almost the same levels. 
 22 Report of the International Narcotics Control Board for 
2004 ..., chap. I. 
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 23  Other countries affected by illicit drug cultivation either 
do not have poverty reduction strategy papers (for 
example, Afghanistan, Colombia, Myanmar and Peru) or 
do not consider the problem of illicit drug cultivation in 
connection with poverty (for example, Pakistan and 
Viet Nam). 
 24  United Nations, Treaty Series, vol. 520, No. 7515. 
 25  Ibid., vol. 976, No. 14152. 
 26  Ibid., vol. 976, No. 14151. 
 27  For the 2005 technical report on narcotic drugs, see 
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 28  Report of the International Narcotics Control Board for 
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Control Board for 2004 ..., para. 166. 
 30  Precursors and Chemicals Frequently Used in the Illicit 
Manufacture of Narcotic Drugs and Psychotropic 
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Control Board for 2005 on the Implementation of 
Article 12 of the United Nations Convention against 
Illicit Traffic in Narcotic Drugs and Psychotropic 
Substances of 1988 (United Nations publication, Sales 
No. E.06.XI.5). 
 31  United Nations, Treaty Series, vol. 1019, No. 14956. 
 32  Operation Purple and Operation Topaz are voluntary 
international tracking programmes for potassium 
permanganate and acetic anhydride, respectively, 
whereas Project Prism is an international initiative 
focusing on precursors of amphetamine-type stimulants. 
 33  Regulation (EC) No. 273/2004 of the European 
Parliament and of the Council of the European Union, on 
drug precursors; Council regulation (EC) No. 111/2005, 
laying down rules for the monitoring of trade between 
the Community and third countries in drug precursors; 
Commission of the European Communities regulation 
(EC) No. 1277/2005, laying down implementing rules 
for regulation (EC) No. 273/2004 of the European 
Parliament and of the Council on drug precursors and for 
Council regulation (EC) No. 111/2005, laying down 
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Manufacture of Narcotic Drugs and Psychotropic 
Substances: Report of the International Narcotics 
Control Board for 2005 ... . 
 35  Ibid. 
 
 36  The Project Prism Task Force is composed of members 
representing the major geographical regions, namely 
Australia, China, the Netherlands, South Africa and the 
United States, as well as the European Commission, 
Interpol and the World Customs Organization as 
competent international bodies. The Board, through its 
secretariat, guides the task force within the scope of its 
treaty mandates. 
 37  A “body packer” is a person who takes into his or her 
body, orally or otherwise, small packets of illicit drugs 
in order to smuggle them across international borders. 
 38  Report of the International Narcotics Control Board for 
2001 (United Nations publication, Sales No. E.02.XI.1), 
paras. 231-234. 
 39  The GIABA secretariat was formally established in 
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States have approved its budget and plan of action. 
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conduct evaluations of money-laundering situations 
among ECOWAS member States. 
 40  Report of the International Narcotics Control Board for 
2004 ..., para. 268. 
 41  United Nations Office on Drugs and Crime, World Drug 
Report 2005 (United Nations publication, Sales 
No. E.05.XI.10), volume 1, “Analysis”, p. 62. 
 42  Report of the International Narcotics Control Board for 
2004 ..., para. 342. 
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illicitly for use in the illicit manufacture of heroin in the 
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 44  Report of the International Narcotics Control Board for 
2003 ..., para. 357. 
 45  “Report of the Eleventh United Nations Congress on 
Crime Prevention and Criminal Justice, Bangkok, 
18-25 April 2005” (A/CONF.203/18), chap. I, 
resolution 1. 
 46  The Paris Pact initiative emerged from the Paris 
Statement (S/2003/641, annex), which had been issued at 
the end of the Conference on Drug Routes from Central 
Asia to Europe, held in Paris on 21 and 22 May 2003. 
 47  A “drug swallower” (also called a “body packer”) is a 
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of Irish Students (Dublin, 2005). 
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Annex I 
 
 
  Regional groupings used in the report of the International 
Narcotics Control Board for 2005 
 
 
 The regional groupings used in the report of the International Narcotics 
Control Board for 2005, together with the States in each of those groupings, are 
listed below. 
Africa 
Algeria 
Angola 
Benin 
Botswana 
Burkina Faso 
Burundi 
Cameroon 
Cape Verde 
Central African Republic 
Chad 
Comoros 
Congo 
Côte d’Ivoire 
Democratic Republic of the Congo 
Djibouti 
Egypt 
Equatorial Guinea 
Eritrea 
Ethiopia 
Gabon 
Gambia 
Ghana 
Guinea 
Guinea-Bissau 
Kenya 
Lesotho 
Liberia 
  
Libyan Arab Jamahiriya 
Madagascar 
Malawi 
Mali 
Mauritania 
Mauritius 
Morocco 
Mozambique 
Namibia 
Niger 
Nigeria 
Rwanda 
Sao Tome and Principe 
Senegal 
Seychelles 
Sierra Leone 
Somalia 
South Africa 
Sudan 
Swaziland 
Togo 
Tunisia 
Uganda 
United Republic of Tanzania 
Zambia 
Zimbabwe 
 
Central America and the Caribbean 
Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
El Salvador 
Grenada  
Guatemala 
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
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Antigua and Barbuda 
Bahamas 
Barbados 
Belize 
Costa Rica 
Cuba 
Dominica 
Dominican Republic 
Saint Kitts and Nevis 
Saint Lucia 
El Salvador 
Grenada  
Guatemala 
Haiti 
Honduras 
Jamaica 
Nicaragua 
Panama 
Saint Vincent and the Grenadines 
Trinidad and Tobago 
North America 
Canada 
Mexico 
 
 United States of America 
South America 
Argentina 
Bolivia 
Brazil 
Chile 
Colombia 
Ecuador 
 
Guyana 
Paraguay 
Peru 
Suriname 
Uruguay 
Venezuela (Bolivarian Republic of) 
 
East and South-East Asia 
Brunei Darussalam 
Cambodia 
China 
Democratic People’s Republic 
   of Korea 
Indonesia 
Japan 
Lao People’s Democratic  
   Republic 
 
Malaysia 
Mongolia 
Myanmar 
Philippines 
Republic of Korea 
Singapore 
Thailand 
Timor-Leste 
Viet Nam 
 
South Asia 
Bangladesh 
Bhutan 
India 
 
Maldives 
Nepal 
Sri Lanka 
 
West Asia 
Afghanistan 
Armenia 
Azerbaijan 
Bahrain 
Georgia 
Iran (Islamic Republic of) 
Iraq 
Lebanon 
Oman 
Pakistan 
Qatar 
Saudi Arabia 
Syrian Arab Republic 
Tajikistan 
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Israel 
Jordan 
Kazakhstan 
Kuwait 
Kyrgyzstan 
 
Turkey 
Turkmenistan 
United Arab Emirates 
Uzbekistan 
Yemen 
 
 
Europe 
Albania 
Andorra 
Austria 
Belarus 
Belgium 
Bosnia and Herzegovina 
Bulgaria 
Croatia 
Cyprus 
Czech Republic 
Denmark 
Estonia 
Finland 
France 
Germany 
Greece 
Holy See 
Hungary 
Iceland 
Ireland 
Italy 
Latvia 
Liechtenstein 
 
Lithuania 
Luxembourg 
Malta 
Monaco 
Netherlands 
Norway 
Poland 
Portugal 
Republic of Moldova 
Romania 
Russian Federation 
San Marino 
Serbia and Montenegro 
Slovakia 
Slovenia 
Spain 
Sweden 
Switzerland 
The former Yugoslav Republic of 
   Macedonia 
Ukraine 
United Kingdom of Great Britain 
   and Northern Ireland 
 
Oceania 
Australia 
Cook Islands 
Fiji 
Kiribati 
Marshall Islands 
Micronesia (Federated States of) 
Nauru 
New Zealand 
 
Niue 
Palau 
Papua New Guinea 
Samoa 
Solomon Islands 
Tonga 
Tuvalu 
Vanuatu 
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Annex II 
 
 
  Current membership of the International Narcotics Control 
Board 
 
 
  Joseph Bediako Asare 
 
 
 Born in 1942. National of Ghana. Private 
Consultant and Psychiatrist. 
 Medical Academy of Krakow, Poland (1965-
1971); postgraduate training at Graylands and 
Swanbourne Psychiatric Hospitals, Perth, Australia 
(1976-1977); Leicestershire Area Health Authority 
(1977-1980). Chief Psychiatrist, Ghana Health Service; 
and specialist in charge at Accra Psychiatric Hospital; 
Chairman, Ghana Chapter, West African College of 
Physicians; Vice-President, West African College of 
Physicians; Adviser to the Ministry of Health of Ghana 
(since 1984); Member of the Narcotics Control Board 
of Ghana (since 1990); Chairman, Subcommittee on 
Demand Reduction, Narcotics Control Board of Ghana 
(since 1991). Part-time lecturer in psychiatry, 
University of Ghana medical school (since 1984). 
Senior Registrar in Psychiatry, West Berkshire and 
South Oxford Area Health Authority (1981-1982); 
Faculty Fellow of the International Council on Alcohol 
and Addictions training programme on alcohol and 
drug abuse in Benin City, Nigeria (1986 and 1987); 
President, Psychiatric Association of Ghana (1999-
2002). Member, Royal College of Psychiatrists (1980); 
Fellow, West African College of Psychiatrists; Fellow, 
Ghana College of Physicians and Surgeons. Author of 
numerous works, including: Substance Abuse in 
Ghana; The Problem of Drug Abuse in Ghana: a Guide 
to Parents and Youth (1989); Alcohol Use, Sale and 
Production in Ghana: a Health Perspective (1999); 
Alcohol and Tobacco Abuse in Deheer (1997); 
“Psychiatric co-morbidity of drug abuse”, Assessing 
Standards of Drug Abuse (1993); “Baseline survey of 
the relationship between HIV and substance abuse in 
Ghana” (2004). Recipient of the Grand Medal (Civil 
Division) of Ghana (1997). Participant in numerous 
meetings, including: consultative group that developed 
the manual on assessment standards of care in drug 
abuse treatment (1990-1992); NGO World Forum on 
Drug Demand Reduction, Bangkok (1994); drug 
programme expert meeting, Cleveland, United States 
of America (1995); Drug Expert Forum for Western 
and Central Africa, Cameroon (1995); local expert 
meeting for West Africa, Dakar (2003). 
 Member of the International Narcotics Control 
Board (2005). 
 
 
  Sevil Atasoy 
 
 
 Born in 1949. National of Turkey. Director and 
Professor of Forensic Science, Institute of Forensic 
Science, Istanbul University (since 1988); Professor of 
Biochemistry, Cerrahpasa School of Medicine, Istanbul 
University (since 1988); Educational Counselor, 
Turkish International Academy against Drugs and 
Organized Crime (TADOC ) (since 2000). 
 Bachelor of Science in Chemistry (1972), Master 
of Science in Biochemistry (1976) and Doctor of 
Philosophy (Ph.D.) in Biochemistry (1979), Istanbul 
University. Hubert H. Humphrey Fellow, United States 
Information Agency (1995-1996); also recipient of 
various other fellowships, including: German 
Academic Exchange Program (1976, 1978 and 1994), 
Istanbul University Research Foundation (1997 and 
1998), Ministry of Justice of Turkey (1982, 1985 and 
1986), North Atlantic Treaty Organization (1978) and 
European Molecular Biology Organization (1985). 
Recipient of numerous awards, including: Best Woman 
Scientist of the Year, Kadinca Journal (1993); 
Motherland (Anavatan) Party (2002); Rotary 
International (1993 and 2001), for the improvement of 
investigative techniques in Turkey. Guest scientist, 
University of California, Berkeley, School of Public 
Health, and Los Angeles, Drug Abuse Research Center; 
Department of Genetics, Stanford University; 
Department of Genetics, Emory University; California 
Criminalistics Institute; Federal Bureau of 
Investigation, Virginia; Crime Laboratories, Los 
Angeles Sheriff’s Department; Federal Criminal Police 
(BKA), Wiesbaden, Germany; United Nations Drug 
Laboratory, Vienna; Ludwig-Maximilian University; 
Munich Institute for Physical Biochemistry and 
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Institute of Legal Medicine; Center of Human 
Genetics, Bremen University; Institute of Legal 
Medicine, Muenster University. Expert witness in civil 
and criminal courts (since 1980). Director, Department 
of Narcotics and Toxicology, Ministry of Justice of 
Turkey (1980-1993); Chairman, Department of 
Forensic Basic Sciences, Istanbul University (1983-
1987); Chairman, first Regional Symposium on 
Criminalistics (2000); and Chairman, third European 
Academy of Forensic Science Meeting (2003). 
Member of the Istanbul University Senate (1987-2005) 
and Research Foundation (1987-2002); Member of the 
Experts Group on Technical Challenges to the Drug 
Community, United Nations Office on Drugs and 
Crime (UNODC) and Office of National Drug Control 
Policy of the United States (2003 and 2004); Member 
of the expert group on risk reduction linked to 
substance use other than by injection, Pompidou Group 
of the Council of Europe (2002); Member of the 
Mediterranean Network of the Pompidou Group (since 
2001). Member of the Turkish delegation to the 
Commission of Narcotic Drugs (2001 and 2002); the 
special commissions on the improvement of judiciary 
and security affairs, Prime Ministry, VIII. 
Development Plan for the Years 2001-2005, the 
Republic of Turkey Higher Commission on Human 
Rights (1997-1998). Adviser on improving 
investigations and protecting child victims, General 
Command of Gendarmerie Internal Security Units 
(2001-2003); adviser on prevention of violence, suicide 
and drug abuse, Land Forces Command (2000-2004); 
adviser on driving under influence of controlled 
substances, Traffic Accidents Prevention Commission, 
Turkish Grand National Assembly (2000); adviser on 
preventing drug abuse and violence in schools, 
Ministry of National Education (since 1999); adviser 
on drug testing and the improvement of treatment of 
offenders, General Directorate of Correctional 
Facilities, Ministry of Justice (since 1999). Founding 
editor, Turkish Journal of Legal Medicine (1982-1993). 
Member of the scientific board of national and 
international journals, including the International 
Criminal Justice Review, the Turkish Journal on 
Addiction, the Turkish Journal of Forensic Sciences 
and the Croatian Journal of Legal Medicine. Founding 
President, Turkish Society of Forensic Sciences (since 
1998); Honorary Member of the Mediterranean 
Academy of Forensic Sciences (since 2003); Member 
of the Standing Committee, European Academy of 
Forensic Sciences (1999-2003). Member of the 
International Society of Forensic Toxicology; the Indo-
Pacific Association of Law, Medicine and Science; the 
European Network of Forensic Science Institutes; the 
International Association of Forensic Toxicologists; the 
American Academy of Forensic Sciences; the 
American Society of Crime Laboratory Directors; the 
Forensic Science Society, United Kingdom of Great 
Britain and Northern Ireland; the American Society of 
Criminology; the Interagency Council on Child Abuse 
and Neglect; and the United Nations Academic 
Council. Participant in projects on illicit drug issues, 
including: Crime Mapping of Drug Offences for the 
Ministry of Home Affairs (1998-2000); Global Study 
of Illicit Drug Markets: Istanbul, Turkey for the United 
Nations Interregional Crime and Justice Research 
Institute (2000-2001); National Assessment of Nature 
and Extent of Drug Problems in Turkey, for UNODC 
(2002-2003); European School Survey on Alcohol and 
Other Drugs (2002-2003); Modeling the World Heroin 
Market, for the RAND Drug Policy Research Center 
and the Max Planck Institute (2003). Author of over 
130 scientific papers, including papers on drug testing, 
drug chemistry, drug markets, drug-related and drug-
induced crime, drug abuse prevention, clinical and 
forensic toxicology, neuropharmacology, crime scene 
investigation and deoxyribonucleic acid (DNA) 
analysis, including “Excavating Y-chromosome 
haplotype strata in Anatolia”, Human Genetics (2004) 
“DNA fingerprinting of cannabis sativa, accessions 
using RAPD and AFLP markers”, Forensic Science 
International (2003); “H. gamma-vinyl-GABA 
potentiates the severity of naloxone-precipitated 
abstinence signs in morphine-dependent rats”, 
Pharmacological Research (1998). 
 Member of the International Narcotics Control 
Board (2005). Member of the Standing Committee on 
Estimates (2005).  
 
 
  Madan Mohan Bhatnagar  
 
 
 Born in 1934. National of India. Various senior 
positions in narcotics control and administration in the 
Government of India (since 1972). Member of the 
Delhi High Court Bar Association (since 1993). 
 Bachelor of Law (1956) and Master of Arts in 
Political Science (1955), Patna University, India. 
Deputy Narcotics Commissioner (1972-1974). Officer 
on Special Duty (Narcotics) (1976-1979). Narcotics 
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Commissioner of India (1979-1985). Director-General, 
Narcotics Control Bureau, Government of India (1988-
1990). Member (Anti-Smuggling and Narcotics) of the 
Central Board of Excise and Customs and Additional 
Secretary to the Government of India (1990-1992). 
Author of numerous publications, including: “Current 
national laws and policies on narcotics control in 
India”, Current Research on Drug Abuse in India, All 
India Institute of Medical Sciences Research Book; 
“Drug trafficking: Indian perspective”, Narcontrol, 
Journal of Narcotics Control Bureau of India. Drafter 
of the provisions of the Narcotic Drugs and 
Psychotropic Substances Act of India (1985). Drafter 
of the licit opium production and export policy for 
India and the national strategy for combating the illicit 
traffic in drugs for India. Member of the expert group 
to study the modification of the Single Convention on 
Narcotic Drugs of 1961, Vienna (1982). Chairman of 
several international conferences on drug control, inter 
alia, the Tenth Meeting of Heads of National Drug Law 
Enforcement Agencies (HONLEA), Asia and the 
Pacific (1983), the Indo-Pakistan Committee meeting 
against drug trafficking (1989) and the South Asian 
Association for Regional Cooperation meeting on 
harmonization of drug laws (1989). First Vice-
Chairman, Second Interregional Meeting of Heads of 
National Drug Law Enforcement Agencies, Vienna 
(1989). Participant in the Indo-United States bilateral 
talks on narcotics, Washington, D.C. (1989). 
Participant in the seventeenth special session of the 
General Assembly (1990). Member of the 
intergovernmental expert group on the economic and 
social consequences of drug abuse and illicit 
trafficking, Vienna (1990). Expert and Vice-Chairman, 
Economic and Social Commission for Asia and the 
Pacific (ESCAP) regional seminar on drug abuse, 
Manila (1990). Head of the Indian delegation to the 
Commission on Narcotic Drugs (1990 and 1992), 
several meetings of HONLEA and the Subcommission 
on Illicit Drug Traffic and Related Matters in the Near 
and Middle East. Vice-Chairman, Commission on 
Narcotic Drugs (1992).  
 Member of the International Narcotics Control 
Board (since 2002). Chairman of the Committee on 
Finance and Administration (2002). Member of the 
Standing Committee on Estimates (since 2002). 
Rapporteur of the Board (2003). First Vice-President of 
the Board (2004). Member of the Committee on 
Finance and Administration (since 2004). Vice-
Chairman of the Standing Committee on Estimates 
(2005). 
 
 
  Elisaldo Luiz de Araújo Carlini 
 
 
 Born in 1930. National of Brazil. Full Professor 
of Psychopharmacology, Federal University of São 
Paolo (since 1978); Director, Brazilian Centre for 
Information on Psychotropic Drugs (since 1988). 
 Master of Science, Yale University, United States 
(1962). Founder and President of the Latin American 
Society of Psychobiology (1971-1973). Member and 
Founder of the Academy of Sciences of the State of 
São Paulo (1976). President, Brazilian Society of 
Medication Vigilance (1991-1993). National Secretary, 
Sanitary Surveillance, Ministry of Health of Brazil 
(1995-1997). Member of the World Health 
Organization (WHO) Expert Advisory Panel on Drug 
Dependence and Alcohol Problems, Geneva (1997-
1998 and since 2002). Member of the Brazilian 
Academy of Sciences (2003). Recipient of numerous 
honours and awards, including: Councillor Emeritus, 
Federal Council of Narcotics of Brazil (1987); 
Honorary President, XI Symposium on Brazilian 
Medicinal Plants, João Pessoa, Brazil (1990); Member 
emeritus, Department of Biological Psychiatry, 
Brazilian Association of Psychiatry (1993). “Doctor of 
the Year”, Brazilian Chapter of the Medical Society of 
Israel (1993). “Personality of the Year”, Brazilian 
Association of Pharmachemical Industries (1996); 
Medal of “Grand Officer” of the Order of Rio Branco, 
Presidency of the Republic of Brazil (1996); Grand 
Cross Class of the Order of Scientific Merit, 
Presidency of the Republic of Brazil (2000); Doctor 
honoris causa, Federal University of Rio Grande do 
Norte, Brazil (2002). Author of more than 
300 publications, including: “Use of anorectic 
amphetamine-like drugs by Brazilian women”, Eating 
Behaviors (2002); “Plants and the central nervous 
system” (2003).  
 Member of the International Narcotics Control 
Board (since 2002).  
 
 
  Tatyana Borisovna Dmitrieva 
 
 
 Born in 1951. National of the Russian Federation. 
Director, V. P. Serbsky State Research Centre for 
Social and Forensic Psychiatry (since 1998). Chief 
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Expert Psychiatrist, Ministry of Health and Social 
Development of the Russian Federation (2005). 
 Graduate of the Ivanovskii State Medical Institute 
(1975). Master of Science (1981) and Doctor of 
Philosophy (Ph.D.) (1990) in medical sciences. 
Professor of Medicine (since 1993). Head of the 
Department of Psychiatry (1986-1989), Deputy 
Director of Research (1989-1990) and Director (1990-
1996), V. P. Serbsky State Research Centre for Social 
and Forensic Psychiatry. Minister of Health of the 
Russian Federation (1996-1998). Chairman, Russian 
Security Council Commission on Health Protection 
(1996-2000).  
 Member of the Presidium of the Russian 
Academy of Medical Sciences (since 2001); Vice-
Chairman, Russian Society of Psychiatrists (since 
1995); Vice-President, World Association for Social 
Psychiatry Academician; Member of the Russian 
Academy of Medical Sciences (since 1999); 
Corresponding Member of the Russian Academy of 
Medical Sciences (since 1997). Author of over 
300 scientific works, recipient of five authors’ 
certificates for inventions and author of two books on 
drug abuse therapy: Abuse of Psychoactive Substances 
(General and Forensic Psychiatric Practice) (2000); 
and Abuse of Psychoactive Substances: Clinical and 
Legal Aspects (2003). Editor-in-Chief, Russian 
Psychiatric Journal. Editor-in-Chief, Clinical Research 
on Medication in Russia. Member of the editorial 
boards of several Russian and foreign medical journals, 
including the journal Narcology. Member of the 
editorial council, International Medical Journal; and 
member of the editorial council, Siberian Journal of 
Psychiatry and Narcology. Recipient of the Order for 
Services to the Country, fourth class (2001) and the 
Order of Honour (1995). Participant and speaker on 
psychiatry and drug abuse therapy at national and 
international congresses and conferences, including 
those organized by WHO, the European Union, the 
Council of Europe, the World Psychiatric Congress and 
the World Psychiatric Association. 
 Member of the International Narcotics Control 
Board (2005). 
 
 
  Philip Onagwele Emafo 
 
 
 Born in 1936. National of Nigeria. 
 Lecturer, Biochemistry, University of Ibadan 
(1969-1971). Lecturer and Senior Lecturer, 
Pharmaceutical Microbiology and Biochemistry, 
University of Benin, Nigeria (1971-1977). Chief 
Pharmacist and Director, Pharmaceutical Services, 
Federal Ministry of Health of Nigeria (1977-1988). 
Chairman, Pharmacists Board of Nigeria (1977-1988). 
Member of the WHO Expert Advisory Panel on the 
International Pharmacopoeia and Pharmaceutical 
Preparations (1979-2003). Rapporteur-General, 
International Conference on Drug Abuse and Illicit 
Trafficking, Vienna (1987). Chairman, Commission on 
Narcotic Drugs at its tenth special session (1988). 
Member of the Secretary-General’s Group of Experts 
on the United Nations Structure for Drug Abuse 
Control (1990). Member of the WHO Expert 
Committee on Drug Dependence (1992, 1994 and 
1998). Consultant to the United Nations International 
Drug Control Programme (1993-1995). Member of the 
ad hoc intergovernmental advisory group established 
by the Commission on Narcotic Drugs to assess 
strengths and weaknesses of global drug control efforts 
(1994). Member of the expert group convened by the 
Secretary-General pursuant to Economic and Social 
Council resolution 1997/37 to review the United 
Nations machinery for drug control (1997-1998). 
Member of the Advisory Group of the International 
Narcotics Control Board to review substances for 
control under article 12 of the United Nations 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances of 1988 (1998-1999). 
Consultant to the Organization of African Unity, Addis 
Ababa (1998-1999). 
 Member of the International Narcotics Control 
Board (since 2000). Member of the Standing 
Committee on Estimates (2000-2004). Rapporteur of 
the Board (2001). President of the Board (2002-2003). 
First Vice-President of the Board (2005). 
 
 
  Gilberto Gerra 
 
 
 Born in 1956. National of Italy. Coordinator of 
the Centre for Studies on Drug Addiction, Drug 
Addiction Service, Health Department of Parma, Italy. 
University lecturer (master’s degree in neurology) on 
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psychopharmacology, University of Parma. Recipient 
of a university degree in medicine (1981), a master’s 
degree in internal medicine (1986) and a master’s 
degree in endocrinology (1989). 
 Medical doctor at outpatient Drug Addiction 
Service, Health Department, Parma (1987-1994); head 
of Drug Addiction Service, Health Department, Parma 
(1995-2001). University lecturer (master’s degree in 
internal medicine and physical therapy), University of 
Parma (1990-1996). Researcher of drug-related issues 
at the University of Parma and other universities in 
Italy and the United States (New York State Psychiatric 
Institute, Columbia University) (1994, 1996 and 2001); 
participant in a research project supported by the 
National Institute on Drug Abuse Invest Programme 
(1996); coordinator of the Regional Committee for 
Addiction Research of the Emilia Romagna region 
(1995-2001); research collaboration with the Istituto 
Superiore de Sanità, Rome (1998-2000); consultant to 
the Ministry of the Interior for research on substance 
abuse (1996-1997); consultant to the United Nations 
International Drug Control Programme on 
amphetamine derivatives (1996-1999); consultant to 
the Department of Social Affairs on pharmacological 
and clinical aspects of substance abuse (1998-2000); 
expert for the National Plan of Information for Drug 
Prevention (Presidency of Ministries Consilium) 
(1999); lecturer at several universities in Italy on 
neurobiology of substance abuse (1998-2005). 
Consultant to the National Department on Drug Policy 
in the field of neurobiology of addiction, 
pharmacology and prevention (2003-2005). Member of 
the National Scientific Committee for Health 
Education and Prevention of Substance Abuse of the 
Ministry of Education of Italy (1997-2001); member of 
the expert group of the Ministry of the Interior 
(European Information on Drugs and Drug Addiction 
(Reitox) focal point) to prepare the national report on 
substance abuse for the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) (1998); 
member of the International Society of 
Psychoneuroendocrinology; member of the College on 
Problems of Drug Dependence (2002-2005); member 
of the Scientific Committee of the Italian Society on 
Drug Addiction (2000-2004); member of the Scientific 
Board of the international journal Heroin Addiction 
and Related Clinical Problems; member of the 
Scientific Board of the Bollettino per le 
Farmacodipendenze e l’Alcoolismo (Italian Journal on 
drug addiction and alcoholism), published by the 
Ministry of Health of Italy, in collaboration with the 
United Nations Interregional Crime and Justice 
Research Institute. Co-author of the Italian Ministry of 
Interior of the national report on drug abuse for 
EMCDDA; referee of five international journals on 
substance abuse and psychiatry; contributed to over 
42 publications in scientific medical journals (1994-
2005), including “Aggressive responding in abstinent 
heroin addicts: neuroendocrine and personality 
correlates,” Progress in Psycho-Neuropharmacology 
and Biology (2004); “Substance use among high-
school students: relationship with temperament, 
personality traits and parental care perception”, 
Substance Use and Misuse (2004); “Long-term 
methadone maintenance effectiveness: psychosocial 
and pharmacological variables”, Journal of Substance 
Abuse Treatment (2003); “Effects of ecstacy on 
dopamine system function in humans”, Behavioural 
Brain Research (2002); “Intravenous flumazemil 
versus oxazepam tapering in the treatment of 
benzodiazepine withdrawal: a randomized placebo-
controlled study”, Addiction Biology (2002). Speaker 
at the United Nations International Drug Control 
Programme expert meeting on amphetamine-type 
stimulants, Vienna (1996); speaker at the North 
Atlantic Treaty Organization Advanced Study Institute 
conference on the biosocial bases of violence, Rhodes, 
Greece (1996); participant at the National Institute on 
Drug Abuse consensus conference concerning 
detoxification with alpha-2-agonists, clonidine and 
lofexidine, Bethesda, Maryland, United States (1998); 
participant at the annual meeting of the International 
Society of Psychoneuroendocrinology, Pisa, Italy 
(2003); speaker at the United Nations Office on Drugs 
and Crime meeting on young people and drug abuse: 
prevention and treatment, Stockholm (2003); expert at 
the EMCDDA meeting on targeted prevention, family 
prevention and community prevention, Lisbon (2003); 
speaker at an Andean Parliament meeting on anti-drug 
policies, Guayaquil, Ecuador (2003); speaker at a 
meeting organized by EMCDDA and the European 
Parliament on drug use among young people, Malaga, 
Spain (2003). 
 Member of the International Narcotics Control 
Board (since 2004). Member of the Standing 
Committee on Estimates (2004). Member of the 
Committee on Finance and Administration (2004). 
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Chairman of the Committee on Finance and 
Administration (2005). 
 
 
  Hamid Ghodse 
 
 
 Born in 1938. National of the Islamic Republic of 
Iran. Professor of Psychiatry and of International Drug 
Policy, University of London (since 1987). Director, 
International Centre for Drug Policy, St. George’s 
University of London (since 2003); President, 
European Collaborating Centres for Addiction Studies 
(since 1992); Member of the Executive Committee of 
the Federation of Clinical Professors, United Kingdom 
(since 1994); Member of the Scientific Committee on 
Tobacco and Health, United Kingdom (since 2000); 
Director of the Board of International Affairs and 
Member of the Council, Royal College of Psychiatrists 
(since 2000); Non-Executive Director, National 
Clinical Assessment Authority of England and 
subsequently patients safety agency (since 2001); 
Chairman, Higher Degrees in Psychiatry, University of 
London (since 2003); Member of the Medical Studies 
Committee, University of London (since 2003). 
 Recipient of the following degrees: Doctor of 
Medicine (M.D.), Islamic Republic of Iran (1965); 
Diploma Psychological Medicine, United Kingdom 
(1974); Doctor of Philosophy (Ph.D.), University of 
London (1976); and Doctor of Science, University of 
London (2002). Fellow of the Royal College of 
Psychiatrists, United Kingdom (1985); Fellow of the 
Royal College of Physicians, London (1992); Fellow of 
the Royal College of Physicians of Edinburgh, 
Edinburgh (1997); Fellow of the Faculty of Public 
Health Medicine, United Kingdom (1997). Member of 
the WHO Expert Advisory Panel on Alcohol and Drug 
Dependence (since 1979); Adviser, Joint Formulary 
Committee, British National Formulary (since 1984); 
Honorary Consultant Psychiatrist, St. George’s and 
Springfield University Hospitals, London (since 1978); 
Honorary Consultant Public Health, Wandsworth 
Primary Care Trust (since 1997); Director, Regional 
Drug Dependence Treatment Training and Research 
Unit, London (1987-1993); Director of the Education 
and Training Unit and of the Research, Evaluation and 
Monitoring Unit and Chairman of the Department of 
Addictive Behaviour and Psychological Medicine, 
St. George’s Hospital Medical School, University of 
London, and Joint Faculty of Health Sciences, 
Kingston University (1987-2003). Consultant 
Psychiatrist, St. Thomas’s Teaching Hospital and 
Medical School, London (1978-1987); member, 
rapporteur, chairman and convener of various WHO 
and European Community expert committees, review 
groups and other working groups on drug and alcohol 
dependence; M. S. McLeod Visiting Professor, 
Southern Australia (1990); Honorary Professor, Peking 
University (since 1997). Visiting Professor, Keele 
University, United Kingdom (since 2002). Author or 
editor of over 300 scientific books and papers on drug-
related issues and addictions, including the following 
books: The Misuse of Psychotropic Drugs, London 
(1981); Psychoactive Drugs and Health Problems, 
Helsinki (1987); Psychoactive Drugs: Improving 
Prescribing Practices, Geneva (1988); Substance 
Abuse and Dependence, Guildford (1990); Drug 
Misuse and Dependence: the British and Dutch 
Response, Lancashire, United Kingdom (1990); Misuse 
of Drugs (3rd ed.) London (1997); Drugs and 
Addictive Behaviour: a Guide to Treatment (3rd ed.), 
Cambridge (2002); Young People and Substance 
Misuse, London (2004). Addiction at Workplace, 
Aldershot (2005). Editor-in-Chief, International 
Psychiatry (since 2002); Editor, Substance Misuse 
Bulletin; Member of the Editorial Board, International 
Journal of Social Psychiatry. Convener of WHO expert 
groups on medical education (1986), pharmacy 
education (1987), nurse education (1989) and rational 
prescribing of psychoactive drugs. Member of the 
British Medical Association (since 1995); Member of 
the Executive Board, Medical Council on Alcoholism 
(since 1997); Honorary Secretary/Chairman, 
Association of Professors of Psychiatry of the British 
Isles (since 1991); Chairman, Association of European 
Professors of Psychiatry; Director, National 
Programme on Substance Abuse Deaths (since 1997); 
Member of the International Association of 
Epidemiology (since 1998); Member of the Institute 
for Learning and Training in Higher Education (since 
2001). 
 Member of the International Narcotics Control 
Board (since 1992). Member of the Standing 
Committee on Estimates (1992). President of the Board 
(1993, 1994, 1997, 1998, 2000, 2001, 2004 and 2005). 
 
 
  Melvyn Levitsky 
 
 
 Born in 1938. National of the United States. 
Retired Ambassador in the United States Foreign 
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Service; Professor of International Relations and 
Public Administration, Maxwell School of Citizenship 
and Public Affairs, Syracuse University; Distinguished 
Fellow, Daniel Patrick Moynihan Institute of Global 
Affairs, Maxwell School of Citizenship and Public 
Affairs, Syracuse University. 
 United States diplomat for 35 years, serving as, 
inter alia, Deputy Assistant Secretary of State for 
Human Rights and Humanitarian Affairs, United States 
Department of State (1982-1983); Deputy Director, 
Voice of America (1983-1984); Ambassador of the 
United States to Bulgaria (1984-1987); Executive 
Secretary and Special Assistant to the Secretary of the 
United States Department of State (1987-1989); 
Assistant Secretary of State for International Narcotics 
Matters (1989-1993); and Ambassador of the United 
States to Brazil (1994-1998). Consul, United States 
consulates in Frankfurt, Germany (1963-1965) and 
Belem, Brazil (1965-1967). Political officer, United 
States Embassy in Moscow (1973-1975). Officer-in-
charge for bilateral relations, Office of Soviet Union 
Affairs (1975-1978), and Director, Office of United 
Nations Political Affairs (1980-1982), United States 
Department of State. Recipient of several United States 
Department of State Meritorious and Superior Honor 
Awards, Presidential Meritorious Service Awards and 
the United States Secretary of State’s Distinguished 
Service Award. Member of the Washington Institute of 
Foreign Affairs, the American Academy of Diplomacy, 
the American Foreign Service Association. Member of 
the Advisory Board, Drug Free America Foundation. 
Member of the Institute on Global Drug Policy. 
Member of the Board, Global Panel of the Prague 
Society. Member, Public-Private Working Group on 
Sale of Controlled Substances via the Internet (Harvard 
University Law School). 
 Member of the International Narcotics Control 
Board (since 2003). Chairman of the Committee on 
Finance and Administration (2004); Chairman of the 
Working Group on Strategy and Priorities (2005). 
 
 
  Robert Jean Joseph Chrétien Lousberg 
 
 
 Born in 1941. National of the Netherlands. 
Former Head of the Netherlands regulatory office for 
narcotic drugs and psychotropic substances. Former 
associate and senior scientist, National Institute of 
Health, Bethesda, Maryland, United States. Senior 
scientist and lecturer, University of Utrecht, 
Netherlands. 
 Recipient of a doctoral degree, University of 
Utrecht (1969). Author of numerous articles published 
in international journals on pharmacologically active 
principles of opiate and cannabinoid origin. Co-
coordinator for the regulation of methadone 
programmes for the treatment of heroin addicts. 
National coordinator of the investigation of leuco-
encephalopathy among heroin addicts. Member of the 
delegation of the Netherlands at numerous sessions of 
the Commission on Narcotic Drugs. Member of 
International Narcotics Control Board expert groups on 
the preparation of article 12 of the 1988 Convention. 
Member of the delegation of the Netherlands at the 
United Nations Conference for the Adoption of a 
Convention against Illicit Traffic in Narcotic Drugs and 
Psychotropic Substances (1988). Representative for 
European Union directives and regulations on 
article 12 of the 1988 Convention. Appointments by 
the Minister of Health of the Netherlands: member of 
the supervisory board of the national drug information 
and monitoring system and the board investigating the 
medical prescription of heroin for the treatment of 
heroin addicts; member of the supervisory board for 
the assessment and monitoring of drugs in the 
Netherlands; and member of the supervisory board of 
the national agency for national hemp production for 
scientific and medicinal purposes. Expert, assessment 
missions to Albania and the former Yugoslav Republic 
of Macedonia carried out within the scope of the 
European Union-Phare licit drug control project. 
Representative at meetings for the assessment of new 
synthetic drugs by the Extended Scientific Committee 
of the European Monitoring Centre for Drugs and Drug 
Addiction, Lisbon. Chairman, Pompidou 
Group/International Narcotics Control Board 
Conference on the Control of Psychotropic Substances 
in Europe. Chairman, WHO Working Group on 
Revised Guidelines for the WHO Review of 
Dependence-Producing Psychoactive Substances for 
International Control.  
 Member of the International Narcotics Control 
Board (since 2002). Vice-Chairman of the Committee 
on Finance and Administration (2003). Second Vice-
President of the Board (2004). Vice-Chairman (2003) 
and Chairman (2004) of the Standing Committee on 
Estimates. Rapporteur of the Board (2005). 
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  Rainer Wolfgang Schmid 
 
 
 Born in 1949. National of Austria. Associate 
Professor, Department of Medical and Chemical 
Laboratory Diagnostics, University Hospital of Vienna, 
Medical University of Vienna. Head of the Section on 
Biomedical and Toxicological Analysis. 
 Recipient of a doctoral degree in Chemistry, 
University of Vienna (1977). Postgraduate training in 
neurochemistry and neuropharmacology, Laboratory of 
Preclinical Pharmacology, National Institute of Mental 
Health, Washington, D.C. (1978-1980). Recipient of a 
Master’s degree in Toxicology, University of Vienna 
(1998). Author of 85 articles published in the fields of 
drug addiction, neuropharmacology, clinical 
pharmacology and analytical chemistry. Co-Chairman, 
4th International Congress of Therapeutic Drug 
Monitoring and Clinical Toxicology, Vienna (1995). 
Member of the expert panel on designer drugs of the 
Ministry of Health of Austria and of the Drug Expert 
Forum of the City of Vienna (since 1997). Project 
leader of several scientific projects of the city of 
Vienna: monitoring designer drugs at large youth 
events (since 1997). Member of the scientific 
committee of international scientific congresses on 
drug addiction, clinical toxicology and toxicological 
analysis. Member of numerous national and 
international scientific toxicological associations. 
Participant at drug-related meetings of the European 
Union (Pompidou Group and European Union-
Parliament). Member of the Austrian delegation to the 
Commission on Narcotic Drugs (1999-2001). 
 Member of the International Narcotics Control 
Board (since 2002). Member of the Standing 
Committee on Estimates (since 2002). Vice-Chairman 
of the Standing Committee on Estimates and member 
of the Committee on Finance and Administration 
(2004). Chairman of the Standing Committee on 
Estimates (2005). 
 
 
  Camilo Uribe Granja 
 
 
 Born in 1963. National of Colombia. Medical 
Director, Hospital of San Martín (Meta); toxicologist, 
Marly and Palermo clinics; General Director, New 
Clinic Fray Bartolomé de las Casas; consultant, 
National Drug Council. Numerous university teaching 
posts in forensics and clinical toxicology. 
 Medical doctor, School of Medicine, University 
of Our Lady of the Rosary (1989); specialization in 
toxicology, School of Medicine, University of Buenos 
Aires (1990); specialization in occupational toxicology 
(1997), University Teacher’s Certificate (1998), 
diplomas in hospital management (1998) and social 
security administration (1999), University of Our Lady 
of the Rosary; diploma in toxicological emergencies, 
FUNDASALUD (1998); master in social services 
management, Alcala de Enares University (2002). 
Former forensic medical doctor, toxicologist, technical 
coordinator and manager in several hospitals and 
institutions. Scientific Director, Toxicology Clinic, 
Uribe Cualla; Toxicological Assessment Centre; 
Director, Clinical Toxicology, Fray Bartolomé de Las 
Casas Clinic (until 1991); Vice-President, Tropical 
Medicine Institute Corporation “Luis Patiño Camargo” 
(until 1992); Medical Coordinator and Director, 
Emergency National Plan (1993); Director, Health 
Services Management Programme, School of Public 
Administration, College of Public Administration (until 
2000); General Director, National Institute of Drugs 
and Food Administration (2001-2002). Vice-President 
(1988-1990 and 1995-1998) and President (2000-
2003), Latin American Toxicology Association; Vice-
President (2002-2003), International Toxicology 
Federation. Member of the Colombian Association of 
Internal Medicine. Member of the Spanish Association 
of Toxicology. Executive Director, non-governmental 
organizations association (until 1998); member of the 
Directive Group of the Cundinamarca’s Medical 
School; member of the Colombian Medical Academy. 
Author of numerous works, including: the chapter on 
benzodiazepines in Therapeutic Compendium of the 
Colombian Internal Medicine Association (1992); 
Criminal intoxication with scopolamine-like 
substances; Handbook on Toxicological Emergency 
Management; Manual on the Treatment of Intoxication 
by Plaguicides (1995); Investigation Protocol “Trauma 
and Alcohol”, Hospital of Kennedy (1993); numerous 
research protocols. Recipient of numerous honours, 
including: honourable mention for services to 
Colombian society in the field of toxicology, First 
International Congress of Toxicology, University of 
Antioquia; distinction by the Latin American 
Association of Toxicology for contributions to the field 
of toxicology (1998). Participant in numerous 
professional conferences and seminars, including 
several meetings of the Latin American Congress of 
Toxicology; National Congress of Toxicology and 
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Environmental Protection, Medellín (1999); Seventh 
Colombian Congress of Pharmacology and 
Therapeutics and the first international symposium on 
the theme “Biodiversity as source of new drugs” 
(2001); Congress of Aerial Security in the Colombian 
Caribbean Area (2001); Second National Congress, 
Investigation and Health (2002). 
 Member of the International Narcotics Control 
Board (2005). 
 
 
  Brian Watters 
 
 
 Born in 1935. National of Australia. Chairman, 
Australian National Council on Drugs (since 1998). 
 Arts degree, majoring in medical sociology, 
University of Newcastle, Australia; trained in addiction 
counselling at University of Newcastle; qualified 
psychiatric chaplain. Major in the Salvation Army 
(1975-2000), including work as Commander of the 
Salvation Army’s addiction treatment programme in 
eastern Australia; consultant and media spokesman on 
addiction issues; adviser to the Salvation Army’s 
HIV/AIDS services in eastern Australia; President of 
the Network of Alcohol and Drug Agencies in New 
South Wales; member of New South Wales’ Health 
Minister’s Drug Advisory Council. Member of the 
Board, “Drug Arm, Australia”; patron, “Drug Free 
Australia”; member of the Leadership Council, 
International Substance Abuse and Addiction 
Coalition. Member of several Australian government 
committees, including: the expert advisory group on 
sustained release naltrexone; the state and national 
reference groups on the Council of Australian 
Governments “Diversion of Offenders” scheme; and 
the national “Tough on Drugs” reference group for 
non-governmental organization treatment grants. 
Frequent contributor to Australian newspapers, 
magazines and journals, including the journal of the 
National Drug and Alcohol Research Centre; several 
publications, including Drug Dilemma: a Way 
Forward, and contributor to “Prevention, demand 
reduction and treatment: a way forward for Australia”, 
Heroin Crisis (1999). Officer of the Order of Australia 
(2003), for outstanding services in anti-drug policy 
development and drug treatment. Keynote speaker at 
national and international conferences, including: 
International Council on Alcohol and Addictions, 
Vienna; European Cities against Drugs, Stockholm; 
Australian Conference on Drugs Strategy, Adelaide; 
International Substance Abuse and Addiction 
Coalition, Madrid. Participant, Commission on 
Narcotic Drugs (2003). Speaker of the National 
Chemical Diversion Conference, Darwin, Australia 
(2005). 
 Member of the International Narcotics Control 
Board (2005). 
 
 
   
 
 
The role of the International Narcotics Control Board 
 
 
 The International Narcotics Control Board (INCB) is an independent and quasi-judicial control organ, established 
by treaty, for monitoring the implementation of the international drug control treaties. It had predecessors under the 
former drug control treaties as far back as the time of the League of Nations. 
 
Composition 
 
 INCB consists of 13 members who are elected by the Economic and Social Council and who serve in their 
personal capacity, not as government representatives (see annex II of the present publication for the current 
membership). Three members with medical, pharmacological or pharmaceutical experience are elected from a list 
of persons nominated by the World Health Organization (WHO) and 10 members are elected from a list of 
persons nominated by Governments. Members of the Board are persons who, by their competence, impartiality 
and disinterestedness, command general confidence. The Council, in consultation with INCB, makes all 
arrangements necessary to ensure the full technical independence of the Board in carrying out its functions. INCB 
has a secretariat that assists it in the exercise of its treaty-related functions. The INCB secretariat is an 
administrative entity of the United Nations Office on Drugs and Crime, but it reports solely to the Board on 
matters of substance. INCB closely collaborates with the Office in the framework of arrangements approved by 
the Council in its resolution 1991/48. INCB also cooperates with other international bodies concerned with drug 
control, including not only the Council and its Commission on Narcotic Drugs, but also the relevant specialized 
agencies of the United Nations, particularly WHO. It also cooperates with bodies outside the United Nations 
system, especially the International Criminal Police Organization (Interpol) and the Customs Co-operation 
Council (also called the World Customs Organization). 
 
Functions 
 
 The functions of INCB are laid down in the following treaties: the Single Convention on Narcotic Drugs of 
1961 as amended by the 1972 Protocol; the Convention on Psychotropic Substances of 1971; and the United 
Nations Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances of 1988. Broadly 
speaking, INCB deals with the following: 
 (a) As regards the licit manufacture of, trade in and use of drugs, INCB endeavours, in cooperation with 
Governments, to ensure that adequate supplies of drugs are available for medical and scientific uses and that the 
diversion of drugs from licit sources to illicit channels does not occur. INCB also monitors Governments’ control 
over chemicals used in the illicit manufacture of drugs and assists them in preventing the diversion of those 
chemicals into the illicit traffic; 
 (b) As regards the illicit manufacture of, trafficking in and use of drugs, INCB identifies weaknesses in 
national and international control systems and contributes to correcting such situations. INCB is also responsible 
for assessing chemicals used in the illicit manufacture of drugs, in order to determine whether they should be 
placed under international control. 
 In the discharge of its responsibilities, INCB: 
 (a) Administers a system of estimates for narcotic drugs and a voluntary assessment system for 
psychotropic substances and monitors licit activities involving drugs through a statistical returns system, with a 
view to assisting Governments in achieving, inter alia, a balance between supply and demand; 
 (b)  Monitors and promotes measures taken by Governments to prevent the diversion of substances 
frequently used in the illicit manufacture of narcotic drugs and psychotropic substances and assesses such 
substances to determine whether there is a need for changes in the scope of control of Tables I and II of the 
1988 Convention; 
 (c) Analyses information provided by Governments, United Nations bodies, specialized agencies or other 
competent international organizations, with a view to ensuring that the provisions of the international drug control 
treaties are adequately carried out by Governments, and recommends remedial measures; 
 (d) Maintains a permanent dialogue with Governments to assist them in complying with their obligations 
under the international drug control treaties and, to that end, recommends, where appropriate, technical or 
financial assistance to be provided. 
 INCB is called upon to ask for explanations in the event of apparent violations of the treaties, to propose 
appropriate remedial measures to Governments that are not fully applying the provisions of the treaties or are 
encountering difficulties in applying them and, where necessary, to assist Governments in overcoming such 
   
 
difficulties. If, however, INCB notes that the measures necessary to remedy a serious situation have not been 
taken, it may call the matter to the attention of the parties concerned, the Commission on Narcotic Drugs and the 
Economic and Social Council. As a last resort, the treaties empower INCB to recommend to parties that they stop 
importing drugs from a defaulting country, exporting drugs to it or both. In all cases, INCB acts in close 
cooperation with Governments. 
 INCB assists national administrations in meeting their obligations under the conventions. To that end, it 
proposes and participates in regional training seminars and programmes for drug control administrators. 
 
Reports 
 
 The international drug control treaties require INCB to prepare an annual report on its work. The annual 
report contains an analysis of the drug control situation worldwide so that Governments are kept aware of 
existing and potential situations that may endanger the objectives of the international drug control treaties. INCB 
draws the attention of Governments to gaps and weaknesses in national control and in treaty compliance; it also 
makes suggestions and recommendations for improvements at both the national and international levels. The 
annual report is based on information provided by Governments to INCB, United Nations entities and other 
organizations. It also uses information provided through other international organizations, such as Interpol and 
the World Customs Organization, as well as regional organizations. 
 The annual report of INCB is supplemented by detailed technical reports. They contain data on the licit 
movement of narcotic drugs and psychotropic substances required for medical and scientific purposes, together 
with an analysis of those data by INCB. Those data are required for the proper functioning of the system of 
control over the licit movement of narcotic drugs and psychotropic substances, including preventing their 
diversion to illicit channels. Moreover, under the provisions of article 12 of the 1988 Convention, INCB reports 
annually to the Commission on Narcotic Drugs on the implementation of that article. That report, which gives an 
account of the results of the monitoring of precursors and of the chemicals frequently used in the illicit 
manufacture of narcotic drugs and psychotropic substances, is also published as a supplement to the annual 
report. 
 Since 1992, the first chapter of the annual report has been devoted to a specific drug control issue on which 
INCB presents its conclusions and recommendations in order to contribute to policy-related discussions and 
decisions in national, regional and international drug control. The following topics were covered in past annual 
reports: 
 1992: Legalization of the non-medical use of drugs 
 1993: The importance of demand reduction 
 1994: Evaluation of the effectiveness of the international drug control treaties 
 1995: Giving more priority to combating money-laundering 
 1996: Drug abuse and the criminal justice system 
 1997: Preventing drug abuse in an environment of illicit drug promotion 
 1998: International control of drugs: past, present and future 
 1999: Freedom from pain and suffering 
 2000: Overconsumption of internationally controlled drugs 
 2001: Globalization and new technologies: challenges to drug law enforcement in the twenty-first century 
 2002: Illicit drugs and economic development 
 2003: Drugs, crime and violence: the microlevel impact 
 2004: Integration of supply and demand reduction strategies: moving beyond a balanced approach 
 Chapter I of the report of the International Narcotics Control Board for 2005 is entitled “Alternative 
development and legitimate livelihoods”.  
 Chapter II presents an analysis of the operation of the international drug control system based primarily on 
information that Governments are required to submit directly to INCB in accordance with the international drug 
control treaties. Its focus is on the worldwide control of all licit activities related to narcotic drugs and 
psychotropic substances, as well as chemicals used in the illicit manufacture of such drugs. 
 Chapter III presents some of the major developments in drug abuse and trafficking and measures by 
Governments to implement the international drug control treaties by addressing those problems. Specific 
comments are made on the drug control situation in each of the countries in which an INCB mission or technical 
visit took place. 
 Chapter IV presents the main recommendations addressed by INCB to Governments, the United Nations 
Office on Drugs and Crime, WHO and other relevant international and regional organizations. 
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aUnited Nations Office on Drugs and Crime. 
bThe INCB secretariat reports on substantive matters to INCB only. 
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